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Abstract 
Ovarian cancer remains the most lethal gynaecological cancer mainly due to the lack 
of reliable biomarkers and eventual development of chemo-resistance. This 
emphasizes the need for better therapies. Ovarian cancer is considered as an 
immunogenic tumour and adoptive immunotherapy is a promising treatment strategy. 
However, co-inhibitory molecules such as programmed death-ligand 1 (PD-L1), 
highly expressed on ovarian cancer cells interacts with its receptor, programmed 
death-1 (PD-1), expressed on T cells, causing immunosuppression.  
The aim of this Ph.D. was to 1) develop more efficient and targeted gene delivery 
agents by functionalizing poly(ethylenimine) (PEI) with various hydrophobic groups 
and folic acid (FA) targeting ligand, 2) deliver PD-L1 small interfering RNA (siRNA) 
or short hairpin RNA (shRNA) into ovarian cancer cells to block PD-1/PD-L1 
interactions and 3) to study how T cell function and anti-tumour activity are affected 
as a consequence of PD-L1 knockdown. 4) In addition, detection of soluble PD-L1 
(sPD-L1), using an enzyme linked immunosorbent assay (ELISA) and an Acoustic 
Membrane MicroParticle (AMMP) technology was also studied for its potential use as 
a biomarker for ovarian cancer diagnosis. 
When PEI was functionalized with various hydrophobic functional groups (ethyl, 
octyl, deodectyl, benzl, phenyl urea) using the established methyl-
carboxytrimethylene carbonate (MTC) platform, cytotoxicity was greatly reduced (for 
PEI, Mn=10 kDa) and gene transfection efficiency was substantially enhanced (Teo 
et al., 2013, Yang et al., 2013). Hydrophobic modification, however, did not improve 
siRNA delivery and PEI polymers functionalized with FA targeting groups (FA, 
poly(ethylene glycol) (PEG), PEG-FA), were investigated for PD-L1 delivery. FA-
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functionalized PEI displayed a higher specificity of uptake into ovarian cancer cells. 
PD-L1 knockdown in ovarian cancer cells using FA-functionalized PEI/PD-L1 siRNA 
polyplexes rendered tumour cells more susceptible to killing by chimeric antigen 
receptor (CAR) expressing T cells (Teo et al., 2015). In addition, an in-house ELISA, 
but not the AMMP platform, successfully detected sPD-L1 in patient plasma which 
differentiated patients with benign or malignant disease. 
In conclusion, PD-L1 has tremendous potential as a therapeutic and diagnostic 
target for ovarian cancer. Furthermore, modified PEI gene delivery agents has been 
shown to be an effective therapeutic tool in ovarian cancer and its use may be 
extended to a wide range of diseases which arise due to errant genes. 
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Chapter 1  
Introduction 
 
1.1 General introduction 
The first medical description of cancer was found in an ancient Egyptian text written 
in 2500 BC which described it as "a bulging tumour in the breast like touching a ball 
of wrappings", for the case of breast cancer. Regarding treatment, the ancient script 
noted that "There is none" (Mukherjee, 2010). 
Since then, the knowledge of cancer biology has grown tremendously and it is now 
widely understood to originate from genetic instability as well as microenvironmental 
factors (Hanahan and Weinberg, 2011, Bissell and Hines, 2011). Cancer cells 
contain oncogenic and tumour suppressor mutations, which enable them to sustain 
proliferative signalling, evade growth suppressors, resist cell death, induce 
angiogenesis, enable replicative immortality and activate invasion and metastasis 
(Hanahan and Weinberg, 2011). In the last decade, increasing evidence has also 
propelled the notion that immune evasion is another important characteristic of 
cancer (Hanahan and Weinberg, 2011).  
Debulking surgery and chemotherapy remain the mainstream treatments of various 
cancers. However, for many patients, the incomplete removal of tumours as well as 
problems of chemoresistance demonstrate the need for continual development of 
efficacious and safe treatments. With cancer being a genetic disease, extensive 
research has been dedicated to the improvement of materials for gene delivery 
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(Ozpolat et al., 2014, Wang et al., 2015, Pack et al., 2005). In addition, the 
restoration of immune function in the cancer microenvironment has shown potential 
for a new cancer therapy (Thibodeaux and Curiel, 2011). This thesis describes the 
development of materials for gene delivery and how gene therapy may shape the 
cancer microenvironment to enhance the immunotherapy of cancer. 
 
1.2 Ovarian cancer 
Ovarian cancer is a complex disease with various histological subtypes recognized. 
Although it is about 10% as common as breast cancer, ovarian cancer has a 
disproportionately high mortality rate, making it the most lethal gynaecological 
malignancy. The subtype of ovarian cancer that results in the highest death rate is 
known as high-grade serous ovarian cancer. In general, the overall five-year survival 
rates of ovarian cancer patients ranges between 30% to 50% (Team, 2014) and 
accounts for 4.2% of cancer-related deaths worldwide (Ferlay et al., 2010). Ovarian 
cancer may be categorised into four stages according to the Federation of 
Gynaecological Oncologists (FIGO) system (FIGO, 2014). Stage 1 means that the 
cancer is only in the ovaries. Stage two means that the cancer has grown outside the 
ovary and is growing within the area enclosed by the pelvis. There may also be 
cancer cells in the abdomen. Stage 3 means that the cancer has spread beyond the 
pelvis and into the abdominal cavity and may also be found in the lymph nodes in the 
upper abdomen, groin or behind the uterus. Stage four ovarian cancer refers to the 
spread of cancer cells to distant organs such as the breast or lungs. 
The current standard treatment of ovarian cancer is a combination of cytoreductive 
surgery and platinum/taxane-based chemotherapy (Bast et al., 2009). Despite 
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advancement in radical surgery and combination chemotherapy, the survival rate of 
patients has only modestly improved in the past twenty years (Vaughan et al., 2011). 
The main reasons ovarian cancer remains such a lethal disease is due to its late 
presentation, development of chemoresistance and the heterogeneity of the disease 
(Bast et al., 2009). The majority of patients are diagnosed at advanced stages of the 
cancer, when wide spread metastasis has already occurred, making surgical 
cytoreduction very difficult (Bast et al., 2009). Fortunately around 70% of residual 
tumours will initially respond to aggressive chemotherapy, prolonging the lifespan of 
the patient (Bast et al., 2009). However, chemoresistance is frequently acquired and 
when this occurs treatment options are usually palliative (Banerjee and Kaye, 2013, 
Stronach et al., 2011). In addition, ovarian cancer is a diverse disease consisting of 
histological subtypes which are aetiologically and molecularly distinct. Recent 
microarray experiments show that the different subtypes of ovarian cancer are more 
genetically similar to non-ovarian tumours than to each other (Tothill et al., 2008). 
Despite the heterogeneity of the disease, ovarian cancer patients are treated with 
the same therapeutic regimen (Vaughan et al., 2011). In this regard, intense 
research into new ovarian cancer therapies are underway, some of which include 
anti-angiogenic therapies (e.g. anti-vascular endothelial growth factor (VEGF) 
antibodies), DNA damage inhibitors (e.g. poly ADP-ribose polymerase (PARP) 
inhibitors) immunotherapy and gene therapy (Vaughan et al., 2011). In particular, 
immunotherapy has demonstrated immense potential to combat cancer and was 
highlighted as the breakthrough of the year in 2013 by Science Magazine (Couzin-
Frankel, 2013). 
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1.3 Cancer and the immune system  
The idea that the immune system could play a role in controlling the development of 
tumours is known as immune-surveillance and was conceived more than a century 
ago by Paul Ehrlich (Ehrlich, 1908). This concept however, was controversial due to 
insufficient knowledge about the immune system, thus hindering the validation of the 
hypothesis (Dunn et al., 2002). With the establishment of immune-deficient mouse 
models in the 1990s, strong evidence supporting Ehrlich’s hypothesis began to 
emerge. Interferon-γ (IFN-γ) was found to be integral for the immunological rejection 
of transplanted tumours (Dighe et al., 1994). This was further demonstrated by the 
increased spontaneous primary tumour formation in mice lacking IFN-γ 
responsiveness (absence of IFN-γ receptor or the signal transducers and activators 
of transcription 1 (STAT1) transcription factor required for IFN receptor signalling) or 
lacking adaptive immunity (Rag2-/- mice without T cells, B cells and natural killer 
cells) compared to immunocompetent mice (Kaplan et al., 1998, Shankaran et al., 
2001). Work from other laboratories also validated the concept of tumour 
immunosurveillance showing that the immune system plays a role to protect mice 
from cancer (Dighe et al., 1994, Kaplan et al., 1998, Shankaran et al., 2001, Smyth 
et al., 2000, Street et al., 2002, Laurent et al., 2013, Vesely et al., 2011). In 2001, a 
landmark study by Shankaran et al. showed that all transplanted methylcholanthrene 
sarcomas, derived from immune competent wild type mice, formed tumours in naive 
syngeneic wild-type hosts (Shankaran et al., 2001). On the other hand, only 40% of 
transplanted MCA sarcomas derived from Rag2-/- mice formed tumours in naive 
syngeneic wild-type hosts- indicating that the immune system suppressed tumour 
formation (Shankaran et al., 2001).  
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Further findings that the immune system not only controlled tumour growth 
quantitatively but also tumour immunogenicity and quality, prompted a refinement of 
the ‘immunesurveillance hypothesis’ into the ‘immunoediting hypothesis’ (Shankaran 
et al., 2001). ‘Immunoediting’ is the concept that the immune system plays a dual 
role in protecting the host against tumour formation but on the other hand also 
shapes tumour immunogenicity (Schreiber et al., 2011). Cancer immunoediting is 
known to occur in three distinct stages- “elimination,” “equilibrium,” and “escape” 
(Vesely et al., 2011, Dunn et al., 2002, Dunn et al., 2004, Dunn et al., 2004, Dunn et 
al., 2006, Smyth et al., 2006, Swann and Smyth, 2007) (Figure 1.1). 
Elimination describes the phase when the innate and adaptive immune systems 
work together to detect and destroy the tumour before it becomes clinically apparent. 
If however, a rare cancer variant was not destroyed in the elimination phase, it may 
enter the equilibrium phase, where its outgrowth is prevented by immunologic 
mechanisms, mainly of the adaptive immune response. Editing of tumour 
immunogenicity also occurs during the equilibrium phase. However, the constant 
immune selection pressure on genetically unstable tumour cells disposes it to 
overcome immune control and enter into the escape phase. Tumours may escape 
the adaptive immune destruction by the development of variants with down regulated 
tumour antigens or with defects in the antigen processing or presentation machinery. 
In addition, tumours may also induce anti-apoptotic signalling molecules such as 
STAT3 and B cell lymphoma 2 (BCL-2), which lead to reduced immune recognition 
and increased resilience to the cytotoxicity of the immune system, respectively 
(Vesely et al., 2011, Dunn et al., 2002, Dunn et al., 2004, Dunn et al., 2004, Smyth et 
al., 2006, Zitvogel et al., 2006, Khong and Restifo, 2002). 
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Figure 1.1. The cancer immunoediting concept. Cancer immunoediting is an 
extrinsic tumour suppressor mechanism that is engaged after cellular transformation 
and failure of intrinsic tumour suppressor mechanisms. It consists of three phases: 
elimination, equilibrium, and escape. In the elimination phase, innate and adaptive 
immunity work together to destroy developing tumours before they become clinically 
apparent. If a rare cancer cell variant is not destroyed in the elimination phase, it 
may then enter the equilibrium phase, in which its outgrowth is prevented by 
immunologic mechanisms such as the secretion of Interferon-12 (IL-12) and IFN-γ 
and the recruitment of T cells. Editing of tumour immunogenicity also occurs during 
the equilibrium phase. However constant immune selection pressure may lead to 
tumour variants which are able to escape recognition and destruction by the immune 
system. This last phase is known as the escape phase, where tumours emerge to 
cause clinically apparent disease. 
 
Reproduced from (Schreiber et al., 2011) 
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1.4 The immunogenicity of ovarian cancer  
Increasing evidence suggests that ovarian cancers are immunogenic tumours, where 
the immune system is able to recognise and mount anti-tumour responses (Table 
1.1) (Kandalaft et al., 2011). This evidence includes clinical and epidemiologic data 
that showed spontaneous anti-tumour immune responses in ovarian cancer which 
also correlated with prognosis in a proportion of patients. In addition, tumour immune 
escape mechanisms were also found to be active. 
 
Table 1.1. Evidence demonstrating that ovarian cancers are immunogenic.  
Finding Reference 
Tumour-reactive T cells in tumour, ascites and 
blood  
 
 
 
 
 
 
Antigen specific antibody production 
 
 
Association between tumour infiltrating 
lymphocytes (TILs) and good prognosis 
 
 
(Peoples et al., 1993), (Kooi et al., 1993), 
(Halapi et al., 1993), (Peoples et al., 1995), 
(Fisk et al., 1995), (Dadmarz et al., 1996), 
(Negus et al., 1997), (Peoples et al., 1998), 
(Hayashi et al., 1999), (Santin et al., 2000), 
(Schlienger et al., 2003), (Santin et al., 2001), 
(Sato et al., 2005) 
 
(Goodell et al., 2006), (Knutson et al., 2006); 
(Kalli et al., 2008) 
 
(Woo et al., 2001), (Curiel et al., 2004), (Sato et 
al., 2005), (Hamanishi et al., 2007), (Clarke et 
al., 2009), (Shah et al., 2008), (Adams et al., 
2009) 
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Table 1.2. Immune escape mechanisms of ovarian cancer. 
Presence of immune-suppressive cells in cancer 
microenvironment 
 
Pro-tumour vasculature 
 
 
Immune-suppressive molecules 
e.g. Vascular endothelial growth factor (VEGF) 
 
Immune-suppressive cytokines 
 
 
Indoleamine 2,3-dioxygenase (IDO) 
 
Blocking antibodies targeting co-inhibitory 
molecules 
 
 
 
(Woo et al., 2001), (Sato et al., 2005), (Shah et 
al., 2008) 
 
(Bagnato et al., 1999), (Buckanovich et al., 
2008), (Motz et al., 2014)  
 
(Ramakrishnan et al., 2005), (Motz and Coukos, 
2011), (Facciabene et al., 2011) 
 
(Ramakrishnan et al., 1989), (Gastl et al., 1993), 
(Woo et al., 2001), (Coward et al., 2011) 
 
(Inaba et al., 2009) 
 
(Carlsten et al., 2009), (Kryczek et al., 2006), 
(Hamanishi et al., 2007), (Siva et al., 2008), 
(Abiko et al., 2013), (Maine et al., 2014), (Labrie 
et al., 2014) 
 
1.4.1 Anti-tumour immune responses in ovarian cancer  
The process of mounting an adaptive immune response starts with tumour antigen 
uptake and presentation by antigen presenting cells (APCs) such as dendritic cells 
(DCs). These tumour antigens may include non-mutated genes that are 
overexpressed by cancer cells or mutated neo-antigens (Robbins et al., 2013, Segal 
et al., 2008). The APCs then travel to the lymph nodes where T cells are primed and 
activated. The activated and tumour antigen-targeted T cells then home to the 
tumour site and initiate an anti-tumour response (Mellman et al., 2011). CD4 positive 
T helper 1 (TH1) cells and TH17 cells have also been shown to promote CD8 positive 
cytotoxic T cell responses (Martin-Orozco et al., 2009, Mellman and Steinman, 2001, 
Steinman et al., 2000). 
Tumour reactive T cells were found in blood, ascites and tumours of ovarian cancer 
patients (Dadmarz et al., 1996, Fisk et al., 1995, Halapi et al., 1993, Hayashi et al., 
1999, Kooi et al., 1993, Negus et al., 1997, Peoples et al., 1998, Peoples et al., 
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1995, Peoples et al., 1993, Santin et al., 2000, Santin et al., 2001, Sato et al., 2005, 
Schlienger et al., 2003). In particular, tumour infiltrating lymphocytes (TILs) were 
detected within the tumour stroma and epithelium of about 50% of patients (Santin et 
al., 2001, Negus et al., 1997, Sato et al., 2005, Schlienger et al., 2003). The 
presence of TILs is indicative of an immune response to tumour antigens and hence, 
cancer immunogenicity (Nakano et al., 2001, Schumacher et al., 2001, Blankenstein 
et al., 2012). These TILs were discovered to undergo oligoclonal expansion (Hayashi 
et al., 1999, Halapi et al., 1993), display tumour antigen recognition (Santin et al., 
2001, Kooi et al., 1993, Peoples et al., 1995, Dadmarz et al., 1996) and exhibit 
tumour-specific cytolytic activity in vitro (Santin et al., 2000). In addition, ovarian 
cancer patients developed antibody responses to multiple tumour associated 
antigens such as p53 (Goodell et al., 2006), folic acid receptor-α (FRα) (Knutson et 
al., 2006) and insulin-like growth factor binding protein-2 (Kalli et al., 2008). 
Interestingly, the immune signature of ovarian cancer may also have the potential to 
be used as a prognostic marker. A study by Zhang et al. demonstrated that the 
presence of CD3 positive TILs correlated with positive clinical outcome (Zhang et al., 
2003). Patients with CD3 positive TILs present in tumours had a median overall 
survival duration of 53 months compared to 18 months for patients whose tumours 
had tested negative for the presence of TILs (Zhang et al., 2003). In addition, T 
regulatory (Treg) cells from patient blood and tumour microenvironment, were found 
to be associated with poorer prognosis (Curiel et al., 2004). However, a later study 
by Sato et al. found no correlation of CD3 positive TILs and Treg cells with survival 
(Sato et al., 2005). Instead, they showed that CD8 positive TILs, the ratio of CD8 
positive to CD4 positive cells and the ratio of CD8 positive to Treg cells served as 
prognostic markers of survival (Sato et al., 2005). A recent meta-analysis study of 
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1815 ovarian cancer patients also demonstrated that CD8 positive TILs functioned 
as a robust biomarker for prognosis regardless of tumour stage, grade or histology 
(Hwang et al., 2012). Webb et al. proposed that the retention of CD8 positive T cells 
in the tumour was dependent on the expression of the αE(CD103)/β7 integrin 
molecule on T cells, which binds to the epithelial cell surface molecule E-cadherin on 
tumour tissues (Webb et al., 2014). The correlation of TILs with positive prognosis 
was also found in other cancers such as breast, melanoma, esophageal, colorectal 
and renal cell carcinomas (Schumacher et al., 2001, Marrogi et al., 1997, Vesalainen 
et al., 1994, Halpern and Schuchter, 1997, Naito et al., 1998, Nakano et al., 2001). 
Therefore, TILs not only plays a role in controlling cancer progression, they may also 
serve as independent prognostic tools. These findings suggest that ovarian cancer is 
an immunogenic tumour.  
 
1.4.2 Immune-escape strategies of ovarian cancer 
Ovarian cancer may escape immune destruction via the recruitment of immune-
suppressive cells, alteration of the tumour vasculature to reduce the number of TILs, 
secretion of immune-suppressive cytokines, growth factors and enzymes, 
downregulation of MHC class I and II molecules and expression of immune-
suppressive molecules. 
Ovarian cancer cells and ascitic macrophages recruit immune-suppressive cells, 
such as Treg cells, plasmacytoid dendritic cells (PDCs) and myeloid-derived 
suppressor cells, into the cancer microenvironment by the secretion of chemokines 
such as CXCL12, CCL22 and CCL28 (Woo et al., 2001, Facciabene et al., 2011, 
Wei et al., 2005, Zou et al., 2001). Treg cells, attracted by CCL22 and CCL28, are 
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key mediators of peripheral tolerance and have been detected in blood, ascites and 
tumours of patients with late stage ovarian cancer (Woo et al., 2001, Sakaguchi et 
al., 2001, Wood and Sakaguchi, 2003). Treg cells dampen the adaptive immune 
response against tumours by (i) the production of immune-suppressive cytokines 
and growth factors, such as IL10, IL-35, vascular endothelial growth factor A 
(VEGFA) and transforming growth factor (TGF)-β (Becker and Schrama, 2013); (ii) 
modulation of APCs and/or effector T cells via contact dependent mechanisms e.g. 
CTLA-4 and PD-1 (Roncarolo et al., 2001, Curiel et al., 2004, Wang et al., 2009); (iii) 
direct killing of effector T cells (Becker and Schrama, 2013). Strategies aimed at 
Treg depletion in tumour-bearing mice has shown efficacy in immune mediated 
tumour shrinkage (Sutmuller et al., 2001, Steitz et al., 2001). The secretion of 
CXCL12 causes the recruitment of myeloid suppressor cells, which represent a 
group of immune-suppressive immature myeloid cells consisting of granulocyte, 
macrophage and dendritic precursor cells (Gabrilovich et al., 2007). These cells have 
been shown to reduce the adaptive immune response against tumours in mice and 
humans (Nagaraj and Gabrilovich, 2008).  
In addition, the ovarian tumour vasculature also plays a role in shaping tumour 
immunogenicity by regulating T cell infiltration into tumours. The expression of Fas 
ligand (FasL) on endothelial cells in ovarian tumour vasculature has been reported 
and was found to be associated with reduced CD8 positive T cell infiltration (Motz et 
al., 2014). Treg cells, on the other hand, were unaffected by FasL expression and 
were able to enter the cancer microenvironment (Motz et al., 2014). Furthermore, the 
over expression of endothelin-1 (ET-1) in ovarian cancer was found to cause the 
suppression of intercellular adhesion molecule 1 (ICAM-1) clustering on endothelial 
cell membranes which inhibited lymphocyte adhesion and penetration through the 
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endothelium (Buckanovich et al., 2008, Bagnato et al., 1999). Therefore the 
composition of the tumour vasculature may create an environment conducive for the 
immune escape of tumours by the reduction of TILs. 
Moreover, successful T cell infiltration into the ovarian cancer mass does not 
guarantee tumour elimination due to the presence of multiple immune-suppressive 
molecules present. Ovarian cancer cells and Treg cells secrete the growth factor, 
VEGFA (Ramakrishnan et al., 2005, Facciabene et al., 2011, Motz and Coukos, 
2011). Besides its role in angiogenesis, VEGFA has also been found to promote 
immune tolerance by the inhibition of DC maturation (Gabrilovich et al., 1996). 
Immature or incompletely mature DCs contribute to immune tolerance of tumours by 
the induction of effector T cell anergy and/or Treg cell proliferation (Banchereau and 
Steinman, 1998, Lutz and Schuler, 2002). In addition, VEGF induces the expression 
of programmed cell death ligand 1 (PD-L1, also known as B7-H1) on myeloid 
dendritic cells (Curiel et al., 2003). PD-L1 is a crucial negative regulatory ligand of 
the B7 family. The interaction of PD-L1 with its receptor, PD-1, expressed on 
activated effector T cells, transduces a signal that inhibits cytokine production, T cell 
proliferation and cytolytic function (Riley, 2009). The production of VEGF is therefore 
one of the strategies of ovarian cancer immune-escape. 
Other immune-suppressive cytokines and growth factors detected at elevated levels 
in the tumour microenvironment include IL-6 (Coward et al., 2011, Gastl et al., 1993), 
IL-10 (Curiel et al., 2003) and TGF-β (Woo et al., 2001). These soluble factors 
reduce adaptive immune responses by disrupting DC function. For example, IL-6 
and M-CSF switch DC maturation towards macrophage differentiation by the 
upregulation of M-CSF receptor on monocytes (Menetrier-Caux et al., 1998). In 
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addition, IL-10 up regulates PD-L1 on DC leading to T cell anergy and/or apoptosis 
(Curiel et al., 2003). 
The metabolic enzyme, indoleamine 2, 3-dioxygenase (IDO), has also been found to 
be expressed by ovarian cancers and infiltrating myeloid cells (Inaba et al., 2009). 
The activation of IDO causes the catalysis and local depletion of tryptophan, which is 
a crucial amino acid needed by T cells for proliferation and function (Munn et al., 
1998). Consequently, reduced numbers of CD8 positive TILs were found in ovarian 
cancer tissues which expressed high levels of IDO (Inaba et al., 2009). 
Many ovarian tumour cells down regulate MHC class I and II molecules, which are 
needed for CD8 and CD4 activation respectively (Sterman et al., 2006, Han et al., 
2008). A study by Han et al. demonstrated that the down regulation of MHC 
molecules on ovarian cancer cells led to low numbers of TILs which in turn resulted 
in a poor prognosis (Han et al., 2008). 
Ovarian cancer cells and inflammatory cells (DC, monocytes and lymphocytes) 
present in the cancer microenvironment also express co-inhibitory molecules. 
Examples of such molecules include PD-L1, B7-H4, galectin-9, CD155 and CD200, 
which dampen effector T cell responses by the induction of T cell anergy or 
apoptosis (Maine et al., 2014, Hamanishi et al., 2007, Abiko et al., 2013, Kryczek et 
al., 2006, Labrie et al., 2014, Carlsten et al., 2009, Siva et al., 2008). Most co-
inhibitory molecules are part of the B7 family of molecules, which also includes co-
stimulatory molecules for T cell activation (Zou and Chen, 2008). Under the normal 
physiological state, co-inhibitory molecules are necessary for self-tolerance and the 
prevention of autoimmunity (Zou and Chen, 2008). The upregulation of these co-
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inhibitory molecules suggests that ovarian cancer escapes destruction by the 
immune system via T cell co-inhibitory signalling.  
 
1.5 Co-signalling pathways 
The activation state of T cells is controlled by two main signals, firstly, the antigen-
specific signal through the T cell receptor (TCR)ζ/CD3 and CD8-CD4-T-lymphocyte 
specific protein tyrosine kinase complexes and secondly the co-receptor signal 
through receptors of the CD28 receptor family. Co-receptor signalling may be 
stimulatory or inhibitory. Co-stimulatory signalling receptors include CD28 and 
inducible T cell co-stimulator (ICOS; CD278) whereas co-inhibitory signalling 
receptors include cytotoxic T-lymphocyte antigen-4 (CTLA-4), programmed death-1 
(PD-1; CD279), lymphocyte activation gene-3 (LAG-3) and T cell immunoglobulin 
and mucin protein 3 (TIM-3) (Figure 1.2). Many of the CD28 family of receptors 
interact with the B7 family molecules to generate the second signal which controls T 
cell activation. There are seven known members of the B7 family namely B7-1 
(CD80), B7-2 (CD86), B7h (CD275), B7-H1 (PD-L1; CD274), B7-DC (PD-L2; 
CD273), B7-H3 (CD276), and B7-H4 (B7x; B7S1) (Figure 1.2).  
 
39 
 
 
Figure 1.2. Co-inhibitory pathways. T cells may express multiple inhibitory receptors, 
which interact with molecules of the B7 family ligands, to cause inhibition of T cell 
function, expansion and survival. 
 
Reproduced from (Freeman and Sharpe, 2012) 
 
1.5.1 CD28/CD80 or CD86 co-stimulatory pathway 
The co-stimulatory CD28 receptor is expressed on T cells and has two known 
ligands namely B7-1 (CD80) and B7-2 (CD86), which are expressed on activated 
APCs (June et al., 1994). Following CD28 ligation, the serine/threonine kinase, Akt, 
is phosphorylated and activated via phosphatidylinositol 3-kinase (PI3K) recruitment 
(Parry et al., 2005). Akt plays an important role in cell survival, cytokine synthesis 
and glucose metabolism and leads to T cell activation, cytokine production, 
enhanced T cell survival and proliferation (June et al., 1994, Parry et al., 2005).  
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1.5.2 ICOS/B7RP-1 co-stimulatory pathway 
Another T cell co-stimulatory receptor is ICOS, which binds to its ligand B7RP-1 (L-
COS; B7h; B7H-2; GL-50) (Yoshinaga et al., 2000). This interaction results in 
enhanced T cell proliferation, cytokine production and upregulation of CD154 (CD40 
ligand), which is involved in maturation and activation of APCs, B and T cells 
(Grewal and Flavell, 1998).  
 
1.5.3 CTLA-4/CD80 or CD86 co-inhibitory pathway 
The co-inhibitory receptor CTLA-4 is expressed on activated T cells and binds to 
CD80/CD86 with a higher affinity than CD28 (Collins et al., 2002). CTLA-4 is the 
most extensively studied co-inhibitory molecule, to date, and is the first co-inhibitory 
molecule receptor to be clinically targeted. Besides reducing the binding of 
CD80/CD86 ligand to CD28, CTLA-4 has been suggested to dampen T cell 
activation via the recruitment of serine/threonine phosphatase PP2A and SRC 
homology 2 (SH2)-domain-containing protein tyrosine phosphatase 2 (SHP-2) 
thereby inhibiting the phosphorylation of the TCR and Akt activation (Parry et al., 
2005, Rudd et al., 2009). In addition, CTLA-4 interaction with CD80/CD86 induces 
upregulation of IDO in tolerogenic DC populations leading to reduction of T cell 
activity (Munn et al., 2004). Evidence of CTLA-4 function has been clearly shown in 
CTLA-4 deficient mouse models, which develop lymphoproliferative disorders with 
lethal numbers of polyclonal T cells infiltrating peripheral organs (Munn et al., 2004).  
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1.5.4 PD-1/PD-L1 or PD-L2 co-inhibitory pathway 
PD-1 is a monomeric 288 amino acid type I transmembrane receptor member of the 
immunoglobulin (Ig) superfamily, which exists as a monomeric glycoprotein (Zhang 
et al., 2004). PD-1 was first discovered in 1992 as an up regulated gene in apoptotic 
T cell hybridoma (Ishida et al., 1992). The human PD-1 molecule is coded by the 
CD279 gene on chromosome 2 and consists of 5 exons (Figure 1.3A) (Keir et al., 
2008). The extracellular region of PD-1 comprises of a single immunoglobulin-like 
variable (IgV) domain and the transmembrane domain is made up of a 20 amino acid 
stalk. The cytoplasmic region of PD-1 is made up of approximately 95 amino acids 
and contains an immunoreceptor tyrosine-based switch motif (ITSM) as well as an 
immunoreceptor tyrosine-based inhibitory motif (ITIM), of which the ITSM has been 
shown to play an important role in mediating suppression of lymphocyte activation 
(Freeman et al., 2000, Chemnitz et al., 2004) (Figure 1.3B). PD-1 is expressed by 
activated T cells, B cells, APCs (monocytes and CD11c+ positive DCs) and NK cells 
(Ishida et al., 1992, Freeman et al., 2000, Pardoll, 2012). PD-1 is not expressed on 
resting T cells but is uniformly expressed on the T cell membrane after T cell 
activation (Nishimura et al., 1996). It has been shown that upon T cell-APC 
interaction, PD-1 redistributes and concentrates at the immune synapse (Pentcheva-
Hoang et al., 2007). Whether PD-1 requires dimerization to transduce signals is 
unclear (Keir et al., 2008). PD-1 has two known binding ligands namely PD-L1 (B7-
H1) (Figure 1.4) and PD-L2 (B7-DC), discovered in 2000 and 2001 respectively, both 
of which are members of the B7 family (Figure 1.4) (Freeman et al., 2000, Dong et 
al., 1999, Latchman et al., 2001, Tseng et al., 2001). The ligation of PD‐1 
suppresses T cell activation and affects cytokine production, especially that of IFN‐γ, 
TNF‐α and IL‐2 (Keir et al., 2008). Upon ligation of PD-1, SHP-1 and/or 2 are 
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recruited which dephosphorylate and deactivate downstream signal transducers 
such as CD3ζ, ZAP70 and PKCθ, which are necessary for T cell activation and 
proliferation (Riley, 2009, Parry et al., 2005). Although the exact mechanisms of PD-
1 mediated signalling are still debatable, it has been shown to deactivate T cells by 
the suppression of PI3K/Akt signalling and by blocking CD28 mediated expression of 
survival gene B-cell lymphoma-extra-large (Bcl-xL) (Parry et al., 2005, Chemnitz et 
al., 2004, Riley, 2009). PD‐1 ligation also inhibits the expression of transcription 
factors that are associated with T‐cell function such as GATA‐3, Tbet, and 
eomesodermin (Eomes) (Nurieva et al., 2006). Suppression of the TCR ‘stop signal’ 
also occurs after PD-1 ligation resulting in increased T cell motility, which causes 
shortened T cell – target cell contact duration and the lowering T cell activation (Fife 
et al., 2009). PD-1 is also highly expressed on Treg cells and interaction with its 
ligands in the presence of CD3 and TGF-β leads to the de novo conversion of naive 
CD4 positive T cells to Treg cells (Francisco et al., 2009, Haxhinasto et al., 2008). 
Therefore, the PD-1 pathway not only results in a decrease of effector T cell function, 
but also an increase in immune-suppressive Treg function. In addition, the ligation of 
PD-1 expressed on B cells causes the inhibition of B cell clonal responses and 
blocking antibodies against PD-1 have shown to increase antigen-specific antibody 
responses (Nicholas et al., 2013).  
The PD-1 ligands, PD-L1 and PD-L2, are monomeric type I transmembrane 
glycoproteins consisting of an intracellular, transmembrane and immunoglobulin-like 
constant (IgC)- and IgV-type extracellular domains (Dong et al., 1999, Latchman et 
al., 2001, Freeman, 2008). They are oriented in the same direction, 42 kb apart on 
human chromosome 9p24.2 and share 38% homology (Latchman et al., 2001). The 
main difference between PD-L1 and PD-L2 is a 14-amino acid gap in the IgV region 
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of PD-L2 (Freeman, 2008). The human PD-L1 protein is made up of 290 amino acids 
and is encoded by CD274 which comprises of seven exons (Figure 1.4A). The 
endodomain of PD-L1 is short and has no known function (Figure 1.4B) (Dong et al., 
1999).  
PD-L1 messenger RNA (mRNA) is widely expressed in many tissues and organs. 
PD-L1 protein is expressed on resting B cells, T cells, APCs (DCs and 
monocytes/macrophages) and NK cells and is further up-regulated upon activation 
(Keir et al., 2006). PD-L1 is also expressed on vascular endothelial cells, 
mesenchymal stem cells, cultured bone-marrow-derived mast cells, immune 
privileged tissues (e.g. placenta and cornea) and many cancers (Curiel et al., 2003, 
Dong et al., 2002, Dong et al., 1999, Freeman et al., 2000, Saudemont et al., 2005, 
Mazanet and Hughes, 2002, Hori et al., 2006, Petroff et al., 2002). The expression of 
PD-L1 on nonhematopoietic cells is particularly interesting as it suggests that PD-L1 
may regulate potentially self-reactive T cell responses in peripheral organs. 
The expression of PD-L1 on cancer cells is largely controlled by cytokines such as 
interferons, of which IFN-γ is the most potent (Spranger et al., 2013, Bald et al., 
2014, Duraiswamy et al., 2014, Brown et al., 2003, Curiel et al., 2003, Dong et al., 
2002). INF‐γ is secreted by activated T cells in response to immunogens in the 
adaptive immune response. INF‐γ has been shown to up regulate PD‐L1 on various 
cell types via Janus kinase (JAK)/STAT1-, myeloid differentiation marker 88 
(MyD88), Tumour necrosis factor receptor-associated factor (TRAF6‐) and 
MAPK/ERK kinase (MEK-) dependent pathways (Liu et al., 2007, O'Shea et al., 
2002, Loke and Allison, 2003). Physiologically, this mechanism creates a negative 
feedback loop, known as the adaptive immune resistance, to prevent the over 
activation of cytotoxic T cells. However, cancer cells may exploit this pathway to 
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escape the immune system (Pardoll, 2012). Interestingly, low PD-L1 expression is 
found on tumour cell lines and this might be attributed to the lack of the complete 
cancer environment and cytokines in the artificial cell culture dish (Dong et al., 2002). 
Constitutive surface expression of PD-L1 on cancer cells may also be the result of 
various oncogenic signalling pathways (Atefi et al., 2014, Parsa et al., 2007). 
Inhibition or loss of phosphatase and tensin homolog (PTEN), induces Akt activation 
and increases post-transcriptional expression of PD-L1 in glioma cells (Parsa et al., 
2007)(Parsa et al., 2007)(Parsa et al., 2007)(Parsa et al., 2007)(Parsa et al., 
2007)(Parsa et al., 2007)(Parsa et al., 2007)(Parsa et al., 2007)(Parsa et al., 
2007)(Parsa et al., 2007)(Parsa et al., 2007)(Parsa et al., 2007). However, signalling 
pathways vary among different cell types and human melanoma cells, do not show 
any association between PTEN, Akt and PD-L1 expression (Atefi et al., 2014). The 
suppression of c-Myc transcription factor has also shown to increase PD-L1 mRNA, 
via STAT1 inactivation, and cell surface expression of PD-L1 protein on Burkitt 
lymphoma cell lines, by inhibiting actin polymerization (Durand-Panteix et al., 2012, 
Schlee et al., 2007). 
Although it is widely known that PD-L1 interacts with PD-1 to cause T cell 
inactivation and apoptosis, it has also been shown that PD‐L1 binds to CD80 (B7-1), 
with greater affinity than CD28. This binding suppresses T cell response by the 
prevention of CD28 - CD80 mediated co-stimulatory signalling (Butte et al., 2007). In 
addition, PD-L1 may also act as a receptor, when bound to CD80, which can 
transmit inhibitory signals into the T cells they are expressed on (Keir et al., 2008, 
Quezada and Peggs, 2013, Butte et al., 2007). As both PD-L1 and CD80 are 
expressed on activated T‐cells, B cells, macrophages and DCs, it is possible that 
bidirectional interaction occurs (Keir et al., 2008). Upon ligation, PD‐L1 also 
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promotes the production of IL‐10, a cytokine implicated in the death of activated T‐
cells (Dong et al., 1999, Georgescu et al., 1997).  
While PD-L1 is generally regarded as an immune-suppressive molecule, its 
expression is not necessarily associated with tumour immune evasion. Expression of 
PD-L1 may instead reflect an ongoing anti-tumour immune response that involves 
the production of IFN-γ, which causes PD-L1 upregulation (Taube et al., 2012). This 
is consistent with retrospective studies in tumour types, such as mismatch repair-
proficient CRC, melanoma, non-small-cell lung carcinoma (NSCLC) and Merkel cell 
carcinoma where PD-L1 expression on the tumour has been shown to be a positive 
prognostic factor (Lipson et al., 2013, Taube et al., 2012, Droeser et al., 2013, 
Velcheti et al., 2014). Moreover, the presence of PD‐L1 does not always lead to 
tolerance. PD‐L1 has been shown to increase immunogenicity towards transplanted 
allogeneic PD‐L1 expressing islet B cells, leading to accelerated transplant rejection 
in a mouse model (Subudhi et al., 2004). PD‐L1 was also shown to enhance T cell 
growth when CD3 positive T cells were incubated with PD‐L1 antibodies (Dong et al., 
1999). PD‐L1 also caused the stimulation of proliferation of resting allogeneic CD4 
positive T cells (Tamura et al., 2001). These discrepancies may reflect the differential 
involvement of PD‐L1 in different microenvironments and when it is ligated to 
different receptors (Hamanishi et al., 2007, Dong et al., 2003). Although the role of 
PD‐L1 in the regulation of T‐cell responses seem to be complex and still under 
debate, PD‐L1 has been found to be constantly inhibitory on tumour immunity 
(Hirano et al., 2005). 
PD-L2 is encoded by the CD273 gene and comprises of seven exons. Expression of 
PD-L2 is much more restricted than PD-L1 and is inducibly expressed only on 
macrophages, DCs, bone marrow-derived mast cells and cancers such as B cell 
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lymphomas (Rosenwald et al., 2003, Tseng et al., 2001, Latchman et al., 2001). 
Cytokines such as granulocyte-macrophage colony-stimulating factor (GM-CSF), IL-
4 and IFN-γ have been shown to up regulate PD-L2 (Yamazaki et al., 2002). IFN-γ 
upregulates PD-L2 via activation of nuclear factor kappa-light-chain-enhancer of 
activated B cells (NF-κB) (Liang et al., 2003). PD-L2 plays an important role in 
maintaining peripheral tolerance, particularly in the lung (Matsumoto et al., 2008, 
Akbari et al., 2010). Recently, PD-L2 was also found to bind a second cognate 
receptor, repulsive guidance molecule B (RGMb) (Xiao et al., 2014). 
PD-1 interacts with the IgV domain of both ligands in a 1:1 receptor/ligand 
stoichiometry (Freeman, 2008). Although PD-L1 and PD-L2 have been shown to 
suppress T cell activation upon interaction with PD-1, most studies have focused on 
PD-L1 as the target for cancer immunotherapy as blocking antibodies targeting PD-
L2 have had low efficacy in cancer therapy (Latchman et al., 2001, Dong et al., 2002, 
Freeman et al., 2000, Duraiswamy et al., 2013). Blocking antibodies targeting PD-L1 
on the other hand showed substantial restoration of T cell function and tumour 
regression in various cancers (Brahmer et al., 2012, Herbst et al., 2014, Dong et al., 
2002). Blocking antibodies targeting PD-1 made headlines after clinical trials showed 
unprecedented responses in 20–40% of patients with melanoma, renal, and non-
small cell lung cancer (Table 1) (Topalian, Hodi, et al., 2012, Hamid et al., 2013). 
 
Recently, a new homologue of PD-1, PD-1H (VISTA), was discovered. It is 
expressed on naive T cells, NK cells, DCs and macrophages, but not on B cells 
(Flies et al., 2011, Wang, Rubinstein, et al., 2011). Wang et al. showed that PD-1H 
suppresses T cell responses by functioning as a ligand which interacts with an 
unknown receptor on T cells (Wang, Rubinstein, et al., 2011).  
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Figure 1.3. (A) Genomic and (B) amino acid structure of human PD-1. (A) The PD-1 
gene (CD279) is located on chromosome 2q37.3. The blue bars represent the exons 
(EX) and the lines represent introns. The gene encodes a short signal sequence 
(EX1), an Ig domain (EX2), stalk and transmembrane domain (EX3 and 4), a short 
12 amino acid sequence marking the start of the cytoplasmic domain (EX4) and the 
C-terminal intracellular residue and a long 3’UTR (EX5). Adapted from (Shi et al., 
2013) (B) Amino acid sequence of full length PD-1. 
 
5’ 3’
EX1 EX2 EX3 EX4 EX5
(A)
(B)
10 20 30 40 50
MQIPQAPWPV VWAVLQLGWR PGWFLDSPDR PWNPPTFSPA LLVVTEGDNA 
60 70 80 90 100
TFTCSFSNTS ESFVLNWYRM SPSNQTDKLA AFPEDRSQPG QDCRFRVTQL
110 120 130 140 150
PNGRDFHMSV VRARRNDSGT YLCGAISLAP KAQIKESLRA ELRVTERRAE
160 170 180 190 200
VPTAHPSPSP RPAGQFQTLV VGVVGGLLGS LVLLVWVLAV ICSRAARGTI
210 220 230 240 250
GARRTGQPLK EDPSAVPVFS VDYGELDFQW REKTPEPPVP CVPEQTEYAT 
260 270 280
IVFPSGMGTS SPARRGSADG PRSAQPLRPE DGHCSWPL  
Legend:
Signal peptide
Ectodomain
Transmembrane
Endodomain
PD-1
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Figure 1.4. (A) Genomic and (B) amino acid structure of human PD-L1. (A) The PD-
L1 gene CD274 is located on chromosome 9p24. The bars (yellow: coding regions; 
striped: noncoding regions) represent the exons (EX) and the lines represent introns. 
CD274 comprises of a noncoding 5’UTR and signal sequence (EX1), IgV-like 
domain (EX2), IgC-like domain (EX3), the transmembrane domain, intracellular 
domain and 3’UTR region (EX4-7). Adapted from (Shi et al., 2013) (B) Amino acid 
sequence of full length PD-L1. 
 
 
 
 
 
 
5’ 3’
EX1 EX2 EX3 EX4 EX5
(A)
(B)
PD-L1
EX6 EX7
10 20 30 40 50
MRIFAVFIFM TYWHLLNAFT VTVPKDLYVV EYGSNMTIEC KFPVEKQLDL
60 70 80 90 100
AALIVYWEME DKNIIQFVHG EEDLKVQHSS YRQRARLLKD QLSLGNAALQ
110 120 130 140 150
ITDVKLQDAG VYRCMISYGG ADYKRITVKV NAPYNKINQR ILVVDPVTSE
160 170 180 190 200
HELTCQAEGY PKAEVIWTSS DHQVLSGKTT TTNSKREEKL FNVTSTLRIN
210 220 230 240 250
TTTNEIFYCT FRRLDPEENH TAELVIPELP LAHPPNERTH LVILGAILLC
260 270 280 290
LGVALTFIFR LRKGRMMDVK KCGIQDTNSK KQSDTHLEET  
Legend:
Signal peptide
Ectodomain
Transmembrane
Endodomain
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1.5.4.1 Splice variants of PD-1 and its ligands 
In addition to its full length isoform, PD-1 has been reported to have four different 
splice variants lacking exon 2, exon 3, both exon 2 and 3, or exons 2 through 4 
(Nielsen et al., 2005). All the isoforms, excluding the splice variant lacking exon 3 
(PD-1Δex3), are expressed at similar levels as the full length isoform of PD-1 in 
resting PBMCs and all variants show upregulation upon T cell activation. PD-1Δex3 
lacks the transmembrane domain and forms the soluble form of PD-1 which has 
been found in sera and synovial fluid of patients with rheumatoid arthritis (Wan et al., 
2006).  
Three isoforms of human PD-L1 have been identified. PD-L1 isoform 1 is the full 
length protein which is also referred to as the 'canonical' sequence (Figure 1.5). PD-
L1 isoform 2, produced by alternative splicing, lacks the IgV-like domain (missing 
amino acids 19 to 132) encoded in exon 2 (PD-L1 Δex2) (Figure 1.5) (He et al., 
2005, He et al., 2005). PD-L1 isoform 3 lacks parts of the the IgV-like domain, the 
transmembrane domain and the endodomain (missing amino acids 179 to 290) 
encoded by exon 2-7 (PD-L1 Δex2-7) (Figure 1.5). However, it has been 
hypothesized that isoform 3 may be produced at very low levels due to the presence 
of a premature stop codon in the mRNA, leading to nonsense-mediated mRNA 
decay (Ota et al., 2004). 
Three splice variants of PD-L2 have been identified from activated PBMCs 
(Latchman et al., 2001, He et al., 2004). PD-L2 isoform 1 is the full length isoform 
whereas PD-L2 isoform 2 is without the IgV- like exon, which renders it unable to 
bind PD-1. PD-L2 isoform 3 is missing both IgC- like and transmembrane domain 
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while preserving the intracellular residues and may code for a soluble form of PD-L2 
(He et al., 2004).  
 
Figure 1.5. PD-L1 protein isoforms. Isoform 1 is the full length PD-L1 protein and is 
also denoted as the 'canonical' sequence. Isoform 2 lacks the IgV-like domain 
(missing amino acids 19 to 132) and isoform 3 lacks parts of the the IgV-like domain, 
the transmembrane domain and the endodomain (missing amino acids 179 to 290). 
Isoform 3 is expected to be produced at extremely low levels due to the presence of 
a premature stop codon in the mRNA, leading to nonsense-mediated mRNA decay 
(Ota et al., 2004). Transmembrane sequences are underscored. 
 
 
1.5.4.2 Soluble forms of PD-L1  
Soluble forms of PD-1 and PD-L2, produced by the translation of splice variants that 
lack transmembrane regions, have been discovered and identified (He et al., 2004, 
Wan et al., 2006). The splice variant of PD-L1 lacking the transmembrane region 
(isoform 3) however, is not expected to be translated, due to a premature stop codon 
in the mRNA. Despite the ambiguity of PD-L1 isoform 3, soluble PD-L1 (sPD-L1) has 
been detected by enzyme-linked immunosorbent assay (ELISA) in the serum of 
healthy individuals (Chen et al., 2011) and was also found to be elevated in 
Isoform 1 1 MRIFAVFIFMTYWHLLNAFTVTVPKDLYVVEYGSNMTIECKFPVEKQLDLAALIVYWEME 60
Isoform 2 1 MRIFAVFIFMTY…………………………………………………………………………………….. 12
Isoform 3 1 MRIFAVFIFMTYWHLLNAFTVTVPKDLYVVEYGSNMTIECKFPVEKQLDLAALIVYWEME 60
Isoform 1 61 DKNIIQFVHGEEDLKVQHSSYRQRARLLKDQLSLGNAALQITDVKLQDAGVYRCMISYGG 120
Isoform 2 ………………………………………………………………………………………………………….
Isoform 3 61 DKNIIQFVHGEEDLKVQHSSYRQRARLLKDQLSLGNAALQITDVKLQDAGVYRCMISYGG 120
Isoform 1 121 ADYKRITVKVNAPYNKINQRILVVDPVTSEHELTCQAEGYPKAEVIWTSSDHQVLSGKTT 180
Isoform 2 13 ………...WHLLNAPYNKINQRILVVDPVTSEHELTCQAEGYPKAEVIWTSSDHQVLSGKTT 66
Isoform 3 121 ADYKRITVKVNAPYNKINQRILVVDPVTSEHELTCQAEGYPKAEVIWTSSDHQVLSGD…. 178
Isoform 1 181 TTNSKREEKLFNVTSTLRINTTTNEIFYCTFRRLDPEENHTAELVIPELPLAHPPNERTH 240
Isoform 2 67 TTNSKREEKLFNVTSTLRINTTTNEIFYCTFRRLDPEENHTAELVIPELPLAHPPNERTH 126
Isoform 3 ………………………………………………………………………………………………………
Isoform 1 241 LVILGAILLCLGVALTFIFRLRKGRMMDVKKCGIQDTNSKKQSDTHLEET 290
Isoform 2 127 LVILGAILLCLGVALTFIFRLRKGRMMDVKKCGIQDTNSKKQSDTHLEET 176
Isoform 3 ………………………………………………………………………………………
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serum/plasma of patients with renal cell carcinoma, rheumatoid arthritis and 
systemic lupus erythematosus (Frigola et al., 2011, Wan et al., 2006, Her et al., 
2009). sPD-L1 was found to have a molecular weight of approximately 45 kDa and 
confirmed to contain the N-terminus of PD-L1 as well as the Ig-V ligand-binding 
domain required for interaction with PD-1 by tandem mass spectrometry (Figure 1.6) 
(Frigola et al., 2011). The secretion/shedding of sPD-L1 was found to correlate with 
matrix metalloproteinase activity, which also plays a role in protein ectodomain 
shedding (Chen et al., 2011, Arribas and Borroto, 2002). sPD-L1 may therefore be 
produced by post translational mechanisms such as shedding. The protein was 
found to be biologically active and interacted with PD-1 for the induction of apoptosis 
in T cells (Chen et al., 2011, Frigola et al., 2011). sPD-L1 has been shown to be 
produced and released by cancer cells and activated mature DCs (Frigola et al., 
2012). On the other hand, it was not released by immature DCs, macrophages, 
monocytes, or T cells (Frigola et al., 2012). In addition, the molecule showed 
prognostic potential in renal cell carcinoma as well as aggressive diffuse large B-cell 
lymphoma (Frigola et al., 2011, Rossille et al., 2014). 
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Figure 1.6. Peptides identified (shaded areas) by nano-flow liquid chromatography 
electrospray tandem mass spectrometry in sPD-L1. Peptides which were excluded 
from the analysis either contained N-glycosylations (N) or were too small to be 
detected (open boxes). 
 
Reproduced from (Frigola et al., 2011) 
 
1.5.4.3 Other members of the B7 family 
Besides PD-L1 and PD-L2, other B7 molecules involved in the co-signalling pathway 
include B7-H3 and B7-H4 (B7x; B7S1). B7-H3 acts as a co-stimulatory ligand when it 
binds to the TREM family of receptors on activated T cells (Hofmeyer et al., 2008). 
This interaction causes T cell proliferation, enhances induction of cytotoxic T cells 
and increases production of IFN-γ (Chapoval et al., 2001). Expression of B7-H3 on 
monocytes and DCs can be induced by inflammatory cytokines and a combination of 
phorbol myristate acetate and ionomycin (Chapoval et al., 2001).  
B7-H4 acts as a co-inhibitory ligand and has been implicated as one of the pathways 
ovarian cancer adopts to escape immune attack (Dangaj et al., 2013, Sica et al., 
2003, Prasad et al., 2003, Zang et al., 2003). It has been shown to decrease T cell 
proliferation, cell cycle progression and cytokine production (Smith et al., 2014). 
However, the study of B7-H4 in the ovarian cancer setting has been hindered due to 
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the lack of specific antibodies against B7-H4, leading to many discrepancies in the 
literature (Smith et al., 2014). 
Choi et al. showed B7-H4 expression in 85% of freshly isolated ovarian tumours by 
immunohistochemistry (IHC) using an in-house antibody (Choi et al., 2003). Kryczek 
et al. showed that most of the B7-H4 was expressed intracellularly and only 5% of 
ovarian tumours had surface expression of B7-H4 (Kryczek et al., 2006). On the 
other hand, Dangaj et al. showed 100% of ovarian cancer and ascites samples 
showed surface expression of B7-H4 with the use of a commercially available 
antibody (Dangaj et al., 2013). The study of B7-H4 has been difficult due to 
inconsistent results arising from the use of different antibodies (Smith et al., 2014). 
B7-H4 however, may have potential to serve as a target molecule for ovarian cancer 
immunotherapy in the future. 
 
1.6   Role of PD-1 and it’s ligands in ovarian cancer 
PD-1 has been shown to be up regulated in a high proportion of TILs in the ovarian 
cancer setting (Matsuzaki et al., 2010, Duraiswamy et al., 2014). A high PD-1 
expression on TILs may be indicative of an anergic or exhausted state (Duraiswamy 
et al., 2013). Expression of PD-1 on CD8 positive T cells was shown to be up-
regulated by cytokines, IL-6 and IL-10 or by tumour-derived APCs (Matsuzaki et al., 
2010). In the ID8-VEGF ovarian cancer mouse model, two-thirds of CD8 positive 
TILs and one-third of CD4 positive TILs expressed PD-1 and were associated with 
an exhausted phenotype (Duraiswamy et al., 2014).  
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PD-L1 has also been demonstrated to be highly expressed in the ovarian cancer 
setting. Dong et al. was the first to show up regulated PD‐L1 protein expression in 
ovarian cancer. The majority (87%) of freshly isolated ovarian cancer tissues stained 
positive for cytoplasmic and membranous PD-L1 (Dong et al., 2002). In contrast, 
healthy human ovaries stained negative for PD-L1 (Dong et al., 2002, Dong et al., 
1999). PD-L1 protein expression was also found on monocytes from blood and 
ascites of ovarian cancer patients and on tumour infiltrating DCs (Maine et al., 2014, 
Krempski et al., 2011). Curiel et al. demonstrated that PD-L1 was expressed on 
monocyte derived MDCs derived from the lymph nodes draining from the 
retroperitoneum of patients with ovarian cancer and not on patients without tumours 
(Curiel et al., 2003). Moreover, blood derived MDCs had substantially lower amounts 
of PD-L1 than when they were obtained from tumour associated lymph nodes of 
ovarian cancer patients (Curiel et al., 2003). This finding suggested that PD-L1 
expression is dependent on tumour microenvironmental factors (Curiel et al., 2003). 
In the ID8 ovarian cancer mouse model, PD-L1 protein was also highly expressed by 
mouse ovarian tumour cells and tumour-derived myeloid cells, which included DCs, 
tumour associated macrophages (TAM) and myeloid-derived suppressor cells 
(Duraiswamy et al., 2013). Abiko et al. showed that the expression of PD-L1 on 
tumour cells was highly dependent on the immune environment of the tumour. For 
example, PD-L1 upregulation in HM1 mouse ovarian tumours only occurred in the 
presence of IFN-γ producing activated lymphocytes in vivo (Abiko et al., 2013).  
PD-L1 expressed on cancer cells and inflammatory cells was shown to bind to PD-1, 
as well as other unknown receptors, on T cells to induce T cell exhaustion and 
apoptosis (Dong et al., 2002). It may also be possible that PD-L1 binds to CD80 
expressed on T cells to trigger a co-inhibitory signal in the ovarian cancer setting 
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(Butte et al., 2007). There has been some debate about how PD-L1 affects T cells in 
ovarian cancer immunity. Work by Liu et al. showed that suppression of T cell activity 
might be brought about by the production of arginase I by MDSCs after PD-1/PD-L1 
ligation (Liu, Yu, et al., 2009). Dong et al. reported that PD-L1 expressed on tumour 
cells promoted T cell apoptosis but did not alter CD8 positive T cell cytolytic function 
(Dong et al., 2002). Hirano et al. demonstrated that tumour associated PD-L1 formed 
a molecular shield to prevent destruction by CD8 positive T cells without impairing 
their function (Hirano et al., 2005). On the other hand, Blank et al. showed that PD-
L1 inhibited the effector phase of tumour rejection and altered CD8 positive cytolysis 
function (Blank et al., 2004). Abiko et al. also reported that PD-L1 dampened CD8 
positve T cell function. In addition, they showed that the attraction of CD8 positive T 
cells to target tumour cells was significantly inhibited and that the T cells ‘ignored’ 
PD-L1 expressing tumour cells. They also showed that PD-L1 expressing ovarian 
cancer cells induced mouse CD8 positive T cells to express a gene signature 
associated with an exhausted phenotype (Abiko et al., 2013). 
Blocking antibodies against PD-1 or PD-L1 have been shown to increase the number 
of CD8 and CD4 positive TILs and reduce Treg cell infiltration into the ovarian 
tumour, which led to subsequent tumour shrinkage in both mouse models and 
human clinical trials (Duraiswamy et al., 2013, Curiel et al., 2003, Matsuzaki et al., 
2010). Memory and effector signalling molecules such as T-box transcription factor 
(T-bet), Eomes, Akt and S6 kinase were up regulated upon treatment with PD-1/PD-
L1 blocking antibodies (Duraiswamy et al., 2013). Consequently, the regression of 
tumours in the ID8 ovarian cancer mouse model was observed after anti-PD-1 or 
anti-PD-L1 treatment (Duraiswamy et al., 2013). On the other hand, blocking 
antibodies against PD-L2 were ineffective (Duraiswamy et al., 2013). 
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Krempski et al. reported an immature (CD11c+CD8α-Gr-1lo/intCD11b+) subset of DCs 
that expressed both PD-1 and PD-L1, which infiltrated tumours in the ID8 ovarian 
model (Krempski et al., 2011). These cells inhibited T cell proliferation and 
functioned through PD-1 in a contact-dependent manner. T cell function was 
restored and tumour burden reduced upon treatment with anti-PD-1 blocking 
antibody. Krempski et al. also showed for the first time that the engagement of PD-1 
caused the suppression of NF-κB activation, which regulates cytokine production 
(Krempski et al., 2011). Consequently a large increase in release of pro-tumour 
immune regulatory cytokines, such as IL-6, IL-10, and G-CSF was observed 
(Krempski et al., 2011). Similar cytokine release profiles were also reported in other 
ovarian cancer studies (Maine et al., 2014). IL-10 also induced upregulation of PD-
L1 in the cancer microenvironment (Maine et al., 2014).  
PD-L1 may also function as a prognostic marker in ovarian cancer. Hamanishi et al. 
reported that the 5-year survival rate of patients with high expression of PD-L1 was 
significantly lower than that with low expression (Hamanishi et al., 2007). In addition, 
PD-L1 expression in the ovarian cancer microenvironment inversely correlated with 
intraepithelial infiltrating CD8 positive T cells, a known immunological prognostic 
indicator (Hamanishi et al., 2007). The authors suggested that PD‐L1 expression 
inhibited the intra-tumour migration of CD8 T cells and concluded that PD-L1 was an 
independent poor prognostic factor for both overall and progression-free survival 
(Hamanishi et al., 2007). A second investigation on prognostic biomarkers by 
Hamanishi et al. included other immunological markers such as cyclooxygenase 
(COX)-1, COX-2, TGF-β1, CD1α, CD4, CD8, CD57, forkhead box (FOX)- P3 and 
PD-1, on top of PD-L1 and PD-L2.  
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Among the markers studied, PD-L1 expression had the closest correlation to 
unfavorable prognosis (Hamanishi et al., 2011). Both studies by Hamanishi et al. 
were, however, performed on a small cohort (n=70) of patients (Hamanishi et al., 
2011, Hamanishi et al., 2007). In addition, a study by Maine et al. showed that there 
was a strikingly higher PD-L1 expression on monocytes from blood and ascites of 
ovarian cancer patients compared to patients with benign or borderline disease (94). 
PD-L2 expression on the other hand did not correlate with patient prognosis 
(Hamanishi et al., 2007). 
These data suggest that PD-L1 plays an important role in the clinical course of 
ovarian cancer by affecting the local immune microenvironment. The PD-1/PD-L1 
interaction could therefore be a potential therapeutic target.  
 
1.7 Immunotherapy of ovarian cancer 
 
1.7.1 Blocking antibodies targeting co-inhibitory molecules  
Blocking antibodies targeting co-inhibitory molecules, especially CTLA-4 and PD-1, 
have been widely investigated for tumour immunotherapy and have resulted in the 
reduction of tumour burden in various mouse models and clinical trials (Duraiswamy 
et al., 2014, Hodi et al., 2008, Kandalaft et al., 2011, Dong et al., 2002, Krempski et 
al., 2011, Topalian, Hodi, et al., 2012, Topalian et al., 2014). The anti CTLA-4 
blocking antibody, Ipilimumab (MDX-CTLA-4; Yervoy), was the first blocking 
antibody targeting co-inhibitory molecules to receive U.S. Food and Drug 
Administration (FDA) approval for the treatment of late stage melanoma in 2011 
(Sharma et al., 2011, Hodi et al., 2010). Although less than 15% of late stage 
melanoma patients responded to Ipilimumab therapy, it paved the way and gave new 
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promise for immune co-inhibitory molecule blockade therapy for cancer patients 
(Hodi et al., 2010).  
Promising results from pre-clinical trials targeting the PD-1/PD-L1 pathway led to the 
clinical development of many anti-PD-1 and anti-PD-L1 blocking antibodies (Table 
1.3) (Mullard, 2013, Shin and Ribas, 2015). Among them, Pembrolizumab (formerly 
known as MK-3475 and lambrolizumab) received FDA approval for treatment of 
melanoma in September 2014 and Nivolumab (MDX1106, BMS936558, BMS-ONO) 
received FDA approval for treatment of melanoma and non-small cell lung cancer in 
December 2014 (Research, 2015). Pembrolizumab is a humanized monoclonal IgG4 
antibody against PD-1. It has been studied widely for the treatment of melanoma and 
has shown unprecedented sustained tumour regression in 38% of patients in a 
phase 1 study evaluating the safety and clinical activity of the drug (Hamid et al., 
2013, Robert et al., 2014). Nivolumab is a fully humanized IgG4 monoclonal PD-1 
antibody. Nivolumab was first investigated in a phase I clinical trial for the treatment 
of classic immunogenic tumour types of melanoma and renal cell carcinoma as well 
as non-immunogenic tumour types namely colorectal cancer (CRC), castrate-
resistant prostate cancer and NSCLC (Brahmer et al., 2010). Interestingly, 
Nivolumab also showed anti-tumour efficacy in non–small-cell lung cancer which has 
been considered to be non-immunogenic and poorly responsive to immune-based 
therapies (Holt et al., 2011). The drug was well tolerated and resulted in responses 
in both immunogenic and non-immunogenic tumours, with durable and persistent 
responses even after drug discontinuation (Brahmer et al., 2010, Topalian et al., 
2014). Importantly, 71% of patients with advanced melanoma showed and 
maintained objective responses to the drug (Topalian et al., 2014). In addition, 
treatment of relapsed or refractory Hodgkin’s Lymphoma with Nivolumab resulted in 
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an objective response in 87% of patients, including 17% with a complete response 
and 70% with a partial response; the remaining 13% of patients had stable disease 
(Ansell et al., 2014). Response rates to PD-1/PD-L1 blocking antibody treatments 
may be predicted by PD-L1 expression on tumour or tumour-infiltrating immune cells 
(Topalian, Hodi, et al., 2012, Brahmer et al., 2010, Taube et al., 2014, Herbst et al., 
2014). 
Although ipilimumab and anti-PD-L1 antibodies have not been compared head to 
head, some studies have shown that blocking antibodies targeting the PD-1/PD-L1 
pathway resulted in higher therapeutic efficacy and lower immunotoxicity than 
antibodies targeting CTLA-4 (Ott et al., 2013). This is consistent with the more 
severe immune toxicity seen in CTLA-4 knockout mice, as compared with the 
relatively mild phenotypes of PD-1 knockout mice (Phan et al., 2003, Tivol et al., 
1995, Nishimura, Nose, et al., 1999, Dong et al., 2004, Keir et al., 2006). One of the 
reasons for this effect is that CTLA-4 and PD-1 control different stages of immune 
activation and signal through completely different pathways (Parry et al., 2005). 
CTLA-4 predominantly regulates early stage T cell activation in lymphatic tissue, 
when DCs and other APCs prime the T cells (Karman et al., 2012, Topalian, Drake, 
et al., 2012, Ribas, 2012). On the other hand, PD-1 controls the effector phase of T 
cell activation in peripheral tissue (Carreno and Collins, 2002, Greenwald et al., 
2005, Keir et al., 2008).  
In ovarian cancer, Ipilimumab was tested in a phase I/II trial which involved 11 stage 
IV ovarian cancer patients. Significant anti-tumour effects were observed in 1 out of 
11 patients (9%) who showed tumour shrinkage accompanied by increased antibody 
responses to NY-ESO-1, a tumour specific antigen (Hodi et al., 2008, Hodi et al., 
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2003). However, grade 3 inflammatory toxicities also occurred in 2 out of 11 (18%) 
patients (Hodi et al., 2008, Hodi et al., 2003).  
Blocking antibodies targeting the PD-1/PD-L1 pathway were also tested for 
immunotherapy of ovarian cancer in the ID8 ovarian cancer mouse model and in 
clinical trials. The i.p. injection of either PD-1 or PD-L1 blocking antibodies into the 
ID8-VEGF mouse model caused tumour rejection in 25% and 37.5% of mice 
respectively (Duraiswamy et al., 2014). This was accompanied by increased TIL 
proliferation and granzyme B production and decreased number of Treg cells 
(Duraiswamy et al., 2014). Synergistic anti-tumour effects were observed when PD-1 
or PD-L1 blocking antibodies were administered in combination with anti CTLA-4 
blocking antibody in subcutaneous solid tumour models of CT26 colon carcinoma, 
and ID8-VEGF ovarian carcinoma (Duraiswamy et al., 2014). In addition, synergistic 
anti-tumour activity was observed when anti-PD-1 antibody was used in combination 
with vaccination (GVAX or FVAX vaccination which consists of irradiated ID8 cells 
expressing granulocyte macrophage colony-stimulating factor or FLT3 ligand 
respectively) in the ID8 mouse model (Duraiswamy et al., 2013). A fully human, IgG4 
monoclonal anti-PD-L1 antibody, BMS-936559, developed by Bristol-Myers Squibb, 
was tested in a phase I clinical trial involving 207 patients with selected advanced 
cancers non–small-cell lung cancer, melanoma, colorectal cancer, renal-cell cancer, 
pancreatic cancer, gastric cancer, breast cancer and ovarian cancer). Among the 17 
ovarian cancer patients included in the trial, 1 (6%) showed a partial response to the 
drug and 3 (18%) had stable disease lasting at least 24 weeks (Brahmer et al., 
2012). BMS-936559 also showed durable tumour regression (objective response 
rate of 6 to 17%) and prolonged stabilization of disease (rates of 12 to 41%) in 
NSCLC, melanoma, and renal cell cancer patients with advanced cancers (Brahmer 
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et al., 2012). Grade 3 or 4 drug-related adverse events were noted in 19 of 207 (9%) 
patients.  
 
Table 1.3. PD-1 and PD-L1 blockade agents in clinical development. 
Target Agent Class Reference 
PD-1 
 
Nivolumab (MDX1106,  
BMS936558, BMS-ONO) 
 
IgG4 fully human antibody 
 
(Brahmer et al., 2010) 
(Ansell et al., 2014) 
(Taube et al., 2014) 
(Topalian et al., 2014) 
 
Pembrolizumab (MK3475M, 
lambrolizumab, Merck) 
IgG4 engineered 
humanized antibody 
(Hamid et al., 2013) 
(Robert et al., 2014) 
(Tumeh et al., 2014) 
Pidilizumab (CT-011, Cure 
Tech) 
IgG1 humanized antibody (Berger et al., 2008) 
 
AMP-224 (Amplimmune-GSK) 
 
Fc-PD-L2 fusion protein 
 
N.A. 
 
AMP-514 (MEDI0680, 
Amplimmune) 
 
Monoclonal antibody 
 
N.A. 
 
AUNP-12 (Pierre Fabre, 
Aurigene) 
 
Branched 29-amino acid 
peptide 
 
N.A. 
PD-L1 
 
BMS-935559 (MDX-1105, 
BMS-ONO) 
 
IgG4 fully human antibody 
 
N.A. 
 
BMS-936559 (BMY) 
 
IgG4 fully human antibody 
 
(Brahmer et al., 2012) 
 
MPDL3280A (Genentech) 
 
IgG1 engineered 
humanized antibody 
 
(Herbst et al., 2014) 
 
 
MEDI4736 (MedImmune, AZ) 
 
IgG1 engineered 
humanized antibody 
 
(Segal et al., 2014) 
(Lutzky et al., 2014) 
 
MSB0010718C (Merck-
Serono) 
 
IgG1 antibody 
 
N.A. 
N.A.: not available; IgG: immunoglobulin G; Fc:  fraction crystallisable; PD-1: 
programmed cell death-1; PD-L1/2: PD-1: programmed cell death- ligand 1/2 
 
1.7.2 Adoptive T cell therapy  
The presence of large numbers of functional tumour-reactive T cells, which home to 
the cancer, are essential for effective cancer immunotherapy. Adoptive T cell 
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therapy, involving the ex vivo expansion and adoptive transfer of tumour reactive 
autologous TILs back into the patient, have shown promising clinical responses in 
ovarian cancer patients (Kandalaft et al., 2011, Aoki et al., 1991, Fujita et al., 1995). 
In pilot clinical trials, stage III ovarian cancer patients, who received adoptive transfer 
of ex vivo expanded TILs, had a higher 3-year disease free survival rate of 82.1% 
compared to 54.5% for patients who did not receive adoptive TIL therapy (Aoki et al., 
1991, Fujita et al., 1995). However not all patients are eligible for TIL adoptive 
therapy because their tumours either yield no tumour-reactive TILs or are 
unresectable (Kandalaft et al., 2011). To overcome this problem, T cells can be 
genetically engineered to either express a cloned TCR, with high affinity to tumour-
associated epitopes, or a chimeric antigen receptor (CAR), a recombinant receptor 
targeting cancer antigens, for the redirection of T cell specificity (Figure 1.7) 
(Kandalaft et al., 2011).  
CARs are recombinant receptors consisting of targeting moieties attached in series 
to hinge, transmembrane and activating intracellular domains (Sadelain, 2009). 
CARs therefore provide both cell surface antigen-binding and T cell activating 
functions in a single molecule (Sadelain et al., 2009). In contrast to the physiologic 
TCR, which display HLA restriction, CARs bind molecules which do not require 
peptide processing or HLA expression. They are therefore HLA independent and are 
broadly applicable to HLA-diverse patient populations. In this respect, CARs are also 
able to target tumour cells which have down regulated proteasomal antigen 
processing or HLA expression, two processes which contribute to tumour escape 
from TCR-mediated immunity (Zhou and Levitsky, 2012). Furthermore, as any cell 
surface molecule can be recognised by CARs, tolerance to self-antigens, which limit 
the scope of T cell reactivity, can be overcome. In addition, CARs are not only able 
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to bind proteins but also glycolipid structures and carbohydrates and therefore have 
an expanded range of potential targets (Sadelain et al., 2013).  For the purpose of 
this thesis, adoptive T cell therapy using CAR engineered T cells will be discussed. 
The first generation of CARs had signalling domains derived from a single molecule 
between CD3-ζ or Fc receptor-γ (FcR-γ) with CD4, CD8, CD16, or CD25 (Figure 
1.8). The triggering of these molecules was able to initiate tyrosine kinase and 
phosphatidylinositol pathways to promote gene transcription and cellular responses 
against cancer cells (Irving and Weiss, 1991, Romeo and Seed, 1991, Letourneur 
and Klausner, 1991, Romeo et al., 1992). However, the strength of signal provided 
by first generation CARs was insufficient for T cells to elicit a robust cytokine 
response and limited therapeutic responses were reported (Hwu et al., 1995, 
Kershaw et al., 2006, Gong et al., 1999).  
The second generation of CARs consist of both activating domains as well as co-
stimulatory signalling domains (e.g. CD28, 4-1BB, DAP10, OX40, or ICOS) in a 
tripartite fusion receptor (Figure 1.8) (Sadelain et al., 2013). The additional co-
stimulatory domains conferred greater signalling strength and persistence to the T 
cells, resulting in their overall greater potency (Maher et al., 2002). Savoldo et al. 
showed that T cells transduced with a CD28/CD3ζ CAR had greater persistence in 
patients compared to transduction with the CD3ζ-only CAR (Savoldo et al., 2011). 
The third generation of CARs encompasses an activation domain and two co-
stimulatory domains combined the cytoplasmic domain (Figure 1.8) (Sadelain et al., 
2013). Dual co-signalling domains have been shown to confer greater anti-tumour 
potency to tumour antigen-targeted T cells in some mouse models (Carpenito et al., 
2009, Zhong et al., 2010, Tammana et al., 2010, Wang, Jensen, et al., 2007). The 
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first clinical study of a CD20-specific CD28/4-1BB/CD3ζ CAR, however, did not show 
dramatically improved responses (Till et al., 2012). More investigation is needed for 
a better understanding of optimal CAR signalling for the promotion of sustained T 
cell survival and function. Still little is known about optimal CAR design- rules for 
epitope selection, CAR length, protrusion from T cell membrane and affinity of CARs 
are not well defined and more study is needed (Sadelain et al., 2013). 
To date, the most impressive clinical responses (up to 60-85%) have been obtained 
in the treatment of blood cancers using CAR T cells targeting CD19, which is 
expressed on various lymphomas and leukemias of B-cell origin (Riviere et al., 2013, 
Grupp et al., 2013, Kochenderfer et al., 2013). However, the application of CAR T 
cells to treat solid malignancies has been limited. Reasons for this include the lack of 
CAR T cell tumour infiltration, persistence of the T cells and the immune-suppressive 
environment of the solid tumour (Gilham et al., 2012). 
In ovarian cancer, several tumour associated antigens such as mesothelin (Beatty et 
al., 2014, Lanitis et al., 2012), FRα (Song et al., 2011, Kershaw et al., 2006), NKG2D 
ligands (Song et al., 2013) and proteins of the ErbB2 family (Parente-Pereira et al., 
2013, Davies et al., 2012), have been identified and incorporated as targets for CAR 
T cells. The adoptive transfer of CAR T cells, targeting the FRα, has been reported in 
a phase I clinical trial involving 14 ovarian cancer patients (Kershaw et al., 2006). 
Although the study demonstrated therapeutic safety, no clinical anti-tumour 
responses were reported (Kershaw et al., 2006). This was most likely due to the 
weak signalling of the first generation transgenic CAR, a diluted percentage of T 
cells expressing the CARs as well as the poor persistence of the CAR T cells 
(Kershaw et al., 2006, Kandalaft et al., 2011).  
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To strengthen T cell signalling, a second generation FRα targeting CAR T cell was 
developed. This transduced CAR incorporated an additional CD137 (4-1BB) co-
stimulatory signalling domain (Song et al., 2011). These CAR T cells showed anti-
tumour activity and in vivo persistence in human ovarian cancer xenograft mouse 
models and will be used for future clinical trials in ovarian cancer patients (Song et 
al., 2011, Kandalaft et al., 2012).  
To circumvent the problem of the low percentage of CAR T cells used in adoptive 
transfer, Wilkie et al. developed a strategy to selectively purify CAR T cells using IL-
4, a cytokine that normally exerts a weak mitogenic activity on T cells (Wilkie et al., 
2010). This was done by the co-expression of a chimeric IL-4 cytokine receptor (4αβ) 
and an ErbB2 targeting CAR, named T1E28z (Wilkie et al., 2010, Parente-Pereira et 
al., 2013). These dual CAR-expressing T cells were called T4 cells (Parente-Pereira 
et al., 2013). 4αβ consists of the IL-4 receptor α (IL-4Rα) ectodomain fused to the βc 
subunit, which is used by IL-2 and IL-15 for the transmission of proliferative signals. 
IL-4 would therefore mimic the actions of IL-2, when exposed to 4αβ expressing 
CAR T cells, and cause STAT3/STAT5/ERK phosphorylation and exponential 
proliferation of the T cells. The purity of T4 cells increased from 35% to 55% after 7 
days of culture in IL-4 (Parente-Pereira et al., 2013). Furthermore, T4 cells 
demonstrated tumour regression in a xenograft ovarian cancer mouse model 
(Parente-Pereira et al., 2013). 
The limited success of CAR T cell therapy in ovarian cancer may also be due to the 
heterogeneity of the disease. Ovarian cancer expresses a diverse and varied 
repertoire of cell surface antigens, which vary not only among individuals about also 
within a single patient. Therefore, CAR T cells which target single molecules may be 
inadequate to combat such a disease. To overcome this problem, Urbanska et al. 
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developed a ‘universal’ biotin targeting CAR T cell which targets any antigen that has 
been pre-targeted with specific biotinylated molecules (Urbanska et al., 2012). These 
CAR T cells displayed anti-tumour efficacy in an epithelial cell adhesion molecule 
(EpCAM) expressing ovarian cancer xenograft mouse model which was pre-treated 
with biotinylated-EpCAM antibodies (Urbanska et al., 2012). In this way, CAR T cells 
are not limited to a fixed antigen specificity and can be custom-made for each 
individual. 
Despite the advances of adoptive CAR T cell therapy, the immune-suppressive 
nature of the tumour microenvironment remains a significant obstacle. To overcome 
this problem, adoptive CAR T cell therapy has been used in combination with 
blocking antibodies targeting co-inhibitory pathways such as PD-1 (John et al., 
2013).  
 
 
Figure 1.7. Genetically engineered T cells expressing either (A) CAR or (B) TCR. 
CAR binds to molecules which do not require peptide processing or HLA expression 
whereas the TCR displays HLA restriction. CAR: chimeric antigen receptor; scFV: 
single-chain variable fragment; ER: endoplasmic reticulum; TCR: T cell receptor. 
Reproduced from (Kershaw et al., 2014), open access. 
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Figure 1.8. Different generations of CARs. The first generation of CARs has 
signalling domains derived from a single molecule between CD3-ζ or FcR-γ with 
CD4, CD8, CD16, or CD25. The second generation CAR consists of both activating 
domains as well as co-stimulatory signalling domains (e.g. CD28, 4-1BB, DAP10, 
OX40, or ICOS) in a tripartite fusion receptor. The third generation CAR 
encompasses an activation domain and two co-stimulatory domains combined the 
cytoplasmic domain. CAR: chimeric antigen receptor; scFV: single-chain variable 
fragment; mAb: monoclonal antibody; TM: transmembrane; FcR: fragment 
crystallisable receptor. 
Reproduced from (Sadelain et al., 2013). 
 
1.7.3 Vaccines 
Vaccines have been widely studied for use in ovarian cancer immunotherapy 
(Reinartz et al., 2004, Gulley et al., 2008, Benencia et al., 2008, Diefenbach et al., 
2008, Odunsi et al., 2007). However, they have shown limited efficacy as a 
monotherapy in ovarian cancer patients and need to be used in combination with 
other therapeutic regimens such as chemotherapy or blocking antibodies targeting 
co-inhibitory molecules for improved effectiveness (Odunsi et al., 2014, Duraiswamy 
et al., 2013). One of the reasons for vaccine inefficacy stems from the heterogeneity 
of ovarian cancer which leads to the lack of well characterized rejection antigens 
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(Kandalaft et al., 2011). For example, the bona fide ovarian cancer antigen, NY-
ESO-1,  was shown to be only expressed in fewer than 30% of ovarian cancers, 
highlighting the limitations of a monovalent vaccine (Odunsi et al., 2007). To 
circumvent this problem, autologous tumour lysate, tumour-derived RNA or whole 
tumour antigen vaccines were introduced (Chu et al., 2012, Chianese-Bullock et al., 
2008, Tsuda et al., 2004). These vaccines provided the opportunity to induce 
immunity to a broad range of antigens. In addition, DC based cell vaccines, where 
mature DCs were pulsed with whole autologous tumour lysate, were also used. In a 
phase I clinical trial, three of six subjects treated with the DC vaccine demonstrated a 
longer progression-free survival post-vaccination compared to the interval between 
prior chemotherapy and pre-vaccine recurrence (Hernando et al., 2002). 
However, cancer vaccines are still limited by their inability to elicit a rapid and 
aggressive T cell response, which is needed to reject established tumours. A 
potential solution is to use cancer vaccines in combination with other immune 
modulation therapies. In an ID8 ovarian cancer mouse model, the GVAX or FVAX 
vaccine failed to produce an effective anti-tumour response even though it promoted 
tumour-reactive TIL expansion. The reason for vaccine inefficacy was due to the 
influx of Treg cells and other immune-suppressive cell populations (myeloid derived 
suppressor cells or pDCs), which accompanied anti-tumour TIL proliferation, for the 
maintenance of homeostasis. Tumour rejection only occurred when ID8 mice were 
treated with a combination of vaccine and anti-PD-1 blocking antibody, which served 
to break the homeostatic mechanisms (Duraiswamy et al., 2013).  
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1.8 Gene therapy 
Gene therapy has emerged as a promising treatment strategy for genetic disorders 
including cancer (Scholz and Wagner, 2012). A large majority (96%) of high-grade 
serous ovarian tumours are characterized by TP53 mutations as well as other 
somatic mutations such as breast cancer susceptibility gene 1 (BRCA1) and 2 
(BRCA2), neurofibromatosis Type 1, retinoblastoma 1and cyclin-dependent kinase 
12. As such gene therapy is believed to hold immense potential for the treatment of 
ovarian cancer (Network, 2011). 
The most extensively studied gene therapy approach is the delivery of plasmid DNA 
into specific cells of the patient to replace or correct defective genes (Mulligan, 
1993). In 1998, a discovery by Andrew Fire and Craig Mello opened up the field of 
gene therapy to RNA interference (RNAi), which won them the Nobel Prize in 
Physiology and Medicine in 2006. Fire et al. first discovered that double-stranded 
RNA (dsRNA) could result in sequence-specific gene silencing, which they termed 
RNAi, in nematode worm Caenorhabditis elegans (Fire et al., 1998). The 
phenomenon of RNAi operates in mammals as well (Elbashir et al., 2001). RNAi 
involves the silencing of a target protein, by the use of various RNAi molecules such 
as dsRNA, small interfering RNA (siRNA), short hairpin RNA (shRNA) and micro 
RNA (miRNA) (Elbashir et al., 2001, Hannon, 2002). The previously used dsRNAs, 
composed of over 30 base pairs, are less utilized as they are known to stimulate 
immune responses in mammalian cells. They were therefore replaced by synthetic 
siRNAs, which are double stranded duplexes composed of 21 base pairs (Zamore et 
al., 2000). siRNA has shown promise for specific, post-transcriptional knockdown of 
disease-causing genes and have been used in several clinical trials (Tuschl, 2001, 
70 
 
Davis et al., 2010, Tabernero et al., 2013). Further discoveries with great potential 
include shRNA-induced gene silencing, which is plasmid based (Paddison et al., 
2002, Brummelkamp et al., 2002, Sui et al., 2002). As such, therapeutic nucleic 
acids which differ in chemistry and size have become available. In addition, gene 
editing tools, such as zinc-finger technology, transcription activator like effector 
nuclease (TALEN) and in particular, clustered regularly interspaced palindromic 
repeats (CRISPR)/Cas-9, which allow for site specific changes, have been 
developed. They have potential to serve as powerful tools for the application of gene 
therapy. Specifically, CRISPR/Cas-9 came in as runner up for development of the 
year in 2013, after immunotherapy. The thesis will focus on the use of plasmid DNA 
molecules, shRNA and siRNA for gene therapy applications. 
In order for therapeutic nucleic acids to exert their effects, they must first reach their 
intended site of action. Plasmid DNA molecules and shRNA require nuclear entry, 
while siRNA will need to accumulate within the cytoplasm. However, if administered 
alone, the majority of nucleic acids will be degraded enroute by nucleases within 
minutes (Wiethoff and Middaugh, 2003). In addition, the large sizes of nucleic acids 
prevent them from cellular entry. This necessitates the development of delivery 
systems for the protection and ferrying of nucleic acids to their target site (Luo and 
Saltzman, 2000). Gene delivery vectors can be broadly classified into 2 classes, 
namely viral and non-viral, which will be discussed in sections 1.8.2 and 1.8.3. The 
recently emerging field of RNAi has benefited from the existing expertise in plasmid 
DNA studies. Despite many common mechanistic similarities, differences in nucleic 
acid sizes, particularly between siRNA and plasmid DNA, and location for 
mechanism of action mean that delivery agents face distinct sets of challenges 
depending on cargo type. In order to overcome the barriers for the efficient delivery 
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of nucleic acid to cells, gene carriers need to be carefully designed to tailor to the 
different needs of the various nucleic acid cargo.  
The different classes of gene delivery vectors as well as the hurdles limiting nucleic 
acid delivery and strategies adopted to overcome them will be reviewed, with 
particular attention on plasmid DNA and siRNA delivery. 
 
1.8.1 Gene therapy in cancer- clinical trials 
To date, most of the gene therapy clinical trials have been aimed at the treatment of 
cancer (64.4% of all gene therapy trials) (Ginn et al., 2013). Many different cancers 
including lung, skin, gynaecological, urological, neurological and gastrointestinal 
tumours, as well as paediatric tumours and haematological malignancies have been 
targeted. There are currently three main cancer gene therapy strategies, namely the 
use of oncolytic viruses, suicide-gene therapy and gene-based immunotherapy 
(Freytag et al., 2007).  
Oncolytic viruses are able to infect and multiply selectively within tumours and early 
studies have focused on the use of these viruses for the stimulation of the immune 
system against cancer. Oncolytic viruses were subsequently armed with immune 
stimulatory genes such as IL-12 (Toda et al., 1998) and GM-CSF (Hu et al., 2006, 
Senzer et al., 2009) to augment antitumor immunity. A good example of an oncolytic 
virus used in cancer gene therapy is Talimogene laherparevec (T-VEC), which is 
armed with the GM-CSF gene. In a phase I trial involving 30 patients with various 
tumours (breast, head and neck, gastrointestinal cancer and malignant melanoma), 
the virus was generally well tolerated. In addition, GM-CSF expression, virus 
72 
 
replication and HSV antigen-associated tumour necrosis were observed (Hu et al., 
2006). In a phase II trial, 50 melanoma patients were treated with multiple intra-
tumoural injections of the virus. The overall response rate by Response Evaluation 
Criteria in Solid Tumors (RECIST) was 26%, with complete responses observed in 8 
out of 50 patients (Senzer et al., 2009). Notably, T-VEC has also recently completed 
phase III clinical trials, involving 436 melanoma patients. Patients received either 
intra-tumoural T-VEC injections (295 patients) or subcutaneous administration of 
GM-CSF (141 patients). The overall durable response rate (DRR) was 16.3% for 
patients who received T-VEC treatment, compared with 2.1% among participants 
who were administered GM-CSF. The objective overall response (ORR) rate was 
26.4% among the T-VEC group, which includes 10.8% with a complete response, 
compared with an ORR of 5.7% and a complete response of 0.7% in the group 
receiving GM-CSF (Andtbacka et al., 2013). These promising results have prompted 
phase III trials in head and neck cancer, which is currently ongoing.   
Suicide gene therapy, also known as gene-directed enzyme prodrug therapy or 
prodrug-activation has also been used in clinical trials for the treatment of cancer. It 
involves the delivery of genes that code for enzymes, which metabolize prodrugs into 
locally active anti-tumour agents. Examples of genes tested in clinical trials include 
the herpes simplex thymidine kinase (Hstk) gene, to induce susceptibility of cancer 
cells to anti-viral agents such as ganciclovir (Rainov, 2000), the mammalian 
cytochrome P450 2B (CYP2B) gene (Braybrooke et al., 2005), to increase 
chemosensitivity to ifosfamide and cyclophosphamide, the bacterial cytosine 
deaminase (cd) gene, to induce susceptibility to 5-fluorocytosine (Freytag et al., 
2007). In particular, the use of an adenovirus for Hstk and cd combined transgene 
delivery was well tolerated in a phase I clinical trial, involving 16 prostate cancer 
73 
 
patients (Freytag et al., 2002). In addition, 19% of patients demonstrated an 
objective response (Freytag et al., 2002, Freytag et al., 2007). Another phase I 
clinical study involving the intra-tumoural cd gene transfer followed by treatment with 
CYP2B, showed that treatment was well tolerated in twelve patients (nine with breast 
cancer and three with melanoma). In addition, one patient had a partial response 
and four patients had stable disease (Braybrooke et al., 2005). 
The third strategy is gene-based immunotherapy. This involves the enhancement of 
host immunity responses against tumour cells. One such therapy that has received 
FDA approval, in 2010, for the treatment of recurrent prostate cancer is the use of a 
genetically modified DC named Provenge (Dendreon Corporation, generic name 
sipuleucel-T). Phase III clinical trials showed that prostate cancer patients who had 
received sipuleucel-T had a 22% lower risk of death than patients who received a 
placebo (Kantoff et al., 2010). Other gene-based immunotherapeutic strategies that 
have been used in clinical trials include genetically modified T cells, which has been 
described in section 1.7.2. 
 
1.8.2 Viral gene delivery vectors 
Viral vectors are the most efficient class of gene carriers reported to date. They 
contain a vector DNA, which comprises of a therapeutic gene cassette and non-
coding cis acting elements, which are required for functions such as the packaging of 
vector genome into the viral capsid and integration of vector genome into the host 
chromatin (Thomas et al., 2003). Viral genes encoding for structural and replication 
proteins are separated and introduced as helper DNA which are delivered as 
heterologous plasmids or incorporated into the chromosomal DNA of the packaging 
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cell. The insertion of the packaging domain in the vector DNA, but not the helper 
DNA, ensures that only the vector DNA can be packaged into viral particles. These 
viruses retain the ability to infect cells and introduce genetic load but are replication-
defective (Kay et al., 2001, Thomas et al., 2003). 
The five main classes of clinically applicable viral vectors are derived from 
retroviruses, lentiviruses, adenoviruses, adeno-associated viruses (AAVs) and 
herpes simplex viruses (HSVs) (Kay et al., 2001, Thomas et al., 2003). The genome 
of the vectors may either integrate into host chromatin (retroviral- and lentiviral-
vectors) or persist in the cell nucleus as episomes, which are stable DNA molecules 
that do not integrate into the host’s genome (adenoviral-, AAV- and herpes viral-
vectors). 
Retroviruses are lipid-enveloped particles containing single-stranded RNA. After 
entry into cells, the viral RNA is reverse-transcribed into linear double-stranded DNA 
that is integrated into the host’s chromatin. However, a key limitation of the retroviral 
vectors is their inability to cross the intact nuclear membrane to transduce non-
dividing cells. They may however be useful for the transduction of dividing tumour 
cells and lymphocytes.  
Lentiviruses form part of the retrovirus family. The distinguishing feature and major 
advantage of lentiviruses is their ability to penetrate the intact nuclear membrane to 
efficiently transduce non-dividing cells and integrate their vector genome into the 
host chromatin.  
Adenoviruses contain a double-stranded linear DNA genome. The advantages of 
adenoviral vectors include broad tropism, high transduction efficiency and relative 
ease of large scale production. However, the lack of stable integration of viral 
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genome as well as safety issues remain limitations of the adenoviruses for use as 
transduction agents (Raper et al., 2003).  
AAVs are human parvoviruses which are dependent on extra genes from herpes or 
adenoviruses for replication. The advantages of AAVs include sustained gene 
expression, broad tropism, minimal inflammatory responses and low toxicity. The 
disadvantages of AAVs include difficulties in scaling up production and a limitation in 
the size of the gene that can be delivered (typically < 4.5 kb) (Somia and Verma, 
2000). 
HSVs are linear double-stranded DNA genome. HSV type 1 (HSV-1) is the most 
commonly engineered herpes virus due to the vector’s ability to carry large 
transgenes of size of up to 40 kb (Thomas et al., 2003). An advantage of this viral 
vector is its high transduction efficiency in a wide variety of cell types. The 
disadvantages include difficulties in achieving long-term transgene expression.  
To date, most of the clinical trials in ovarian cancer patients were based on viral 
(adenovirus and retrovirus mediated) delivery of genes such as p53, BRCA1 as well 
as suicide gene therapy, described in section 1.8.1 (Alvarez and Curiel, 1997, Tait et 
al., 1997, Tait et al., 1999). Phase I gene therapy trials involving retroviral mediated 
BRCA1 gene delivery, administered via i.p. injection, showed that the treatment was 
well tolerated by a cohort of 12 ovarian cancer patients (Tait et al., 1997). In a 
subsequent phase II clinical trial, however, patients showed no clinical response, no 
disease stabilization, and no or little vector stability. The trial was terminated after 
treatment of six patients (Tait et al., 1999). It is unfortunate that gene therapy in the 
clinic has faced multiple problems of immunogenicity, vector instability and lack of 
gene transfer efficiency (Tait et al., 1999). These problems, together with the death 
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of 18-year old Jesse Gelsinger due to fatal inflammatory responses to the adenoviral 
vector used in the ornithine transcarbamylase deficiency trial in 1999, casted a 
shadow over the safety of viral vectors (Raper et al., 2003). Retroviral gene vectors 
also led to the subsequent development of leukemia-like disorders in patients due to 
the retroviral insertion near the promoter of a proto-oncogene (Thomas et al., 2003). 
However, despite multiple disappointments in earlier viral-mediated gene therapy 
trials, newly developed viral vectors have shown promising results in pre-clinical 
models. Notably, the use of a lentivirus pseudotyped with Sendai virus envelopes 
(F/HN-SIV) has shown a good safety profile in a mouse model for up to two years. In 
addition, F/HN-SIV-mediated gene delivery led to prolonged gene expression which 
was observed in human differentiated airway cultures and human lung slices 
(Griesenbach et al., 2012, Mitomo et al., 2010).   
  
1.8.3 Non-viral gene delivery vectors 
In 2001, cationic liposomes delivering the adenovirus type 5 early region 1A (E1A) 
gene to repress human epidermal growth factor receptor 2 (HER-2) expression 
showed promising results in a clinical study involving 12 ovarian cancer patients 
(Hortobagyi et al., 2001). However, a major hurdle of non-viral vectors is their low 
gene transfection efficiencies, which have limited their use in clinical trials. 
Gene microarray studies also revealed that delivery materials may themselves 
induce gene expression changes even in the absence of nucleic acid load (Beyerle 
et al., 2010, Merkel, Beyerle, et al., 2011). This can potentially cause toxicity 
problems and other off-target effects, some of which will be discussed in this section.  
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1.8.3.1 Cationic liposomes 
Cationic liposomes are the most extensively investigated non-viral vectors for gene 
delivery. They typically consist of a positively charged head group linked to a 
hydrophobic lipid domain (Zhu and Mahato, 2010). Common hydrophilic head groups 
include amino acids, amidinium, pyridinium, guadinium salts, monoamines (tertiary 
or quaternary amines) or polyamines (Heyes et al., 2002). The main function of the 
cationic head group is to electrostatically bind and condense negatively charged 
DNA to form positively charged nanoparticles, called lipoplexes (Balazs and Godbey, 
2011). This allows for enhanced cellular uptake as well as, in the case of multivalent 
head groups such as 2,3-dioleyloxy-N-[2(sperminecarboxamido)ethyl]-N,N-dimethyl-
l-propanaminium trifluoroacetate (DOSPA) and di-octadecyl-amido-glycyl-spermine 
(DOGS), endosomal escape of the lipoplexes (Balazs and Godbey, 2011, Zhu and 
Mahato, 2010). The hydrophobic domain usually comprises of aliphatic fatty acid 
chains or steroids such as cholesterol. The degree of unsaturation, alkyl chain 
length, and configuration of the hydrophobic chain(s) have been shown to influence 
gene transfection. In general, cationic lipids bearing two linear fatty acid chains 
results in higher gene transfection efficiency and are also less toxic. Increased gene 
transfection has also been observed with a higher degree of unsaturation in the alkyl 
chains of cationic lipids, presumably due to an enhancement in membrane 
fusogenicity and fluidity (Balazs and Godbey, 2011, Zhu and Mahato, 2010). 
However, the effect of alkyl chain length on gene transfection efficiency is less 
straightforward and is found to vary with the accompanying cationic head group (Zhu 
and Mahato, 2010). The most common linker groups are carbamate, ether, ester and 
amide. The chemical stability and biodegradability of the chosen linker groups exert 
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a profound impact on the overall stability, toxicity and transfection efficiency of the 
lipoplexes.  
In addition to the nature and structure of the difference components of the cationic 
liposome, numerous other factors such as the stoichiometric ratio of DNA to 
liposome and method of preparation of lipoplexes also influence the gene 
transfection efficiency and toxicity (Simoes et al., 2005).  
 
1.8.3.2 Cationic polymers 
Just like cationic lipids, cationic polymers compact nucleic acids into positively 
charged nanoparticles, conferring nucleic acid protection from nuclease degradation, 
prolonged blood circulation time, enhanced tissue accumulation and improved 
cellular uptake (Luo and Saltzman, 2000, Pack et al., 2005). Examples of cationic 
polymers include poly-L-lysine (PLL), polycarbonates and poly(ethylenimine) (PEI).  
Poly-L-lysine (PLL) is among one of the earliest cationic polymers to be studied for 
gene delivery (Wagner et al., 1998). Although PLLs are able to bind DNA, their 
applications in gene delivery are limited by high cytotoxicity, low transfection 
efficiency and poor stability, especially when used alone without modifications 
(Jeong et al., 2007, Pack et al., 2005, Park et al., 2006, Wagner et al., 1998). The 
inherently low transfection efficiencies of PLLs is mainly due to the protonation of all 
the primary ε-amine groups in the lysine residues at physiological pH. They are thus 
unavailable to buffer the acidic endosomal environment and are unable to mediate 
DNA escape into the cytosol and cell nucleus (Wagner et al., 1998).  Co-incubation 
of cells with PLL/DNA polyplexes and fusogenic peptides or the weak base 
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chloroquine has been found to improve gene transfection. However, the innate 
cellular toxicity of these endosomolytic agents restricts their use in vivo (Wagner et 
al., 1998). Chemical conjugation of the ε-amine groups of PLL with endosomal 
escape moieties such as imidazole groups (Putnam et al., 2001) or histidine (Midoux 
and Monsigny, 1999) has been reported to improve gene transfection. In addition, 
the conjugation of PLL with targeting ligands has also been shown to reduce 
toxicities and enhance gene transfection efficiencies (Liu et al., 2011). To improve 
the stability of PLL/DNA polyplexes, researchers have also conjugated hydrophilic 
moieties, such as poly(ethylene glycol) (PEG), to PLL (Katayose and Kataoka, 1997, 
Katayose and Kataoka, 1998, Harada-Shiba et al., 2002). Although early studies with 
PLL were promising, low transfection efficiencies and poor biodegradability have 
restricted their applications (Pack et al., 2005). 
Poly(carbonates) are a relatively new class of biodegradable material used for 
therapeutic delivery of genes. They are attractive biomaterials because they can be 
degraded via hydrolysis and enzymatic degradation thus producing less toxic acidic 
end products (Albertsson and Eklund, 1995, Suyama and Tokiwa, 1997). Advances 
in metal-free organo-catalytic living ring-opening polymerization of cyclic carbonate 
monomers, in particular, has provided an efﬁcient and cost-effective means to 
synthesize carbonate-based polymers for gene delivery applications (Yang et al., 
2011, Nederberg et al., 2007). The well controlled reaction allows for the possibility 
to synthesize designed molecules to a high accuracy (Nederberg et al., 2007). 
Poly(carbonates) which have been used for gene delivery include amine-
functionalized polycarbonates, in a diblock or triblock copolymer structure (Yang et 
al., 2011, Ong et al., 2011), PEGylated poly(dimethylaminoethyl methacrylate) based 
cationic polymers (Venkataraman, Ong, Ong, Joachim Loo, Rachel Ee, et al., 2011) 
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and triamine end-functionalized poly(trimethylene carbonate) (Mindemark and 
Bowden, 2010). 
PEI was first introduced by Boussif et al. as a gene delivery vector in 1995 (Boussif 
et al., 1995). Since then, PEI has been widely regarded as a superior gene 
transfection agent in a variety of transformed cell lines, primary cells, and animal 
models (Boussif et al., 1995, Gebhart and Kabanov, 2001, Abdallah et al., 1996). 
PEI comes in two main structural forms- branched and linear. Commercially 
available branched PEI (bPEI) contains primary, secondary and tertiary amines at an 
approximate ratio of 1:2:1, while linear PEI (LPEI) only contains secondary amines in 
its backbone (except for the terminal groups) (von Harpe et al., 2000). An LPEI 
derivative is commercially available as jetPEI®. 
The high gene transfection efficiency of PEI has been widely attributed to its large 
buffering capacity, enabling PEI to function as an extremely efficient ‘proton sponge’ 
(Pack et al., 2005, Behr, 1997). The ‘proton sponge’ hypothesis remains the most 
generally accepted mechanism of PEI/DNA escape from the endosomal/lysosomal 
pathway, into cell cytoplasm. They hypothesis is associated with the high density of 
secondary and tertiary amines present in PEI, many of which remain unprotonated at 
physiological and endosomal pH thus aiding in endosomal buffering. After 
endocytosis of PEI/DNA polyplexes, the protonation of amines in PEI results in the 
ATPase mediated active transport of protons and accompanying chloride ions and 
water, in a process to maintain the acidic pH of the endosome. This leads to 
increased osmotic pressure, which consequently results in endosomal swelling, 
rupture, and the release of the PEI/DNA polyplexes into the cytosol, hence escaping 
the lysosomal degradation pathway (Behr, 1997). PEI/DNA polyplexes may also 
81 
 
escape the endosome through pores which form as a result of swelling, without 
endosomal rupturing (Bieber et al., 2002). In addition, it was observed that the free 
fraction of PEI, i.e. excess PEI that is not involved in DNA binding, could be a key 
factor in PEI/DNA polyplex escape from the endosomes (Benjaminsen et al., 2013). 
This was true regardless of when the free PEI was added to the co-incubation of 
PEI/DNA polyplexes with cells (Kircheis et al., 2001). However, the ‘proton sponge’ 
hypothesis continues to be debated (Funhoff et al., 2004). Some groups have 
attempted to prove or disprove the hypothesis by measuring endosomal or 
lysosomal pH as a function of PEI concentration (Benjaminsen et al., 2013, Godbey 
et al., 2000). Nevertheless, the mechanism of PEI/DNA polyplex escape from the 
endosomal pathway after internalization remains elusive. 
Among the various PEI molecular weights and structures, bPEI (molecular weight = 
25 kDa, Mn = 10 kDa) and LPEI (molecular weight = 22 or 25 kDa) have emerged as 
more suitable candidates for gene transfection (Godbey et al., 1999, Gebhart and 
Kabanov, 2001, Choosakoonkriang et al., 2003, Intra and Salem, 2008, Wightman et 
al., 2001).  As such, they are usually used as the benchmark for the evaluation and 
investigation of new non-viral vectors for gene delivery applications. However, a 
major drawback to widespread clinical use of PEI, is the in vitro and in vivo toxicity 
(Zhu and Mahato, 2010). Higher molecular weight PEIs induces greater cytotoxicity 
than their low molecular weight counterparts, presumably due to their higher charge 
densities (Fischer et al., 1999, Kleemann et al., 2009, Wightman et al., 2001). High 
molecular weight PEI, but not low molecular weight PEI, aggregated on the outer 
surface of the plasma membrane, leading to necrosis (Fischer et al., 1999). 
PEI/nucleic acid polyplexes also have a propensity to non-specifically interact with 
blood components and this may lead to the premature clearance by cells of the 
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mononuclear phagocyte system before it can reach target cells (Ogris et al., 1999). 
Furthermore, the non-biodegradability of PEI is also a major obstacle for in vivo 
applications due to the limited renal clearance, which increases the likelihood of 
accumulation in the body to induce long-term toxicity. A higher degree of branching 
has also been found to increase the haemolytic properties and cytotoxicity of PEI-
based polymers as such, LPEI has been shown to have substantially lower toxicity 
than bPEI (Fischer et al., 2002). In addition, PEI polymer, without any nucleic acid 
load, has been shown to alter the expression of several genes involved in apoptosis 
and inflammatory signalling (Merkel, Beyerle, et al., 2011). To date, extensive 
modifications to reduce cytotoxicity, increase specificity of cellular uptake and 
increase stability have been made to branched and linear structures of PEI for 
various gene delivery applications (reviewed in (Kichler, 2004, Neu et al., 2005)). 
Notably, a LPEI derivative, in the form of commercially available jetPEI® has been 
used in phase I/II clinical trials in bladder cancer (Sidi et al., 2008) and phase I 
clinical trials in pancreatic cancer (Buscail et al., 2015). The clinical results showed 
that the gene therapy had a favourable safety profile, with 22% of bladder cancer 
patients having complete responses and 41% of pancreatic cancer patients showing 
stable disease (Buscail et al., 2015, Sidi et al., 2008). 
 
1.8.4 Plasmid DNA design 
Apart from delivery carriers, the design of plasmid DNA also plays a role in 
determining gene transfection efficiency. For a gene to be expressed, it needs to 
enter the nucleus of the cell. Nuclear transport of plasmid DNA has been shown to 
be a sequence-specific process, mediated by specific eukaryotic sequence elements 
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present on the plasmid DNA (Miller and Dean, 2009). For example, the insertion of a 
SV40 DNA nuclear targeting sequence (DTS) has been shown to mediate plasmid 
nuclear import in all cells and cell lines tested. Plasmid DNA without SV40 DTS 
remained in the cell cytoplasmic until cell division occurred (Miller and Dean, 2009). 
Moreover, cell specific DNA promoters have also been discovered. The transcription 
of genes may therefore be controlled based on the presence of unique sets of 
transcription factors present in particular cell types. For instance, the inclusion of the 
smooth muscle g-actin (SMGA) promoter only allows nuclear import of plasmid DNA 
in airway or vascular smooth muscle cells but not in other cell types (Miller and 
Dean, 2008).  
 
1.8.5 Barriers limiting nucleic acid delivery and strategies adopted to overcome 
them  
It is important to understand the stages of successful nucleic acid delivery (Figure 
1.9) for a more effective approach to the modular design of non-viral vectors with 
good biocompatibilities and high transfection efficiencies.  
The major barriers to nucleic acid delivery have been identified to be (1) nucleic acid 
packaging, (2) stability of carrier/nucleic acid polyplexes in the bloodstream and 
extracellular matrix, (3) cellular uptake, (4) intracellular trafficking, (5) nucleic acid 
unpackaging, and (6) biocompatibility. Due to the immense amount of information 
available for different classes of nucleic acid delivery vectors, the focus of this 
section will be on the strategies employed in polymeric nucleic acid delivery systems 
for overcoming the various barriers of plasmid DNA and siRNA delivery. For the 
purposes of this thesis, ‘gene’ may refer to plasmid DNA or siRNA. 
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Figure 1.9. The stages of non-viral vector mediated nucleic acid delivery into the 
cell. (Stage I): Nucleic acid packaging by non-viral vectors via electrostatic 
interactions to form non-viral vector/nucleic acid polyplexes. (Stage II): Cellular 
uptake of polyplexes via various endocytotic pathways. (Stage III): Endosomal 
release of polyplexes into the cytosol. If polyplexes are not able to escape the 
endosome, they will be degraded in the lysosomes. (Stage IV): Unpackaging of 
nucleic acid and non-viral vector. (Stage V): Nuclear entry of nucleic acids (plasmid 
DNA). (Stage VI): Transcription and translation of nucleic acids into proteins of 
interest.  
Adapted from (Wong, Pelet, et al., 2007) 
 
1.8.5.1 Nucleic acid packaging 
Nucleic acid packaging is the essential first step to bind and condense (in the case of 
plasmid DNA) genetic material into particles, also known as polyplexes, of 
appropriate charge and size. This serves to protect nucleic acids from nuclease 
degradation and enable them to traverse cellular membranes. The three main 
strategies used for nucleic acid packaging include: electrostatic interactions, non-
Nucleic 
acid
Non-viral vector
Non-viral vector/
nucleic acid polyplex
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electrostatic interactions and encapsulation (Park et al., 2006, Wong, Pelet, et al., 
2007, Wiethoff and Middaugh, 2003). 
Electrostatic interactions between polyanionic plasmid DNA or siRNA and 
polycationic vectors are entropically driven and remain as the most dominant form of 
nonviral vector/nucleic acid interactions reported. The majority of cationic polymer 
systems incorporate primary, secondary, tertiary and/or quaternary amines which are 
protonated to different degrees at physiological pH. An optimal N/P ratio (where N is 
the number of polymeric nitrogen atoms and P the number of nucleic acid 
phosphorus atoms) is essential for efficient nucleic acid condensation and nucleic 
acid release to achieve successful gene transfection (Pack et al., 2005, Wiethoff and 
Middaugh, 2003). However, an excessive cationic charge has also been associated 
with high cytotoxicity and hemolysis (Dobrovolskaia et al., 2008). To circumvent 
problems relating to charge associated cytotoxicity, researchers have introduced 
alternative gene packaging methods using neutral polymers such as 
lipopolythioureas (Leblond et al., 2007) or polyvinyl pyrolidone (Park et al., 2006) 
which may interact with nucleic acid via van der Waals interactions and/or hydrogen 
bonding. Nucleic acid encapsulation is the packaging of nucleic acid within a 
liposomal matrix or a biodegradable polymeric scaffold (Wong, Pelet, et al., 2007). 
These materials protect the nucleic acids from the extracellular environment and 
mediate controlled and/or sustained release of the genetic material (Park et al., 
2006).  
However, due to the many significant physicochemical variations between plasmid 
DNA and siRNA, chief among which is size, there remains distinct differences in the 
binding mechanisms of the nucleic acids (Bruno, 2011). Plasmid DNA has a size of 
several thousand base pairs, while siRNA has only roughly 21 to 23 base pairs 
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(Scholz and Wagner, 2012). Moreover, siRNA is also more rigid than plasmid DNA, 
due to its shorter length (Biswas and Torchilin, 2013, Hagerman, 1988). 
Consequently siRNA interacts less efficiently with cationic polymers, compared to 
plasmid DNA and this may lead to incomplete binding and the formation of 
undesirably large polyplexes (Merkel et al., 2010, Gary et al., 2007). To overcome 
this problem, researchers have increased the charge density of various polymeric 
systems, by micelle formation (Mok et al., 2010) or amine group incorporation 
(Eichman et al., 2000), to improve the binding efficiency of siRNA. Chemical 
crosslinking of siRNA strands directly to polymeric carriers has also been shown to 
be an effective strategy to incorporate siRNA onto delivery systems (Lee et al., 2012, 
Lee et al., 2011). Another approach includes increasing the charge density of siRNA 
by cross-linking so that they become more ‘plasmid DNA-like’. This method has been 
shown to improve the stability of polymer siRNA polyplexes (Bolcato-Bellemin et al., 
2007). 
 
1.8.5.2 Stability in the bloodstream and extracellular matrix 
Extracellular stability, pertaining to colloidal stability, is another pertinent issue which 
affects the bioavailability of nucleic acid polyplexes. Generally, polyplexes with a net 
cationic charge are more stable due to the presence of electrostatic repulsions 
between individual particles (Pack et al., 2005). However, the high concentration of 
ions and negatively charged proteins such as serum albumin and glycosaminoglycan 
present in the physiological environment may exert a screening effect to weaken the 
inter-particle electrostatic repulsive forces as well as electrostatic interactions 
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between the cationic vector and DNA. This may eventually lead to the aggregation of 
and/or dissociation of polyplexes over time. 
Other potential problems lie in the non-specific adsorption of serum proteins 
(opsonization) to polyplexes and the activation of serum complements, which will 
predispose DNA/polymer polyplexes to premature clearance by the mononuclear 
phagocyte system. In attempt to improve the serum stability of polyplexes, 
researchers have conjugated PEG moieties (molecular weights 500 to 5000 Da) to 
cationic polymers in a process termed PEGylation. Attachment of PEG functional 
groups is the most popular approach to improve the colloidal and serum stability as 
well as reduce the immunogenicity of cationic polyplexes (Lee and Kim, 2005). 
PEGylation allows the formation of a hydrophilic shield which reduces the net 
surface charge of the polyplexes thereby preventing particle aggregation and 
opsonisation. However, PEGylation has also been associated with a reduction of 
polyplex cellular uptake and gene transfection efficiencies (Wang, Ke, et al., 2007). 
PEG has also been shown to activate complement and may induce immune 
responses (Arima et al., 2008). Careful optimization of several variables such as 
PEG chain length and/or molecular architecture (e.g. block or graft) need to be taken 
into consideration for the success of the PEGylation approach (Wang, Ke, et al., 
2007, Venkataraman, Ong, Ong, Joachim Loo, Ee, et al., 2011). Other moieties that 
have been used to improve the colloidal stability of polyplexes include 
poly(vinylpyrrolidone) (PVP), poly(methyl acrylate) and sugars (e.g. glucose 
galactose and mannose) (Pack et al., 2005, Jeong et al., 2007, Park et al., 2006). 
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1.8.5.3 Cellular uptake 
Nanoparticles interacting with the exterior of a cell plasma membrane may trigger a 
cell internalization process termed ‘endocytosis’ (Sahay, Alakhova, et al., 2010). 
Endocytosis is a multi-stage process. It involves the engulfment of nanoparticles in 
membrane invaginations which are subsequently pinched off to form membrane-
bound vesicles (known as endosomes) and the intracellular delivery of material into 
different cellular components (Sahay, Alakhova, et al., 2010). Endocytosis is broadly 
classified into phagocytosis and pinocytosis of which the latter is further catergorized 
into clathrin dependent endocytosis (also known as clathrin-mediated endocytosis 
(CME)) and clathrin independent endocytosis (Conner and Schmid, 2003). The 
clathrin-independent pathways are sub-classified into 1) caveolae-mediated 
endocytosis, 2) clathrin- and caveolae-independent endocytosis and 3) 
macropinocytosis. Clathrin- and caveolae-independent pathways are further 
classified as Arf6-dependent, flotillin-dependent, Cdc42-dependent and RhoA-
dependent endocytosis (Mayor and Pagano, 2007). The route of entry of polymeric 
nanoparticles is hugely dependent on material composition surface chemistry 
(Rejman et al., 2005, von Gersdorff et al., 2006), charge (Fröhlich, 2012), size 
(Rejman et al., 2004), geometry (Agarwal et al., 2013) and cell type (von Gersdorff et 
al., 2006). 
In general, polyplexes are recognized to be primarily internalized via CME and/or 
caveolae-dependent endocytic mechanisms (Rejman et al., 2005, von Gersdorff et 
al., 2006). Mechanistically, CME involves engulfment of receptors (e.g. low density 
lipoprotein or transferrin receptors) when they are associated with their ligands, in a 
coated pit. Alternatively, internalization events may be triggered by receptor 
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independent CME, which involves nonspecific ionic or hydrophobic interactions with 
the plasma membrane (Bareford and Swaan, 2007). The formation of the coated pit 
is due to the polymerization of a cytosolic protein named clathrin-1, together with 
other assembly proteins such as AP180 and AP-2. A small GTPase, dynamin then 
pinches off the assembled vesicle from the plasma membrane (Pucadyil and 
Schmid, 2009). Once in the cell, the vesicles fuse with the early endosomes and are 
subsequently sorted to late endosomes/lysosomes, to trans-Golgi network or to the 
recycling endosomes to be transported back to plasma membrane (Rappoport, 
2008). Examples of nanoparticles which have shown preferential cellular uptake 
include poly(ethylene glycol)-polylactide (PEG-co-PLA) nanoparticles, poly(lactic-co-
glycolic acid) (PLGA) nanoparticles, silica-based nanomaterials and chitosan 
nanoparticles (Sahay, Alakhova, et al., 2010). The caveolae-dependent endocytic 
pathway involves the membrane protein, caveolin-1, which is necessary for 
biogenesis of caveolae. The location of caveolae are in the lipid rafts, which are 
cholesterol-rich plasma membrane regions involved in endocytosis and signal 
transduction (Simons and Toomre, 2000). After pinching off from the plasma 
membrane, the caveolae vesicles fuse with caveosomes or multi-vascular bodies 
which have a neutral pH (Parton and Simons, 2007). Notably, nanomaterials which 
enter the cell via the caveolae-dependent endocytic pathway are able to bypass 
lysosomes and avoid degradation, although there are certain exceptions (Carver and 
Schnitzer, 2003, Rejman et al., 2006). Moreover, the caveolae-mediated endocytosis 
pathway usually leads to the trans-vascular delivery of nanomaterials within the cell 
(Oh et al., 2007). This pathway may therefore be beneficial for cellular delivery of 
proteins and nucleic acids (Rejman et al., 2006). In this regard, researchers have 
attached ligands to nanoparticle surfaces which target individual pathways. Such 
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ligands may include cyclic RGD peptides (Oba et al., 2008) and antibodies against 
aminopeptidase P (APP) (Oh et al., 2007) to promote cellular entry via the caveolae-
dependent pathway. In addition, self-assembly of nanomaterials compared to its free 
chains may also affect pathway of cellular entry. Sahay et al. found that Pluronic® 
P85 (P85), an amphiphilic triblock copolymer of poly(ethylene oxide) (PEO) and 
poly(propylene oxide) (PPO), entered cells via the caveolae-dependent endocytic 
pathway when in free polymer form. However, when self-assembled to form micelles, 
the particles entered cells predominantly via CME (Sahay et al., 2008). 
The nanoparticle charge is an important factor in cellular uptake mechanisms. 
Particles which are positively charged have been shown to be preferentially 
internalized by various cell types as compared to neutral or negatively charged 
nanomaterials (Gratton et al., 2008). This may be due to electrostatic interactions 
between cationic polyplexes and anionic proteoglycans of the cell membrane which 
promote cellular uptake (Rejman et al., 2005). The majority of reports suggests that 
cationic particles primarily enter cells via CME (Sahay, Alakhova, et al., 2010, 
Harush-Frenkel et al., 2008). However, there are some exceptions, most notably, 
cationic PEI based polyplexes, have been shown to utilize multiple pathways 
including caveolae-mediated endocytosis (Rejman et al., 2005, Akinc et al., 2005, 
von Gersdorff et al., 2006). Some anionic particles have also been reported to be 
internalized by cells. Examples include core-cross-linked polymeric micelles (cl-
micelles) of poly(ethylene oxide)-b-poly(methacrylic acid) (PEO-b-PMA) copolymer 
and DOXIL® (a PEGylated liposome), which enter cells predominately through 
caveolae-mediated endocytosis (Harush-Frenkel et al., 2008, Sahay, Kim, et al., 
2010). 
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As most diseases involve specific cell types, targeted delivery and uptake of 
polyplexes is also necessary to augment therapeutic effects and limit dose 
dependent cytotoxicities and side effects. Targeting ligands are frequently 
conjugated to polymeric nucleic acid delivery systems to confer polyplex interaction 
with particular cell surface receptors that are solely expressed or overexpressed on 
certain cell populations (Gu et al., 2007, Pack et al., 2005, Pathak et al., 2009). 
Commonly used targeting ligands utilized for nucleic acid delivery include 
endogenous ligands (Lam et al., 2009), carbohydrates (Kunath et al., 2003), 
antibodies (Chiu et al., 2004) and peptides (Blessing et al., 2001). For the successful 
application of targeting approaches, various factors such as degree of ligand 
conjugation, conjugation chemistry, ligand-receptor affinity, ligand density per 
polyplex and spacer length between ligand and cationic segments have to be 
carefully considered and optimized (Pack et al., 2005). 
 
1.8.5.4 Endosomal escape and intracellular trafficking 
The primary mode of polyplex internalization has been shown to be via clathrin- 
and/or caveolae-dependent endocytic mechanisms (Rejman et al., 2005, von 
Gersdorff et al., 2006). Polyplexes internalized by clathrin mediated endocytosis are 
enveloped into vesicles which may fuse with early endosomes. Endosomes are 
acidified compartments where the pH has been shown to fall from ~ pH 6 to 5 as the 
endosome progresses from early to late stage. Late endosomes may then fuse with 
lysosomes, where enzymatic degradation of the polyplexes occurs (Khalil et al., 
2006, Rejman et al., 2005). Polyplexes will need to escape the endosomes so that 
the nucleic acid cargo can be transported to the site of action. As mentioned 
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previously, the sites of action for plasmid DNA and siRNA are at the nucleus and the 
cytoplasm respectively. Many researchers have leveraged on the rapid decrease of 
endosomal pH and incorporated pH sensitive moieties into polymer design to aid in 
endosomal escape. Such moieties include protonable amines (e.g. primary, 
secondary, tertiary amines, imidazole groups (Midoux and Monsigny, 1999)), 
fusogenic domains (e.g. lytic peptides like HA2 subunit of the influenza hemaglutinin 
(Plank et al., 1994), neutral lipids like 1,2-Dioleoyl-sn-glycero-3-
phosphoethanolamine (DOPE) (Pichon et al., 2010)) and alkylated carboxylic acid 
groups (Cheung et al., 2001). Notably, timing for endosomal escape is also crucial. 
For plasmid DNA, a later endosomal escape, after microtubule-mediated transport of 
the endosome to the perinuclear region, may be desirable (Bausinger et al., 2006). 
Plasmid DNA polyplexes which escape too early maybe hindered from reaching the 
nucleus by the cellular cytoskeleton, which impedes the migration of DNA which are 
larger than 500 base pairs (Lukacs et al., 2000, Dauty and Verkman, 2005). On the 
other hand, an early release of siRNA ployplexes is favourable to allow high amounts 
of siRNA to be released to the cytosol where they can interact with RNA-induced 
silencing complex (RISC) for mRNA degradation (Scholz and Wagner, 2012). 
After the escape of polyplexes from the endosomal compartment, plasmid DNA 
polyplexes still need to be trafficked to the nucleus. Passive nuclear uptake of DNA 
may take place during cell division in proliferating cells. As such, the transfection 
efficiency of polyplexes has been shown to be dependent on the cell cycle. Higher 
levels of gene expression were observed when the transfection was performed 
shortly before the mitotic phase (i.e. S and G2 phases) (Mannisto et al., 2005, 
Brunner et al., 2000). One of the reasons for this finding is due to the transient 
breakdown in nuclear membrane during cell division therefore allowing DNA or 
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polyplexes to gain entry into the nucleus. On the other hand, the exact mechanism of 
active nucleic acid transport through the cytoplasm and into the nucleus of non-
dividing cells remains unclear. Suh et al. suggested that bPEI/DNA polyplexes in 
endosomes may be transported by motor protein driven machinery along 
microtubules through the cytoplasm towards the nucleus (Suh et al., 2003). The 
transport of DNA along microtubules, via the retrograde motor dynein and other 
cytosolic proteins, to localize in the nucleus has also been reported by other groups 
(Vaughan and Dean, 2006). However, as mentioned above, the dense network of 
actin cytoskeleton also hinders the cytosolic transport of DNA (Dauty and Verkman, 
2005). Once at the perinuclear region, plasmid DNA, which are larger than 9 nm, will 
need to enter the nucleus, by active transport, through the nuclear pore complex. 
Efforts to enhance nuclear localization of uncomplexed DNA or in polyplex form 
include conjugation of nuclear localization signals (NLS) such as TAT and SV40, 
which are peptide sequences borrowed from viruses, to polymers or by electrostatic 
complexation with DNA (De Laporte et al., 2006, Martin and Rice, 2007, Branden et 
al., 1999). These NLS bind to cytosolic import proteins which enable the active 
transport of the modified polyplexes or DNA through the nuclear pore and have 
shown to effectively improve transfection efficiencies (Allen et al., 2000, Branden et 
al., 1999). However, Zanta et al. suggested that the attachment of more than one 
NLS might instead impede plasmid DNA entry into the nucleus. DNA molecules may 
span the length of the nuclear pore and having two NLS may cause the DNA to be 
pulled into the nucleus simultaneously through two pores thus hindering the entry 
process.  
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1.8.5.5 Nucleic acid unpackaging 
An optimal balance between nucleic acid binding and release from polyplexes is 
crucial for successful gene tranfection. Although the exact mechanism of nucleic acid 
unpackaging remains unclear, the competitive displacement of nucleic acids by 
anionic membrane lipids, cytosolic or nuclear proteins and/or genomic DNA has 
been proposed as the main method for the intracellular release of nucleic acids from 
polyplexes (Jeong et al., 2007, Pack et al., 2005, Wong, Pelet, et al., 2007). 
Therefore, over-stabilized polyplexes may hinder effective gene transfection. To 
improve nucleic acid release from polyplexes in a time- and location-specific manner, 
many biodegradable or stimuli-responsive polymers have been designed (Grigsby 
and Leong, 2010). One example is the incorporation of glutathione-sensitive disulfide 
bonds, which cleave in the presence of glutathione containing cytosol, enabling the 
breakdown of the polyplex and aiding in the release of the nucleic acid cargo (Li, 
Cheng, et al., 2014, Takae et al., 2008).  
 
1.8.5.6 Biocompatibility 
Another important prerequisite for the successful clinical application of nucleic acid 
delivery vectors is good biocompatibility. High cytotoxicities as well as complement 
activation by conventional synthetic cationic polymers, such as PLL and PEI, pose 
substantial problems for clinical applications of polymeric vectors (Hunter, 2006, 
Merkel, Urbanics, et al., 2011). Complement activation initiates a biochemical 
cascade that results in the clearance of foreign particles by phagocytes. It also 
causes an alteration of cellular immunity by enhancing DCs and T cell activation as 
well as heightened B-cell responses (Dobrovolskaia et al., 2008). Delivery of nucleic 
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acids using cationic polymers may therefore pose life-threatening hypersensitivity 
reactions. 
Efforts to overcome problems of cytotoxicity, hemolysis and immune activation 
include the conjugation of hydrophilic moieties (PEG, carbohydrates and PVP) as 
well as hydrophobic functional groups to polymeric vectors (Liu, Nguyen, et al., 2009, 
Merkel, Urbanics, et al., 2011, Thomas and Klibanov, 2002, Yang et al., 2013). 
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Chapter 2  
Hypothesis and aims 
 
The hypothesis of this work was that ovarian cancer may be made more 
immunogenic by delivering nucleic acids (siRNA or shRNA) to knockdown PD-L1 
protein expression specifically on cancer cells. The goal of this work is therefore to 
enhance immunotherapy of ovarian cancer by developing more efficient and less 
toxic PEI-based nucleic acid transfecting agents which can be used to knockdown 
PD-L1 specifically on cancer cells (Figure 2.1). In addition, a secondary goal of this 
work was to establish an acoustic detection assay for the quantification of sPD-L1 as 
a potential biomarker for ovarian cancer diagnosis. The work is divided into five 
sections with several specific aims listed: 
To improve the transfection efficiency of PEI-1.8 by hydrophobic group conjugation 
and to investigate how the structure of conjugated hydrophobic groups influence the 
properties of modified PEI-1.8. This will be discussed in chapter 4. 
To reduce the toxicity of PEI-10 by hydrophobic group conjugation. This will be 
discussed in chapter 5. 
To increase targeting and specificity of PEI-10 to ovarian cancer cells by conjugation 
of FA and PEG moieties on PEI-10. This will be discussed in chapter 6. 
To improve CAR-expressing T cell mediated immunotherapy of ovarian cancer by 
PD-L1 knockdown in cancer cells using FA and PEG modified PEI-10. This will be 
discussed in chapter 6 and 7. 
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To establish an acoustic detection assay for the quantification of sPD-L1 as a 
potential biomarker for ovarian cancer diagnosis. This will be discussed in chapter 8. 
 
 
 
Figure 2.1. Increasing the immunogenicity of ovarian cancer by delivering nucleic 
acids (siRNA or shRNA) using PEI-based carriers to knockdown PD-L1 protein 
expression on cancer cells. PD-L1: programmed cell death- ligand 1; PD-1: 
programmed cell death receptor-1; PEG: polyethylene glycol. 
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Chapter 3  
Materials and methods 
 
3.1 Materials 
Branched PEI with Mn of 1.8 kDa (PEI-1.8) and branched PEI with Mn of 10 kDa 
(PEI-10) were obtained from Sigma-Aldrich, Gillingham, UK and were freeze dried 
before use. All other reagents used in the synthesis were bought from Sigma and 
used as received. 3-(4,5-Dimethyl-2-thiazolyl)-2,5-diphenyl tetrazolium bromide 
(MTT) was purchased from Merck, and used as received. Bicinchoninic acid (BCA) 
protein assay reagent was obtained from Pierce, USA. Hoechst 33342, propidium 
iodide, SYBR® Safe and YOYO-1 iodide, ultrapure agarose, were purchased from 
Invitrogen, Singapore or Sigma-Aldrich, Gillingham, UK. The human IFN-γ ELISA kit 
was purchased from eBiosciences, Hatfield, UK. SYBR green PCR master mix, 
qPCR primers SuperScript III first-strand cDNA synthesis kit, Dynabeads CD3/CD28 
and ProLong Gold Antifade Mountant, Pierce™ Crosslink Magnetic IP/Co-IP Kit were 
purchased from Life Technologies, Paisley, UK. RNeasy mini kit was purchased from 
Qiagen. Retronectin and Cytokines (IL-2 and IL-4) were purchased from Takara Bio 
Europe, Saint-Germain-en Lye, France and Peprotech, London, UK, respectively. D-
luciferin was purchased from PerkinElmer, Coventry, UK. SKOV-3 and OVCAR-3 
human ovarian cancer and HepG2 human liver carcinoma cell lines were purchased 
from ATCC (USA). The firefly luciferase-expressing SKOV-3-luc-D3 cell line (SKOV- 
3-Luc) was purchased from Caliper (PerkinElmer, Waltham, MA, USA). SKOV-3, 
SKOV-3-Luc, OVCAR-3 and OVCAR-8 cells were cultivated in RPMI-1640 
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supplemented with 10% fetal bovine serum (FBS) and 5% L-glutamine-penicillin-
streptomycin solution (Sigma-Aldrich, Gillingham, U.K). HepG2 cells were cultured in 
minimum essential medium (MEM) supplemented with 10% FBS, 5% non-essential 
amino acids and 5% L-glutamine-penicillin-streptomycin solution (Sigma-Aldrich, 
Gillingham, U.K). 
 
3.2 Monomer synthesis 
 
3.2.1 Synthesis of methyl-carboxytrimethylene carbonate monomers with 
hydrophobic functional groups 
Synthesis of MTC–benzyl (Figure 3.1A): The synthesis of MTC-benzyl was reported 
previously (Pratt et al., 2008). Briefly, 2,2-Bis(methylol)propanoic acid (bis-MPA) (20 
g, 149.1 mmol, MW 134.1) and sodium hydroxide (5.96 g, 149.1 mmol) were 
dissolved in DMSO (100 mL) and reacted overnight at 80 ºC. Benzyl bromide (30.6 
g, 178.9 mmol) was added dropwise the next day and the reaction was cooled to 
room temperature by adding 500 mL of water. After which, the solution was 
extracted with diethyl ether three times and concentrated by rotary evaporation to 
half its volume. This solution was washed with water, sodium bicarbonate and brine 
solutions and dried. MPA-benzyl (10.0 g, 30%) was obtained by recrystallization 
using tetrahydrofuran (THF)/hexane (1:1). Triphosgene (3.18 g, 0.011 mol) was 
dissolved in dry dichloromethane (DCM, 150 mL) and was added dropwise, over 30 
min, to a dry DCM solution of MPA-benzyl (4.76 g, 0.0212 mol, MW 224.3) and 
pyridine (11 mL, 0.127 mol) kept at -75 ºC (dry ice/acetone) in nitrogen atmosphere. 
The reaction was kept chilled for 2 h and after which, allowed to warm up to room 
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temperature. The reaction was then stopped by quenching with saturated aqueous 
NH4Cl (75 mL). The organic layer was then washed three times with 1 M aqueous 
HCl (100 mL) and once with saturated aqueous NaHCO3 (100 mL). It was then dried 
over MgSO4, filtered, evaporated and recrystallized from ethyl acetate to obtain white 
crystals of MTC-benzyl (3.86 g, 72.6%). 1H NMR (400 MHz, CDCl3, 22 ºC): δ 7.38 
(m, 2H, C5H6), 5.24 (s, 2H, -OCH2C5H6) 4.72 (d, 2H, -CH2OCOO), 4.21 (d, 2H, -
CH2OCOO), 4.21 (t, 2H, -OCH2C5H6), 1.36 (s, 3H, -CH3). 
 
Synthesis of MTC–phenylurea (Figure 3.1B): The synthesis of MTC-phenylurea was 
reported previously (Kim et al., 2010). MTC-urea was formed by coupling MTC-OH 
with phenylureaethanol.  
For the preparation of MTC-OH, ethyl acetate (250 mL), MTC-benzyl (24.3 g, 97 
mmol) and palladium on carbon (Pd/C, 10% w/w, 1.6 g) was swirled under H2 (3 
atm) for 24 h. THF (250 mL) was then added and the mixture was filtered through 
THF-wetted Celite. The filtrate was evaporated to obtain MTC-OH as a white solid 
that was used without further purification (15.6 g, 99%). 
For the preparation of phenylureaethanol, ethanolamine (2.96 g, 48.5 mmol) was 
dissolved in dry tetrahydrofuran (THF, 30 mL) and chilled to 0°C (ice bath). 
Phenylisocyanate (5.19 g, 4.74 mL, 43.6 mmol) dissolved in dry THF (30 mL) was 
then added dropwise, over 30 min, to the ethanolamine/THF mixture. The resulting 
mixture was stirred for 16 h at room temperature. After which, THF was evaporated 
and the remaining crude product was recrystallized from ethyl acetate and stirred 
vigorously for an additional 4 h. The recrystallized solids were collected by filtration, 
washed with ethyl acetate and dried until a constant weight was reached, giving a 
yield of 7.0 g (~86%) phenylureaethanol. 1H NMR (400 MHz, DMSO-d6, 22°C):   
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8.59 (s, 1H, PhNH), 7.39 (d, 2H, PhH), 7.21 (t, 2H, PhH), 6.95 (t, 1H, PhH), 6.10 (t, 
1H, PhNHC(O)NH), 4.78 (t, 1H, -OH), 3.43 (q, 2H, -CH2OH), 3.17 (q, 2H, -
NHCH2CH2OH). 
MTC-OH was reacted with oxalyl chloride to form MTC-Cl by standard procedures 
described previously (Kim et al., 2010). MTC-Cl was dissolved in dry DCM (50 mL) 
and was added dropwise to a chilled (0°C) DCM solution (50 mL) containing 
phenylureaethanol (4.10 g, 22.8 mmol) and pyridine (1.81 g, 1.85 mL, 22.8 mmol). 
The reaction was stirred for 30 min after which the solution was allowed to warm up 
to room temperature and stirred for a further 16 h. Purification was then performed 
by column chromatography using silica gel. Ethyl acetate/hexane (1:1) was first used 
as eluent before gradually increasing the polarity and finishing with ethyl acetate. 
The product fractions were collected and the solvent was removed by rotational 
evaporation. The isolated product, MTC-phenylurea, was dried under vacuum until a 
constant weight was reached, yielding 6.0 g of an off white/slight yellow oil which 
crystallized upon standing (80%). 1H NMR (400 MHz, CDCl3, 22°C): δ 7.39 (d, 2H, 
PhH), 7.25 (m, 2H, PhH), 7.02 (t, 1H, PhH), 4.68 (d, 2H, -CH2OCOO), 4.30, (t, 2H, -
COOCH2-), 4.20 (d, 2H, -CH2OCOO), 3.55 (t, 2H, -CH2NHC(O)NHPh), 1.30 (s, 3H, -
CH3). 
 
Synthesis of MTC–ethyl (Figure 3.1C): Bis-MPA (22.1 g, 0.165 mol) and Amberlyst-
15 (6.8 g) were dissolved in ethanol (150 mL) and refluxed overnight. The resins 
were then filtered out and the filtrate was evaporated. DCM (200 mL) was then 
added to the resulting liquid and the mixture was filtered to remove unreacted 
reagent and by-products. After which, the solution was dried over MgSO4 and 
evaporated to obtain ethyl 2,2-bis(methylol)propionate as a clear and colorless liquid 
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(24.3 g, 91%).1H NMR (400 MHz, CDCl3, 22°C):  4.09 (q, 2H, -OCH2CH3), 3.74 (d, 
2H, -CH2OH), 3.57 (d, 2H, -CH2OH), 1.18 (t, 3H, -OCH2CH3), 0.98 (s, 3H, -CH3). 
Triphosgene (11.7 g, 0.039 mol) dissolved in dry DCM (150 mL) was added 
dropwise, over 30 min, to a dry DCM solution (150 mL) of ethyl 2,2-
bis(methylol)propionate (12.6 g, 0.078 mol) and pyridine (39 mL, 0.47 mol) at -75°C 
(dry ice/acetone) in nitrogen atmosphere. The reaction mixture was kept chilled for 2 
h and later allowed to warm up to room temperature. The reaction was stopped by 
quenching with saturated aqueous NH4Cl (75 mL). After which, the organic layer was 
washed three times with 1 M aqueous HCl (100 mL) and once with saturated 
aqueous NaHCO3 (100 mL). It was then dried over MgSO4, filtered and evaporated. 
Finally, the residue was recrystallized from ethyl acetate to give MTC-ethyl as white 
crystals (8.0 g, 55%). 1H NMR (400 MHz, CDCl3, 22°C): δ 4.67 (d, 2H, -CH2OCOO), 
4.25 (q, 2H, -OCH2CH3), 4.19 (d, 2H, -CH2OCOO), 1.30 (s, 3H, -CH3), 1.27 (t, 3H, -
OCH2CH3). 
 
Synthesis of MTC–octyl (Figure 3.1D) and MTC-deodecyl: Bis-MPA (5.00 g, 37 
mmol), bis-(pentafluorophenyl) carbonate (PFC, 31.00g, 78 mmol) and cesium 
fluoride (CsF, 2.5g, 16.4 mmol) were dissolved in THF (70 mL) and stirred for 20 h. 
The solvent was then evaporated under vacuum and the residue was re-dissolved in 
DCM. The solution was allowed to stand for approximately 10 min, during which, the 
pentafluorophenol by-product precipitated and was recovered. The 19F NMR of 
pentafluorophenol showed the characteristic 3 peaks of pentafluorophenol and a 
single peak in the GC-MS with a mass of 184. The filtrate was extracted with sodium 
bicarbonate and water and was dried with MgSO4. The solvent was then evaporated 
under vacuum and the product was recrystallized using an ethyl acetate/hexane 
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mixture (1:1) to obtain MTC-C6F5 as a white crystalline powder. The GC-MS had a 
single peak with mass of 326 g/mol. 1H-NMR (400MHz in CDCl3): δ 4.85 (d, J = 
10.8Hz, 2H, CHaHb), 4.85 (d, J = 10.8Hz, 2H, CHaHb), 1.55 (s, 3H, CCH3).  
MTC-C6F5 (5.5 g, 16.9 mmol, MW 326.2), octanol (2.0 g, 15.4 mmol) and PROTON 
SPONGE (3.29 g, 15.4 mmol) were dissolved in THF (8 mL) and stirred for 12 h. 
After which ammonium acetate in excess was added and reaction was stirred for an 
additional 3 h. Purification was performed by adding the mixture directly to a silica 
gel column. MTC-octyl was then isolated by column chromatography using 
hexane/ethyl acetate as the eluent to yield an oil. MTC-octyl 1H NMR (400 MHz, 
CDCl3, 22°C): δ 4.71 (d, 2H, -CH2OCOO), 4.23 (d, 2H, -CH2OCOO), 4.22 (t, 2H, -
OCH2CH2), 1.68 (t, 2H, -OCH2CH2(CH2)5), 1.36 (s, 3H, - CH3), 1.31 (t, 10H, -
CH2(CH2)5 CH3), 0.90 (t, 3H, - (CH2)5CH3).  
MTC-deodecyl was synthesized in the same way as MTC-octyl but by replacing 
ethanol with dodecanol. MTC-deodecyl 1H NMR (400 MHz, CDCl3, 22°C): δ 4.69 (d, 
2H, -CH2OCOO), 4.23 (d, 2H, -CH2OCOO), 4.21 (t, 2H, -OCH2CH2), 1.68 (t, 2H, -
OCH2CH2(CH2)5), 1.35 (s, 3H, - CH3), 1.28 (t, 10H, -CH2(CH2)5 CH3), 0.90 (t, 3H, - 
(CH2)5CH3). 
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Figure 3.1. Synthesis procedures of MTC monomers with hydrophobic functional 
groups. (A) MTC-benzyl, (B) MTC-phenylurea, (C) MTC-ethyl and (D) MTC-octyl. 
 
(A) 
(B) 
(C) 
(D) 
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3.2.2 Synthesis of methyl-carboxytrimethylene carbonate monomers with 
poly(ethylene glycol) and folic acid functional groups 
Synthesis of MTC–SSPEG (Figure 3.2A): MTC-OCH2CH2CH2SS(2-Py) was first 
synthesized according to the procedure reported previously (Pratt et al., 2008).  
MTC-OCH2CH2CH2SS(2-Py) (0.164 g, 0.5 mmol) was reacted with 
heterobifunctionalized PEG with thiol and hydroxyl end groups (HS-PEG-OH, Mn 
5,000 Da, 0.5 g, 0.1 mmol), by dissolving in acetonitrile (2 mL) followed by addition 
of acetic acid (20 L). The mixture was stirred overnight and dried using the rotary 
evaporator. The residue was then purified on a Sephadex LH-20 column using THF 
as eluent. MTC-SSPEG was obtained as a white solid (0.59 g, 97%). 1H NMR (400 
MHz, CDCl3, 22 C): δ 4.69 (d, 2H, -CH2OCOO-), 4.30 (t, 2H, -COOCH2-), 4.21 (d, 
2H, -CH2OCOO-), 3.63 (s, 455H, H of PEG), 2.96 (t, 2H, -CH2SS-), 2.73 (t, 2H, -
SSCH2CH2C(O)NH-PEG), 2.60 (t, 2H, -SSCH2CH2C(O)NH-PEG), 2.08 (m, 2H, -
CH2CH2SS-), 1.32 (s, 3H, -CH3). 
Synthesis of MTC–SSPEG-FA (Figure 3.2B): FA (87.4 mg, 0.198 mmol) and MTC-
SSPEG (0.33g, 0.066 mmol) were dissolved in dry DMSO (4 mL) and reacted with 
N,N'-dicyclohexylcarbodiimide (DCC, 54.4 mg, 0.264 mmol), which was also 
dissolved in dry DMSO (1 mL), for 48 h. The γ-carboxylic acid has a higher reactivity 
than the α-carboxylic acid and thus should be the main site of activation by DCC/ N-
hydroxysuccinimide esters (NHS) (Wang et al., 1997, Wang et al., 1996). The 
solution was dialyzed against DMSO using a dialysis membrane with molecular cut-
off of 1 kDa (Spectra/Por 7, Spectrum Laboratories Inc.) for 48 h, and then 
precipitated in a mixture of THF and diethyl ether (1:3) and washed three times. 
MTC-SSPEG-FA was obtained as a yellow solid (0.32 g, 93%) by drying under 
vacuum. 1H NMR (400 MHz, DMSO-d6, 22 C): δ 8.64 (d, 1H, H-a), 8.00 (t, 1H, H-e), 
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7.52 (m, 2H, H-b), 6.92 (m, 1H, H-d), 6.61 (m, 2H, H-c), 4.58 (m, 3H, H-g and H-l), 
4.55 (m, 2H, H-f), 4.37 (d, 2H, H-l), 4.21 (t, 2H, H-n), 3.20 (m, 2H, H-p), 2.88 (t, 2H, 
H-q), 2.78 (t, 2H, H-r), 2.33 (m, 1H, H-j), 1.60-2.00 (m, 4H, H-k and H-o), 1.18 (s, 3H, 
-CH3) (Figure 6.1). 
 
 
Figure 3.2. Synthesis procedures of MTC monomers with PEG and FA functional 
groups. (A) MTC-SSPEG and (B) MTC-SSPEG-FA. 
 
 
3.3 Modification of poly(ethylenimine) 
The modification procedure of PEI, regardless of molecular weight (PEI-1.8, Mn 1.8 
kDa or PEI-10, Mn 10 kDa), with MTC monomers is similar and has been published 
during the course of this Ph.D. (Teo et al., 2013, Yang et al., 2013, Teo et al., 2015).  
 
 
 
(A) MTC-SSPEG 
(B) MTC-SSPEG-FA 
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3.3.1 Modification of poly(ethylenimine), Mn = 1.8 kDa 
The synthesis of MTC-benzyl modified PEI-1.8, PEI-benzyl(1), is described here as a 
typical example of the modification steps of PEI-1.8. In a glove box, MTC-benzyl 
(0.0375 g, 0.15 mmol) was added dropwise to a solution of PEI-1.8 (0.270 g, 0.15 
mmol based on 1 mole = 1800 g = Mn) dissolved in DCM (2 mL). The molar feed 
ratio of PEI-1.8: MTC-benzyl was 1:1 (Figure 4.1). The reaction was stirred for 1 h at 
room temperature. After which, the polymers were purified by precipitation in 
anhydrous ether and dried by rotary evaporation. PEI-1.8 were modified with MTC-
ethyl, MTC-deodecyl, MTC-phenylurea and MTC-benzyl under the same reaction 
conditions. For the synthesis of PEI1.8-ethyl(2), PEI1.8-ethyl(4) and PEI1.8-
ethyl(10), the PEI-1.8:MTC-ethyl molar feed ratio was changed to 1:2, 1:4 and 1:10 
respectively and 1H-NMR are shown in Figure 4.2.  
PEI1.8-benzyl(1),  1H-NMR (400MHz, MeOD, 22 C): δ 7.36 (m, 5.5H, PhH), 5.18 (s, 
2.2H, -CH2Ph), 4.23 (m, 2.2H, -CH2OCOO-), 3.69 (m, 2.2H, -CH2OCOO-), 2.47-2.87 
(br, m, 167H, H of PEI-1.8), 1.22 (m, 3.3H,–CH3) (Figure 4.1B). 
PEI1.8-octyl(1),  1H-NMR (400MHz, MeOD, 22 C): δ 4.10 (d, 4H, H of -CH2OCOO- 
and –COOCH2-), 3.65 (m, 2H, -CH2OCOO-), 2.50-2.90 (br, m, 167H, H of PEI-1.8), 
0.89-1.65 (m, 18H, H of –(CH2)6CH3 and –CH3) (Figure 4.1C).  
PEI1.8-dodecyl(1),  1H-NMR (400MHz, MeOD, 22 C): δ 4.10 (d, 3.6H, H of -
CH2OCOO- and –COOCH2-), 3.65 (m, 1.8H, -CH2OCOO-), 2.62-2.90 (br, m, 167H, 
H of PEI-1.8), 0.89-1.65 (m, 26H, H of –(CH2)10CH3 and –CH3) ) (Figure 4.1D).  
PEI1.8-phenylurea(1),  1H-NMR (400MHz, MeOD, 22 C): δ 7.34 (d, 1.8H, PhH), 
7.24 (t, 1.8H, PhH), 6.97 (t, 0.9H, PhH), 4.19 (m, 3.6H, H of -CH2OCOO- and –
COOCH2-), 3.66 (m, 3.6H, H of -CH2OCOO- and –CH2NH(C(O)NHPh), 2.43-2.95 
(br, m, 167H, H of PEI-1.8), 1.19 (m, 2.7H,–CH3) (Figure 4.1E).  
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PEI1.8-ethyl(1),  1H-NMR (400MHz, MeOD, 22 C): δ 4.16 (m, 4.8H, H of -
CH2OCOO- and –COOCH2-), 3.65 (m, 2.4H, -CH2OCOO-), 2.62-2.88 (br, m, 167H, 
H of PEI-1.8), 0.89-1.65 (m, 8H, H of –CH2CH3 and -CH3). NMR data of PEI-
ethyl(2), (4) and (10) were similar to those of PEI-ethyl(1) (Figure 4.2). 
 
3.3.2 Modification of poly(ethylenimine), Mn = 10 kDa 
 
Synthesis of PEI10-benzyl(25), PEI10-phenylurea(3) and PEI10-ethyl(3) follows the 
same procedure as the modification of PEI-1.8 with MTC monomers described in 
section 3.3.1 (Figure 5.1A). 
PEI10-ethyl(25), PEI10-ethyl(25), 1H-NMR (400MHz, MeOD, 22 °C): δ 4.16 (m, 
114.7H, H of -OCH2CH3 and -CH2OCOO), 3.64 (t, 71.4H, -CH2OCOO), 2.50-2.82 (br, 
m, 930H, H of PEI-10), 1.25 (s, 176.4H, -CH3) ) (Figure 5.1B). 
PEI10-phenylurea(3), 1H-NMR (400MHz, MeOD, 22 °C): δ 7.38 (d, 6.5H, PhH), 7.27 
(t, 6.8H, PhH), 7.00 (t, 3.4H, PhH), 4.23 (m, 12.9H, H of -CH2OCOO- and -
COOCH2), 2.69-3.04 (br, m, 930H, H of PEI-10), 1.21 (m, 24.1H,–CH3)  
(Figure 5.1C). 
PEI10-benzyl(3), 1H-NMR (400MHz, MeOD, 22 °C): δ 7.36 (d, 16.8H, PhH), 5.18 (t, 
6.3H, -CH
2
Ph), 7.00 (t, 3.1H, PhH), 4.23 (m, 6.3H, -CH
2
OCOO-), 2.64-2.76 (br, m, 
930H, H of PEI-10), 1.24 (m, 12.2H,–CH
3
) (Figure 5.1D). 
 
Synthesis of PEI10-PEG(1) and PEI10-PEG-FA(1) (Figure 6.1): A DCM solution (2 
mL) of either MTC-SSPEG (76.0 mg, 0.2 mmol) or MTC-SSPEG-FA (163.9 mg, 0.2 
mmol) was added dropwise to a solution of PEI-10 (2g, 0.2 mmol based on 1 mol = 
10 000g = Mn), dissolved in dry DCM (4 mL) and left to react for 2 h at room 
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temperature. The polymers were purified by dialysis against DMSO and then water 
over 3 days. Water was removed by freeze drying.  
PEI10-PEG(1), 1H NMR (400 MHz, MeOD, 22 C): δ 3.62 (s, 455H, H of PEG), 2.58-
2.83 (m, br, 930H, H of PEI-10) (Figure 6.1C). 
PEI10-PEG-FA(1), 1H NMR (400 MHz, D2O, 22 C): δ 8.57 (s, 1H, H-a), 7.63 (d, 2H, 
H-b), 6.78 (d, 2H, H-c), 3.63 (s, 500H, H of PEG), 2.63 (m, 930H, H of PEI-10) 
(Figure 6.1B). 
 
Synthesis of PEI10-FA(1): Sulfo-NHS (173.7 mg, 0.8 mmol) and 1-ethyl-3-(-3-
dimethylaminopropyl) carbodiimide hydrochloride (EDC) (153.4 mg, 0.8 mmol) were 
dissolved in 2-(N-morpholino)ethanesulfonic acid (MES, pH 6.0) buffer (1 mL) and 
reacted with FA (176.6 mg, 0.4mmol) which was dissolved in MES buffer (pH 6.0, 3 
mL). The reaction was stirred at 55 °C for 2 h, filtered and added dropwise to a 
solution of PEI-10 (2g, 0.2 mmol) dissolved in MES buffer (3 mL). The reaction was 
allowed to cool to room temperature and stirred for a further 2 h. After which, PEI10-
FA(1) was purified by ultracentrifugation (molecular weight cut off 10 kDa) and freeze 
dried. 
PEI10-FA(1), 1H NMR (400 MHz, D2O, 22 C): δ 8.50 (s, 1H, H-a), 7.56 (d, 2H, H-b), 
6.67 (d, 2H, H-c), 2.27-3.93 (m, 930H, H of PEI-10) (Figure 6.1A). 
 
3.4 1H NMR spectroscopy 
1H NMR spectra were recorded on a Bruker Advance 400 NMR spectrometer at 400 
MHz at room temperature. The 1H NMR measurements were carried out with a pulse 
repetition time of 2.0 s, an acquisition time of 3.2 s, a 30° pulse width, 5208-Hz 
spectral width, and 32 K data points. Solvents used include CDCl3, MeOD and 
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DMSO-d6 which have the corresponding chemical shifts δ = 7.26, 3.33 and 2.50 ppm 
respectively. 
 
3.5 Measurement of buffering capacity 
The buffering capacity of modified PEI-1.8 was measured as described previously 
(Zheng et al., 2011). Unmodified or modified PEI (0.1 mmol nitrogen atoms) was first 
dissolved in 150 mmol sodium chloride (NaCl, 5 mL) solution. 0.01 M hydrochloric 
acid (HCl, 15 mL) was added to lower the pH to 2 and the solution was then titrated 
against 0.01 M sodium hydroxide (NaOH) until pH reached 11, using an auto titrator 
(Spectralab Instruments). The corresponding unmodified PEI was used as controls. 
The buffering capacity is defined as the percentage of amine groups which get 
protonated over the pH of 5.1-7.4 and is calculated by the following equation. 
Buffering capacity (%) = 100 x (ΔVNaOH x 0.01 M)/N mol. Where ΔVNaOH is the volume 
of NaOH (0.01 M) which is required to increase the pH from 5.1 to 7.4 and N mol is 
the total number of moles of protonable amines. 
 
3.6 Nucleic acid binding and heparin displacement assay 
Polymer/nucleic acid polyplexes were formed at defined N/P ratios, by gently mixing 
a fixed amount of nucleic acid with varying concentrations of polymer. N/P ratio 
refers to the ratio between the nitrogen content of the polymer and the phosphorus 
content of the nucleic acid. Polymer/nucleic acid polyplexes were formed in RNase 
free water (Qiagen, Manchester, UK) and the mixture was incubated at room 
temperature for 30 min. After which, an equivolume of SYBR® Safe Green dye was 
added. The fluorescence emitted by SYBR® Safe Green dye, when intercalated with 
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free nucleic acid, was measured by a TECAN microplate reader. Nucleic acid 
binding is reported as percentage fluorescence of free nucleic acid control according 
to the following equation. Relative fluorescence(%) = 100 x (Fsample - Fblank)/(Ffree nucleic 
acid - Fblank). Where Fsample is the fluorescence of the polyplex formed at a specific N/P 
ratio, Fblank is the fluorescence of the dye with RNase free water and Ffree nucleic acid is 
the fluorescence of free nucleic acid read at excitation and emission wavelengths of 
502 and 530 nm, respectively.  
The heparin displacement assay was done by adding an equal volume of heparin 
solution (of defined concentrations) to polymer/nucleic acid polyplexes formed at N/P 
30. The mixtures were incubated for 1 h at room temperature before SYBR® Safe 
Green dye was added. The relative fluorescence was calculated as described above. 
 
3.7 Particle size and zeta potential measurements 
Polymer/nucleic acid polyplexes were prepared at varying N/P ratios as described in 
Section 3.6. Samples were then diluted up to 1 mL using RNase free water as 
described in previous publications (Bartlett et al., 2007, Davis et al., 2010). Size and 
zeta potential of the polyplexes were measured by dynamic light scattering (DLS) 
using the Zetasizer Nano (Malvern Instrument Ltd., Worcestershire, UK) equipped 
with a He-Ne laser. Scattered light was detected at an angle of 90º and at a fixed 
temperature of 25 ºC. 3 measurements per sample were recorded for both particle 
size and zeta potential measurements and reported as the mean ± standard 
deviation of 3 readings. 
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3.8 Plasmid DNA and siRNA transfection 
SKOV-3 and SKOV-3-Luc cells were seeded in 24 well plates at 80 000 cells per 
well. HepG2, OVCAR-3 and OVCAR-8 cells were seeded in 24 well plates at 100 
000 cells per well. The cells were allowed to adhere to the plastic for 24 h before 
adding 50 µL of polymer/nucleic acid polyplexes, of various N/P ratios, to each well. 
The final concentration of plasmid DNA was 4.55 µg/mL and the final concentration 
of siRNA used was 200 nM. The cells were incubated with the polymer/nucleic acid 
polyplexes for 4 h, which was shown to be the optimal incubation time (Akinc et al., 
2005, Yue et al., 2011), at 37 ºC. After which, the media containing polymer/nucleic 
acid polyplexes was replaced with fresh media and the cells were grown for a further 
68 h before analysis. Reporter plasmids used were the 6.4 kb firefly luciferase 
(pCMV-luciferase VR1255C) driven by the cytomegalovirus promoter (Carl Wheeler, 
Vival, San Diego, CA, USA). GFP-reporter gene (encoding a red-shifted variant of 
wildtype GFP driven by the cytomegalovirus promoter) was obtained from Clontech 
(USA). Pooled PD-L1 and scrambled siRNA were purchased from Thermo Fisher 
Scientific, St Leon-Rot, Germany and Qiagen, Manchester, UK, respectively. 
 
3.9 In vitro luciferase expression 
Following transfection with the 6.4 kb firefly luciferase DNA, the cell culture medium 
in each well was removed and the cells rinsed once with phosphate-buffered saline 
(PBS) before adding 0.2 mL of reporter lysis buffer, Promega, USA. The cell lysate 
was collected after two cycles of freezing at -80 ºC and thawing. Cell debris was 
removed by centrifugation at 20,800 x g for 5 min at 4 ºC. 20 µL of supernatant was 
mixed with 100 µL of luciferase substrate, Promega, USA, for the determination of 
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relative light units (RLU) using a luminometer (Lumat LB9507, Berthold, Germany). 
The RLU readings were normalized against the protein concentration of the 
supernatant determined using the BCA protein assay to give the overall luciferase 
expression efficiency. Free DNA was used as a negative control. Data is expressed 
as mean ± standard deviation of three replicates from three independent 
experiments.  
 
3.10 Flow cytometry analysis  
Cells were re-suspended in 100 µL of PBS and stained with antibodies for 30 mins at 
4 ºC. They were then washed extensively with PBS before analysis using the flow 
cytometer (FACSCalibur cytometer with CellQuest Pro software, BD Biosciences). 
Antibodies (anti-PD-L1, anti-PD-1, anti-CD107a, anti-EGF, anti-CD4, anti-CD8, anti-
CD3) for flow cytometry analysis were purchased from eBiosciences, Hatfield, UK. 
Matched isotype controls were used for each antibody to determine cell population of 
interest. Flowjo (Treestar, Ashland, OR) software was used for the analysis of flow 
cytometry data. Relative protein expression was expressed as [(MFI PD-L1 siRNA 
treated sample − MFI isotype )/MFI scrambled siRNA treated sample − MFI isotype 
)] × 100%, where MFI represents median fluorescent intensity. Results are 
expressed as mean ± standard error of mean (SEM) of four independent 
experiments. 
 
3.11 Confocal imaging 
For confocal imaging, SKOV-3-Luc cells were seeded on 13 mm diameter glass 
cover slips at a seeding density of 30 000 cells per slide. They were then transfected 
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as described above. For extracellular staining, the cells were fixed with 2% 
paraformaldehyde for 7 min, washed three times with PBS containing 1% FBS and 
stained with antibodies (mouse anti-human PD-L1 primary antibody, eBiosciences, 
Hatfield, UK, diluted 1:100). For intracellular staining, the cells were fixed with 4% 
paraformaldehyde for 20 min, washed three times with PBS containing 1% FBS and 
saponin (final concentration 0.05 mg/mL) and stained with antibodies. After which, 
the steps for extracellular and intracellular staining are the same. The cells were 
washed three times and stained with secondary antibody (Alexa Fluor ® 488 Goat 
anti-mouse secondary antibody, Life Technologies, Paisley, UK, diluted 1:400). The 
cells were washed five times with PBS, mounted on a glass slide using ProLong 
Gold Antifade Mountant, Life Technologies, Paisley, UK, and imaged with the Leica 
TCS SP5 Confocal Laser Scanning Microscope, using the Leica Application Suite 
(LAS) software. 
 
3.12 Western blot 
For western blot, SKOV-3-Luc cells were seeded in 6 well plates at 400 000 cells per 
well and transfected with siRNA as described above. Cells were lysed 3 days post 
transfection using the RIPA lysis buffer (Santa Cruz Biotechnology, Heidelberg, 
Germany) and samples were run through a 12% sodium dodecyl sulfate (SDS) 
polyacrylamide gel. Proteins were transferred at 100 V for 70 min onto a 
nitrocellulose membrane (Life Technologies, Paisley, UK). To determine PD-L1 
expression, the portion of the membrane, containing proteins of molecular weights 
30-70 kDa, was incubated with polyclonal goat anti-PD-L1 antibody (R&D systems, 
Abingdon, UK). The portion of the membrane containing proteins of molecular 
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weights 70 kDa and higher was incubated with polyclonal rabbit anti-calnexin 
antibody (Enzo Life Sciences, Exeter, UK). The membrane was incubated with the 
primary antibodies overnight at 4 ºC. After which, the membrane was washed three 
times with phosphate-buffered saline/ 1% tween (PBST) and incubated for 1 h with 
horseradish peroxidase-conjugated secondary antibodies (Dako, Cambridgeshire, 
UK). To determine Rab27a expression, mouse monoclonal anti-Rab27a antibody 
(Abcam, Cambridge, UK) was used as the primary antibody.  
 
3.13 Real-time quantitative polymerase chain reaction (rt-PCR)  
After transfection, total RNA was extracted, purified and converted to cDNA at 
defined times post transfection using the RNeasy kit and SuperScript III first-strand 
cDNA synthesis kit, according to manufacturer's instructions. qPCR primers (PD-L1: 
sense 5′-TATGGTGGTGCCGACTACAA-3′, antisense 5′- 
TGCTTGTCCAGATGACTTCG-3′; β-Actin: sense 5′-
GCTCGTCGTCGACAACGGCTC-3′, antisense 5′- 
CAAACATGATCTGGGTCATCTTCTC- 3′) PCR was performed using StepOnePlus 
Real-Time PCR System (Applied Biosystems, Paisley, UK) and analysed using the 2 
(-delta delta C(T)) method (Livak and Schmittgen, 2001). Results are expressed as 
mean ± standard error of mean of three independent experiments. 
 
3.14 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay 
The cytotoxicity of the polymers was studied using the standard MTT assay protocol. 
Briefly, HepG2 and SKOV-3 were seeded onto 96-well plates at densities of 10 000 
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or 16 000 cells per well and SKOV-3-Luc and OVCAR-8 cells were seeded at 
densities of 13 000 cells per well. The cells were allowed to adhere to the plastic for 
24 h before adding 10 µL of polymer/nucleic acid polyplexes, of various N/P ratios, to 
each well. The cells were incubated with the polymer/nucleic acid polyplexes for 4 h, 
which is the optimal incubation time (Akinc et al., 2005, Yue et al., 2011), at 37 ºC. 
After which, the media containing polymer/nucleic acid polyplexes was replaced with 
fresh media and the cells were grown for a further 68 h. Subsequently, 100 µL of 
MTT solution (10 µL of 5 mg/mL MTT solution diluted in 100 µL media) were added 
to each well and the cells were incubated for 1 h at 37 ºC. The MTT solution was 
then removed and 100 µL of DMSO was added to dissolve the formazan crystals. 
Absorbance was read using the microplate spectrophotometer (TECAN) at 
wavelengths of 550 nm and 690 nm. Cytotoxicity of the polymers are derived from 
the relative cell viability which was calculated based on the following quation. 
Relative cell viability = 100 x [(A550 - A690)sample/(A550 - A690)control]. Data is 
expressed as mean ± standard deviations of at least eight replicates per N/P ratio 
from two to three independent experiments. 
 
3.15 Studies to determine intracellular fate of plasmid DNA 
Plasmids encoding for luciferase were labelled with YOYO®-1 iodide (Life 
Technologies, Singapore), a dimeric cyanine nucleic acid dye, at a molar ratio of 
300:1 (DNA:dye). The mixture was kept at room temperature for 2.5 h. YOYO®-1 
iodide has been shown to fluorescent when bound to double stranded DNA (Rye et 
al., 1992). SKOV-3 cells were seeded on 24-well plates at a seeding density of 80 
000 cells per well. Polymer/DNA polyplexes were formed at N/P 30. All the 
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polyplexes formed using different polymers contained a fixed amount (2.5 µg) of 
YOYO-1-labeled DNA. 50 µL of polymer/DNA polyplex solution was added to each 
well, and the cells were incubated with the polymer/DNA polyplexes for 4 h, which is 
the optimal incubation time (Akinc et al., 2005, Yue et al., 2011). After which, the 
cells were rinsed once with 1 mL of PBS and incubated with a heparin wash solution 
(100 IU/mL heparin and 75 mmol/L sodium azide in PBS) for 30 min to remove any 
bound extracellular polyplexes (de Bruin et al., 2007). The removal of extracellular 
polymer/DNA polyplexes by the heparin wash solution was confirmed by checking 
under a LSM 510 DUO confocal microscope (Carl Zeiss, USA). The cells were 
trypsinized and washed twice with ice cold PBS before they were re-suspended in in 
PBS, according to ATCC’s protocol. The median fluorescence intensity (MFI) of 
YOYO®-1 iodide, which represent the average amount of DNA that has entered a 
given cell in the population studied, were analysed by flow cytometry (BD LSR II) 
from 10,000 events and reported as mean standard deviation of three individual 
experiments. 
 
3.16 Selective uptake studies of siRNA into SKOV-3-Luc ovarian cancer cells or 
peripheral blood mononuclear cells  
PBMCs were isolated from whole blood, using Ficoll density gradient. The PBMCs 
were added to CFSE labelled SKOV-3-Luc cells in a 1:1 ratio and left on ice. 
Polymer/Alexa Fluor 488 tagged siRNA polyplexes (Qiagen, Manchester, UK) (N/P 
50) were added to the cells and incubated at 37 °C for 30 min. siRNA which was not 
internalized by cells was quenched with trypan blue (20 µg/mL) and cells were 
washed extensively with PBS before analysis by flow cytometry. PBMCs and SKOV-
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3-Luc tumour cell populations were analysed by analysing the CFSE-negative and 
positive populations, respectively. The MFI, which represents the median amount of 
siRNA that has entered a given cell in the population studied, was analysed by 
Flowjo, Treestar. Results represent mean ± standard error of mean of three 
independent experiments. 
 
3.17 Co-immunoprecipitation  
The Pierce™ Crosslink Magnetic IP/Co-IP Kit was purchased from LifeTechnologies, 
Paisley, UK, and used as described in the manual. Polyclonal rabbit anti-PD-L1 
antibody (Sino Biological, Inc., Beijing, China) and mouse anti-Rab27a antibody 
(Santa Cruz, Biotechnology, Heidelberg, Germany) were crosslinked onto the beads 
in the spin columns. Equal volume and concentration of SKOV-3-Luc cell lysate were 
added to the individual columns and incubated overnight at 4 ºC, with end-on-end 
gentle rotation. The crosslinked proteins were eluted and analysed by western blot.  
 
3.18 Primary ovarian cancer cell isolation and culture 
Blood and tumour samples were obtained under approval of the West London 
Research Ethics Committee (reference 08/H0707/188; ovarian cancer patients) and 
South East London Research Ethics Committee 1 (reference 09/H0804/92; healthy 
volunteers). 
Solid tumours were mechanically disaggregated and separated into a single-cell 
suspension using 2 mg/mL Dispase (Sigma-Aldrich, Gillingham, U.K) and pressed 
through a 30 µm cell strainer from Miltenyi Biotec Ltd., Surrey, UK. Tumour cells 
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were isolated from fibroblast cells based on differential adherence time to plastic. 
The mixture of cells was first placed in a flask and left for 30 min at 37 ºC. After this 
period, tumour cells were still in suspension while fibroblast adhered to plastic. 
Tumour cells may also be isolated using CD326 (EpCAM) MicroBeads (Miltenyi 
Biotec Ltd., Surrey, UK). 
Tumor cells were placed in mammary epithelial basal medium (Lonza) containing 5 
mg/ml insulin (Actrapid; Novo Nordisk, Crawley, UK), 20 ng/ml human epidermal 
growth factor (Life Technologies, Paisley, UK), 10 ng/ml basic fibroblast growth 
factor (Life Technologies, Paisley, UK), and 0.4% FBS (Sigma-Aldrich, Gillingham, 
UK) and cultured in Ultra Low Attachment plates (Corning, distributed by Sigma-
Aldrich, Gillingham, UK). 
 
3.19 Culture and retroviral transduction of primary human T cells 
Recombinant DNA Constructs encoding for two chimeric receptors named T1E28z 
and 4αβ were generated. T1E28z consists of the T1E peptide, which is a chimera 
derived from TGF-α and epidermal growth factor (EGF) (Stortelers et al., 2002), 
fused with the CD28 transmembrane and intracellular signalling domain as well as 
the CD3ζ intracellular signalling domain. 4αβ consists of the ectodomain (amino 
acids 1–233)  of the interleukin-4 receptor-α (IL-4Rα) fused to the transmembrane 
and endodomain (amino acids 241–551) of the shared β-chain used by the 
interleukin-2 receptor (IL-2R) and interleukin-15 receptor (IL-15R) (Wilkie et al., 
2010). The 4αβ construct was inserted upstream of the T1E28z construct and 
separated by a furin cleavage site and Thosea asigna (T2A) peptide (Appendix 7.1). 
Gene synthesis was performed by GenScript (Piscataway, NJ). The chimeric cDNA 
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was inserted into the SFG retroviral vector (scFv(G250)-CD4TM-γ retroviral vector) 
and PG13 retroviral packaging cells were used to produce the retrovirus into 
conditioned cell culture medium, as described previously (Parente-Pereira et al., 
2013). 
To generate CAR T cells, written informed consent was obtained from blood donors 
before enrolling them in the study which was approved by the Hammersmith and 
Queen Charlotte Hospital's Research Ethics Committee, mentioned in section 3.18. 
The peripheral blood obtained from healthy volunteers were then retrovirally 
(scFv(G250)-CD4TM-γ retroviral vector) transduced to express chimeric cytokine 
receptors T1E28z and 4αβ in equimolar amounts (Parente-Pereira et al., 2013). 
These CAR T cells were named T4 cells. 
 
3.20 In vitro co-culture studies of tumour and T4 cells 
SKOV-3-Luc cells were seeded and treated with polymer/siRNA polyplexes as 
described earlier in section 3.8. At 72 h post transfection, functional grade mouse 
anti-human PD-L1 antibody (MIH1 clone, eBiosciences, Hatfield, UK) or control 
antibody (50 μg/mL) was added to the tumour cell culture medium and incubated at 
37 °C for 2 h. T4 cells were added to SKOV-3-Luc tumour cells (1:1 ratio) or 
OVCAR-8 cells (1:4) ratio, and incubated for defined time periods. After co-culture, 
T4 cells were isolated from the cell culture medium by centrifugation and analysed 
for CD107a expression by flow cytometry. The conditioned medium was stored at 
−20 °C for IFN-γ analysis. The viability of SKOV-3-Luc cells was analysed by the 
MTT assay. Results for both CD107a expression and cell viability were expressed as 
mean ± standard error of mean of three independent experiments. 
121 
 
3.21 In vivo studies of T4 immunotherapy with siRNA treated ovarian cancer cells 
All in vivo experimentation adhered to current United Kingdom Home Office 
guidelines, as specified in project license 70/7997. SKOV-3-Luc cells were treated 
with scrambled or PD-L1 siRNA ex vivo. One day post transfection, siRNA treated 
SKOV-3-Luc cells (1.5 million cells) were inoculated intraperitoneally (i.p.) into 
severe combined immunodeficiency (SCID) Beige mice. Tumour engraftment was 
confirmed after 5 days by bioluminescence imaging (BLI), which involved the 
administration of D-luciferin (150 mg luciferin/kg body weight), via i.p. injection. Mice 
were imaged under isoflurane anesthesia, 12 min after injection with D-luciferin. 
625,000 T4 cells (200 µL per mouse) were given to the mice via i.p. injection and 
mice administered with PBS served as controls. The mice were imaged daily up to a 
maximum of 4 days post T4 treatment. BLI was performed using an IVIS Spectrum 
Imaging platform (PerkinElmer, Waltham, MA) with Living Image software 
(PerkinElmer). Image acquisition was conducted on a 15- or 25-cm field of view with 
autoexposure and small/medium binning. The animals were inspected daily and 
were culled when experimental endpoints had been achieved or, if symptomatic, as 
a result of tumour growth (whichever sooner). 
 
3.22 Protein analysis by ELISA 
IFN-γ analysis: Conditioned cell culture medium was analysed for human IFN-γ 
using the human IFN-γ ELISA kit (eBiosciences, Hatfield, UK) according to the 
manufacturer's protocol. Results were expressed as mean ± standard error of mean 
of three independent experiments. 
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sPD-L1 analysis: Immuno Maxisorb 96-well plates (Fisher Scientific, Loughborough, 
UK) were coated with rabbit polyclonal anti-human PD-L1 antibody (Sino Biological, 
Inc., Beijing, China), diluted in coating buffer (0.1M sodium carbonate, pH 9.5) to a 
final concentration of 1 µg/mL, overnight at 4 ºC. The plate was washed with wash 
buffer (PBS with 0.05% Tween-20) three times. 200 µL of assay diluent (PBS with 
10% heat inactivated FCS, at pH 7.0) was added as a blocking agent to each well 
and incubated for 1 h at room temperature. Plasma samples obtained from patients 
were centrifuged at 18 400 g, using a table top centrifuge. 100 µL of plasma samples 
or recombinant PD-L1 protein (rPD-L1, Sino Biological, Inc., Beijing, China), used to 
create the standard curve, were added to each well of the plate and incubated at 4 
ºC overnight. The plate was washed five times before 100 µL of PD-L1 detection 
antibody (R&D Systems, Abingdon, UK), at a concentration of 0.1 µg/mL, was added 
to each well and incubated for 2 h at room temperature. After incubation, the plate 
was washed again with wash buffer five times. Streptavidin-HRP complex 
(Biolegend, London, UK) was diluted 1:1000 times in AD and added to the plate and 
was incubated for 2 h at room temperature. The plate was washed seven times and 
50 µL of Tetramethylbenzidine (TMB) substrate (BD Bioscience, Oxford, UK) was 
added to each well and incubated for 30 minutes at room temperature. Following 
this, 50 µl of stop solution (1M phosphoric acid) was added to each well and 
absorbance at 450 nm was measured with reduction at 570 nm using a multi plate 
reader. 
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3.23 Protein analysis by the ViBE Bioanalyzer, Bioscale 
Preparation of bead conjugated antibodies: 20 µg of antibody was reacted with 1 mg 
of beads in anhydrous DMF for 1 h at room temperature. Unconjugated antibody was 
washed off using PBST (repeat steps 5 times) while beads were placed on a 
DynaMag™ magnet. 
Preparation of fluorescein tagged antibodies (Fl-Ab): Three times molar excess of 
antibodies were reacted with fluorescein in anhydrous DMF for 2 h at room 
temperature. Fl-Ab were purified using Zeba spin columns (Life Technologies, 
Paisley, UK) according to the manufacturer’s protocol. 
96-well plate set up for the simultaneous addition of bead-conjugated antibody and 
Fl-Ab to rPD-L1 or plasma samples: 40 µL of each component (bead-conjugated 
antibody, Fl-Ab, recombinant protein/plasma) were added per well of a standard 
round-bottom 96-well plate. The plate was placed on a shaker for 4 h before the 
components were passed over the sensor membrane. 
96-well plate set up for the sequencial addition of Fl-Ab to a mixture of bead-
conjugated antibodies and rPD-L1 or plasma samples: 40 µL of bead-conjugated 
antibodies were added to 40 µL of recombinant protein/plasma samples per well of a 
standard round-bottom 96-well plate. The plate was placed on a shaker for 2 h 
before 40 µL of Fl-Ab was added per well. The plate was placed on a shaker for a 
further 2 h before the components were passed over the sensor membrane. 
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3.24 Statistical analysis 
All data were analysed for normality using the Shapiro-Wilk and the Kolmogorov-
Smirnov tests. These tests are based on a null hypothesis that the data are normally 
distributed. Failure to reject null hypothesis occurred when the probability obtained 
was >0.05. All statistical analyses were carried out using the Prism GraphPad 5 
(GraphPad, La Jolla, USA) software, using either the one-way ANOVA or the 
unpaired two-tailed Student’s t-test. When p<0.05 was obtained using the one-way 
ANOVA, either the Tukey's HSD or Dunnett’s post-hoc test was applied. The type of 
post-hoc test applied is mentioned in figure legends. 
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Chapter 4 
Hydrophobic group modification of 1.8 kDa 
poly(ethylenimine) for plasmid gene delivery 
 
4.1 Background and aims 
Non-viral gene carriers are intensely researched due to their advantages of being 
reproducible, cost effective and designable (Pack et al., 2005, Luo and Saltzman, 
2000, Davis et al., 2010). Most non-viral DNA carriers are cationic polymers, which 
include cationic polycarbonates (Ong et al., 2011), poly(amino acid) based polymers 
(Osada et al., 2009), polyamidoamine (Zhang et al., 2005), cationic 
polyphosphoesters (Wen et al., 2004) and poly(ethylenimine) (PEI) (Boussif et al., 
1995). Specifically, bPEI (Mn 10 kDa, PEI-10) has been widely used as a gene 
transfection agent for both in vitro and in vivo applications. Its success has been 
widely attributed to its ability to escape the endosomes via a process described as 
the “proton sponge” hypothesis (Boussif et al., 1995, Lemkine and Demeneix, 2001). 
However, PEI-10 has an unfavourable toxicity profile, caused by a high cationic 
charge density which compromises the integrity of the plasma cell membrane. It also 
depolarizes the mitochondrial membranes, leading to the onset of apoptosis (Fischer 
et al., 1999, Moghimi et al., 2005). Low molecular weight bPEI 1.8 kDa (Mn 1.8 kDa, 
PEI-1.8) on the other hand, is less cytotoxic and can also be eliminated from 
systemic circulation through the kidneys (Seymour et al., 1987). However the smaller 
mass of PEI-1.8 results in the inefficiency of the polymer to serve as a gene 
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transfecting agent. This is due to its weak DNA binding abilities and inadequate DNA 
protection from nucleases (Godbey et al., 1999). 
To overcome the low transfection efficiency of PEI-1.8, researchers have explored 
various strategies, such as crosslinking low molecular weight PEI to form degradable 
high molecular weight PEI (Kim et al., 2005, Xiang et al., 2012) and modifying PEI-
1.8 with poly(ethylene glycol) (PEG), targeting peptides and hydrophobic groups 
(Kim et al., 2009, Kichler, 2004). Particularly, PEI-1.8 conjugation with hydrophobic 
groups has been shown to be an effective strategy to improve gene transfection 
efficiency in various cell types (Kim et al., 2009, Thomas and Klibanov, 2002, Zheng 
et al., 2011, Neamnark et al., 2009, Mahato et al., 2001, Hsu et al., 2011, Han et al., 
2001). For instance, the conjugation of cholesterol to PEI-1.8, in a 1:1 molar ratio, to 
form a lipopolymer increased the luciferase transfection efficiency of PEI-1.8 to be 
equal to that of PEI-10, while also maintaining low cytotoxicities in both the human 
embryonic kidney transformed cells (293T) and colon adenocarcinoma cells (CT-26)  
(Han et al., 2001). Zheng et al. also showed that the functionalization of PEI-1.8 with 
lipoic acid increased transfection efficiencies in the cervical carcinoma cell line 
(HeLa) and in 293T cells, as compared to the PEI-1.8 (Zheng et al., 2011). 
Moreover, the work highlighted the need to balance the charge density and the 
degree of lipoic acid modification for efficient transfection efficiencies. The 
attachment of hydrophobic groups to PEI molecules endows amphiphilicity to the 
polymer. Amphiphilic particles are necessary for the process of cell membrane 
penetration, where nanoparticles must cross from the hydrophilic extracellular space 
to the hydrophobic cell membrane (28). Tuning of the hydrophilic/hydrophobic 
balance to increase gene transfection has not only shown effectiveness in polymeric 
systems, but also in peptide delivery agents (29, 30). However, although it has been 
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generally accepted that hydrophobic modification increases the gene transfection 
efficiency of low molecular weight PEI, very few studies have explored how the 
structure of the conjugated hydrophobic groups affects the function of the modified 
PEI-1.8. Difficulties in obtaining well defined final polymer compositions stemming 
from limitations in current chemical synthesis routes, may contribute to the lack of 
structure-function relationship studies (Neamnark et al., 2009, Doody et al., 2006). 
Researchers also face the arduous task of customizing individual reaction routes for 
the conjugation of different functional groups to PEI-1.8. Consequently, the choice of 
functional groups used for conjugation to PEI-1.8 is backed by little rationale.  
The aim of this part of the study was to elucidate the structures of hydrophobic 
groups that improve PEI-1.8 gene transfection efficiency. This was done by 
judiciously modifying PEI-1.8 with different functional groups, which include ethyl, 
octyl, deodecyl, benzyl and phenylurea using an established methyl-
carboxytrimethylene carbonate (MTC) monomer platform (Kim et al., 2010, Pratt et 
al., 2008, Sanders et al., 2010). Various functional groups may be easily conjugated 
to the amines of PEI-1.8 via the MTC monomer platform, which involves a simple 
and highly controllable ring-opening reaction. Modified and unmodified PEI-1.8/DNA 
polyplexes (called polyplexes) were then investigated for their DNA binding ability, 
particle size, zeta potential, cytotoxicity and in vitro gene transfection efficiency in 
SKOV-3 human ovarian cancer cells and HepG2 human liver carcinoma cells. 
Specifically, the influence of increasing hydrophobicity (ethyl, octyl, deodecyl), 
aromaticity (octyl and benzyl), hydrogen bonding (benzyl and phenylurea) and 
substitution degree of primary amine groups in PEI-1.8 with hydrophobic groups 
(called conjugation degree) on PEI-1.8 function were studied. The data in this 
chapter has been published (Teo et al., 2013). 
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4.2 Results and discussion 
4.2.1 Modification and characterization of 1.8 kDa poly(ethylenimine) 
To study the structure-function relationship between hydrophobic groups and 
modified PEI-1.8 polymer properties, PEI-1.8 was conjugated judiciously to various 
functional groups using the MTC monomer platform. Specifically, MTC was 
conjugated with varying lengths of alkyl chains namely, ethyl, octyl and deodecyl (to 
study the effects of increasing hydrophobicity) and with benzyl (to study the effects of 
aromaticity). MTC was also conjugated with phenylurea, to study the effects of 
hydrogen bonding, which may aid in DNA binding (Li, Tian, et al., 2014, Allen et al., 
2011). Importantly, the MTC monomers were able to react with the amines of PEI-
1.8 in a typical amine initiated, ring-opening reaction, regardless of the hydrophobic 
functional group attached (Figure 4.1A). The reaction was fast, highly controllable, 
easily purified and resulted in modified polymers which correlated well to feed molar 
ratios of MTC monomers to PEI-1.8 as verified by 1H NMR analysis (Figure 4.1B-E). 
For example, the synthesis of PEI1.8-benzyl(1) was performed by reacting MTC-
benzyl and PEI-1.8 in a molar ratio of 1:1. The resulting PEI1.8-benzyl(1) product 
was found to contain MTC-benzyl and PEI-1.8 in a molar ratio of 1.1:1, which was 
obtained by comparing relative integral intensities of benzyl signals of MTC-benzyl 
(7.35-7.39 ppm) and PEI methylene signals (2.4-2.9 ppm) (Figure 4.1B). Such well 
controlled reactions are necessary for the accurate study of structure-function 
relationships as it enables the synthesis of well-defined polymers.  
To determine whether an optimal number of conjugated functional groups in the 
polymer exists, MTC-ethyl was reacted with PEI-1.8 at various molar feed ratios of 1, 
2, 4 or 10:1. This corresponds to a conjugation degree (number of amine groups 
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reacted with MTC) of 1, 2, 4 or 10. The molar feed ratios were chosen based on the 
knowledge that there are approximately 10 primary, 20 secondary and 10 tertiary 
amine groups in every PEI-1.8 molecule (Dick and Ham, 1970). The compositions of 
modified PEI-1.8 were confirmed using 1H NMR (Figure 4.2) and are also 
documented in Table 4.1. 
However, changing the conjugation degree not only decreases the number of free 
amines, it may also affect the pKa values of the available amines (Engler et al., 
2011). This might in turn influence the buffering properties of the modified polymers 
and affect endosomal escape of the polyplexes (Akinc et al., 2005, Pack et al., 
2005). To study whether the modification of PEI-1.8 affects its buffering capacity, 
acid-base titration experiments were performed. As the ester linkages were prone to 
cleavage in highly alkaline pH, the polymer solutions were first acidified to pH 2 and 
the pH was then gradually increased. The buffering capacity of polymers PEI1.8-
ethyl(1), PEI1.8-ethyl(2), PEI1.8-ethyl(4) and PEI1.8-ethyl(10) were found to range 
from 20.3% to 21.2%, which were comparable to unmodified PEI-1.8 (21.9%) (Table 
4.1). The stable buffering capacity of modified PEI-1.8, suggests that most of the 
conjugation reactions took place at the primary amine sites of PEI-1.8, thus leaving 
the secondary and tertiary amines to be free for the sequestering of protons in the 
cellular endosome (Behr, 1997, Sonawane et al., 2003). Therefore, the properties of 
endosomal escape are expected to be preserved, despite modification of PEI-1.8. 
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Figure 4.1. Synthesis scheme of MTC-modified PEI-1.8 and composition of 
synthesized polymers determined by nuclear magnetic resonance spectroscopy 
(NMR). (A) Synthetic route and chemical compositions; a is defined as the total 
number of primary amines and b is the total number of secondary amines calculated 
based on the ratio of 1:2:1 (primary:secondary:tertiary amines) of 1 mol PEI-10 = 
1800 g; x is the number of MTC molecules reacted per molecule of PEI-1.8 (Dick 
and Ham, 1970). (B) 1H NMR spectrum of PEI1.8-benzyl(1) (C) 1H NMR spectrum of 
PEI1.8-octyl(1) (D) 1H NMR spectrum of PEI1.8-deodecyl(1) (E) 1H NMR spectrum of 
PEI1.8-phenylurea(1) All polymers were dissolved in MeOD for NMR analysis. PEI: 
polyethylenimine; MeOD: ethanol; ppm: parts per million. 
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Figure 4.2. 1H NMR spectrum of PEI1.8-ethyl with conjugation degrees of 1, 2, 4 
and 10 (A-D respectively) using MeOD as a solvent. PEI: polyethylenimine; MeOD: 
ethanol; ppm: parts per million. 
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Table 4.1. Physical properties of unmodified and modified PEI-1.8 polymers 
Polymer ID Conjugate 
group 
Mole ratio
a
  
(PEI-1.8:conjugate 
group) 
PDI
b
 Buffering capacity (%) 
PEI-1.8 - - 0.28 21.9 
PEI1.8-ethyl(1) MTC-ethyl 1:1.2 0.10 21.2 
PEI1.8-ethyl(2) MTC-ethyl 1:1.8 0.16 22.4 
PEI1.8-ethyl(4) MTC-ethyl 1:4.1 0.19 21.2 
PEI1.8-ethyl(10) MTC-ethyl 1:9.9 0.13 20.3 
PEI1.8-octyl(1) MTC-octyl 1:1 0.16 - 
PEI1.8-
deodecyl(1) 
MTC-
deodecyl 
1:0.9 0.20 - 
PEI1.8-
phenylurea(1) 
MTC-
phenylurea 
1:0.9 0.13 - 
PEI1.8-benzyl(1) MTC-benzyl 1:1.1 0.19 - 
a PEI-1.8:MTC conjugate group mole ratio is based on 1 mole PEI-1.8 =1800 g and 
10 primary amine groups per mole.  
b Polydispersity index (PDI) measurements are of polyplexes formed at N/P ratio 40. 
MTC: Methyl-carboxytrimethylene carbonate 
PEI-10: Polyethylenimine  
 
4.2.2 DNA binding and stability of polyplexes 
To study whether modified PEI-1.8 could bind DNA, the SYBR green® DNA binding 
assay was performed. Increasing the N/P ratio (molar ratio of nitrogen content in PEI 
to phosphorus content of DNA) for most of the polymers tested, resulted in a trend 
showing decreased relative fluorescence of SYBR green® dye (Figure 4.3A and B). 
This indicates that the polymers condense DNA and when higher concentrations of 
polymers are used, less amount of free DNA is available for SYBR green® to 
intercalate with. Higher N/P ratios (~2.5) of modified PEI-1.8, with a functional group 
conjugation degree of 1, were needed to achieve 50% relative fluorescence 
compared to unmodified PEI-1.8 which required an N/P ratio of ~1.6 (Figure 4.3A). A 
reduction in the number of free primary amine groups, which are needed for DNA 
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condensation, in modified PEI-1.8 may be a possible explanation for the higher N/P 
ratios needed.  
In addition, Figure 4.3B shows that increasing the conjugation degree of MTC-ethyl 
to PEI-1.8 resulted in reduced DNA binding. This was especially evident when 
analysing the binding ability of PEI1.8-ethyl(10), which required higher N/P ratios 
above 10 for 50% relative fluorescence (Figure 4.3B). A conjugation degree of 10 
means that ~100% of primary amines in PEI-1.8 have been converted to amide 
linkages. PEI1.8-ethyl(10) therefore carried less positive charge needed for DNA 
binding. The maximum degree of MTC-ethyl conjugation, such that DNA binding 
ability was not altered, was found to be 4 (Figure 4.3B). 
An effective DNA carrier should not only be able to condense DNA to protect the 
plasmids from nuclease degradation, it should also be able to release the DNA cargo 
intracellularly (Green et al., 2008). The stability of the polymer/DNA polyplexes 
formed by PEI1.8-ethyl(1), PEI1.8-ethyl(2), PEI1.8-ethyl(4) and PEI1.8-ethyl(10) at 
N/P 30 was studied using the heparin displacement assay. Heparin is an anionic 
molecule which challenges the binding stability of the DNA and polymer. PEI1.8-
ethyl(1), PEI1.8-ethyl(2) and unmodified PEI-1.8 had similar stability profiles and 
released ~100% of bound DNA at a heparin concentration of 2 mg/mL (Figure 4.3C). 
On the other hand, PEI1.8-ethyl(4) and PEI1.8-ethyl(10) released almost all of their 
bound DNA from the polyplexes at lower heparin concentrations of 1 mg/mL and 0.5 
mg/mL respectively (Figure 4.3C). A balance between DNA binding and stability has 
to be reached when designing polymers for gene transfection. This can be easily 
done by altering the conjugation degree of primary amine groups in PEI-1.8. 
134 
 
  
Figure 4.3. Plasmid DNA binding and stability studies of polymer/DNA polyplexes 
determined by the SYBR green® exclusion assay. (A) DNA binding of PEI-1.8 
modified with different functional groups at a conjugation degree of 1 and with (B) 
MTC-ethyl at various conjugation degrees. DNA binding is measured as a decrease 
in relative fluorescence of SYBR green® dye. (C) Stability of polyplexes challenged 
with increasing concentrations of heparin. A relative fluorescence of 100% indicates 
SYBR green® dye intercalated with free DNA, while 0% corresponds to the 
fluorescence of non-intercalating dye. Results represent mean ± standard error of 
mean of four independent experiments, each with four replicates. The one-way 
ANOVA and Dunnett’s post-hoc analysis were used to calculate statistical 
significance between modified PEI-1.8 and unmodified PEI-1.8, (* p<0.05). N/P ratio: 
ratio of nitrogen in polymers to phosphorous content in DNA. 
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4.2.3 Size and zeta potential measurements 
To determine the size and surface charge of the nanoparticles, polyplexes were 
monitored by DLS measurements. 
Modified PEI-1.8 polymers were able to condense plasmid DNA, at N/P ratio 10-40, 
to form particles with sizes ranging from ~92 to 166 nm (Figure 4.4A). On the other 
hand, unmodified PEI-1.8/DNA polyplexes were substantially larger (~2 µm), only at 
high N/P ratio 40 (Figure 4.4A). Nanoparticles with sizes below 200 nm are desirable 
as they have been shown to preferentially enter and accumulate in cells, mainly via 
clathrin-mediated endocytosis, better and more rapidly than larger sized particles 
(Gratton et al., 2008, Rejman et al., 2004). Furthermore, the modified PEI-1.8/DNA 
polyplexes displayed low polydispersity index (PDI) values ranging from 0.1 to 0.2, 
indicating uniform particle sizes (Table 4.1). Interestingly, a single hydrophobic 
modification of PEI-1.8 was sufficient to cause a significant decrease in particle size 
compared to unmodified PEI-1.8. This may be due to the hydrophobic interactions 
which have been shown to aid in particle assembly (Grzelczak et al., 2010, Nel et al., 
2009). Zheng et al. also reported a decrease in particle size after lipoic acid 
conjugation to PEI-1.8 via dicyclohexylcarbodiimide (DCC)/N-hydroxysuccinimide 
(NHS) coupling (Zheng et al., 2011). 
Modified PEI-1.8/DNA polyplexes had higher cationic charge (~28-40 mV) than 
unmodified PEI-1.8 (20 mV) (Figure 4.4B). Increased charge density of DNA 
polyplexes formed with lipid-modified low molecular weight PEI-1.8 have also been 
reported by other groups (Bahadur et al., 2011, Zheng et al., 2011). Zheng et al. 
suggested that the elevated charge density was due to better packaging of DNA 
ability of lipoic acid modified low molecular weight PEI brought about by hydrophobic 
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interactions (Zheng et al., 2011). A cationic surface charge on nanoparticles is 
advantageous as it increases their interaction with anionic charged phospholipid 
head groups or protein domains, such as salicylic acid and syndecan, on the plasma 
cell membrane which may lead to endocytosis (Gratton et al., 2008, Kopatz et al., 
2004). However, if the cationic density is not controlled, these interactions may 
compromise the integrity of the plasma membrane leading to toxicity (Leroueil et al., 
2008). Interestingly, the charge on nanoparticles has also been shown to determine 
their intracellular fate. Cationic particles were routed for transcytosis, while the 
anionic particles reached the lysosomes in Madin-Darby canine kidney cells (Harush-
Frenkel et al., 2008). In general, the modified polymers formed polyplexes which 
were ~100 nm in size and had an overall cationic charge, properties which are 
favourable for transfection agents. 
 
 
Figure 4.4. (A) Particle size and (B) zeta potential of modified PEI-1.8/DNA 
polyplexes, formed at various N/P ratios, analysed by dynamic light scattering (DLS). 
Unmodified PEI-1.8/DNA polyplexes formed at N/P ratio 40 were used as a control. 
The results represent mean of two independent experiments, each with three 
replicates. N/P ratio: ratio of nitrogen in polymers to phosphorous content in DNA. 
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4.2.4 Cytotoxicity of polyplexes 
The toxicity of the polyplexes was analysed using the 3-(4,5-Dimethyl-2-thiazolyl)-
2,5-diphenyl tetrazolium bromide (MTT) cell proliferation assay.  Both SKOV-3 and 
HepG2 cells, incubated with modified PEI-1.8 polymer/DNA polyplexes, remained 
viable (~80% cell viability) up to N/P 30 (Figure 4.5). However it was also shown that 
hydrophobic modification using MTC-ethyl (only in HepG2 cells), MTC-octyl, MTC-
deodecyl and MTC-phenylurea of PEI-1.8 increased the toxicity of the polymer 
(Figure 4.5). Hydrophobic groups have been shown to disrupt membrane integrity 
which leads to cytotoxicity (McKarns et al., 1997). Several groups have also reported 
higher toxicity levels when cells were incubated with alcohols or nanoparticles with 
longer alkyl chains compared to shorter chains (Chompoosor et al., 2010, McKarns 
et al., 1997). Importantly, we have shown that modified PEI-1.8/DNA polyplexes, at 
all N/P ratios tested, exerted minimal cytotoxicity (~80% cell viability) on the cell lines 
tested and may function as DNA transfecting agents. 
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Figure 4.5. Viability of (A) SKOV-3 and (B) HepG2 cells after incubation with 
polyplexes formed at various N/P ratios, analysed using the MTT assay. Unmodified 
PEI-1.8/DNA polyplexes prepared at N/P 40 were used as a control. Results 
represent mean ± standard deviation of 3 independent experiments, each with eight 
replicates. N/P ratio: ratio of nitrogen in polymers to phosphorous content in DNA. 
 
4.2.5 In vitro luciferase gene expression  
The in vitro luciferase gene expression studies were performed by incubating SKOV-
3 and HepG2 cells with luciferase plasmid DNA/polymer polyplexes formed at N/P 
ratios ranging from 10 to 40 and by analysing the luciferase expression. Notably, for 
most functional groups (especially ethyl, benzyl and phenylurea) tested, a single 
modification of PEI-1.8 with MTC was sufficient to enhance transfection efficiencies 
compared to unmodified PEI-1.8 (Figure 4.6 A, C). 
To explore the effect of increasing alkyl chain length of MTC functional groups on 
PEI-1.8 transfection efficiency, polymers PEI1.8-ethyl(1), PEI1.8-octyl(1) and PEI1.8-
deodecyl(1) were evaluated for luciferase expression. PEI1.8-ethyl(1)/DNA 
polyplexes, formed at N/P ratios 20 and above, showed an improvement of 
transfection efficiency in both cell lines tested (Figure 4.6 A, C). This could be due to 
the higher DNA uptake, observed in SKOV-3 cells, when PEI1.8-ethyl(1) was used 
as a transfecting agent instead of unmodified PEI-1.8 (Figure 4.7B). The higher 
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charge density of PEI1.8-ethyl(1)/DNA polyplexes (~32.6 mV) compared to PEI-
1.8/DNA polyplexes (~20.3 mV) may be the reason for the increased cellular uptake 
of PEI1.8-ethyl(1)/DNA polyplexes (Table 4.1). On the other hand, PEI1.8-octyl(1) 
and PEI1.8-deodecyl(1) resulted in less enhancement of transfection efficiency 
compared to PEI1.8-ethyl(1) and unmodified PEI-1.8 (Figure 4.6 A, C). These results 
correlated with the lower cellular uptake of DNA polyplexes when PEI-1.8 was 
modified with longer hydrophobic groups such as MTC-octyl and MTC-deodecyl 
(Figure 4.7B). The lower intracellular uptake of PEI1.8-octyl(1) and PEI1.8-
deodecyl(1)/DNA polyplexes compared to PEI1.8-ethyl(1)/DNA polyplexes was not 
due to charge differences as all three polymers carry similar cationic charges (Figure 
4.4B). Differences in cellular uptake of the three polymers may therefore be due to 
the length of conjugated alkyl functional group, where short alkyl chain length (ethyl) 
resulted in better intracellular uptake (Figure 4.7B). Thomas et al. also reported a 
similar finding, where PEI-10 acylated with alanine resulted in higher β-galactosidase 
transfection efficiencies, in COS-7 cells, than PEI-10 modified with more hydrophobic 
leucine (Thomas and Klibanov, 2002). The results re-emphasize that a balance of 
hydrophobicity is necessary for enhancement of transfection efficiency. 
To investigate whether changing the structure of the conjugated functional group 
from an alkyl to an aromatic structure would exert any influence on transfection 
efficiencies, luciferase expressions of cells treated with PEI1.8-octyl(1) and PEI1.8-
benzyl(1)/DNA polyplexes were compared. MTC-octyl and MTC-benzyl have similar 
chemical composition differing mainly by structure. SKOV-3 and HepG2 cells treated 
with PEI1.8-benzyl(1)/DNA polyplexes, at N/P ratios 20 and above, resulted in 
enhanced transfection efficiencies by up to 3- and 23-times respectively compared to 
cells treated with PEI1.8-octyl(1)/DNA polyplexes (Figure 4.6A, C). The difference in 
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transfection efficiencies might be due to the higher cellular uptake of DNA polyplexes 
formed with PEI1.8-benzyl(1) than PEI1.8-octyl(1) (Figure 4.7B). This might in turn 
be due to the increased zeta potential of PEI1.8-benzyl(1)/DNA polyplexes (~40.8 
mV) compared to PEI1.8-octyl(1)/DNA polyplexes (~32.9 mV) (Table 4.1). Another 
possible reason for the higher DNA internalization with the PEI1.8-benzyl(1) polymer 
may be due to the finding that aromatic residues are more favourably inserted into 
the bilayer membrane and are thus able to better perturb the membrane, compared 
to alkyl moieties (White and Wimley, 1999, Wimley and White, 1996, Yau et al., 
1998, Arbuzova et al., 2000). The π-electronic structure, flat-rigid shape and 
associated quadrupolar moments of aromatic residues may be the cause for 
favourable interactions with the bilayer interface (White and Wimley, 1999). These 
results suggest that cellular uptake and transfection efficiencies are not solely 
determined by hydrophobicity, but that aromaticity also plays an important role. 
Hence, modification with an aromatic molecule (MTC-benzyl) enhanced DNA 
internalization and improved transfection efficiency compared to its alkyl isomer 
(MTC-octyl) (Figure 4.6A, C). 
To study whether the incorporation of a hydrogen bonding group (such as urea) 
affects luciferase transfection efficiency, PEI1.8-benzyl(1) and PEI1.8-phenylurea(1) 
were compared. However, there were little differences in the transfection efficiency 
between the polymers, in both cell lines (Figure 4.6A,C). This may be attributed to 
the benzyl group, present in both MTC-benzyl and MTC-phenylurea, which plays a 
more dominant role in promoting cellular uptake and transfection. 
Finally, to study the effect of changing the conjugation degree of primary amine 
groups, luciferase expression levels mediated by PEI1.8-ethyl(1), PEI1.8-ethyl(2), 
PEI1.8-ethyl(4) and PEI1.8-ethyl(10)/DNA polyplexes in SKOV-3 and HepG2 cells 
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were investigated. Transfection efficiencies in both cell lines were higher than 
unmodified PEI-1.8 when MTC-ethyl conjugation degree on PEI-1.8 was 1, 2 and 4 
(Figure 4.6B, D). The results could be correlated to higher DNA internalization of 
PEI1.8-ethyl(1) and PEI1.8-ethyl(4) compared to unmodified PEI-1.8/DNA polyplexes 
(Figure 4.7B). Similarly, more DNA was observed in cells treated with PEI1.8-ethyl(4) 
as compared to unmodified PEI-1.8 when viewed by confocal microscopy (Figure 
4.7C).  
Interestingly, although a substantially higher amount of DNA was internalized into 
cells when DNA was complexed with PEI1.8-ethyl(4) compared to PEI1.8-ethyl(1) 
(Figure 4.7B), eventual transfection efficiencies mediated by PEI1.8-ethyl(4) were 
not significantly higher than those mediated by PEI1.8-ethyl(1) (Figure 4.6B, D). This 
might be due to different intracellular trafficking and nuclear transport mechanisms of 
PEI1.8-ethyl(1) and PEI1.8-ethyl(4)/DNA polyplexes. Although it is uncertain how 
increasing the MTC-ethyl conjugation degree (from 1 to 4) on PEI-1.8 affects DNA 
nuclear translocation, previous studies have shown that hydrophobicity is an 
important factor which determines nuclear transport of cargo, such as plasmid DNA 
(Ribbeck and Görlich, 2002, Vandenbroucke et al., 2007). Plasmid DNA, which is still 
bound to PEI-10, has been shown to travel to the nucleus along microtubules (Suh et 
al., 2003). It may be possible that plasmid DNA also travels to the nucleus when it is 
still bound to MTC-ethyl modified PEI1.8. The hydrophobicity of the polyplex may aid 
nuclear translocation as the inner lining of nucleoporins are filled with hydrophobic 
phenylalanine‐rich repeats, which allow amphiphilic molecules through (Rout and 
Wente, 1994). However, the hydrophobic/hydrophilic balance of amphiphilic 
molecules also affects nuclear translocation and optimization steps are necessary to 
determine the best conjugation ratio (Ribbeck and Görlich, 2002). When the MTC-
142 
 
ethyl conjugation degree of PEI-1.8 was increased to 10, where ~100% of the 
primary amines were substituted, a drastic drop in transfection efficiency was 
observed for all N/P ratios tested (Figure 4.6 B, D). The inefficient DNA binding and 
low cellular DNA internalization mediated by PEI1.8-ethyl(10) may factor for the 
reduction in luciferase expression (Figure 4.7B). Therefore, low MTC-ethyl 
conjugation degrees of 1, 2 and 4 onto PEI-1.8 increases DNA internalization of 
polyplexes. On the other hand, a higher degree of MTC-ethyl conjugation 
(conjugation degree of 10) on PEI-1.8 hinders DNA internalization and transfection 
efficiencies. 
As a whole, modification of PEI-1.8 with functional MTC monomers has shown to 
increase transfection efficiency of PEI-1.8. In particular, the highest transfection 
efficiencies were attained when PEI-1.8 was modified with short length alkyl chains 
(MTC-ethyl with conjugation degrees of 1, 2 and 4) and benzyl containing functional 
groups (MTC-phenylurea and MTC-benzyl) to form PEI1.8-ethyl(1), PEI1.8-ethyl(2), 
PEI1.8-ethyl(4), PEI1.8-phenylurea(1) and PEI1.8-benzyl(1) correspondingly. These 
polymers resulted in up to 9-fold and 43-fold increase in transfection efficiency 
compared to unmodified PEI-1.8, in SKOV-3 and HepG2 cells respectively. 
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Figure 4.6. The in vitro luciferase expression of (A, B) SKOV-3 and (C, D) HepG2 
cells after incubation with polyplexes formed at various N/P ratios. (A, C) Luciferase 
transfection efficiency mediated by PEI-1.8 modified with different functional groups 
at a conjugation ratio of 1 and (B, D) PEI-1.8 modified with MTC-ethyl at conjugation 
degrees of 1, 2, 4 and 10. Results represent mean ± standard error of mean (SEM) 
of 3 independent experiments, each done in triplicate. The one-way ANOVA and 
Tukey’s HSD post-hoc analysis were used to calculate statistical significance among 
groups, (* p<0.05). N/P ratio: ratio of nitrogen in polymers to phosphorous content in 
DNA; RLU: relative light units. 
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Figure 4.7. Intracellular uptake of polyplexes analysed using (A) flow cytometry and 
(B) confocal microscopy. (A) Representative flow cytometry plots of SKOV-3 cell 
population and intracellular uptake of PEI1.8-ethyl(4)/YOYO-1 labelled DNA 
polyplexes. (B) All polyplexes wereformed by complexing polymers with YOYO-1 
labelled DNA at N/P ratio 30. Intracellular uptake was measured after incubation of 
polyplexes with SKOV-3 cells for 4 h and represented as median fluorescence 
intensity (MFI). The results represent mean ± standard error of mean of three 
independent experiments, each in triplicate. The one-way ANOVA and Tukey’s HSD 
post-hoc analysis were used to calculate statistical significance among groups, (* 
p<0.05). N/P ratio: ratio of nitrogen in polymers to phosphorous content in DNA (B) 
Confocal images of the intracellular uptake of PEI-1.8/DNA polyplexes and PEI1.8-
ethyl(4)/DNA polyplexes. YOYO-1 labelled DNA (green); nuclei stained with Hoechst 
33342 (blue); scale bar: 10 nm.  
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4.3 Summary and conclusions 
PEI-1.8 was modified with various hydrophobic groups such as ethyl, octyl, 
deodecyl, phenylurea and benzyl, by facile ring-opening of functionalized carbonate 
monomers based on nucleophilic addition chemistry. The synthesized product 
compositions correlated well with functional carbonate and PEI-1.8 feed ratios. This 
allows for an accurate study of the relationship between structure of hydrophobic 
conjugation group and PEI-1.8 transfection efficiency. The modified PEI-1.8 
polymers were able to condense plasmid DNA into cationic nanoparticles in 
comparison to the unmodified PEI-1.8 which formed particles which were on the 
micron scale. The stability of the polyplexes were found to be easily adjusted by 
controlling the degree of functional carbonate conjugation. PEI-1.8 modified with 
shorter alkyl chains, MTC-ethyl (at MTC to PEI-1.8 of 1, 2 and 4:1 molar ratio) and 
with aromatic groups, benzyl or phenylurea (at 1:1 molar ratio) mediated the highest 
gene transfection efficiency. Hydrogen bonding, brought about by urea groups was 
not found to exert an effect on transfection efficiencies of modified PEI-1.8. These 
findings provide insights to modification of PEI-1.8 for development of effective and 
less cytotoxic non-viral vectors. In the next chapter, PEI-10 will be modified with 
MTC-ethyl, MTC-phenylurea and MTC-benzyl, based on the findings from this 
chapter, and investigated for improvements in gene transfection efficiency.  
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Chapter 5  
Hydrophobic modification of 10 kDa poly(ethylenimine) for 
nucleic acid delivery 
 
5.1 Background and aims 
In chapter 4, the systematic modification of low molecular weight branched PEI (PEI-
1.8, 1800 kDa) with hydrophobic groups to improve transfection efficiency was 
described. Importantly, the relationship between the structure of the conjugated 
hydrophobic groups and function of the modified PEI-1.8 polymers was elucidated. 
This chapter focuses on investigating whether the same hydrophobic modification 
strategies of PEI-1.8 may be applied to branched PEI (PEI-10, 10 000 kDa) 
modification to achieve better transfection properties. Although PEI-10 has been 
shown to be one of the most efficient gene carriers (Boussif et al., 1995, Sonawane 
et al., 2003), its application has been limited by its high toxicity profile, brought about 
by its high positive surface charge (Kircheis et al., 2001, Uduehi et al., 2001).  
Branched PEI-10 consists of primary (terminal), secondary and tertiary amines in the 
ratio of 1:2:1 (Dick and Ham, 1970). Titration of the PEI-10 polymer resulted in 
estimated pKa values of primary, secondary and tertiary amines to be approximately 
4.5, 6.7 and 11.6 respectively (Willner et al., 1993, Choosakoonkriang et al., 2003). It 
has therefore been hypothesized that the majority of primary amines, which are 
protonated at physiological pH 7.4, are responsible for the high cationic charge 
density, and thus cytotoxicity, of PEI-10 (Moghimi et al., 2005). Researchers have 
attempted to reduce the cytotoxicity of PEI-10 by modifying the primary amines on 
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PEI-10 to reduce the charge density of the polymer. Thomas et al. showed that the 
acylation of PEI-10 with alanine not only resulted in reduced cytotoxicity but also a 
~2-fold increase of luciferase expression efficiency in African green monkey 
fibroblast (COS-7) cells (Thomas and Klibanov, 2002). Moreover, PEI-10 
modification with N-isopropylacrylamide (Tian et al., 2012) and acetylation of PEI-10 
(Gabrielson and Pack, 2006) successfully reduced the cytotoxicity of PEI-10 and 
increased transfection efficiency. Wang et al. reported that the conjugation of 
cystamine derivatives to the primary amines of PEI-10 reduced cytotoxicity and led 
to an almost a two-fold enhancement of luciferase expression efficiency in 293T 
cells, compared to unmodified PEI-10. Furthermore, the introduction of a methyl 
group to cystamine improved transfection efficiencies of modified PEI-10 (Wang, 
Zheng, et al., 2011).  
The aim of this chapter is to modify PEI-10 with hydrophobic functional groups 
(MTC-ethyl, MTC-phenylurea and MTC-benzyl) that showed the greatest 
improvement in gene transfection efficiency of PEI-1.8 in chapter 4 (Teo et al., 
2013). The rationale of modifying PEI-10 with hydrophobic groups is primarily to 
reduce the high cytotoxicity of PEI-10 and secondly, to increase gene transfection 
efficiencies (Thomas and Klibanov, 2002). Modified PEI-10 polymers were then 
investigated for gene binding abilities, particle size, surface charge, cytotoxicity and 
in vitro green fluorescent protein (GFP) transfection efficiency in two ovarian cancer 
cell lines, SKOV-3 and OVCAR-3. In addition, modified PEI-10 polymers were also 
tested for PD-L1 siRNA transfection. Some data from this chapter has been 
published (Yang et al., 2013).  
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5.2 Results and discussion 
5.2.1 Modification of 10 kDa poly(ethylenimine) 
To conjugate ethyl, phenylurea and benzyl to PEI-10, the MTC monomer platform 
was utilized (Pratt et al., 2008, Sanders et al., 2010). Briefly, MTC reacts with the 
amines of PEI-10 to form carbamate linkages and primary hydroxyl groups. At the 
same time, hydrophobic functional groups present on the MTC monomer were also 
installed on the PEI-10 molecule (Figure 5.1A). There are approximately 58 primary 
amines, 116 secondary amines and 58 tertiary amines in PEI-10 (Dick and Ham, 
1970). The conjugation ratios of MTC-ethyl, MTC-phenylurea and MTC-benzyl: PEI-
10 were designed to be 25:1, 3:1 and 3:1, to form polymers PEI10-ethyl(25), PEI10-
phenylurea(3) and PEI10-benzyl(3) respectively. These ratios were selected so that 
modified PEI-10 had approximately the same percentage of amines substituted with 
hydrophobic functional groups, as that of the modified PEI-1.8 which showed the 
highest improvement in transfection efficiency. For example, the optimal MTC-benzyl 
conjugation on PEI-1.8 was found to be 1:1, which equates to a 2.5% amine 
substitution. This in turn equates to a conjugation ratio of three MTC-benzyl groups 
per PEI-10 molecule. The composition of the synthesized product, or degree to 
which PEI-10 was functionalized, was easily controlled by the PEI:MTC feed ratios 
and product compositions were determined by 1H NMR analysis (Figure 5.1B-D). For 
instance, the resulting PEI10-benzyl(3) product was found to contain MTC-benzyl 
and PEI-1.8 in a molar ratio of 3.1:1. This was obtained by comparing relative 
integral intensities of benzyl signals of MTC-benzyl (7.39 ppm) and PEI methylene 
signals (2.6-2.7 ppm) (Figure 5.1D). The composition of polymers PEI10-ethyl(25) 
and PEI10-phenylurea(3) is reported in Table 5.1. 
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Figure 5.1. Synthesis scheme of MTC-modified PEI-10 and composition of 
synthesized polymers determined by nuclear magnetic resonance (NMR) 
spectroscopy. (A) Synthetic route and chemical compositions; a is defined as the 
total number of primary amines and b is the total number of secondary amines 
calculated based on the ratio of 1:2:1 (primary:secondary:tertiary amines) of 1 mol 
PEI-10 = 10,000 g; x is the number of MTC molecules reacted per molecule of PEI-
10 (Dick and Ham, 1970). (B) 1H NMR spectrum of PEI10-ethyl(25), (C) 1H NMR 
spectrum of PEI10-urea(3) and (D) 1H NMR spectrum of PEI10-benzyl(3) using 
MeOD as a solvent. MTC: methyl-carboxytrimethylene carbonate; MeOD: ethanol; 
ppm: parts per million. 
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Table 5.1. Physical properties of unmodified and MTC-modified PEI-10. 
Polymer ID Conjugate group Mole ratio
a
  
(PEI-10:conjugate group) 
PEI-10 - - 
PEI10-ethyl(25) MTC-ethyl 1:29.4 
PEI10-phenylurea(3) MTC-phenylurea 1:3.4 
PEI10-benzyl(3) MTC-benzyl 1:3.1 
a 
PEI-10:MTC conjugate group mole ratio is based on 1 mole PEI-10 =10 000 g and   
  58 primary amine groups per mole.  
MTC: Methyl-carboxytrimethylene carbonate 
PEI: Polyethylenimine  
 
 
5.2.2 DNA binding  
The gene binding efficiency of modified PEI-10 was analysed by measuring the 
fluorescence emitted by SYBR green® dye when intercalated with free DNA (Kunath 
et al., 2003). For all polymers, the relative fluorescence decreased with increasing 
N/P ratios. This indicates the inaccessibility of the dye to the bound and condensed 
DNA (Figure 5.2).  
PEI10-phenylurea(3) and PEI10-benzyl(3) bound plasmid DNA with similar capacity 
as unmodified PEI-10 (Figure 5.2). On the other hand, PEI10-ethyl(25) required a 
higher N/P ratio of ~3 to achieve 50% relative fluorescence compared to unmodified 
PEI-10 which required an N/P ratio of ~2 (Figure 5.2). In addition, only about 70% of 
total DNA was condensed by PEI10-ethyl(25) compared to PEI10-phenylurea(3), 
PEI10-benzyl(3) and unmodified PEI-10 which condensed ~90% of total DNA (Figure 
5.2). This could be due to the reduction in the number of free primary amine groups 
in PEI10-ethyl(25), which are needed for DNA condensation. It could also be 
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possible that the DNA may be less tightly packed within PEI10-ethyl(25), thus 
allowing SYBR Green® dye to intercalate with the bound DNA. The results show that 
modified PEI-10 polymers are able to bind plasmid DNA to form polyplexes, but that 
gene binding efficiency is hindered with the increasing number of conjugation 
groups. 
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Figure 5.2. Plasmid DNA binding ability of modified and unmodified PEI-10 
polymers, measured as a decrease in relative fluorescence of SYBR green® dye. A 
relative fluorescence of 100% indicates SYBR green® dye intercalated with free 
DNA, while 0% corresponds to the fluorescence of non-intercalating dye. The results 
represent mean ± standard error of mean of two independent experiments, each with 
eight replicates. N/P ratio: ratio of nitrogen in polymers to phosphorous content in 
DNA 
  
5.2.3 Size and zeta potential measurements 
To measure the size and surface charge of the nanoparticles, polymer/DNA 
polyplexes formed by unmodified and modified PEI-10 were monitored by DLS 
measurements. 
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All modified PEI-10/DNA polyplexes formed nanoparticles at various N/P ratios with 
sizes ranging from 95-155 nm in diameter (Figure 5.3A). Interestingly, at a low N/P 
ratio of 10, modified PEI-10 polymers, regardless of functional group, were able to 
condense DNA into particles with substantially smaller diameters (104-155 nm) 
compared to unmodified PEI-10 (~285 nm). At higher N/P ratios, sizes of modified 
and unmodified PEI-10 were comparable (Figure 5.3). Nanoparticles smaller than 
200 nm are desirable as they have been shown to have better intracellular uptake 
(Gratton et al., 2008, Rejman et al., 2004). 
Furthermore, all modified PEI-10/DNA polyplexes had lower positive charges than 
unmodified PEI-10/DNA polyplexes and this was more evident at N/P ratio 20 and 
higher (Figure 5.3B). This may be due to the lower availability of free primary amines 
present in modified PEI-10 compared to unmodified PEI-10 polymers. Additionally, 
charge densities among the modified PEI-10 were similar, across various N/P ratios 
(Figure 5.3B). Interestingly, differences in conjugation ratios of functional groups did 
not cause significant changes in the charge density of modified PEI-10. This is 
unexpected as charge density has been hypothesized to be brought about by the 
presence of free primary amines (Moghimi et al., 2005, Thomas and Klibanov, 2002). 
Likewise, Yang et al. reported that increasing the conjugation ratio of trimethylene 
carbonate (TMC) on PEI-10 from 1 to 25, resulted in polymers with similar zeta 
potentials (Yang et al., 2013). Although primary amines, which have higher electron 
cloud densities, are expected to participate more actively in the nucleophilic ring-
opening reaction with MTC monomers, secondary and tertiary amines may 
participate as well. The charge density of the modified polymers may remain similar 
due to the reaction of secondary and/or tertiary amine reaction with the MTC 
monomers, leaving primary amines available to be protonated at neutral pH. 
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Furthermore, conjugation of amines to MTC not only decreases the number of free 
amines, it may also influence the pKa values of the surrounding available amines 
(Engler et al., 2011). Therefore the relationship between amine groups and charge is 
not trivial and tuning of the conjugation ratios might not always lead to predictable 
charge adjustment.  
In general, a cationic surface charge on nanoparticles is advantageous as it 
increases their interaction with negatively charged phospholipid head groups or 
protein domains, such as salicylic acid and syndecan, on the plasma cell membrane 
leading to endocytosis (Gratton et al., 2008, Kopatz et al., 2004). However, if the 
cationic density is not controlled, these interactions may compromise the integrity of 
the plasma membrane and may lead to toxicity (Leroueil et al., 2008). Polyplexes 
with high surface charges also pose problems during systemic delivery as they 
interact with the negatively charged membranes of blood cells, which may lead to 
erythrocyte aggregation. Such aggregates can have trouble travelling through 
capillaries and usually accumulate in the lungs leading to lung haemorrhage (Malek 
et al., 2009). The lower zeta potentials of polyplexes formed using modified PEI-10 
are expected to exert reduced cytotoxicity as compared to unmodified PEI10/DNA 
polyplexes. 
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Figure 5.3. Measurements of (A) particle size and (B) zeta potential of unmodified 
and modified PEI-10/DNA polyplexes, formed at various N/P ratios in nuclease free 
water, analysed by dynamic light scattering (DLS). The results represent mean ± 
standard deviation of two independent experiments, each with three replicates. N/P 
ratio: ratio of nitrogen in polymers to phosphorous content in DNA. 
 
5.2.4 Cytotoxicity of polyplexes 
To investigate the cytotoxicity of the polymers, SKOV-3 and OVCAR-3 cells were 
incubated with the polymer/DNA polyplexes formed at various N/P ratios and the 
MTT assay was employed. 
DNA polyplexes formed using PEI10-phenylurea(3) and PEI10-benzyl(3) resulted in 
similar toxicity profiles as unmodified PEI-10, in both cell lines tested (Figure 5.4). 
This was unexpected as the charge density of PEI10-phenylurea(3) and PEI10-
benzyl(3) were lower than unmodified PEI-10/DNA polyplexes (Figure 5.3). The 
cytotoxicity of PEI10-phenylurea(3) and PEI10-benzyl(3) might instead be brought 
about by the presence aromatic rings, which may perturb the plasma cell membrane 
causing a loss of membrane integrity and cytotoxicity (Som et al., 2012).  
PEI10-ethyl(25)/DNA polyplexes on the other hand, exerted less cytotoxicity 
compared to PEI10-phenylurea(3), PEI10-benzyl(3) and unmodified PEI-10/DNA 
polyplexes, in both cell lines tested (Figure 5.4). This effect was more evident at 
higher N/P ratios of 30 and 25 for SKOV-3 and OVCAR-3 cells respectively (Figure 
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5.4). This could be due to the lower charge density of PEI10-ethyl(25) compared to 
unmodified PEI-10 (Figure 5.3). Yang et al. also reported that PEI-10 modified with 
MTC-phenylurea and MTC-benzyl were more cytotoxic to the HepG2 liver cancer 
cell line than PEI-10 modified with TMC and MTC-ethyl, at the same conjugation 
ratios (Yang et al., 2013). Therefore, modification of PEI-10 with short alkyl chains, 
such as ethyl, significantly mitigates the cytotoxicity of PEI-10 in various cell lines.   
 
  
Figure 5.4. Viability of (A) SKOV-3 cells and (B) OVCAR-3 cells after incubation with 
modified and unmodified PEI-10/DNA polyplexes, formed at various N/P ratios, 
analysed by MTT assay. The results are represented as mean ± standard error of 
mean of three independent experiments, each with eight replicates. N/P ratio: ratio of 
nitrogen in polymers to phosphorous content in DNA. MTT: 3-(4,5-dimethylthiazol-2-
yl)-2,5-diphenyltetrazolium bromide.  
 
 
5.2.5 In vitro GFP expression assay  
The GFP transfection efficiency of modified and unmodified PEI-10 polymer/DNA 
polyplexes was evaluated by flow cytometry. The results were expressed as 
percentage of cells positive for GFP and the MFI of the total cell population. The 
percentage of GFP positive cells and MFI measure two different parameters of GFP 
transfection. The MFI gives a quantitative measure of the amount of GFP produced 
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in the total cell population. However, this is based on the assumption that MFI 
correlates with the quantity of GFP molecules. When studying percentages of GFP 
positive cells, the amount of GFP expressed is not accounted for. The differences in 
parameters studied are a factor to consider when analysing the in vitro GFP 
transfection results. 
PEI-10 modified with hydrophobic groups, especially PEI10-ethyl(25), mediated 
higher GFP transfection efficiencies than unmodified PEI-10, in both SKOV-3 and 
OVCAR-3 cells (Figure 5.5). This finding was more evident when analysing MFI 
rather than percentages of GFP positive cells (Figure 5.5C and E). This was again 
especially so for PEI10-ethyl(25), in both SKOV-3 and OVCAR-3 cells (Figure 5.5). 
At N/P ratio 10, all polymers had comparable charge density and cytotoxicity (Figure 
5.3B and 5.4). The enhancement of GFP transfection by modified PEI-10 may be 
attributed to the smaller sizes of modified PEI-10/DNA polyplexes compared to 
unmodified PEI-10, at N/P ratio 10 (Godbey et al., 1999). The higher GFP 
transfection might also be due to the presence of hydrophobic groups, which may aid 
in plasma membrane penetration and intracellular uptake of DNA (Thomas and 
Klibanov, 2002, Som et al., 2012). 
Overall, PEI10-ethyl(25) mediated the highest GFP transfection efficiencies at all N/P 
ratios tested (Figure 5.5). It may be possible that PEI10-ethyl(25) polymers packed 
DNA less tightly compared to the other polymers (Figure 5.2) thus allowing easier 
unpackaging of the DNA from the polymer once in the cell. Importantly, PEI10-
ethyl(25) also showed significantly lower cytotoxicity than PEI10-phenylurea(3), 
PEI10-benzyl(3) and unmodified PEI-10 (Figure 5.4), making it an attractive gene 
transfection agent.  
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Although PEI-1.8 and PEI-10 have the same composition, the difference in their 
molecular weights make them very distinct polymers (Godbey et al., 1999). Further 
optimization of hydrophobic modification of PEI-10 is therefore necessary to obtain 
optimal transfection properties. Optimization steps were carried out together with 
Yang et al. and results have been published in the following reference (Yang et al., 
2013). 
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Figure 5.5.  GFP transfection efficiency of (A, B, C) SKOV-3 cells and (D, E) 
OVCAR-3 cells after incubation with unmodified or modified PEI-10/DNA polyplexes, 
formed at various N/P ratios, analysed by flow cytometry. (A) Representative flow 
cytometry plots and histogram of SKOV-3 cells treated with GFP gene alone, PEI-
10/GFP DNA or PEI10-phenylurea(3) polyplexes, formed at N/P ratio 10. GFP 
transfection efficiency may be expressed by (B, D) percentage of GFP positive cells 
or (C, E) median fluorescent intensity (MFI) of the total cell population. The results 
are represented as mean ± standard error of mean of three independent 
experiments, each done in triplicate. The one-way ANOVA and the Dunnett’s post-
hoc analysis were used to determine statistical significance of modified PEI-10 
compared to unmodified PEI-10, (*p<0.05). N/P ratio: ratio of nitrogen in polymers to 
phosphorous content in DNA; GFP: green fluorescent protein.  
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5.2.6 In vitro PD-L1 knockdown assay  
To determine whether PEI10-ethyl(25) could also enhance siRNA transfection 
efficiency compared to PEI-10, knockdown of PD-L1 protein was investigated in a 
firefly luciferase expressing SKOV-3 (SKOV-3-Luc) cell line. 
SKOV-3-Luc cells treated with PEI10-ethyl(25)/PD-L1 siRNA polyplexes 
demonstrated higher membranous PD-L1 protein expression compared to cells 
treated with polyplexes formed with PEI-10, at all N/P ratios tested (Figure 5.6). The 
lower siRNA transfection efficiency of PEI10-ethyl(25)/siRNA polyplexes maybe due 
to the smaller number of free amines available in PEI10-ethyl(25), compared to PEI-
10, which are needed to bind siRNA. As mentioned in section 1.8, short and rigid 
siRNA molecules require polymers with higher charge densities for efficient 
transfection. The results show clearly that polymers need to be optimised to suit 
different nucleic acid cargos. In the case of siRNA, a lower conjugation ratio of 
hydrophobic groups to PEI-10 may result in better transfection efficiencies. siRNA 
transfection will be investigated in greater depth in Chapter 6. 
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Figure 5.6. PD-L1 knockdown transfection efficiency in SKOV-3-Luc cells, using 
unmodified or PEI10-ethyl(25) polymer/PD-L1 siRNA polyplexes formed at various 
N/P ratios. (A) Representative flow cytometry plots of membranous PD-L1 
expression in cells treated with either unmodified PEI-10 or PEI10-ethyl(25)/PD-L1 
siRNA polyplexes compared to cells treated with PEI-10/scrambled siRNA 
polyplexes. All polyplexes were formed at N/P 50. (B) Median fluorescent intensity 
(MFI) of membranous PD-L1 protein of SKOV-3 cells represented as a percentage of 
polymer/scrambled siRNA polyplexes-treated cells. Results represent mean ± 
standard error of mean of three independent experiments, each done in triplicate. 
The Student’s T test was used to determine statistical significance between treated 
groups, (*p<0.05). N/P ratio: ratio of nitrogen in polymers to phosphorous content in 
DNA; PD-L1: programmed cell death- ligand 1.  
 
 
5.3 Summary and conclusions  
PEI-10 was modified with various hydrophobic groups namely ethyl, phenylurea and 
benzyl, by ring-opening of functionalized carbonate monomers based on nucleophilic 
addition chemistry. The synthesized product compositions correlated well with 
functional carbonate and PEI-10 feed ratios. The modified PEI-10 polymers were 
able to bind DNA to form cationic particles with an average size of roughly 100 nm. 
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Importantly, modification of PEI-10 with MTC-ethyl at a conjugation degree of 25 
significantly mitigated the cytotoxicity of PEI-10 in both SKOV-3 and OVCAR-3 cells. 
PEI-10 modified with hydrophobic groups, especially ethyl, significantly enhanced 
the GFP transfection efficiencies compared to unmodified PEI-10, even at low N/P 
ratio 10. These findings provide insight for the development of less toxic and more 
effective non-viral gene carriers and show that carriers need to be individually 
optimised for the nucleic acid cargo being delivered. The facile chemistry provided 
by the MTC platform would therefore be extremely helpful in the optimization 
process. In the next chapter, the conjugation of targeting moieties, specifically FA, on 
PEI-10 will be investigated for its influence on PD-L1 therapeutic siRNA delivery in 
ovarian cancer. 
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Chapter 6  
Programmed death-ligand 1 knockdown using folic acid 
functionalized poly(ethylenimine) in ovarian cancer 
 
6.1 Background and aims 
Ovarian cancer remains the most deadly gynaecological cancer despite major 
advances in conventional therapies such as combination chemotherapy and radical 
surgery (Vaughan et al., 2011). The lethality of ovarian cancer and the clinical need 
for alternative forms of treatment have been highlighted in the chapter 1 of the 
thesis. 
The association between PD-L1, expressed on ovarian cancer cells and associated 
monocytes, and decreased cancer immunogenicity has also been discussed at 
length in chapter 1. In this regard, antibodies blocking the interactions between PD-
L1 and its receptor, PD-1, which is expressed on activated T cells as well as other 
APCs, have shown promise in increasing T cell function and reducing tumour burden 
(Maine et al., 2014, Dong et al., 2002, Brahmer et al., 2010, Brahmer et al., 2012, 
Curiel et al., 2003, Hamid et al., 2013, Topalian, Hodi, et al., 2012). However, 
although PD-L1 expression on ovarian tumour cells and associated monocytes has 
been correlated to immune suppression, it remains unknown whether PD-L1 
expressed on other cells in the tumour microenvironment play a role in tumour 
rejection. PD-L1 has demonstrated distinct functions, including anti-tumour 
responses, when expressed on various cell types. For example, PD-L1 expression 
on neurons is required for the induction of apoptosis of glioma cells, via an unknown 
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PD-L1 receptor (Liu et al., 2013). In addition, PD-L1 expression on naïve T cells is 
needed for DC maturation (Talay et al., 2009). Furthermore, PD-L1 protein has also 
been detected on healthy tissues such as the placenta, activated vascular 
endothelial cells and activated hematopoietic cells (Curiel et al., 2003, Dong et al., 
1999, Hamanishi et al., 2007, Zou and Chen, 2008). Physiologically, PD-L1 controls 
immune responses and prevents hyper reactivity of the immune system (Keir et al., 
2008, Latchman et al., 2004, Keir et al., 2006). As such, PD-L1 knockout mice suffer 
from hyper activity of the immune system and various auto immune diseases 
(Latchman et al., 2004). Anti PD-L1 blocking antibodies however, do not distinguish 
among PD-L1 proteins expressed on the various cell types and may upset the 
delicate balance of immune inhibition and stimulation causing sub-optimal anti-
tumour responses or at worse result in adverse outcomes.  
The aim of this chapter is to specifically block PD-L1/PD-1 interactions in cancer by 
the knockdown of PD-L1 expression in ovarian cancer cells, via RNAi mechanisms. 
To confer specificity to the nucleic acid carrier system for ovarian cancer cells, which 
overexpress FRα (Bagnoli et al., 2003, Campbell et al., 1991, Toffoli et al., 1997), 
PEI-10 was modified with FA and PEG-FA functional groups.  
FRα is membrane associated and binds to FA with a binding affinity of (Kd = 10 nM) 
(Kamen and Caston, 1986). It is noteworthy that the conjugation of molecules to FA 
seldom interferes with the high binding affinity of FA to its receptor and thus with its 
endocytosis into the cell (Paulos et al., 2004). In addition, FA mediates FRα 
endocytosis mainly via the caveolin pathway (Rothberg et al., 1990), which forms 
vesicles that do not contain enzymatic mixtures and also do not enter a degradative 
pathway by fusing with lysosomes (see section 1.10.3). However, some studies have 
also shown that FRα endocytosis occurred via the clathrin mediated pathway 
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(Rijnboutt et al., 1996). These properties make FA a popular ligand for conjugation to 
delivery agents. FA modified PEI-10 were then used to complex siRNA or shRNA to 
form polyplexes with FA moieties on the surface. The attachment of FA groups has 
been shown to enhance nanoparticle uptake into cells by receptor mediated 
endocytosis, whereas PEG has been widely used to increase nanoparticle stability in 
serum (Park, 2010). The incorporation of the PEG linker also showed how distance 
between FA and the PEI backbone might affect selectivity of polyplex uptake. In 
addition, a disulphide bond (-S-S-) was included between PEI-10 and the PEG-FA 
functional group to allow for glutathione-sensitive cleavage of PEG-FA from the 
internalized polyplexes, which has been shown to enhance gene transfection 
efficiency (Li, Cheng, et al., 2014, Takae et al., 2008). The highly permeable 
endothelia and poor lymphatic drainage of tumours has been shown to lead to a 
greater accumulation of circulating nanoparticles and this effect has been termed the 
enhanced permeation and retention (EPR) effect (Maeda, 2010). It is envisioned that 
the modified PEI-10/siRNA or shRNA polyplexes can be accumulated at the ovarian 
cancer site based on EPR and specifically internalized by ovarian cancer cells 
through FRα  mediated endocytosis. The modified PEI-10/siRNA or shRNA 
polyplexes were tested for PD-L1 knockdown efficiency on OVCAR-8 and SKOV-3-
Luc ovarian cancer cell lines as well as on primary ovarian cancer cells, which were 
isolated from ovarian cancer patients. Furthermore, the specificity of particle uptake 
into SKOV-3-Luc cells was studied when challenged with the presence of peripheral 
blood mononuclear cells (PBMCs). The PBMCs consists of professional phagocytes 
which form the mononuclear phagocyte system, which typically remove and destroy 
nanoparticles, preventing them from reaching target sites (Moghimi et al., 2001, 
Alexis et al., 2008). It is therefore essential to synthesize nanoparticles which are 
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able to evade unspecific uptake by PBMCs in the body. Some of the data presented 
in this chapter has been published in a recent paper (Teo et al., 2015). 
 
6.2 Results and discussion 
6.2.1 Folic acid and poly(ethylene glycol) modification of 10 kDa poly(ethylenimine) 
To synthesize FA modified PEI-10, FA was either conjugated directly to the PEI-10 
backbone using 1-ethyl-3-(-3-dimethylaminopropyl) carbodiimide hydrochloride 
(EDC)/sulfo-NHS chemistry or conjugated with a PEG linker (Mn = 5000 Da) using 
the PEG-FA functionalized methylcarboxytrimethylene carbonate (MTC-PEG-FA) 
monomer (Figure 6.1 insert). MTC-PEG-FA was designed and newly synthesized for 
the purpose of this work, which has been described in the following publication (Teo 
et al., 2015).  
FA was first reacted with PEI-10, using EDC/NHS chemistry, at a conjugation ratio of 
3. This low conjugation ratio was chosen as FA has limited solubility in water and a 
high conjugation ratio might adversely affect the solubility of the modified polymer in 
aqueous solutions. Moreover, a conjugation ratio of 3 was sufficient to lower the 
charge density of PEI-10, as shown in chapter 5, which may decrease the toxicity of 
the polymer. However, despite these precautions, the resulting polymer, PEI10-
FA(3), was still insoluble in water as well as in methanol. The conjugation ratio was 
therefore decreased to 1, to form PEI10-FA(1), which had no solubility problems. In 
addition, it was important that FA reacted with PEI10 via its γ-carboxyl group and not 
its α-carboxyl group, as the latter was needed for FA receptor binding (Matsue et al., 
1992, Kane and Waxman, 1989). 1H NMR analysis showed that the PEI10-FA(1) 
composition of 1:1 corresponded well with molar feed ratios (Figure 6.1A). However, 
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both the α- and γ-carboxyl groups may have reacted with EDC and formed product 
consisting of an isomer mixture. FA which reacted with EDC via the γ-carboxyl group 
(γ-isomer) should have been purified by high performance liquid chromatography 
(HPLC) as the γ-isomers are more polar than α-isomers. Another method to ensure 
that only the γ-isomers form, would be to include an additional steps of converting 
FA to pteroyl azide and then reacting it with commercially available 5-methyl 
glutamate to form γ-methyl folate before reaction with EDC/NHS (Wang et al., 1997). 
To incorporate a PEG chain between PEI10 and FA, the MTC-PEG-FA was 
synthesized by the conjugation of FA to MTC-PEG via DCC cross-linking in DMSO. 
PEI-10 was also reacted with MTC-PEG-FA, with a 1:1 feed molar ratio, in a typical 
ring-opening reaction, described previously, to form PEI10-PEG-FA(1). 1H NMR 
analysis of PEI10-PEG-FA(1) showed that the conjugation degree of PEI10: PEG-FA 
was 1:1.1 by comparing the relative integral intensities of ether signals (3.6 ppm) and 
benzyl signals (7.5–7.7 ppm) of MTC-PEG-FA with PEI methylene signals (2.4–2.9 
ppm) (Figure 6.1B).  
In addition, PEI10-PEG(1) was also synthesized, by the reaction of PEI-10 with 
MTC-PEG (Figure 6.1C), and used as a control. The chemical compositions of 
modified PEI are summarized in Table 6.1. 
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Figure 6.1. Synthesis of FA and/or PEG modified PEI-10 and chemical 
compositions. PEI-10 reacted with MTC-PEG or MTC-PEG-FA or FA in 1:1 molar 
ratio to form (A) PEI10-FA (1), with the γ-carboxyl group of FA attached, (B) PEI10-
PEG-FA or (C) PEI10-PEG. 1H NMR spectra of PEI10-PEG-FA and PEI10-FA in 
D2O. Insert: 
1H NMR spectra of MTC-SSPEG-FA in DMSO-d6. MTC: methyl-
carboxytrimethylene carbonate; PEI: polyethylenimine; FA: folic acid; PEG: 
polyethylene glycol; NMR: nuclear magnetic resonance spectroscopy; DMSO: 
dimethyl sulfoxide; D2O: deuterium oxide; Mn: number average molecular weight; 
ppm: parts per million. 
 
 
 
Table 6.1. Composition of unmodified and modified PEI-10 polymers. 
Polymer ID Conjugate group Mole ratioa 
(PEI-10:conjugate group) 
PEI-10 - - 
PEI10-FA(1) FA 1:1 
PEI10-PEG(1) MTC-PEG 1:0.8 
PEI10-PEG-FA(1) MTC-PEG-FA 1:1.1 
a PEI-10:MTC conjugate group mole ratio is based on 1 mole PEI-10 =10 000 g and 
58 primary amine groups per mole.  
MTC: methyl-carboxytrimethylene carbonate; PEI: polyethylenimine; FA: folic acid; 
PEG: polyethylene glycol. 
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6.2.2 siRNA binding and stability studies  
In chapter 5, modified PEI-10 polymers with various degrees of hydrophobic group 
conjugation, have been shown to be able to bind plasmid DNA. However, due to the 
differences in size and thus binding mechanisms of plasmid DNA and siRNA which 
were highlighted in chapter 1, it was important to check whether modified PEI-10 
could also bind siRNA effectively. The siRNA binding ability of modified and 
unmodified PEI-10 polymers was therefore investigated by the SYBR green® siRNA 
binding assay. Unbound siRNA intercalates with SYBR green® and emits a 
fluorescence which can be measured by a plate reader. A lowered fluorescence is 
indicative of polymer/siRNA binding. 
Figure 6.2A shows that all polymers, regardless of modification group, were able to 
bind siRNA to form polyplexes. The lowest N/P ratio needed to maximally reduce 
fluorescence was shown to be N/P ratio 8 for polymers without PEG (PEI-10 and 
PEI10-FA(1)) and 10 for polymers with PEG (PEI10-PEG(1) and PEI10-PEG-FA(1)). 
The higher N/P ratio needed for PEG conjugated polymers to completely bind siRNA 
might be due to the charge shielding effect of PEG, which lowers the charge density 
of the polymers (Kumar et al., 2014). Consequently, a higher concentration of PEG 
conjugated polymers were needed to completely bind siRNA. In this regard, 
polymer/siRNA polyplexes formed at N/P ratio 10 and above were tested for PD-L1 
knockdown efficiencies in ovarian cancer cells.  
In addition, the stability of polyplexes greatly influences transfection efficiencies 
(Wightman et al., 2001). In order for siRNA to initiate RNAi, it has to dissociate from 
the polymer and bind to RISC for mRNA degradation (Scholz and Wagner, 2012). As 
such, the stability of the polyplexes, when challenged with the presence of increasing 
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concentrations of anionic heparin, was investigated using the SYBR green® siRNA 
binding assay. Figure 6.2B shows that 50% of siRNA bound to modified polymers, 
regardless of functional group, were released at a heparin concentration of ~0.25 
mg/mL, whereas a higher concentration of heparin (~0.5 mg/mL) was needed to 
release the same amount of siRNA bound to unmodified PEI-10. The difference in 
stability of modified and unmodified PEI-10/siRNA polyplexes may be attributed to 
the number of free amines available on the polymer. The availability of free amines, 
which is determined by conjugation ratio of functional groups to PEI-10, has been 
shown to be the primary factor influencing stability of polyplexes (Teo et al., 2013).  
 
 
Figure 6.2. siRNA binding and stability studies of polymer/siRNA polyplexes. (A) 
siRNA binding is measured as a decrease in relative fluorescence of SYBR green® 
dye. (B) Stability of polymer/siRNA polyplexes challenged with increasing 
concentrations of heparin. A relative fluorescence of 100% indicates SYBR green® 
dye intercalated with free siRNA, while 0% corresponds to the fluorescence of non-
intercalating dye. Results represent mean ± standard error of mean of two 
independent experiments, each performed with eight replicates. PEI: 
polyethylenimine; FA: folic acid; PEG: polyethylene glycol; N/P ratio: ratio of nitrogen 
in polymers to phosphorous content in DNA.  
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6.2.3 Size and zeta potential measurements 
To measure the size and zeta potential, polyplexes were formed and monitored by 
dynamic light scattering (DLS) measurements. PEG conjugated PEI-10 formed 
larger sized particles (167–244 nm) when bound with siRNA than PEI-10 polymers 
without PEG (104-110 nm) (Table 6.1). Therefore, all polymers (with the exception of 
PEI10-PEG(1)) bound siRNA to form polyplexes with sizes below 200 nm. The larger 
size of PEI10-PEG(1)/siRNA polyplexes may be attributed to the flexible PEG chains 
which enable folding, thus reducing the compactness of the polyplex (Cruz et al., 
2011). Although PEG may produce polyplexes with larger sizes, it might improve 
serum stability of the nanoparticles and prevent aggregation. In general, Polyplexes 
with sizes ~100 nm are able to accumulate in regions of leaky vasculature in tumours 
and polyplexes of smaller sizes (~60 nm) are able to diffuse more readily through the 
interstitium and more deeply penetrate tissues (Jain and Stylianopoulos, 2010). 
Efforts to further reduce particle sizes should be made for the development of more 
efficient nucleic acid carriers. 
The zeta potential measurements reveal that modified PEI-10/siRNA polyplexes had 
a reduction in cationic charge, but still remained positively charged (22–29 mV), 
compared to unmodified PEI-10/siRNA particles (≈37 mV) (Table 6.1). A cationic 
charge mediates intracellular uptake by the process of endocytosis as it increases 
polyplex interaction with anionic charged phospholipid head groups or protein 
domains, such as salicylic acid, and syndecan, on the plasma cell membrane 
(Gratton et al., 2008, Kopatz et al., 2004). However, endocytosis of siRNA as a 
preferred route of intracellular uptake of cationic polyplexes may also pose as a 
disadvantage. The process of endocytosis increases the chance for siRNA to 
interact with toll-like receptors (TLRs) in the endosomal compartments of immune 
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cells as well as with pattern recognition receptors, RIG-I and PKR, which are present 
in most cell types. These interactions may trigger immune-stimulation and cause the 
production of various cytotoxic cytokines including type I interferons, interleukins and 
tumour necrosis factor-α (Kanasty et al., 2012). The use of targeted polyplexes 
which delivery siRNA into target cancer cells may serve to mitigate such undesirable 
effects.  
 
Table 6.2. Size, PDI and zeta potential measurements of unmodified and modified 
PEI/siRNA polyplexes formed at N/P ratio 50. 
Polymer ID Size 
(nm) 
PDI Zeta potential 
(mV) 
PEI-10 110 ± 4 0.19 36.8 ± 2.3 
PEI10-FA(1) 104 ± 2 0.29 28.6 ± 1.6 
PEI10-PEG(1) 224 ± 2 0.35 23.1 ± 2.6 
PEI10-PEG-FA(1) 167 ± 2 0.26 22.8 ± 1.2 
PDI: polydispersity index; MTC: methyl-carboxytrimethylene carbonate; PEI: 
polyethylenimine; FA: folic acid; PEG: polyethylene glycol. 
 
6.2.4 Cytotoxicity of polyplexes 
The cytotoxicity of the polyplexes was investigated by the MTT cell viability assay. 
The cell viability of SKOV-3-Luc cells was significantly higher when treated with 
modified PEI-10/siRNA polyplexes compared to unmodified PEI-10/siRNA 
polyplexes at N/P 40 and above (Figure 6.3). This may be due to the lower charge 
density of modified PEI/siRNA polyplexes compared to unmodified PEI (Table 6.1). A 
single conjugation of PEI-10, regardless of functional group, significantly reduced the 
cytotoxicity of PEI-10. This allows higher N/P ratios to be used to maximize PD-L1 
knockdown while maintaining high cell viability. The lower cytotoxicity of modified 
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PEI-10 make them better siRNA transfecting agents than their unmodified 
counterpart. 
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Figure 6.3. Viability of SKOV-3-Luc cells after treatment with modified or unmodified 
PEI-10/siRNA polyplexes, formed at various N/P ratios, analysed by the MTT assay. 
Results represent mean ± standard error of mean of three independent experiments, 
each performed with eight replicates. The one-way ANOVA and Dunnett’s post-hoc 
analysis were used to calculate statistical significance between modified PEI-10 and 
unmodified PEI-10, (* p < 0.05). N/P ratio: ratio of nitrogen in polymers to 
phosphorous content in DNA; MTT: 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide; PEI: polyethylenimine; FA: folic acid; PEG: 
polyethylene glycol. 
 
6.2.5 In vitro PD-L1 knockdown studies in ovarian cancer cell lines using PD-L1 
siRNA 
To determine whether the modification of PEI-10 enhanced siRNA knockdown, the in 
vitro PD-L1 knockdown experiment was performed by treating SKOV-3-Luc or 
OVCAR-8 cells with polyplexes formed at N/P ratios ranging from 10 to 80. The 
unmodified PEI-10 served as the control and commercially available transfection 
agents were not used. Commercially available pooled PD-L1 siRNA was used for the 
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experiments and the regions of PD-L1 mRNA where they target are shown in 
Appendix 6.1. The PD-L1 cell surface expression was analysed by flow cytometry 
and imaged using confocal microscopy. PD-L1 protein is present both in the 
intracellular space as well as on the plasma membrane, as shown by confocal 
imaging (Figure 6.4). The role of PD-L1 as a co-inhibitory ligand, requires the protein 
to be presented on the plasma cell membrane. Therefore, the cell surface 
expression of PD-L1 protein was closely monitored in this work. Nevertheless, the 
total PD-L1 protein content in SKOV-3-Luc cell lysate was also compared when cells 
were treated with polyplexes. In addition, PD-L1 mRNA was determined after 
treatment with PD-L1 siRNA using quantitative real time-polymerase chain reaction 
(rt-PCR).  
Firstly the optimisation of siRNA dose was performed by using PEI-10 as a 
transfecting agent and determining membranous PD-L1 protein expression by flow 
cytometry. Figure 6.5 shows that the minimum dose of siRNA needed was 200 nM at 
various PEI-10 concentrations. 200 nM of siRNA was therefore used in experiments. 
Exogenous siRNAs share components of the RNAi pathway with endogenous 
miRNAs and competition for RNAi machinery may block normal gene regulation by 
miRNAs which leads to toxicity (Kanasty et al., 2012). Precautions have to be taken 
to use minimal concentrations of siRNA to achieve maximal knockdown levels 
without causing cytotoxicity. 
When optimising N/P ratios of polymer to siRNA, it is observed by flow cytometry 
that the higher the N/P ratio, the greater the PD-L1 knockdown (Figure 6.6A). 
Although all polymers were able to knockdown PD-L1, polymers without PEG (PEI-
10 and PEI10-FA(1)) mediated higher transfection efficiency and resulted in a lower 
PD-L1 protein expression (51%-55%) on SKOV-3-Luc cells compared to polymers 
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with PEG (PEI10-PEG(1) and PEI10-PEG-FA(1)) which resulted in protein 
expression of 62%-65%, using N/P ratios 50 and 80 (Figure 6.6A). This is consistent 
with previous work reporting that polymers with PEG conjugation resulted in 
decreased nucleic acid transfection efficiencies (Knorr et al., 2008, Zhang et al., 
2010). It has been postulated that PEG chains shield the charges of polyplexes and 
this may lead to decreased cell internalization and thus lower transfection 
efficiencies (Moghimi et al., 2001). The lower surface charge of PEG modified PEI-
10 was observed (22.8-23.1 mV) compared to polymers without PEG modification 
(28.6-36.8 mV) (Table 6.1). Notably, although both PEI-10 and PEI10-FA(1)/PD-L1 
siRNA polyplexes resulted in similar levels of PD-L1 knockdown, PEI10-FA(1)/PD-L1 
siRNA polyplexes have a substantially lower toxicity profile compared to unmodified 
PEI-10/siRNA polyplexes (Figure 6.3). PD-L1 protein knockdown was also 
demonstrated in SKOV-3-Luc cells, treated with PEI10-FA(1)/PD-L1 siRNA 
polyplexes formed at N/P 50, by confocal imaging in Figure 6.6E. Western blot data 
also shows PD-L1 knockdown in SKOV-3-Luc cell lysate after treatment with PEI10-
FA(1)/PD-L1 siRNA polyplexes as compared to untreated and PEI10-
FA(1)/scrambled siRNA treated controls (Figure 6.6F). To ensure that PD-L1 
knockdown could be achieved across different ovarian cancer cell lines, OVCAR-8 
cells were also treated with PEI10-FA(1)/PD-L1 siRNA polyplexes, formed at N/P 50, 
and a membranous PD-L1 protein expression of ~75% was obtained three days post 
transfection (Figure 6.7). 
However, despite the high dose of PD-L1 siRNA used, PD-L1 protein expression 
remained above 50%. This was undesirable as the membranous expression of PD-
L1 may still function to inhibit T cell activity via interaction with the PD-L1 receptor, 
PD-1. To determine whether the problem lies in the transfection efficiencies of the 
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polymers, the PD-L1 mRNA level in SKOV-3-Luc cells was determined, after 
treatment with polyplexes formed at N/P 50. Figure 6.6C shows that the polyplexes 
resulted in final PD-L1 mRNA expressions of 17.4%-40%, with PEI10-FA(1) and 
PEI10-PEG-FA(1) polymers mediating the greatest knockdowns. The low mRNA 
levels obtained suggests that the polyplexes were able to effectively transfect the 
cells and that the discrepancy between mRNA levels (17.4%–40%) and higher 
protein levels (53%–65%) may be due to post translational processes such as 
ribosome activity and protein degradation. This observation has also been reported 
by other groups (Wennemers et al., 2012, Wu et al., 2004).  
In this regard, it was hypothesized that the analysis of protein expression three days 
post transfection might not be sufficient to observe pronounced PD-L1 protein 
knockdown. Membranous PD-L1 expression as well as corresponding mRNA levels 
were thus analysed at different time points of 3, 4, 6 and 10 days post transfection. 
Figure 6.6B shows that SKOV-3-Luc cells treated with PEI10-FA(1)/siRNA 
polyplexes maintained stable PD-L1 protein expression up to ten days post 
transfection. Similarly, PD-L1 mRNA expression remained low and stable up to six 
days post transfection, however, it started to increase ten days post transfection 
(Figure 6.6D).  
These results demonstrated that a single treatment of PEI10-FA(1) was sufficient to 
maintain low PD-L1 protein expression (≈60% protein expression) as well as mRNA 
expression (≈20%) for up to 6 days post transfection. Importantly, PEI10-FA(1) had 
significantly mitigated cytotoxicity compared to unmodified PEI-10, making it a better 
transfection agent than its unmodified counterpart. In addition, PEI10-PEG-FA(1) 
also mediated in vitro PD-L1 knockdown and had lower toxicity compared to 
unmodified PEI-10. As PEG has been shown to improve serum stability, PEI10-PEG-
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FA(1) will also be investigated in in vitro functional studies and future in vivo studies. 
Functional studies of PD-L1 knockdown SKOV-3-Luc and OVCAR-8 cells are 
reported in chapter 7.  
 
Figure 6.4. (A) Cell surface membrane and (B) intracellular expression of PD-L1 
protein (red) in untreated SKOV-3-Luc cells. Cell nuclei (blue) are stained with 
Hoechst 33342. Scale bar: (A) 20 µm and (B) 100 µm. PD-L1: programmed cell 
death- ligand 1. 
 
 
 
 
 
(B)(A)
177 
 
  
Figure 6.5. Membranous PD-L1 protein expression on SKOV-3-Luc cells after 
treatment with PEI-10 polymer and different doses of siRNA, formed at N/P ratio 50. 
(A) Representative flow cytometry plots of membranous PD-L1 expression in cells 
treated with PEI-10/PD-L1 siRNA polyplexes compared to cells treated with PEI-
10/scrambled siRNA polyplexes. (B) Median fluorescent intensity (MFI) of 
membranous PD-L1 protein of SKOV-3 cells represented as a percentage of 
polymer/scrambled siRNA polyplexes-treated cells. Results represent mean ± 
standard error of mean of two independent experiments, each performed in triplicate. 
N/P ratio: ratio of nitrogen in polymers to phosphorous content in DNA; PD-L1: 
programmed cell death- ligand 1.  
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Figure 6.6. PD-L1 knockdown assessed in SKOV-3-Luc cells, using unmodified or 
modified PEI-10 polymer/PD-L1 siRNA polyplexes. (A, B) Median fluorescent 
intensity (MFI) of membranous PD-L1 protein and (C, D) mRNA expression of 
SKOV-3-Luc cells represented as a percentage of polymer/scrambled siRNA 
10 20 30 40 50 80
0
20
40
60
80
100
120
P
D
-L
1
 p
ro
te
in
 e
x
p
re
s
s
io
n
 a
s
 a
 p
e
rc
e
n
ta
g
e
 
o
f 
s
c
ra
m
b
le
d
 s
iR
N
A
 t
re
a
te
d
 c
o
n
tr
o
ls
 (
%
)
N/P ratio
 PEI-10
 PEI10-FA(1)
 PEI10-PEG(1)
 PEI10-PEG-FA(1)
3 4 6 10
0
20
40
60
80
100
P
D
-L
1
 p
ro
te
in
 e
x
p
re
s
s
io
n
 a
s
 a
 p
e
rc
e
n
ta
g
e
 o
f 
s
c
ra
m
b
le
d
 s
iR
N
A
 t
re
a
te
d
 c
o
n
tr
o
ls
 (
%
)
Time after siRNA treatment (days)
NS
(A)
(B)
C
o
u
n
t
PD-L1 expression
PEI10-FA/
PD-L1 siRNA
PEI10-PEG-FA/
PD-L1 siRNA
Scramble siRNA 
treated control
(Polyplexes
formed at 
N/P 50)
Isotype
C
o
u
n
t
PD-L1 expression
Isotype Day 3
Day 10
Scramble siRNA 
treated control
(Day 3)
(Polyplexes
formed at 
N/P 50)
PD-L1 
siRNA 
PE
I-1
0
PE
I10
-F
A(
1)
PE
I10
-P
EG
(1)
PE
I10
-P
EG
-F
A(
1)
0
20
40
60
80
100
*
NS
P
D
-L
1
 m
R
N
A
 e
x
p
re
s
s
io
n
 a
s
 a
 p
e
rc
e
n
ta
g
e
 o
f 
s
c
ra
m
b
le
d
 s
iR
N
A
 t
re
a
te
d
 c
o
n
tr
o
ls
 (
%
)
NS
PD-L1
Calnexin100
55
40
U
n
tr
e
a
te
d
 c
o
n
tr
o
l
S
c
ra
m
b
le
d
 s
iR
N
A
P
D
-L
1
 s
iR
N
A
PEI10-FA(1)/
scrambled siRNA
PEI10-FA(1)/
PD-L1 siRNA
3 4 6 10
0
20
40
60
80
100
*
P
D
-L
1
 m
R
N
A
 e
x
p
re
s
s
io
n
 a
s
 a
 p
e
rc
e
n
ta
g
e
 o
f 
s
c
ra
m
b
le
d
 s
iR
N
A
 t
re
a
te
d
 c
o
n
tr
o
ls
 (
%
)
Time after siRNA treatment (days)
NS
(C) (D)
(E)
(F)
179 
 
polyplexes-treated cells. (A, left panel) PD-L1 protein expression 3 days post 
transfection using polymer/siRNA polyplexes at various N/P ratios. (B, left panel) PD-
L1 protein expression at various time points, up to ten days, post transfection using 
PEI10-FA(1)/siRNA polyplexes formed at N/P 50. (Right panel of A and B) 
Representative flow cytometry plots of membranous PD-L1 knockdown in SKOV-3-
Luc cells. (C) PD-L1 mRNA expression assessed 3 days post transfection with 
polymer/siRNA polyplexes formed at N/P 50. (D) mRNA expression at various time 
points, up to ten days, post transfection using PEI10-FA(1)/siRNA polyplexes formed 
at N/P 50. Results represent mean ± standard error of mean of four independent 
experiments, each with eight replicates. E) Confocal images of SKOV-3-Luc cell 
membranous PD-L1 (red) expression after treatment with PEI10-FA(1)/PD-L1 siRNA 
compared to PEI10-FA(1)/scrambled siRNA treated control. Cell nuclei (blue) are 
stained with Hoechst 33342. Scale bar: 100 µm. F) Western blot data (n=2) of total 
PD-L1 protein levels in SKOV-3-Luc cells 3 days post transfection with PEI10-
FA(1)/scrambled or PD-L1 siRNA polyplexes formed at N/P 50. The one-way 
ANOVA and Dunnett’s post-hoc analysis were used to calculate statistical 
significance between modified PEI-10 and unmodified PEI-10, (* p < 0.05). PD-L1: 
programmed cell death- ligand 1; N/P ratio: ratio of nitrogen in polymers to 
phosphorous content in DNA; FA: folic acid; PEG: polyethylene glycol; NS: not 
significant. 
 
 
Figure 6.7. Membranous PD-L1 expression on OVCAR-8 cells analysed three days 
post transfection with PEI10-FA(1)/PD-L1 siRNA polyplexes at (A) various N/P 
ratios. Results represent mean ± standard error of mean of three independent 
experiments, each performed in triplicate. (B) Representative histogram of 
membranous PD-L1 expression after treatment with PEI10-FA/siRNA polyplexes 
formed at N/P 50. Grey histogram represents antibody isotype control, blue filled 
histogram and red open histogram represent PD-L1 expression after SKOV-3-Luc 
cells were treated with PEI10-FA(1)/scrambled siRNA and PEI10-FA(1)/PD-L1 
siRNA polyplexes respectively. PD-L1: programmed cell death- ligand 1; N/P ratio: 
ratio of nitrogen in polymers to phosphorous content in DNA. 
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6.2.6 PD-L1 knockdown studies in ovarian cancer cell lines using PD-L1 shRNA 
Previous studies have shown that shRNA may be more efficient than siRNA in 
mediating knockdown effects as it assimilates into the endogenous microRNA 
(miRNA) pathway and is more stable than siRNA as shRNA is in a vector form 
(McAnuff et al., 2007, Siolas et al., 2005). To determine whether the expression of 
membranous PD-L1 protein could be reduced by using shRNA compared to siRNA, 
SKOV-3-Luc cells were treated with PEI10-FA(1)/PD-L1 shRNA polyplexes, and 
analysed by flow cytometry. Five commercially available PD-L1 shRNA sequences 
were used for the knockdown experiments and regions of PD-L1 mRNA where they 
target are shown in Appendix 6.1. PEI10-FA(1)/PD-L1 shRNA polyplexes were 
formed at N/P ratio 30 which equated to the same concentration (18 µg/mL) of 
polymer used when forming polyplexes with siRNA at N/P 50. 
The PD-L1 expression of SKOV-3-Luc cells was first analysed three days post 
transfection with shRNA polyplexes. However, no protein knockdown was achieved 
(data not shown). PD-L1 protein knockdown was only observed after selection with 
puromycin for eleven days post transfection (Figure 6.8). Membranous PD-L1 protein 
expression was analysed weekly over a period of three weeks. Figure 6.8 shows that 
the shRNA sequences 5 and 9 mediated the highest PD-L1 knockdown (58-62%) to 
form stable cell lines named C5 and C9. Stable cell lines were cultured as pooled 
cells and not as clones from single cells. SKOV-3-Luc cells transfected with 
scrambled shRNA formed the stable cell line named Cscr. Knockdown by shRNA 
resulted in similar knockdown efficiencies achieved by siRNA (Figure 6.6A). 
Interestingly, the PD-L1 expression remained stable over three weeks, as seen by 
the small error bars depicting standard error of mean (Figure 6.8), despite generation 
of stable PD-L1 knockdown cell lines and long term culture (5 weeks). The low 
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knockdown efficiency of shRNA was not surprising as SKOV-3 cells have previously 
been shown to express low levels of Dicer mRNA (Merritt et al., 2008).  Dicer is 
needed to cleave short, hairpin-shaped double stranded RNA precursors (60 to 70 
base pairs), which are produced after transcription of shRNA in the nucleus, into 
shorter miRNAs (19 to 21 base pairs) that can be loaded onto RISC for RNAi. In 
addition, the levels of Dicer and Drosha mRNA were downregulated in 60% and 51% 
of ovarian cancer specimens, respectively (Merritt et al., 2008). shRNA may 
therefore not be an ideal nucleic acid to mediate RNAi in ovarian cancer cells. 
Nevertheless, PEI10-FA(1)/shRNA sequence 5 and 9 resulted in lower PD-L1 
expressions in SKOV-3-Luc cells after transfection and antibiotic selection. 
 
 
Figure 6.8. Membranous PD-L1 expression on SKOV-3-Luc cells analysed two to 
five weeks post transfection with PEI10-FA(1)/PD-L1 shRNA polyplexes formed at 
N/P 30 and after selection with puromycin (0.1 mg/mL). There were a total of 5 
different PD-L1 shRNA sequences which formed stable cell lines named C1-5. 
SKOV-3-Luc cells transfected with scrambled shRNA formed the stable cell line 
named Cscr. (A) Results represent mean ± standard error of mean of three 
independent experiments. (B) Representative histogram of membranous PD-L1 
expression 24 days post transfection. Grey histogram represents antibody isotype 
control, blue filled histogram represents PD-L1 expression after SKOV-3-Luc cells 
were treated with PEI10-FA(1)/scrambled shRNA polyplexes and red and green 
open histrograms represent PD-L1 expression after SKOV-3-Luc cells were treated 
with PEI10-FA(1)/C5 and C9 shRNA polyplexes. PD-L1: programmed cell death- 
ligand 1; N/P ratio: ratio of nitrogen in polymers to phosphorous content in DNA. 
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6.2.7 PD-L1 knockdown studies in isolated primary ovarian cancer cells using PD-
L1 siRNA 
Transfection of primary cells serves as an essential tool for therapeutic applications. 
In this regard, isolated primary ovarian cancer cells were treated with PEI10-
FA(1)/PD-L1 siRNA polyplexes, formed at N/P ratio 50. Membranous PD-L1 
expression was then analysed using flow cytometry.  
Due to the low availability of primary cells, the experiment could only be performed 
once and transfection resulted in a 17% PD-L1 knockdown, compared to scrambled 
siRNA treated controls (Figure 6.9). Primary cells are known to be more difficult to 
transfect than cell lines (Gresch and Altrogge, 2012). The reasons for the low 
transfection efficiencies of primary cells remains unknown, however, one of the 
contributing factors may be the lower dividing rates of primary cells. Although viral 
transduction and electroporation methods have shown higher efficiencies than non-
viral nucleic acid delivery methods, safety problems as well as lack of versatility for in 
vivo use still persist for the respective methods (Gresch and Altrogge, 2012). 
Continual optimisation steps, such as determining the siRNA dose or N/P ratios of 
polymer/siRNA polyplexes, are needed to test for the best conditions necessary for 
primary ovarian cancer cell transfection.  
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Figure 6.9. Membranous PD-L1 expression on primary ovarian cancer cells 
assessed three days post transfection with PEI10-FA(1)/PD-L1 siRNA polyplexes, 
formed at N/P ratio 50. The experiment was performed once due to the lack of cells. 
 
6.2.8 In vitro folic acid competition assay 
To determine whether FA conjugation increases the uptake of polyplexes into SKOV-
3-Luc cells, the intracellular uptake of Alexa Fluor 488 tagged siRNA was compared 
when cells were incubated with PEI10-FA(1) and PEI-10 as well as PEI10-PEG-
FA(1) and PEI10-PEG(1)/siRNA polyplexes. SKOV-3-Luc cells were incubated with 
the polyplexes in the presence of increasing concentrations of free FA for 4 h. If 
intracellular uptake was driven by FA mediated endocytosis, it is expected that 
SKOV-3-Luc cells treated with PEI10-FA(1) and PEI10-PEG-FA(1)/siRNA polyplexes 
will have lower siRNA uptake than PEI-10 and PEI10-PEG(1)/siRNA polyplexes 
correspondingly. 
Figure 6.10A shows that free FA concentration of 1 to 100 µg/mL did not cause any 
change to siRNA uptake compared to conditions without free FA in the cell culture 
media. At these concentrations, PEI-10 and PEI10-FA(1) showed marginally higher 
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siRNA uptake into SKOV-3-Luc cells than PEI10-PEG(1) and PEI10-PEG-
FA(1)/siRNA polyplexes. This could be due to the higher charge density of non-PEG 
conjugated PEI-10 polymer/siRNA polyplexes (28.6-36.8 mV) compared to polymers 
with PEG (22.8-23.1 mV) (Table 6.1). Intracellular uptake of these polyplexes may 
therefore be primarily driven by charge at FA concentrations 0-100 µg/mL. 
Interestingly, at FA concentration of 1000 µg/mL, PEI-10 and PEI10-FA(1) mediated 
substantially higher siRNA uptake than PEI10-PEG(1) and PEI10-PEG-FA(1) into 
SKOV-3-Luc cells (Figure 6.10A). It is possible that free anionic FA present in the 
cell culture media bound to positively charged polyplexes to mediate better siRNA 
uptake. Since PEI-10 and PEI10-FA(1)/siRNA polyplexes were more positively 
charged than PEI10-PEG(1) and PEI10-PEG-FA(1)/siRNA polyplexes (Table 6.1), 
they may bind to free FA better, leading to the increased cellular uptake. However, 
more experiments determining free FA binding, polyplex size and charge will need to 
be performed to make any conclusive statements. Minimal siRNA uptake was 
observed when free FA concentrations were 2000-5000 µg/mL (Figure 6.10A) as FA 
was toxic to cells at high concentrations.  
To eliminate possible interactions between free FA and polyplexes in the cell culture 
media, the experiment was performed differently by pre-incubating SKOV-3-Luc cells 
with free FA for 1 h, to allow for FRα endocytosis (Paulos et al., 2004). The cells 
were then washed to remove free FA in the media before adding the polyplexes to 
the cells for a further 4 h incubation. Figure 6.10B showed that all concentrations of 
free FA did not cause any changes in siRNA uptake of polyplexes, compared to 
conditions without free FA. In addition, siRNA uptake was observed when cells were 
treated with high concentrations of free FA (2000-5000 ppm) as the pre-incubation of 
the cells with free FA, at all concentrations tested, for 1 h did not show observable 
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cellular toxicity and phenotypic changes. PEI-10 and PEI10-FA(1) showed marginally 
higher siRNA uptake into SKOV-3-Luc cells than PEI10-PEG(1) and PEI10-PEG-
FA(1)/siRNA polyplexes at all concentrations of FA (Figure 6.10B). The results 
indicate that uptake of the polyplexes was not primarily driven by FA mediated 
endocytosis and may be charge-driven instead. This could be due to the slower 
internalization kinetics of caveolin-mediated endocytosis (uptake half-time on the 
order of 20 minutes), which is the primary mechanism of FA endocytosis, compared 
to clathrin-mediated endocytosis which occurs due to ionic interactions with the 
plasma membrane (Kanasty et al., 2012). In addition, no spike in intracellular siRNA 
uptake by PEI-10 and PEI10-FA(1)/siRNA polyplexes at FA concentration of 1000 
µ/mL was observed (Figure 6.10B). This indicates that the increased siRNA uptake 
observed when cells were treated with PEI-10 and PEI10-FA(1)/siRNA polyplexes in 
the presence of 1000 µ/mL free FA might be due to the interaction between free FA 
and the polyplexes (Figure 6.10A).  
As a whole, FA modified PEI-10 did not increase uptake of siRNA compared to PEI-
10 without FA conjugation. Instead, cellular uptake of the polyplexes might be driven 
primarily by charge. Furthermore, FA conjugation to PEI10 and MTC-PEG chains 
occurred via both the α- and γ-carboxylic acid reaction with EDC linker. It was 
demonstrated that only FA conjugates attached at the γ-carboxyl moiety retained the 
ability to bind to cell surface FRα with the same affinity as free FA (Wang et al., 
1996). In addition, there may exists an optimum number of FA molecules which 
needs to be presented on the polyplex surface before FA mediated endocytosis can 
occur (Poon et al., 2010). Poon et al. showed that increase in nanoparticle uptake 
only occurred when FA ligands, conjugated to dendrimers, were presented to the cell 
in a cluster arrangement (Poon et al., 2010). PEI-10 may need to be decorated by 
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more FA molecules for FA mediated endocytosis. This may be done by increasing 
the conjugation ratio of MTC-PEG-FA to PEI-10. However, precaution has to be 
taken when increasing the conjugation degree of PEG chains on PEI-10 as PEG has 
been shown to stimulate the immune response and may lead to systemic cytotoxicity 
(Zolnik et al., 2010). Moreover, the number of available FA receptors might be a 
limiting factor as recycling of the receptor back to the cell surface is dependent on 
the dissociation of the ligand and the receptor, which requires the mildly acidic 
environment of the endosome (Wibowo et al., 2013). However, the conjugated PEI10 
may buffer the endosome and prevent release of free FRα. This would therefore limit 
the number of free FRα available on the cell surface.  
 
 
Figure 6.10. Intracellular uptake of Alexa Fluor 488 labelled siRNA after SKOV-3-
Luc incubation with polyplexes, formed at N/P 50, (A) in the presence of various 
concentrations of free FA or (B) after pre-incubation of the cells with various 
concentrations of free FA. Results represent mean of two independent experiments, 
each performed in triplicate. PEI: polyethylenimine; FA: folic acid; PEG: polyethylene 
glycol; MFI: median fluorescent intensity; N/P ratio: ratio of nitrogen in polymers to 
phosphorous content in DNA. 
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6.2.9 In vitro targeting and specific uptake studies of folic acid conjugated 
poly(ethylenimine)/siRNA polyplexes 
Although FA conjugated polymers did not show increase of intracellular siRNA 
uptake, FA modification might have an influence on the type of cells which 
internalizes the polyplexes. To investigate selectivity of polyplex uptake, 
polymer/Alexa Fluor 488 labelled siRNA polyplexes were incubated with 5-(and 6)-
carboxyfluorescein diacetate succinimidyl ester (CFSE) labelled SKOV-3-Luc cells 
which were co-cultured with PBMCs, which do not over express FRα, in a 1:1 ratio. 
The intracellular siRNA uptake was quantified using MFI measured by flow 
cytometry.  
To determine the uptake of siRNA by SKOV-3-Luc cells a gate was drawn around 
the SKOV-3-Luc cell population (Figure 6.11Ai) and the MFI of Alexa Fluor labelled 
siRNA was measured in the CFSE-expressing cell population (Figure 6.11Aii). 
SKOV-3-Luc cells incubated with modified PEI/siRNA polyplexes had higher MFI 
values (234 ± 4 to 245 ± 21) compared to cells incubated with PEI-10/siRNA 
polyplexes (186 ± 15) (Figure 6.11Aiv). A representative histogram of siRNA uptake 
mediated by PEI-10 and PEI10-FA(1) into SKOV-3-Luc cells is shown in Figure 
6.11Aiii.  
To investigate the siRNA uptake into PBMCs, a gate was drawn around the PBMC 
population using the FlowJo (Tree Star) software (Figure 6.11Bi). As tumour cells are 
much larger than PBMCs, no CFSE positive cells were observed in the PBMC gate 
(Plot not shown). The MFI of siRNA was then studied in the CFSE-negative cell 
population. PBMCs incubated with PEI10-FA(1)/siRNA or PEI10-PEG-FA(1)/siRNA 
polyplexes resulted in lower MFI values (402 ± 8 and 446 ± 45, respectively) 
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compared to PEI-10/siRNA polyplexes (509 ± 36) (Figure 6.11Biii). A representative 
histogram of siRNA uptake mediated by PEI-10 and PEI10-FA(1) into PBMCs is 
shown in Figure 6.11Biii. It is unsurprising that the PBMCs, which consist of 
professional phagocytic cells such as monocytes, showed higher uptake of siRNA 
than SKOV-3-Luc tumour cells. Despite the phagocytic nature of the monocytes, 
PEI10-FA(1) and PEI10-PEG-FA(1) demonstrated lower unspecific uptake of siRNA 
into PBMCs compared to PEI-10/siRNA and PEI10-PEG(1)/siRNA polyplexes. 
Therefore, both FA conjugated polymers showed increased siRNA uptake into 
SKOV-3-Luc cells and a reduction in unspecific uptake into PBMCs. This observation 
was more pronounced when PEI10-FA(1) polymer was used.  
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Figure 6.11. Intracellular uptake of Alexa Fluor 488 siRNA into (A) CFSE labelled 
SKOV-3-Luc cells or (B) unlabeled PBMCs. SKOV-3-Luc cells were co-cultured with 
PBMCs at 1:1 ratio and treated with polyplexes, formed at N/P ratio 50. Median 
fluorescent intensity (MFI) of internalized siRNA in specific cell populations was 
measured using flow cytometry by analysing the CFSE positive (SKOV-3-Luc) or 
negative populations (PBMC). Results represent mean ± standard error of mean of 
three individual experiments with three different donors. The one-way ANOVA and 
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Tukey’s post-hoc analysis were used to calculate statistical significance among 
groups. CFSE: 5-(and 6)-carboxyfluorescein diacetate succinimidyl ester; PBMC: 
peripheral blood mononuclear cells; PEI: polyethylenimine; PEG: polyethylene 
glycol; FA: folic acid; PD-L1: programmed cell death- ligand 1. 
 
6.2.10 PD-L1 protein stability on the cell surface membrane  
PD-L1 knockdown experiments achieved a maximum reduction of about 50% of the 
protein. The incomplete knockdown of PD-L1 was hypothesized to be due to the 
stability of the protein on the membrane surface. Various assays which involve the 
use of radioactive isotopes for protein labelling or cycloheximide (CHX), a chemical 
which stops all de novo synthesis of proteins by the inactivation of transfer RNA 
(tRNA) (McKeehan and Hardesty, 1969), have been developed for the study of 
protein half-lives (Zhou, 2004). Unlike the CHX assay, radioactive pulse-chase 
analysis provides minimal distortion of cell physiology. However, as the radioactive 
pulse-chase assay involves the use of radiolabelling, the CHX chase assay was 
used as a safer alternative for the determination of PD-L1 protein half-life. 
Figure 6.12 shows that the PD-L1 expression decreased to a minimum of 43% after 
a 3 h incubation with CHX, regardless of concentration used. Interestingly, after 3 h 
of incubation with CHX, the PD-L1 expression on the plasma membrane increased, 
for all concentrations of CHX tested, and returned to 100% expression at the 24 h 
time point, with the exception of cells treated with 1000 µg/mL CHX (Figure 6.12). 
CHX is toxic to cells and viability of cells at high concentrations of CHX was low 
(data not shown). At 24 h, the re-expression of PD-L1 on SKOV-3-Luc cells treated 
with 1000 µg/mL of CHX had an increasing trend and may reach 100% at a later 
time point (Figure 6.12). The kinetics of PD-L1 re-expression was dose dependent 
and a higher CHX concentration resulted in slower kinetics (Figure 6.12).  
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The drop in PD-L1 expression during the initial 3 h of CHX incubation demonstrated 
that membranous PD-L1 was internalized with a half-life of approximately 2.5 h. 
Similarly, Durand-Panteix et al. reported that the half-life of total PD-L1 protein in an 
EBV-positive Burkitt lymphoma cell line named BL41B95.8, was approximately 2 h 
after treatment with 50 µg/mL of cycloheximide (Durand-Panteix et al., 2012). 
Although treatment with CHX decreases de novo protein synthesis and presentation 
of proteins on the cell surface via the biosynthetic pathway, proteins may also be 
expressed on the plasma membrane by various recycling pathways (Grant and 
Donaldson, 2009). PD-L1 protein has been shown to be stored in intracellular 
compartments of SKOV-3-Luc cells (Figure 6.4). It is possible that the re-expression 
of PD-L1 observed on the SKOV-3-Luc cell surface may be due to an increase in the 
activity of the recycling pathways, which present the stored intracellular PD-L1 on the 
plasma membrane surface. Cancer cells may harbour immune-escape mechanisms 
which require maintenance of constant membranous PD-L1 expression levels. 
However more experiments will need to be done to investigate this proposition, one 
of which is documented in section 6.2.11. In addition a positive control, consisting of 
a well-studied protein with known membranous half-life e.g. cyclin D1 (Alao, 2007), 
should have been included in this experiment.  
Overall, the results of the CHX chase experiment suggest that PD-L1 may have a 
high turnover rate, with a membranous protein half-life of roughly 2.5 h. In addition, 
the PD-L1 protein that is stored in the intracellular compartments may be expressed 
on the cell surface, in the absence of de novo protein synthesis, through various 
recycling pathway mechanisms. However, a positive control would be needed to 
validate these results. The difficulty in knocking down the PD-L1 protein, may 
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therefore be due to the presence of intracellular PD-L1 protein, synthesized before 
siRNA transfection, which gets expressed on the SKOV-3-Luc cell surface.  
 
 
Figure 6.12. Membranous PD-L1 expression on SKOV-3-Luc cells after treatment 
with various concentrations of cycloheximide (CHX) at various time points. (Top 
panel) Representative flow cytometry plots of PD-L1 expression after treatment of 
SKOV-3-Luc cells with 10 μg/mL of CHX for 3 h (left panel) and 24 h (right panel). 
Results represent mean ± standard error of mean of two independent experiments, 
each performed in triplicate. PD-L1: programmed cell death- ligand 1. 
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6.2.11 PD-L1 protein trafficking  
It was hypothesized in section 6.2.10 that intracellular PD-L1 protein may be 
expressed on the plasma membrane via recycling pathways. In addition, Durand-
Panteix et al. previously suggested that intracellular PD-L1 protein is stored in 
secretory lysosomes that transport intracellular PD-L1 on the membrane surface 
(Durand-Panteix et al., 2012). Moreover, many other immunoregulatory molecules 
such as MHC class II, CTLA-4, BTLA, CD40L and FASL have been reported to be 
stored in the intracellular compartments of cells and have also been shown to be 
associated with the secretory lysosomal compartments (Iida et al., 2000, Hiltbold and 
Roche, 2002, Owada et al., 2010, Koguchi et al., 2007, Blott et al., 2001). 
To determine whether PD-L1 is associated with secretory lysosomes in SKOV-3-Luc 
cells, co-immunoprecipitation (co-ip) and western blot experiments were performed 
for PD-L1 and a ras-related protein, Rab27a. Rab27a is a small GTPase molecule, 
associated with secretory lysosomes, which is necessary for the final docking steps 
of vesicles at the immunological synapse (Blott and Griffiths, 2002). 
PD-L1 was detected when Rab27a was immunoprecipitated (Lane 2, Figure 6.13), 
indicating interaction between the two proteins. However, Rab27a was not detected 
when PD-L1 was immunoprecipitated (Lane 3, Figure 6.13). This might be due to the 
anti-PD-L1 antibody competing with Rab27a at the PD-L1 binding site. The results 
show that PD-L1 interacts with Rab27a, which is a marker for secretory lysosomes. 
Therefore, PD-L1 stored in the intracellular compartments of SKOV-3-Luc cells may 
be transported to the plasma membranes via secretory lysosomal trafficking. 
Experiments analysing membranous PD-L1 expression after Rab27a siRNA 
mediated knockdown may be done to confirm this finding.  
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Figure 6.13. Co-immunoprecipitation (co-ip) between PD-L1 (40 kDa) and Rab27a 
(25 kDa) in SKOV-3-Luc cells. Equal amounts of SKOV-3-Luc cell lysate were added 
to lane 1-3. 100 ug of protein was added to lane 4. Lane 1: Control beads with 
control antibody, lane 2: immunoprecipitation of Rab27a, lane 3: immunoprecipitation 
of PD-L1 and lane 4: western blot of SKOV-3-Luc cell lysate. PD-L1: programmed 
cell death- ligand 1.  
 
6.3 Summary and conclusions  
PEI-10 was modified with FA targeting moieties conjugated either directly to the PEI-
10 backbone or attached via a PEG linker to form polymers PEI10-FA(1) and PEI10-
PEG-FA(1). PEI10-PEG(1) was also synthesized and used as a control. The 
modified PEI-10 polymers were able to bind siRNA to form cationic polyplexes of 
sizes lower than 200 nm, with the exception of PEI10-PEG(1). Although all polymers 
were able to knock down PD-L1 protein, modified PEI-10 polymers significantly 
mitigated the cytotoxicity of PEI-10 in SKOV-3-Luc cells, making them better 
transfecting agents than PEI-10. In addition, FA modified PEI-10 polymers were able 
to mediate preferential uptake of siRNA into SKOV-3-Luc tumour cells and had lower 
unspecific uptake by PBMCs compared to unmodified PEI-10/siRNA polyplexes. 
However, the membranous PD-L1 protein expression was only lowered by 
aproximately 50% after siRNA and shRNA treatment. Shuttling mechanisms and 
membrane presentation of PD-L1 stored in secretory lysosomes may be responsible 
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for the difficulty to achieve higher knockdowns. In the next chapter, the functional 
relevance of PD-L1 knockdown on ovarian cancer cells will be studied. 
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Chapter 7  
Enhancement of ovarian cancer immunotherapy by 
blocking programmed death-ligand 1 interactions 
 
7.1 Background and aims 
In the last chapter, the expression of PD-L1 in ovarian cancer cells was reduced by 
the delivery of PD-L1 siRNA using FA and PEG-modified PEI-10 polymers, namely 
PEI10-FA(1) and PEI10-PEG-FA(1). In this chapter, the functional effects of PD-L1 
knockdown in ovarian cancer cells, SKOV-3-Luc and OVCAR-8, on T cell 
immunotherapy was investigated.  
Adoptive T cell immunotherapy, described in section 1.7.2, has been widely used for 
ovarian cancer treatment (Kandalaft et al., 2011, Aoki et al., 1991, Fujita et al., 
1995). However, ovarian tumours including SKOV-3 cells down regulate MHC class I 
and II molecules and as a result, both CD8 cytotoxic T lymphocytes (CTLs) and CD4 
helper T (TH) cells are unable to be activated (Han et al., 2008, Sterman et al., 
2006). CAR expressing T cells, on the other hand, are activated by molecules which 
do not require peptide processing or HLA expression (244). In this regard, CAR T 
cells specific for the ErbB-family of receptors have been developed for ovarian 
cancer treatment as ovarian cancers over express ErbB 1, 2, 3 and 4 (Siwak et al., 
2010, Anglesio et al., 2013, Ocana et al., 2013, Paatero et al., 2013, Parente-Pereira 
et al., 2013). However, one of the biggest challenges faced by researchers in 
creating a single ligand to target the ErbB-family is to overcome the dynamic nature 
of the various ErbB-receptors to form different combinations of homodimers and 
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heterodimers (Sergina et al., 2007, Ritter et al., 2007). This problem was overcome 
by the development of the T1E peptide, which is a chimera derived from TGF-α and 
epidermal growth factor (EGF) (Stortelers et al., 2002). T1E leverages on the natural 
promiscuity of EGF binding of the ErbB-family of receptors (Stortelers et al., 2002). 
Our collaborators from King’s College London fused T1E with the CD28 
transmembrane and intracellular signalling domain as well as the CD3ζ intracellular 
signalling domain to form the CAR named T1E28z (Davies et al., 2012). T cells 
transduced to express T1E28z were able to retarget T cell specificity against the 
extended ErbB family (Davies et al., 2012). In addition, a second chimeric receptor 
named 4αβ was co-expressed with T1E28z to form CAR T cells named T4 cells 
(Figure 7.1, vector construct for 4αβ and T1E28z is shown in Appendix 7.1) (Parente-
Pereira et al., 2013). 4αβ consists of the ectodomain of the interleukin-4 receptor-α 
(IL-4Rα) fused to the transmembrane and endodomain of the shared β-chain used 
by the interleukin-2 receptor (IL-2R) and interleukin-15 receptor (IL-15R) (Wilkie et 
al., 2010). This allows the normally weak-mitogenic IL-4 to exert dual IL-2 and IL-15 
potent growth signals to the T4 cells, thus favouring selective growth and enrichment 
of the gene-modified cells (Wilkie et al., 2010). Parente-Pereira et al. have 
demonstrated that T4 cells exerted tumouricidal activity against ovarian cancer cell 
lines as well as isolated primary ovarian cancer cells.   
The aim of this chapter is to investigate whether PD-L1 knockdown in ovarian cancer 
cell lines, SKOV-3-Luc and OVCAR-8 cells, was able to increase the sensitivity of 
ovarian cancer cells to the tumouricidal activity of T4 cells both in vitro and in vivo. 
Furthermore, the effects of PD-L1 down regulation in ovarian cancer cells on T4 
proliferation and functionality was also investigated by measuring dilution of 
carboxyfluorescein succinimidyl ester (CFSE) labelled T4 cells, IFN-γ production and 
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expression of the degranulation marker, CD107a on T4 cells. In addition, the effects 
of PD-L1 knockdown in SKOV-3-Luc on T4 immunotherapy was investigated in SCID 
beige mice. Some of the data presented in this chapter has been published in a 
recent paper (Teo et al., 2015). 
 
Figure 7.1. Co-expression of T1E28z and 4αβ in human T cells, named T4 cells. IL-
4R: interleukin-4 receptor; IL-2: interleukin-2; IL-15R: interleukin-15 receptor. 
Adapted from (Parente-Pereira et al., 2013). 
 
7.2 Results and discussion 
7.2.1 Characterization of chimeric antigen receptor expressing primary human T 
cells  
The generation of T cells specific for the ErbB family of receptors, involved the 
transduction of isolated PBMCs from healthy donors with T1E28z and 4αβ. The 
transduced PBMCs were then cultured in media supplemented with interleukin-4 (IL-
4). Flow cytometry was used to analyse the surface expression of EGF, indicating 
the T1E peptide, three and eleven days post transduction. Figure 7.2 shows the 
enrichment of transduced lymphocytes, which express the T1E28z CAR, at day 11 
compared to day 3. These results were similar to what was obtained in (Parente-
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Pereira et al., 2013). The T4 cells were therefore grown in IL-4 containing medium 
for a minimum of 11 days before being used in functional experiments.  
For T cells to have efficient anti-tumour activity, both CD4 as well as CD8 positive T 
cells are necessary (Schüler et al., 1999, Nishimura, Iwakabe, et al., 1999, Quezada 
et al., 2010, Kim and Cantor, 2014). To determine whether the process of 
transduction and IL-4 treatment affected the proportions of T cell subsets, cells were 
analysed for CD4 and CD8 positive cells by flow cytometry, before transduction and 
eleven days after transduction. Figure 7.3A confirms that the proportion of CD4 to 
CD8 T cells were not affected by transduction or IL-4 treatment and their proportions 
were maintained in an approximate 2:1 ratio, which is the physiological ratio found in 
healthy humans (Miyahira, 2012). CD8 T cells have been considered to be the main 
effectors of anti-tumour activity due to their secretion of perforin, granzymes and 
cytokines such as tumour necrotic factor-α (TNF-α), interleukin-2 (IL-2) and IFN-γ 
which trigger apoptosis in target cells (C. A Janeway et al., 2005). This was further 
supported by the finding that higher numbers of CD8 TILs served as a good 
prognostic marker for various cancers including ovarian cancer (Hwang et al., 2012, 
Gooden et al., 2011, Galon et al., 2006). However, various studies have also shown 
that CD4 T cells, in particular the TH1 and CD4 CTL subsets, also exert potent anti-
tumour activity by the production of large amounts of IFN-γ and granzyme B (Schüler 
et al., 1999, Nishimura, Iwakabe, et al., 1999, Quezada et al., 2010, Kim and Cantor, 
2014). Importantly, anti-tumour CD8 T cell functions have been made more potent by 
helper effects of CD4 T cells (Gao et al., 2002, Janssen et al., 2003). Hence the 
presence of both CD4 and CD8 T cells are necessary to exert effective anti-tumour 
activity and it is important that the process of transduction and IL-4 treatment does 
favour one cell type over another.  
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However, the CD4 T cells include regulatory T cells (Treg), which suppress immune 
inhibition of tumours, and should be bead separated from the T4 cell population if 
found to be present in high numbers. The T4 cell population was therefore analysed 
for the presence of Treg cells (CD4/CD25/FoxP3 positive cell population) by flow 
cytometry. Figure 7.3B shows that Treg cells were only present in very low 
percentages (less than 1% of lymphocytes) in the T4 cell population and bead 
separation was not necessary.   
As the goal of this work was to determine how T4 cells might be influenced by the 
reduction of PD-L1 expression on tumour cells, the levels of the PD-L1 receptor, PD-
1, on T4 cells was determined. Figure 7.3C shows that both CD4 and CD8 positive 
T4 cells express low amounts of surface PD-1 in the absence of target cells but PD-1 
expression was markedly increased upon co-culture with target SKOV-3-Luc cells at 
all the time points studied. In addition, CD4 T cells expressed an approximately 2.5-
fold higher expression of PD-1 compared to CD8 T cells, when they were grown in 
co-culture (Figure 7.3C). John et al. also demonstrated that exposure of Her-2 CAR 
T cells to targeted cells caused an increased expression of PD-1 on T cells (John et 
al., 2013). Although PD-1 has been associated with T cell exhaustion and anergy 
(Ahmadzadeh et al., 2009, Day et al., 2006, D'Souza et al., 2007), not all cells 
expressing PD-1 are dysfunctional (Duraiswamy et al., 2011). Duraiswamy et al. 
showed that T cells with high PD-1 expression secreted similar levels of cytokines 
such as IFN-γ, TNF-α, IL-2, or macrophage inflammatory protein 1-beta as T cells 
with low PD-1 expressions (Duraiswamy et al., 2011). Despite PD-1 expression, T4 
cells have been shown to have potent anti-tumour activity against ovarian cancer 
cells (Parente-Pereira et al., 2013). This work determined whether manipulation of 
PD-L1 on tumour cells enhanced the anti-tumour activity of T4 cells.  
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A common T cell response to target antigens is the release of cytotoxic IFN-γ (C. A 
Janeway et al., 2005). However, IFN-γ is also a potent up-regulator of membranous 
PD-L1 in various cell types (Keir et al., 2008, Keir et al., 2006). Flow cytometry was 
used to determine whether there was an up regulation of PD-L1 on the surface of T4 
cells after co-culture with SKOV-3-Luc cells. Figure 7.3D shows that membranous 
PD-L1 on T4 cells (both CD4 and CD8 positive) was up regulated after co-culture 
with SKOV-3-Luc cells by ~2-fold compared to when they were grown as a 
monoculture. It is therefore important to also consider the expression of PD-L1 by T4 
cells which may promote self-regulation and dampen anti-tumour responses. On the 
other hand, PD-L1 expression on T cells has been shown to have immune 
stimulatory effects as it is necessary for the maturation of DCs (Talay et al., 2009). A 
delicate balance may therefore exist in the role PD-L1 plays in promoting or inhibiting 
immune response.  
 
 
Figure 7.2. Representative histogram showing the epithelial growth factor (EGF) 
expression of the T1E28z chimeric antigen receptor (CAR) on primary human T cells 
3 and 11 days post transduction. The median fluorescent intensity (MFI) values of T4 
cells are stated in brackets. 
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Figure 7.3. Characterization of T4 cells investigated using blood from five different 
healthy donors. (A) Percentage of CD4 and CD8 T cells in the lymphocyte gate of 
untransduced cells and CAR transduced cells grown in culture with IL-4 for 11 days. 
(B) Representative flow cytometric plots of T4 cells stained for CD4, CD25 and 
intracellular FoxP3. In the first dot plot on the left, cells were selected for double 
positivity of CD4 and CD25 (blue box). Double positive cells were then analysed in 
the second dot plot for FoxP3 positivity to identify regulatory T cells (Treg) cells (red 
box). (C) Membranous PD-1 expression or (D) PD-L1 expression on CD4 and CD8 
positive T cells when cultured alone or after co-culture with SKOV-3-Luc target cells 
(ratio of 1:1) for 24 h, 48 h and 72 h. Representative flow cytometry plots of isotype 
control, PD-1 or PD-L1 expression on CD4 or CD8 T cells are shown when T cells 
were grown as a monoculture or in a co-culture with SKOV-3-Luc cells (1:1) ratio, 
after 24 h. Results represent mean ± standard error of mean of three independent 
experiments. 
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7.2.2 In vitro effects of PD-L1 knockdown in ovarian cancer cells on PD-1 
expression on T4 cells  
Taube et al. recently demonstrated, by immunohistochemical staining (IHC) of 
several cancers (melanoma, non-small cell lung carcinoma (NSCLC), renal cell 
carcinoma, colorectal carcinoma and castration-resistant prostate cancer) that the 
PD-1 expression on TILs correlated closely with PD-L1 expression on tumour cells 
(Taube et al., 2014). This was an important finding as PD-1 mediates T cell inhibitory 
signals and a reduction of PD-1 on T cells in the cancer setting is endeavoured. To 
determine whether PD-L1 knockdown in SKOV-3-Luc cells affects PD-1 expression 
on T4 cells, SKOV-3-Luc cells that were pre-treated with PEI10-FA(1)/PD-L1 or 
scrambled siRNA polyplexes were placed in co-culture with T4 cells. The PD-1 
expression on T4 cells was analysed by flow cytometry after 48 h and 72 h in co-
culture. 
Figure 7.4 shows that the PD-1 expression on T4 cells was not affected by the 
reduced PD-L1 expression on SKOV-3-Luc cells in the co-culture set up. In general, 
PD-1 expression on T cells is triggered through TCR recognition of MHC/antigen 
(Keir et al., 2008), which are presented on the surface of both tumour cells as well as 
APCs. CAR T cells also trigger the up regulation of PD-1 after interaction with target 
antigen (John et al., 2013). The contrasting observations of our study and the study 
by Taube et al. may be due to the different environments the T cells are in as well as 
the different cancer and T cells studied. Taube et al. studied formalin-fixed paraffin-
embedded (FFPE) tissue sections, complete with the milieu of immune cells and 
cells comprising the tumour core and stoma. The co-culture set up, on the other 
hand, comprises only of tumour cells and artificially transduced T cells. The constant 
PD-1 expression on T4 cells in the co-culture set up observed in Figure 7.4, 
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suggests that the PD-1 expression on CAR T cells may not be directly affected by 
changes of PD-L1 expression on tumour cells and may instead be influenced by 
other immune cells as well as the interplay of cytokines they secrete.    
Although the co-culture set up does not accurately reflect the pathological 
environment of the tumour, it serves as a simple model for researchers to study the 
interactions between tumour cells and T cells. Many improvements of the co-culture 
experiment can be made and some include the construction of three-dimensional 
cancer models which may incorporate tumour vasculature as well as a plethora of 
immune cells (White et al., 2014, Griffith and Swartz, 2006).   
  
Figure 7.4. Representative histograms showing the membranous PD-1 expression 
on T4 cells after co-culture with SKOV-3-Luc cells (ratio of 1:1) for 48 h and 72 h. 
SKOV-3-Luc cells were pre-treated with PEI10-FA(1)/scrambled or PD-L1 siRNA 
polyplexes, formed at N/P 50, before the co-culture was set up. The experiment was 
repeated three times, each giving similar results. PD-1: programmed cell death- 1; 
PEI: polyethylenimine; FA: folic acid; N/P ratio: ratio of nitrogen in polymers to 
phosphorous content in DNA. 
 
 
 
PD-1 expression
C
o
u
n
t
Legend:
T4 cells in co-culture with scrambled siRNA 
treated SKOV-3-Luc cells
T4 cells in co-culture with PD-L1 siRNA 
treated SKOV-3-Luc cells
T4 cells alone
Isotype control
48h 72h
205 
 
7.2.3 The proliferation of T4 cells in response to PD-L1 knockdown in ovarian 
cancer cells 
To determine whether the PD-L1 expression on SKOV-3-Luc tumour cells affects T4 
cell proliferation, Alexa Fluor 633 CFSE labelled T4 cells were grown in co-culture 
with SKOV-3-Luc for 72 h. The SKOV-3-Luc cells were pre-treated with PEI10-
FA(1)/PD-L1 or scrambled siRNA polyplexes to alter the membranous expression of 
PD-L1. T4 cells grown alone in culture served as a control. T4 cells, which have 
been previously activated by CD3/CD28 beads, are able to proliferate independently 
of target antigens. To determine whether T4 cells had proliferated, the MFI of 
labelled T4 cells was measured after 72 h and compared to their MFI value 
measured at the start of the experiment (time = 0 h). A lower MFI value after 72 h, 
compared to reference MFI at time 0 h, indicates cell proliferation.  
Figure 7.5 shows that the MFI of T4 cells grown in co-culture with SKOV-3-Luc cells 
(224-229) had a higher MFI than T4 cells grown alone in culture after 72 h (143). 
This indicates dampened T4 cell proliferation in the presence of SKOV-3-Luc cells. 
This was an unexpected observation as T4 cells in the co-culture were able to 
interact with their target antigen and should proliferate more than T4 cells that were 
grown alone. On the other hand, T4 cells grown in the co-culture also had a 
heightened expression of the co-inhibitory molecule, PD-1, compared to T4 cells that 
were grown alone (Figure 7.3C). PD-1 ligation has been shown to inhibit the cycle 
progression (G0 to G1 phase) of T cells by targeting early cell cycle regulators 
(Patsoukis, Brown, et al., 2012, Patsoukis, Sari, et al., 2012). This heightened PD-1 
expression may override any proliferation signals, brought about by CAR 
engagement, to cause an overall dampening in T4 proliferation.  
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In addition, the MFIs of T4 cells grown in co-culture with PD-L1 or scrambled siRNA 
treated SKOV-3-Luc cells for 72 h were similar (Figure 7.5). The T4 cell proliferation 
was also studied after 24 h and 48 h of co-culture. However, changes in the MFI of 
CFSE were slight and not easily observed in the flow cytometry plots. Acute changes 
in proliferation may have thus been overlooked. Alternative proliferation assays such 
as cell counting or Ki-67 incorporation may be considered to study proliferation at 
earlier time points. Nevertheless, the data at the 72 h time point suggests that PD-L1 
knockdown in SKOV-3-Luc cells did not alter the proliferation of T4 cells grown in co-
culture. This could be due to the incomplete knockdown of PD-L1 on tumour cells 
(Figure 6.5A, F) or the upregulation of PD-L1 on SKOV-3-Luc and T4 cells in 
response to IFN-γ production. Furthermore, other co-inhibitory molecules such as 
cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and lymphocyte activation 
gene-3 (LAG-3) may be present in this co-culture set up, and might also cause the 
suppression of T4 proliferation. Alternatively, the expression of PD-L1 on tumour 
cells might not be the key mediators of T cell proliferation. Mueller et al. 
demonstrated that it was the PD-L1 expression on hematopoietic cells (monocytes 
and DCs), and not PD-L1 expression on non-hematopoietic cells (stromal cells or 
tumour tissue) that affected T cell proliferation in chimeric mouse models (Mueller et 
al., 2010). Moreover, previous work from our lab demonstrated that the addition of 
anti-PD-1 or anti PD-L1 blocking antibodies to a similar co-culture set up of ascitic 
monocytes and T cells resulted in the restoration of T cell proliferation (Maine et al., 
2014). PD-L1 knockdown on tumour cells was therefore unable to restore T4 
proliferation at 72 h.  
 
 
207 
 
 
Figure 7.5. Representative histogram showing the proliferation of Alexa Fluor 633 
CFSE labelled T4 cells when cultured alone or with target SKOV-3-Luc cells (ratio of 
1:1) that were pre-treated with PEI10-FA(1)/scrambled or PD-L1 siRNA polyplexes. 
The median fluorescent intensity (MFI) values of T4 cells are stated in brackets. 
CFSE: 5-(and 6)-carboxyfluorescein diacetate succinimidyl ester; PD-L1: 
programmed cell death-ligand 1; PEI: polyethylenimine; FA: folic acid. 
 
7.2.4 In vitro effects of PD-L1 knockdown in ovarian cancer cells on T4 cytokine 
and degranulation responses 
Many studies have demonstrated that T cells, including CAR T cells (John et al., 
2013), have reduced cytotoxic responses in the presence of PD-L1 expressing cells 
and that the addition of anti PD-1 or PD-L1 blocking antibodies restored some T cell 
functionality (Zhang et al., 2007, Porichis et al., 2011, Wong, Scotland, et al., 2007). 
To determine whether PD-L1 knockdown in SKOV-3-Luc cells influences T4 
responses, two cytotoxic T cell functions were examined- the production of IFN-γ 
and the degranulation ability for the release of perforin and granzymes. IFN-γ and 
secreted granzymes have been shown to trigger apoptosis by the induction of pro-
apoptotic molecules such as the surface expression of Fas and its ligands as well as 
the activation of caspases (Pinkoski et al., 2001, Schroder et al., 2004). However, as 
PD-L1 knockdown only reduced ~50% of PD-L1 expression on SKOV-3-Luc cells 
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(Figure 6.5A, F), anti-PD-L1 blocking antibodies were also added to the co-culture. 
The blocking antibody used was an IgG1Κ subtype.  
To determine the concentration of IFN-γ in the co-culture supernatant, an ELISA was 
used. Figure 7.6 shows that T4 cells, in co-culture with SKOV-3-Luc cells that were 
treated with PEI10-FA(1)/PD-L1 siRNA polyplexes and control antibody, secreted 
considerably more IFN-γ than when they were in co-culture with SKOV-3-Luc cells 
treated with PEI10-FA(1)/scrambled siRNA polyplexes and control antibody at 48 
and 72 h. The secretion of IFN-γ by T cells is normally induced by the activation of 
various signalling pathways such as T-bet, Eomes, STAT1 and STAT4 transcription 
mechanisms (Glimcher et al., 2004). The ligation of PD-1 and its signalling 
suppresses the activity of T-bet and Eomes and leads to a decrease of IFN-γ 
production (Nurieva et al., 2006). Blocking PD-L1/PD-1 interactions by RNAi in 
tumour cells therefore helped to restore the production of IFN-γ.  
When anti-PD-L1 antibody was added to SKOV-3-Luc cells treated with PD-L1 
siRNA, the concentration of IFN-γ was further elevated after 48 h but not after 72 h 
(Figure 7.6). The additive effect observed at 48 h may be due to the blocking of PD-
L1 expressed on the surface of T4 cells (Figure 7.3D) by the antibodies, thus 
preventing self-regulation. On the other hand, the lack of additive effect observed 
after 72 h may be attributed to a lowered T4 cell antigen stimulation due to tumour 
cell death at that time point (Figure 7.8B).  
Interestingly, an additive effect was also observed when tumour cells were treated 
with both PD-L1 siRNA and anti-PD-L1 antibody compared to when they were 
treated with scrambled siRNA and anti-PD-L1 antibody at 48 h (Figure 7.6). The 
finding that PD-L1 siRNA treatment further increased IFN-γ production by T4 cells is 
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unexpected as the concentration (50 μg/mL) of anti-PD-L1 antibody used was at 
saturation levels (Figure 7.8B). Therefore the co-culture set up treated with anti PD-
L1 blocking antibody should theoretically have exerted maximum blockade of all PD-
1/PD-L1 interactions and should lead to maximal T4 production of IFN-γ. It may be 
possible that PD-L1 expressed on T cells triggered apoptotic signals in tumour cells 
via interaction with unknown receptors expressed on the cancer cells. This was 
found to be the case in glioma cancer where PD-L1 expressed on neurons mediated 
the apoptosis of cancer cells (Liu et al., 2013). However, the role of PD-L1 
expressed on T cells in the ovarian cancer has not been explored and more studies 
should be invested in this area as optimism over therapeutics based on PD-L1 
blockade grows. 
Perforin and granzymes are located in cytosolic granules which contains lysosomal-
associated membrane glycoproteins (LAMPs), such as CD107a (LAMP-1). Their 
release is mediated by the degranulation activity of T cells, which involves the 
merging of granule membranes with the plasma membrane and the transient transfer 
of LAMP proteins onto the surface of a cell (Krzewski et al., 2013). The secretion of 
cytotoxic perforin and granzymes may therefore be indirectly measured by the 
expression of CD107a on the T4 cell surface by flow cytometry (Betts and Koup, 
2004). T4 cells co-cultured with SKOV-3-Luc cells treated with PD-L1 siRNA and 
control antibody had significantly increased CD107a expression than when co-
cultured with SKOV-3-Luc cells treated with scrambled siRNA and control antibody 
at 48 h (Figure 7.7). The addition of anti-PD-L1 blocking antibodies to SKOV-3-Luc 
cells treated with scrambled siRNA also increased the expression of CD107a on T4 
cells. However, no additive effect was observed when SKOV-3-Luc cells received 
dual treatments of PD-L1 siRNA and anti-PD-L1 antibody at both time points studied 
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(Figure 7.7). Degranulation of T cells and their release of perforin and granzymes are 
also activated by various transcription factors which include T-bet and Eomes 
(Glimcher et al., 2004). Blocking PD-L1/PD-1 interactions should therefore enhance 
degranulation capacity as it restores T-bet and Eome activity (Nurieva et al., 2006). 
Although the functions of degranulation might seem less sensitive to PD-L1/PD-1 
blockage, compared to the production of IFN-γ, this might not be the case due to the 
limitations of the CD107a experiment. As CD107a is expressed transiently on the 
surface of the cell membrane, measurement of CD107a expression level does not 
reflect a cumulative production of perforin and granzymes. An ELISA can be 
performed to quantify concentrations of cytotoxic perforin and granzymes. 
Nevertheless, the analysis of CD107a is a standard way to measure degranulation 
ability of T cells at different time points (Betts and Koup, 2004).  
These results are in agreement with other studies which showed that PD-1/PD-L1 
blockade increased both IFN-γ and degranulation abilities of virus specific CD8 T 
cells in lymphocytic choriomeningitis virus (LCMV) mouse models (Barber et al., 
2006, Erickson et al., 2012).   
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Figure 7.6. IFN-γ release from T4 cells after co-culture with SKOV-3-Luc cells (1:1 
ratio), which were pre-treated with PEI10-FA(1)/scrambled or PD-L1 siRNA 
polyplexes, formed at N/P 50, and anti-PDL1 or control antibody (50 µg/mL). Results 
represent mean ± standard error of mean of three independent experiments, each 
performed in triplicate. The one-way ANOVA and Dunnett’s post-hoc analysis were 
used to calculate statistical significance between various conditions and the control 
group, scrambled siRNA + control Ab, (* p < 0.05, ** p < 0.01). Conditions of SKOV-
3-Luc cells alone and T cells alone were not included in the statistical analysis as 
they were not expected to produce any amounts of IFN-γ. PD-L1: programmed cell 
death- ligand 1; N/P ratio: ratio of nitrogen in polymers to phosphorous content in 
DNA; Ab: antibody; IFN-gamma: gamma interferon. 
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Figure 7.7. Expression of degranulation marker CD107a on T4 cell surface after co-
culture with SKOV-3-Luc cells (1:1 ratio), which were pre-treated with PEI10-
FA(1)/scrambled or PD-L1 siRNA polyplexes, formed at N/P 50, and anti-PDL1 or 
control antibody (50 µg/mL). Results represent mean ± standard error of mean of 
three independent experiments, each performed in triplicate. The one-way ANOVA 
and Dunnett’s post-hoc analysis were used to calculate statistical significance of 
various experimental groups compared to scrambled siRNA + control Ab + T4, (* p < 
0.05). PD-L1: programmed cell death- ligand 1; N/P ratio: ratio of nitrogen in 
polymers to phosphorous content in DNA; Ab: antibody. 
 
7.2.5 The tumoricidal activity of T4 cells in response to PD-L1 knockdown using 
siRNA in ovarian cancer cells 
To determine whether blocking PD-1/PD-L1 interactions by PD-L1 siRNA delivery to 
ovarian cancer cells enhanced T4 cell killing, the viabilities of SKOV-3-Luc cells and 
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OVCAR-8 cells, after co-culture with T4 cells, were analysed by the MTT assay. As 
PD-L1 knockdown only reduced ~50% of PD-L1 expression on both SKOV-3-Luc 
and OVCAR-8 cells (Figure 6.5A, F and Figure 6.6), anti-PD-L1 blocking antibody 
was also added to the co-culture. To determine the minimum concentration of 
blocking antibody needed for maximum T4 cell mediated killing, various 
concentrations of anti PD-L1 blocking antibody were tested and the cell viability of 
the tumour cells was investigated by the MTT assay. Figure 7.8A shows that the 
minimum concentration of anti PD-L1 antibody needed to cause maximum SKOV-3-
Luc death was 10 μg/mL, compared to the isotype antibody control. However, a 
higher concentration of 50 μg/mL of anti PD-L1 blocking antibody was used for the 
experiments both in this section and in section 7.2.3.  
Tumour cells treated with PEI10-FA(1)/PD-L1 siRNA polyplexes and control 
antibodies were significantly more susceptible to T4 killing than tumour cells treated 
with PEI10-FA(1)/scrambled siRNA polyplexes and control antibodies, for both cell 
lines tested (Figure 7.8C). Moreover, addition of anti-PD-L1 blocking antibody to PD-
L1 siRNA treated tumour cells, enhanced tumour cell death in response to T4 cells, 
for both cell lines tested (Figure 7.8C, D). However, to confirm this finding, it is 
necessary to also determine whether PD-L1 knockdown affects tumour cell viability. 
SKOV-3-Luc cells were treated with PEI10-FA(1)/ PD-L1 siRNA or scrambled siRNA 
polyplexes and the cell viability of the monoculture was measured by the MTT assay. 
Figure 7.9 shows that viability of SKOV-3-Luc cells was independent of PD-L1 
knockdown and any change of SKOV-3-Luc cell viability in the co-culture 
experiments was expected to be T4 cell mediated. Blocking PD-1/PD-L1 interactions 
may have therefore caused tumour cell death by the increased T4 production of IFN-
γ and release of cytotoxic perforin and granzymes (Figure 7.6 and Figure 7.7).  
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Figure 7.8B and C also show that tumour cell viabilities were lower when cells were 
treated with both PD-L1 siRNA and anti-PD-L1 antibody compared to when they 
were treated with scrambled siRNA and anti-PD-L1 antibody. The additive T cell 
tumourcidal activity observed suggests that T4 cells might be activated via different 
pathways when PD-L1 siRNA and anti-PD-L1 antibodies were used. PD-L1 siRNA 
limits de novo production of PD-L1 whereas anti PD-L1 blocking antibody blocks 
existing PD-L1 interactions. These results correlated with the finding of increased 
IFN-γ production by T4 cells when in co-culture with tumour cells, which were dual 
treated with PD-L1 siRNA and anti PD-L1 blocking antibody, compared to tumour 
cells with single treatments (Figure 7.6).  
As PEG conjugated polymers have been shown to have improved serum stability, 
PEI10-PEG-FA(1) may be useful for future in vivo studies even though PD-L1 
knockdown in SKOV-3-Luc cells mediated by PEI10-PEG-FA(1) (PD-L1 expression 
~65%) was less efficient than PEI10-FA(1) polymers (PD-L1 expression ~50%) 
(Figure 6.5A). The viability of SKOV-3-Luc cells, pre-treated with PEI10-PEG-FA(1)/ 
PD-L1 siRNA or scrambled siRNA, was therefore investigated by the MTT assay 
after SKOV-3-Luc/T4 cell co-culture. SKOV-3-Luc cells treated with PEI10-PEG-
FA(1)/PD-L1 siRNA polyplexes and control antibodies were significantly more 
susceptible to T4 killing than tumour cells treated with PEI10-PEG-FA(1)/scrambled 
siRNA polyplexes and control antibodies (Figure 7.8D). Addition of anti PD-L1 
blocking antibodies also enhanced T4 cell killing of tumour cells (Figure 7.8D). 
Notably, the contrast in viability of SKOV-3-Luc cells treated with PEI10-FA(1) 
(Figure 7.8B) and PEI10-PEG-FA(1) (Figure 7.8D) is attributed to the biological 
differences of T cell killing capacities from different donors and not because of 
variation in the toxicity of polymer/siRNA polyplexes, which were shown to be similar 
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in Figure 6.3. This reveals the limitations of using primary human T cells, which 
functions vary among donors, in experiments. Nevertheless, the results show that a 
reduced PD-L1 expression of ~65% was sufficient to partially restore tumouricidal 
function of T4 cells. PEI10-PEG-FA(1) may therefore be a useful polymer for in vivo 
applications. Over all, these results demonstrate and re-emphasize the role PD-
1/PD-L1 interactions play in controlling T4 cell responses.  
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Figure 7.8. Viability of SKOV-3-Luc or OVCAR-8 ovarian tumour cells in co-culture 
with T4 cells, analysed by the MTT assay. (A) SKOV-3-Luc viability after treatment 
with various concentrations of either anti PD-L1 or control blocking antibody (50 
µg/mL) and T4 cells (1:1 ratio). Viability of (B) SKOV-3-Luc cells or (C) OVCAR-8 
cells in co-culture with T4 cells. Tumour cells were pre-treated with PEI10-
FA(1)/scrambled or PD-L1 siRNA polyplexes, formed at N/P ratio 50, and anti-PDL1 
or control antibody for 2 h, at antibody concentrations = 50 µg/mL. (D) Viability of 
SKOV-3-Luc cells, pre-treated with PEI10-PEG-FA(1)/scrambled or PD-L1 siRNA 
polyplexes and anti-PDL1 or control antibody, in co-culture with T4 cells. Results 
represent mean ± standard error of mean of four to five independent experiments, 
each performed with eight replicates. The one-way ANOVA and Dunnett’s post-hoc 
analysis were used to calculate significance between various treatment groups and 
the control group, scrambled siRNA + control Ab, (* p < 0.05, NS: not significant). 
PD-L1: programmed cell death- ligand 1; N/P ratio: ratio of nitrogen in polymers to 
phosphorous content in DNA; FA: folic acid; PEG: polyethylene glycol; Ab: antibody. 
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Figure 7.9. Viability of SKOV-3-Luc cells, in mono-culture, after treatment with 
PEI10-FA(1)/scrambled siRNA or PD-L1 siRNA polyplexes, analysed by the MTT 
assay. Results represent mean of two independent experiments, each performed 
with eight replicates. 
 
7.2.6 In vitro effects of PD-L1 knockdown stable ovarian cancer cell lines on T4 
tumoricidal activity 
Stable PD-L1 knockdown SKOV-3-Luc cell lines were previously prepared by PD-L1 
shRNA transfection and described in chapter 6.2.6. Stable cell lines named C5 and 
C9 had the lowest PD-L1 expression compared to scrambled shRNA treated SKOV-
3-Luc named Cscr (Figure 6.7). To determine whether C5 and C9 cells were more 
susceptible to T4 mediated killing than Cscr, the viabilities of the tumour cells were 
analysed by the MTT assay, after co-culture with T4 cells. 
Figure 7.10 shows that the viability of stably created cell lines were similar, after co-
culture with T4 cells, regardless of PD-L1 knockdown. The lack of sensitization of 
PD-L1 knockdown cells to T4 cells is unexpected and may be attributed to the 
illegitimate integrations of shRNA into the genome of the cell. Such unspecific 
integrations have been shown to result in variation of transgene copy number and 
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endogenous integration site structure which may lead to off-targeting effects and 
unpredictable outcomes (Wurtele et al., 2003). The Crispr/Cas-9 system may be 
considered to create stable knockdowns of PD-L1 in human ovarian cancer cells. 
Guide RNA strands allow Cas-9 to create double strand breaks in targeted gene loci 
to permanently disable the gene of interest (Cong et al., 2013, Mali et al., 2013). This 
technology has been used successfully to correct hereditary tyrosinemia, cystic 
fibrosis, sickle cell anaemia, and autism in mouse models (Yin et al., 2014, Schwank 
et al., 2013, Gaj et al., 2013). However, issues of off-targeting effects, where Cas-9 
cuts DNA at places where the sequence is similar but not identical to that of the 
guide RNA, still hinder the technology for clinical applications (Cradick et al., 2013). 
Nevertheless, it may serve as a useful tool to generate PD-L1 knockdown ovarian 
cancer mouse models for the study of various immunotherapies. 
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Figure 7.10. Viability of PD-L1 knockdown stable SKOV-3-Luc cell lines (C5 and C9) 
compared to scrambled shRNA treated SKOV-3-Luc cells (Cscr) after co-culture with 
T4 cells (1:1 ratio) for 48 h and 72 h. Results represent mean ± standard error of 
mean of four independent experiments each with eight replicates. The one-way 
ANOVA and Dunnett’s post-hoc analysis was used to calculate statistical 
significance between different treatment groups and control group, Cscr, NS: not 
significant. 
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7.2.7 In vivo effects of T4 immunotherapy on siRNA treated ovarian cancer cells 
To determine whether PD-L1 knockdown in SKOV-3-Luc cells would improve T4 
immunotherapy in vivo, SCID beige mice were inoculated with SKOV-3-Luc tumour 
cells, which had received prior treatment with PEI10-FA(1)/siRNA polyplexes ex vivo 
by i.p. injection. T4 cells were administered by i.p. injection five days post tumour 
inoculation and the mice were imaged daily to track tumour size by bioluminescent 
imaging (BLI). Mice injected with PBS served as controls. 
Figure 7.11 shows that all mice that received T4 cells responded to the 
immunotherapy and reduced tumour sizes were observed, regardless of PD-L1 
expression. Notably, PD-L1 knockdown tumours responded more than tumours 
which were treated with scrambled siRNA, with the greatest difference observed on 
day two after T4 administration (Figure 7.11B). However this difference was not 
significant and could be attributed to the re-expression of PD-L1 six days post siRNA 
transfection, although in vitro data showed that PD-L1 expression remained low after 
that period of time (Figure 6.6B). In addition, Figure 7.11 showed that tumours 
treated with PBS also slightly reduced in size over time. This could be due to 
fluctuation in BLI imaging or that tumours treated with PEI10-FA(1)/siRNA polyplexes 
were not healthy enough to grow in vivo. Clearly much improvement has to be made 
to achieve a more robust PD-L1 knockdown xenograft model. One strategy would be 
to use CRIPSR/Cas-9 technology for the creation of stable PD-L1 knockdown cell 
lines which can be used to create the xenograft model. Alternatively, it would be 
useful to be able to administer another dose of PEI10-FA(1)/siRNA treatment in vivo 
before treatment with T4 cells. However prior studies such as the optimization of 
siRNA dose, toxicity studies of PEI10-FA(1)/siRNA polyplexes, PD-L1 knockdown 
efficiency and biodistribution would be necessary to be done in vivo and should be 
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performed as future work. PEI10-PEG-FA(1) is expected to have greater stability 
than PEI10-FA(1) and should be tested for future in vivo applications. Combination 
therapies involving the blockade of multiple co-inhibitory pathways such as PD-
L1/PD-1, CTLA-4/CD80 and TIM-3/galectin-9 should also be considered. Various 
studies have already shown that blocking PD-1 in combination with CTLA-4 has 
resulted in enhanced T cell activity and tumour killing (Duraiswamy et al., 2014, 
Quezada and Peggs, 2013, Curran et al., 2010). 
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Figure 7.11. The in vivo study of PD-L1 knockdown tumour burden, compared to 
scrambled siRNA treated tumours, after T4 immunotherapy in siRNA treated SKOV-
3-Luc SCID beige xenografts. SKOV-3-Luc cells were treated ex vivo with PEI10-
FA(1)/siRNA polyplexes, formed at N/P 50, one day before tumour inoculation (1.5 
million tumour cells per mouse via i.p. injection). The tumour was allowed to 
establish for five days before PBS or T4 cells (625,000 T4 cells per mouse) were 
administered. The experiment was performed once with five mice per group. One 
mouse from the PD-L1 siRNA treated tumour cell/ PBS treatment group died due to 
reasons not related to the experiment. (A) BLI images of all mice before and after T4 
cell injection, shown on the same scale with units p/s/cm2/steradian. (B) Serial BLI of 
mice before and after T cell administration. Data shows the means of four or five 
mice in each of the four groups. PD-L1: programmed cell death-ligand 1; BLI: 
bioluminescent imaging; PEI: polyethylenimine; N/P ratio: ratio of nitrogen in 
polymers to phosphorous content in DNA. 
 
7.3 Summary and conclusions 
In summary, this study demonstrates that PD-L1 knockdown using siRNA delivery by 
either PEI10-FA(1) or PEI-PEG-FA(1) polymers effectively blocks PD-1/PD-L1 
interactions and enhances T cell immunotherapy, by increasing the release of IFN-γ, 
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perforin and granzymes, for ovarian cancer treatment in in vitro experiments. The 
addition of anti-PD-L1 antibody further enhances T4 cytotoxicity as it blocks 
membranous PD-L1 that is expressed by T4 cells in response to their release of IFN-
γ. PD-L1 shRNA delivery on the other hand, did not sensitize ovarian cancer cells to 
T4 killing and this may be due to illegitimate integration which might have led to off-
target effects. On this note, siRNA has actually been shown to have more off-
targeting effects than shRNA as it does not integrate into the cell’s nuclear and early 
cytoplasmic processing (Rao et al., 2009). The seed region sequence (positions 2–7) 
of siRNA may complement unintended mRNA sites to produce a dose-responsive 
off-target effect (Jackson, Burchard, Schelter, et al., 2006). For this reason, pooled 
PD-L1 siRNA has been used instead of a single sequence in this work. Further 
precautions against off-targeting problems may also be taken some of which include 
2′-O-methylation modification of the 5′-end of the siRNA guide strand (Jackson, 
Burchard, Leake, et al., 2006), ‘bulge-modification’ of the siRNA backbone (Dua et 
al., 2011) or the increase of thermodynamic asymmetry of the guide and passenger 
strands by A-U base pair enrichment in the 5’ end of the guide strand (Kanasty et al., 
2012). Importantly, the type of nucleic acid carriers employed for siRNA delivery 
greatly influence toxicity of siRNA therapy and it is important to not only protect the 
siRNA load from degradation but deliver them into specific cell types. The FA 
modified PEI polymers developed for this work serves as a useful model for the 
development of nucleic acid delivery agents for clinical applications. Although the in 
vivo results did not show pronounced effects of improved T4 immunotherapy when 
PD-L1 expression was reduced in tumour cells, the data did lean toward that 
direction. However a more robust PD-L1 knockdown xenograft model would need to 
be established before any conclusions can be made. 
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So far, the PD-L1 molecule has been demonstrated to serve as a therapeutic target 
to enhance T cell immunotherapy. Previous work from our lab has shown that sPD-
L1 has potential for use as a biomarker in ovarian cancer diagnosis. In the next 
chapter, a new acoustic-based detection assay to quantify sPD-L1 will be developed 
and explored for its sensitivity and accuracy of biomarker detection. 
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Chapter 8  
The development of an acoustic-based assay for the 
quantification of soluble PD-L1 
  
8.1 Background and aims 
The current tumour marker used for ovarian cancer screening, diagnosis and 
monitoring is cancer antigen-125 (CA-125) (UK, 2014). However, quantification of 
CA-125 as a marker for ovarian cancer suffers from low sensitivity of 72% and 
specificity of 78% for the disease (Patsner and Day Jr, 1987). Therefore, the need to 
develop a highly sensitive and specific diagnostic and prognostic test in ovarian 
cancer remains a high priority. 
sPD-L1 found in patient plasma or serum has been shown to be correlated with 
tumour stage and grade in studies of renal cell carcinoma and diffuse large B cell 
lymphoma (Frigola et al., 2011, Rossille et al., 2014, Rossille et al., 2013). High 
levels of sPD-L1 were also associated with poor prognosis (Frigola et al., 2011, 
Rossille et al., 2014, Rossille et al., 2013). In this regard, our lab investigated the role 
of sPD-L1 in ovarian cancer and its potential use as a diagnostic marker. This was 
done by the development of a sandwich ELISA system for the detection of sPD-L1 in 
102 plasma samples (11 healthy women, 20 and 71 patients with benign tumour 
mass and ovarian cancer, respectively). Work performed by a previous member of 
the lab, Dr Jayanta Chatterjee, showed that there was a significantly higher level of 
sPD-L1 in women with ovarian cancer compared with healthy female volunteers and 
women with benign ovarian tumours (p<0.0001) (Figure 8.1). In addition, his results 
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suggested that there was a correlation between the concentration of sPD-L1 and 
ovarian cancer stage (data not shown). Patients who presented with late stage 
tumours (Stage III-IV) had a median sPD-L1 concentration of ~1000 pg/mL whereas 
patients with stage I or benign tumours had sPD-L1 concentrations below 100 
pg/mL. However, the lower limit of detection (LLOD), defined as the lowest 
concentration of analyte that can be reliably discriminated from the zero standard 
(Price and Newman, 1997), of the ELISA was calculated to be ~70 pg/mL, obtained 
by determining the mean of blank ± 10 standard deviations (Appendix 8.1). 
Therefore, the ELISA was unable to accurately detect sPD-L1 present at levels 
below 70 pg/mL. As such, patients who present with early stage ovarian cancer or 
benign tumour were not able to be stratified based on the quantification of sPD-
L1concentration by ELISA. A more sensitive sPD-L1 detection assay was needed.  
The aim of this chapter was to develop a more sensitive sPD-L1 detection assay so 
that the usefulness of sPD-L1 to differentiate patients with stage I ovarian cancer 
and benign tumours could be evaluated. Factors which influence the sensitivity of an 
assay include capture and detection antibody concentrations, incubation times and 
temperatures, sample/standard volumes, pH, diluents and wash buffer formulation 
and importantly, avidity of antibodies for antigens and experimental error. We 
hypothesized that the sensitivity of sPD-L1 quantification could be improved by the 
development of a new automated detection assay which might be able to decrease 
experimental error and increase the signal to noise ratio (Yan et al., 2011). This 
assay was based on a frequency-modulating technology from BioScale, Inc. named 
the ViBE Bioanalyzer (ViBE) which detects acoustic micro magnetic particle relative 
units (AMMP RU) as an output function. AMMP RU is a function of frequency i.e. 
parts per million (ppm, of antigen)/s. The ViBE detected analyte by measuring the 
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frequency of a vibrating piezoelectric biosensor, which was modulated by magnetic 
bead attachment through the formation of a sandwich. Figure 8.2 shows the basic 
components and principles of a typical antibody sandwich assay using the ViBE. The 
sample containing the analyte was first mixed with magnetic bead-conjugated 
antibody and fluorescein tagged complementary antibody (Fl-Ab) by the researcher 
in a standard 96-well plate, where the sandwich complex formed (step 1). The 
sample was then transferred into the ViBE fluidic chamber (BioScale) and passed 
onto the biosensor membrane, where a magnetic field pulled the magnetic beads 
towards the biosensor surface (step 2). Fl-Abs that were part of the sandwich bound 
to the biosensor surface, which was coated with anti-fluorescein receptors. While the 
magnet was still engaged, the channel was rinsed with wash buffer to remove 
excess matrix biomaterials and reagents (step 3). After which, the magnetic field was 
released and only the beads involved in the formation of the sandwich remained 
bound to the biosensor surface. The vibrational frequency of the biosensor changed 
in relation to the mass of magnetic bead (much like a spring-mass system) attached 
and provided a means of quantitation. The more beads attached, the greater the 
mass and the lower the frequency of vibration. The sensor could be returned to its 
original state by the use of a regeneration solution and re-used for the next round of 
sample analysis (Step 5) (Figure 8.2). For the purpose of this chapter, sPD-L1 may 
consists of recombinant PD-L1 (rPD-L1) or endogeneous sPD-L1 (endo-sPD-L1). 
The development of the sPD-L1 ViBE detection assay first involved a checkerboard 
investigation to find antibody pairs which were sensitive to rPD-L1. Selected antibody 
pairs were then assessed for their performance using standard assays such as spike 
and recovery and linearity-of-dilution. The developed sPD-L1 ViBE assay was then 
used to quantify endo-sPD-L1 in patient plasma samples.   
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Figure 8.1. The concentration of endo-sPD-L1 in human plasma from 11 healthy 
female donors, 20 and 71 women with benign and malignant ovarian tumours 
respectively. The endo-sPD-L1 levels were detected by ELISA. The results are 
represented as mean (the bar) ± standard deviation.  
(Figure reproduced from the PhD thesis of Dr Jayanta Chatterjee, with his kind 
permission) 
 
 
Figure 8.2. The basic components and principles of a typical antibody sandwich 
assay using the ViBE. Step 1, the sample is mixed with bead-conjugated anti PD-L1 
antibodies and fluorescein tagged anti PD-L1 antibodies. Step 2, the beads are 
directed over membrane where binding is enhanced by the application of a magnetic 
field. Step 3, the magnetic field is removed and the beads that did not form the 
sandwich complex are washed off the sensor surface. Step 4, the vibrational 
frequency of the piezoelectric membrane changes in relation to bound beads which 
is converted into an electrical signal. Step 5, the membrane may be regenerated for 
reuse after wash with regeneration buffer (Bioscale).  
 
(Figure adapted from (Fraser et al., 2014)) 
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8.2 Results and discussion 
8.2.1 Antibody candidates 
A range of commercially available monoclonal and polyclonal anti PD-L1 antibodies, 
produced in different species (rabbits, mice and goats), were chosen for the 
development of sPD-L1 ViBE assay (Table 8.1). Monoclonal antibodies recognize a 
single epitope on a target protein whereas polyclonal antibodies recognize multiple 
epitopes. The choice of monoclonal or polyclonal antibodies may have direct 
consequences on the sensitivity of detection assays, where by polyclonal antibodies 
have been found to have large antigen binding capacity but also display cross 
reactivity (Morikawa et al., 1995). In addition, the species used for antibody 
production may also affect antibody properties. Rabbits have been reported to have 
more diverse epitope recognition, less immunodominance, and tend to generate 
antibodies with higher affinity and overall avidity than mice. Rabbit antibodies also 
have enhanced binding properties due to heavy glycosylation (Rossi et al., 2005).  
Antibodies 1-7 were conjugated either to the magnetic beads or fluorescein to form 
B1-7 and Fl-Ab1-7 respectively. Antibodies were reacted in excess with the beads 
(1.2 x 106 molecules of antibody per one bead), according to the company’s protocol, 
via an amine coupling reaction (not disclosed by the company). Although the 
quantification of the number of antibodies per bead was not performed, it is expected 
that each bead was coated with multiple antibodies. The reason for the company’s 
recommendation to conjugate multiple antibodies to a single bead is unexplained. 
From the user’s perspective, this may decrease the sensitivity and accuracy of the 
assay as single or multiple sPD-L1 molecules are able to bind to a single bead but 
result in similar output signals. Rather, it may be better to react beads in excess with 
229 
 
antibodies to ensure that only one antibody molecule is conjugated per bead. On the 
other hand, 3 times molar excess of fluorescein were reacted with antibody via NHS 
coupling with the amines of the antibody. 
 
Table 8.1. Commercially available anti PD-L1 antibodies used for the development 
of the sPD-L1 ViBE assay. 
 
PD-L1 also known as B7-H1: programmed cell death- ligand 1 
 
8.2.2 Checkerboard assay 
To select for the most sensitive antibody pairs for the detection of sPD-L1, a 
checkerboard assay was performed. Histidine-tagged rPD-L1, which comprised of 
the extracellular domain (Met 1-Thr 239) of the protein was dissolved in BioScale 
assay diluent and used as the analyte for the generation of the standard curve. A 
total of 49 combinations of bead-conjugated antibodies and fluorescein antibodies 
Antibody 
number
Company/ 
category number
Hosy
Species
Monoclonal Polyclonal Immunogen Method of 
purification
1 Novus Biologicals/
NBP1-76769
Rabbit  Raised against a 17 amino acid peptide 
from near the centre of human PD-L1 
protein
Affinity purified
2 Antibodies-online/ 
ABIN610286
Mouse  Raised against recombinant human PD-
L1 protein
Protein A affinity 
chromatography
3 Ebiosciences/ 
16-5983-82
Mouse  Prepared from C3H mice serum after 
immunization with B7-H1-transfected L 
cells and fused immune splenocytes and 
P3U1 myeloma cells
Protein A affinity 
chromatography
4 Novus Biologicals/ 
NB110-86971
Rabbit  Prepared from whole rabbit serum after 
repeated immunizations with a synthetic 
peptide corresponding to a region near 
the amino terminus of human PD-L1 
protein
Affinity purified
5 R&D Systems/
MAB1561
Mouse  Mouse myeloma cell line NS0-
derived recombinant human B7-H1/PD-
L1 Phe19Thr239 Accession # Q9NZQ7 
Protein A/G 
affinity 
chromatography
6 R&D Systems/
AF156
Goat  Mouse myeloma cell line NS0-
derived recombinant human B7-H1/PD-
L1 Phe19Thr239 Accession # Q9NZQ7
Antigen Affinity
purified
7 Sino Biologicals/ 
10084-RP01
Rabbit  Recombinant Human B7-H1 protein 
(Sino Biologicals Catalog#10084-H08H)
Protein A affinity 
chromatography
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were investigated for their ability to detect low (100 pg/mL), medium (1000 pg/mL) 
and high (10000 pg/mL) concentrations of rPD-L1 using the ViBE system (Figure 
8.3A). The various antibody pairs and rPD-L1 were first incubated together on a 
standard 96-well plate for 4 h before contact with the sensor surface. Bead-
conjugated antibody only, without the addition of Fl-Ab, were included as negative 
controls. 
Depending on the affinity and avidity of the antibodies to the antigen, three common 
types of response curves may be obtained when analysing ViBE sPD-L1 
immunoassays. They include sigmoidal or S-shaped curves, a low response curves, 
or high-response curves. In this regard, the 5-parameter (5-PL) fitting model was 
applied using the BioScale excel plug-in (Baud, 1993, Yan et al., 2011) (Appendix 
8.2). The quality of curve fit was assessed by calculating the root mean square error 
(RMSE), which was a measure of the spread of the experimental signal values 
obtained around the known standard concentration (Appendix 8.2). A good curve fit 
was obtained when the RMSE was between 80-120% of the actual value (Baud, 
1993). Figure 8.3B-F show representative curves obtained for various antibody pairs 
which resulted in sensitivity to rPD-L1 and had RMSE between 80%-120%. 
However, a minimum of six data points were needed to obtain an accurate fit when 
using 5-PL curve fit (Motulsky, 1996). The results obtained from the checkerboard 
assay were therefore only a rough approximation of rPD-L1 detection by the 
antibody pairs. Nevertheless, antibody pairs such as B5/Fl-Ab 3 and B3/Fl-Ab 5, 
which resulted in higher assay sensitivity could be selected for (Figure 8.3).  
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Figure 8.3. The checkerboard assay for the detection of rPD-L1. (A) Overview of the 
combinations of commercially available antibodies which were used as bead-
conjugated (B-) or Fl-Ab. Antibody pairs that were sensitive to rPD-L1 concentrations 
and which resulted in standard curves are labelled blue and pairs which were not 
able to detect rPD-L1 are labelled grey. The most sensitive antibody pairs are 
denoted by . (B-F) Representative standard curves generated from one experiment 
using bead-conjugated antibodies 2, 3, 5, 6 and 7, correspondingly, and Fl-Ab. 
Bead-conjugated antibodies alone (--) were used as controls; background readings 
are denoted by curves without symbols. Each experiment consisted of duplicate 
samples. 1 mg of bead was labelled with 20 µg of antibody; final concentration of Fl-
Ab used was 50 ng/mL. Antibodies and rPD-L1 were added simultaneously to form 
the sandwich complex. 
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8.2.3 Optimization studies of the standard curve 
Antibody pairs B3/Fl-Ab 5 and B5/Fl-AB 3 were shown to have the highest 
sensitivities based on the results of the checkerboard assay. To further increase the 
sensitivity of the assay various concentrations of bead-conjugated antibodies and 
fluorescein labelled antibodies were tested. Figure 8.4 shows that for both antibody 
pairs, doubling the bead-conjugated antibody concentration from 3.5 x 105 to 7.0 x 
105 beads/mL did not show any improvement in the sensitivity of the assay, whereas 
increasing the concentration of Fl-Ab from 50 ng/mL to 600 ng/mL increased the 
sensitivity.  
Furthermore, the sequence of antibody addition to rPD-L1 was studied. Bead-
conjugated and fluorescein antibodies were added either simultaneously or 
sequentially to rPD-L1 for the formation of the sandwich complex before contact with 
the sensor membrane. As described by its name, the simultaneous protocol involved 
the addition of the bead-conjugated and fluorescein conjugated antibodies to rPD-L1 
at the same time and incubated for 4 h. For the protocol involving sequential addition 
of antibody, the bead-conjugated antibodies were added first and left to incubate for 
2 h with the rPD-L1 before the Fl-Ab was added and incubated for a further 2 h. For 
both protocols, the total incubation time was kept constant at 4 h before contact with 
the sensor surface. The assay was more sensitive when antibodies were added 
simultaneously compared to sequentially (Figure 8.5). This was also the case for the 
antibody pair B3/Fl-Ab 5 (data not shown). A possible reason for the reduction of 
sensitivity, when antibodies were added sequentially, could be due to steric 
hindrance faced by Fl-Abs to bead bound antigen. Additionally, the first antibody may 
have exerted allosteric effects on rPD-L1 and caused spatial structure modification, 
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thus hindering binding with the second Fl-Ab (Roguin and Retegui, 2003). The 
simultaneous protocol was therefore employed for the sPD-L1 ViBE assay.  
Additionally, when the simultaneous protocol was applied for antibody pairs B3/Fl-Ab 
5 and B5/Fl-Ab 3, B5/Fl-Ab 3 resulted in a more sensitive assay than B3/Fl-Ab 5 
(Figure 8.5). This was interesting as the pairs contained the same antibodies, with 
the only difference being the interchange of conjugated material. Although both 
conjugation protocols depended on amine chemistry, the reactivity as well as 
preferential binding site of each antibody may vary with different chemical species 
(bead or fluorescein molecule) involved in the reaction. As such, the coupling of 
bead and fluorescein to antibody 5 and 3 respectively might have resulted in 
conjugated antibodies with unobstructed sPD-L1 binding sites that led to higher 
binding affinities compared to its B3/Fl-Ab 5 counterpart.  
As the ViBE assay requires new sensor membranes to be used for each experiment, 
the intra-assay variability of the standard curve had to be determined to ensure 
consistency of the results among different experiment sets. The sPD-L1 ViBE assay 
performed by the simultaneous addition of B5 (3.5 x 105 beads/mL)/Fl-Ab 3 (600 
ng/mL) antibody pair to rPD-L1, was repeated at least 15 times for the generation of 
a sPD-L1 standard curve (Figure 8.6). Despite the automated ViBE platform, which 
was expected to increase reproducibility, the error bars were still wide and the curve 
of best fit obtained had a R2 value of 0.894, indicating that many data points were 
loosely scattered around the curve. The spread of data points may also be attributed 
to pipetting error when preparing rPD-L1 standards. Although standard curves may 
vary from assay to assay, it is important to ensure that the detection of sPD-L1 in 
samples displays consistency relative to the standard curve. Figure 8.6 also shows 
the 95% confidence interval and the 95% prediction interval of the curve of best fit. 
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The 95% confidence bands denote the area where the user is 95% sure contains the 
true curve and gives a visual sense of how well the data defines the curve of best fit. 
The narrower the confidence bands, the better the data fit. On the other hand, the 
95% prediction bands mark the area which the user is 95% sure will enclose future 
data points. 95% prediction bands includes both the uncertainty of the true position 
of the curve (enclosed by the confidence bands), and also accounts for standard 
deviation of data around the curve. In addition, the reported concentration of rPD-L1 
which resulted in 50% of signal output was 557.7 pg/mL. The affinity constants of the 
antibodies used in the ViBE may therefore be estimated to be 1011 M-1 (Appendix 
8.3) which is considered high affinity binding. Most antibody/antigen binding affinities 
fall in the range of 105 to 1012 M-1 (Butler et al., 1977, Heinrich et al., 2010). In 
addition, the LLOD of B5/Fl-Ab 3 in BioScale assay diluent, was calculated to be ~33 
pg/mL (Appendix 8.1), which was two-fold more sensitive than the ELISA. The 
increase in sensitivity of the ViBE assay compared to the ELISA might be due to the 
different antibodies used, the increase of the signal to noise ratio using the ViBE 
platform as well as the signal readouts measured- acoustic (ViBE) vs colorimetric 
(ELISA). Both types of signal readouts have their limitations which include batch-to-
batch variability of the sensor surface and plate-to-plate variability for acoustic and 
colorimetric assays respectively.  
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Figure 8.4. Representative standard curves generated by one experiment using the 
sPD-L1 ViBE assay to study the effects of antibody concentration. Each experiment 
was performed with duplicate samples. Antibody pairs consisting of (A) B5/Fl-Ab 3 
and (B) B3/Fl-Ab 5 were titrated. Concentrations of bead-conjugated antibodies used 
were 3.5 x 105 and 7 x 105 beads/mL; concentrations of Fl-Ab used were 50 ng/mL, 
200 ng/mL and 600 ng/mL. Antibodies and rPD-L1 were added simultaneously to 
form the sandwich complex. 1 mg of bead was labelled with 20 µg of antibody; final 
concentration of Fl-Ab used was 50 or 200 or 600 ng/mL. 
 
   
Figure 8.5. Representative standard curves generated by one experiment using the 
sPD-L1 ViBE assay, when Fl-Ab were added either simultaneously or sequentially to 
bead-conjugated antibodies and rPD-L1. Each experiment was performed with 
duplicate samples. The simultaneous protocol involved the addition of the bead-
conjugated and fluorescein conjugated antibodies to rPD-L1 at the same time and 
incubated for 4 h. For the protocol involving sequential addition of antibody, the 
bead-conjugated antibodies were added first and left to incubate for 2 h with the rPD-
L1 before Fl-Ab was added and incubated for a further 2 h. For both protocols, the 
total incubation time was kept constant at 4 h before contact with the sensor surface. 
1 mg of bead was labelled with 20 µg of antibody; final concentration of Fl-Ab used 
was 600 ng/mL. 
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Figure 8.6. The standard curve generated by 15 independent experiments of the 
simultaneous addition of B5 (3.5 x 105 beads/mL)/Fl-Ab 3 (600 ng/mL) antibody pair 
to rPD-L1. Each experiment had duplicate samples. The curve of best fit had R2 
value of 0.894. Each data point represents the mean of 15 experiments and error 
bars represent standard deviation. (A) 95% confidence interval and (B) 95% 
prediction interval of the curve of best fit was also calculated using (GraphPad Prism, 
La Jolla, CA) and included in the graph. 
 
8.2.4 Spike-and-recovery assay in plasma from healthy women 
For the sPD-L1 assay to be clinically applicable, the ViBE would need to be able to 
detect sPD-L1 in plasma samples and quantify the concentrations based on a 
standard curve, which consisted of rPD-L1 dissolved in BioScale diluent. However, 
whether the presence of plasma, compared to BioScale assay diluent, would affect 
the detection of sPD-L1 has to be determined. This can be done by performing a 
spike-and-recovery assay, which involved first, the addition (spike) of a known 
amount of rPD-L1 into plasma and BioScale assay diluent. The signal (AMMP RU) 
responses from the plasma and BioScale assay diluent samples were then 
measured (recovery) and compared. The recovery of rPD-L1 in plasma was 
calculated by finding the percentage of measured rPD-L1 in plasma samples to that 
measured in BioScale assay diluent. An acceptable recovery range is defined to be 
(A) (B)
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80-120%, according to guidelines published by the FDA for the development of 
diagnostic detection assays (U.S. Department of Health and Human Services, 2011). 
Plasma from healthy donors were used for the spike and recovery assay as they 
were expected to have very low levels of endo-sPD-L1. The plasma was first 
centrifuged to pellet any fat present and diluted 4 and 8-fold in BioScale assay 
diluent. Dilution of plasma was sometimes necessary as plasma contains 
components that may affect assay response. The spiked rPD-L1 could be detected 
from diluted plasma samples over the range of spiked concentrations tested (Figure 
8.6). However, an 80%-120% recovery of rPD-L1 only occurred within the range of 
rPD-L1 concentrations 2 pg/mL-494 pg/mL when plasma was diluted 4-fold and 2 
pg/mL-1481 pg/mL when plasma was diluted 8-fold (Table 8.2). However, as the 
LLOD of the rPD-L1 quantification in BioScale assay diluent was calculated to be 
~33 pg/mL, only concentrations above the LLOD could be determined reliably. The 
sPD-L1 ViBE assay was therefore able to quantify rPD-L1 in plasma diluted 8-fold at 
a wider range (55 pg/mL-1481 pg/mL) compared to plasma that was diluted 4-fold 
(55 pg/mL-494 pg/mL).  
 
 
 
 
 
 
Table 8.2. Spike and recovery of sPD-L1 in three human plasma samples. Samples 
were diluted either 4- or 8- fold in BioScale assay diluent and spiked with known 
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concentrations of rPD-L1. Values reported for recovery of spiked samples were 
calculated as such: Recovery (%) = 100 x [obtained sPD-L1/(expected sPD-
L1spike+endogenous)], where obtained sPD-L1 is the concentration measured by the 
ViBE; expected sPD-L1spike+endogenous is the sum of concentration of spiked rPD-L1 
and endo-sPD-L1 measured by the ViBE. The results represent the average of three 
individual experiments ± standard deviation. Each experiment was performed in 
duplicate. Blue highlighted regions indicate recovery values between 80-120%, with 
rPD-L1 concentration above LLOD.  
 
SD: standard deviation; sPD-L1: soluble programmed cell death-ligand 1; rPD-L1: 
recombinant programmed cell death-ligand 1 
 
 
 
 
Spiked rPD-L1 (pg/mL)
1:4 dilution 
Mean recovery ± SD
1:8 dilution 
Mean recovery ± SD
2 97.8 ± 1.9 117.2 ± 16.6
6 94.1 ± 21.4 101.9 ± 13.4
18 90.6 ± 12.8 54.6 ± 26.6
55 84.4 ± 10.6 88.4 ± 9.2
165 98.0 ± 7.8 94.9 ± 7.1
494 115.1 ± 5.0 102.0 ± 7.4
1481 132.9 ± 17.1 114.8 ± 6.1
4444 148.2 ± 9.0 135.0 ± 17.5
13333 120.8 ± 22.1 109.9 ± 15.2
40000 65.4 ± 12.6 64.0 ± 5.8
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Figure 8.6. sPD-L1 concentration measured by the ViBE, in relation to spiked 
concentrations of rPD-L1 in plasma, obtained from healthy women, which were 
diluted 4- or 8-fold. The results show the mean sPD-L1 concentration of two 
independent experiments. Each experiment was performed in duplicate. 
 
8.2.5 Linearity-of-dilution assay in plasma from healthy women 
To investigate whether rPD-L1 can be detected over a range of plasma dilutions, a 
linearity-of-dilution assay was performed. Undiluted (neat) plasma samples, obtained 
from healthy donors, were spiked with 500 pg/mL of rPD-L1 and after which the 
plasma samples were diluted 2, 4, 8 and 16-fold. Recovered sPD-L1 concentrations 
were then read using the ViBE assay. Good linearity is important as it provides 
flexibility to the assay. For example, plasma samples with high levels of endo-sPD-
L1 may need to be diluted several-fold to ensure that the levels of endo-sPD-L1 falls 
within the range of the standard curve.   
Table 8.3 shows that the detection of rPD-L1 varied no more than 80% to 120% 
between doubling dilutions, over the range of 0 to 16-fold dilution, for all the plasma 
samples tested . This indicated a good linearity-of-dilution (U.S. Department of 
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Health and Human Services, 2011). However, as the spike-and-recovery assay did 
not include plasma dilutions of 0, 2 and 16, it was uncertain whether the rPD-L1 
detected with those dilutions could be measured reliably, where recovery of spiked 
rPD-L1 fell within the range of 80%-120%. The measured concentration of rPD-L1 
after 16-fold dilution was also very close to the LLOD of the sPD-L1 ViBE assay and 
risked being an unreliable readout. There is therefore a need to determine the range 
of rPD-L1 that can be accurately measured for the different plasma dilutions before 
concrete conclusions can be made. 
 
Table 8.3. Linearity-of-dilution of spiked plasma samples obtained from healthy 
women. Neat plasma was spiked with 500 pg/mL of rPD-L1 and the plasma was 
diluted up to 16-fold. rPD-L1 concentration was measured by the ViBE. A good 
linearity-of-dilution maintains that measured sPD-L1 concentration varies no more 
than 80% to 120% between doubling dilutions (U.S. Department of Health and 
Human Services, 2011). Results represented in the table were obtained from a 
single experiment performed in duplicate. 
 
PD-L1: recombinant programmed cell death-ligand 1 
 
8.2.6 Detection of endogeneous soluble PD-L1 in plasma of patients with ovarian 
tumours  
The endo-sPD-L1 levels in plasma of ovarian cancer patients were measured using 
the sPD-L1 ViBE assay. Endo-sPD-L1 levels, from the same samples, were also 
measured using the ELISA and used as a positive control. The patient plasma used 
in the ViBE assay were diluted either 4 or 8-fold, to keep within the boundaries 
Fold 
dilution
Donor 1 Donor 2 Donor 3
Ave PD-L1 
concentration ±
SD
(pg/mL)
Change in 
concentration from 
previous dilution (%)
Ave PD-L1 
concentration ±
SD
(pg/mL)
Change in 
concentration 
from previous 
dilution (%)
Ave PD-L1 
concentration ±
SD
(pg/mL)
Change in 
concentration 
from previous 
dilution (%)
0 613 ± 79.5 n.a. 882 ± 109.4 n.a. 567 ± 57.9 n.a.
2 659 ± 96.0 107.5 932 ± 294.1 105.7 608 ± 62.2 107.2
4 710 ± 105.8 107.7 910 ± 93.9 97.6 618 ± 149.5 101.6
8 664 ± 62.7 93.5 969 ± 123.5 106.5 637 ± 99.1 103.1
16 669 ± 41.3 100.8 920 ± 134.3 94.9 638 ± 39.5 100.2
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determined from the spike-and-recovery assay. Measured endo-sPD-L1 
concentration were also constrained within 55 pg/mL-494 pg/mL for plasma diluted 
4-fold and 55 pg/mL-1481 pg/mL for plasma diluted 8-fold. Bead-conjugated 
antibody only, without the addition of Fl-Ab, were included as negative controls. 
As the nature (cleaved protein or exosome) of endo-sPD-L1 is unknown, patient 
plasma was not centrifuged to prevent loss of larger protein factions. It was instead 
mixed, using a vortex machine, and the clear liquid portion was sampled for endo-
sPD-L1 quantification. Table 8.4 shows that although the sPD-L1 ViBE assay 
measured endo-sPD-L1 in patient plasma, the bead-conjugated antibody alone 
negative controls were also picking up an equally high signal and the assay was 
therefore void. We hypothesized that plasma components, such as fat might be 
interfering with the signal response. Therefore, the plasma samples were spun using 
a centrifuge and the liquid portion was sampled for endo-sPD-L1 quantification. 
Table 8.4 shows that just like the mixed plasma samples, the bead alone negative 
controls were reading an equally high amount of signal. The sPD-L1 ViBE platform 
was therefore deemed unsuitable for endo-sPD-L1 quantification in patient plasma. 
It was interesting that the bead-conjugated antibody alone negative controls did not 
result in positive signal readouts for the investigations of spike-and-recovery and 
linearity-of-dilution. One reason might be due to the low levels of endo-sPD-L1 in 
healthy plasma. In the same way, plasma from patients 3, 5 and 6, with lower levels 
of endo-sPD-L1 also resulted in lower levels of signal read out in the negative 
control. Positive signal readout in the negative control might therefore be due to the 
presence of endo-sPD-L1. Although the sandwich complex should not have formed 
in the negative control, it might be possible that bead bound endo-sPD-L1 attached 
to the sensor surface by unspecific interactions and resulted in positive signals. On 
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the other hand, rPD-L1 did not display such unspecific binding. Notably, current 
publications about the success of the ViBE platform has only involved studying 
recombinant proteins in various different biological matrixes (Jalali-Yazdi et al., 2014, 
Collins et al., 2013, Chilewski et al., 2014, Yan et al., 2011).  
For the development of more suitable quantitative assays, future studies will need to 
focus on the nature of endo-sPD-L1. Other immunoregulatory molecules such as 
MHC class I and TIM-3 have been shown to undergo proteolytic cleavage and 
released as soluble proteins into plasma (Möller-Hackbarth et al., 2013, Boutet et al., 
2009). It may be possible that sheddases such as a disintegrin and metalloprotease-
10 (ADAM10), ADAM17 and γ-secretase cleaves the ectodomain of membranous 
PD-L1 to release endo-sPD-L1. This might explain why only ectodomain peptides of 
endo-sPD-L1 were identified by mass spectrometry in cell culture media harvested 
from PD-L1 positive lymphoma cell lines, Karpas-299 and SUDHL-1 (Frigola et al., 
2011). Cleaved endo-sPD-L1 may not exist as a pure protein but instead may 
interact with other soluble components to form aggregates. This complex may have 
formed unspecific interactions with the sensor surface, which was coated with 
fluorescein receptors. However endo-sPD-L1 may also be released by other 
mechanisms and pathways by different cells via secretory pathways or by exosome 
budding (Raposo and Stoorvogel, 2013). Imaging by the cryogenic transmission 
electron microscopy (cryo-TEM) may be done to investigate secretory pathways of 
proteins. Knowledge of the nature of endo-sPD-L1 may provide insight to sample 
pre-processing after whole blood collection. For example, anti-clotting agents 
(Heparin, citrate or ethylenediaminetetraacetic acid (EDTA)) may affect the stability 
of endo-sPD-L1, in which case, serum (absence of clotting components) might be 
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preferred. Optimised pre-processing of patient blood might result in better detection 
of endo-sPD-L1 by current established quantification techniques such as the ELISA.  
 
Table 8.4. Endo-sPD-L1 concentrations in plasma from ovarian cancer patients 
measured by the ViBE and ELISA. Samples measured by the ViBE were either 
mixed using a vortex machine or centrifuged. Samples measured by the ELISA were 
mixed using a vortex machine. Results represented in the table were obtained from a 
single experiment performed in duplicate. 
 
 
8.3 Summary and conclusions 
A sPD-L1 ViBE assay, based on a frequency-modulating technology from BioScale, 
Inc, was developed and optimised for the quantification of endo-sPD-L1 in plasma of 
ovarian cancer patients. The assay demonstrated good signal correlation with rPD-
L1 concentration and was 2-fold more sensitive than the ELISA. Furthermore, the 
assay was able to detect rPD-L1 in human plasma and displayed good linearity-of-
dilution. However, the sPD-L1 ViBE assay was unable to reliably detect endo-sPD-
L1 found in plasma of ovarian cancer patients and this might be due to unspecific 
interaction of endo-sPD-L1 with the sensor membrane. The ViBE platform was 
therefore unsuitable for endo-sPD-L1 detection. Pre-processing of patient plasma 
might be necessary to reduce unspecific interactions from occurring. The study of 
the nature of endo-sPD-L1 has been proposed to improve the understanding of the 
protein, which might result in methods to improve sPD-L1 detection techniques. 
Patient Cancer type Stage Grade
Mixed samples Spun samples (26,810 x g)
PD-L1 concentration 
(pg/mL) obtained by ELISA
PD-L1 concentration 
(pg/mL) bead alone 
negative control
PD-L1 concentration 
(pg/mL) antibody pair
PD-L1 concentration 
(pg/mL) bead alone 
negative control
PD-L1 concentration 
(pg/mL) antibody pair
1 Ovarian cancer serous 3C 1 1904  ± 415.3 1860.7  ± 28.1 1029.2 ± 231.9 1455.7 ± 611.9 911.9
2 Ovarian cancer serous 3C 2 5394.6  ± 531.9 7388.6  ± 56.1 7651.9 ± 408.4 6701.6 ± 915.5 2043.4
3 Ovarian cancer serous 3 3 81.3  ± 30.7 150.9  ± 28.3 29.1 ± 15.7 112.3 ± 26.2 642.2
4 Ovarian cancer serous 4 3 10083.2  ± 1776.6 13152.7  ± 2564.2 9871.6 ± 1856.7 10083.2 ± 1776.6 1061.3
5 Ovarian cancer serous 4 3 10.1  ± 48.2 95.3  ± 34.2 8.5 ± 11.8 82.1 ± 15.6 408.4
6 Benign mass n.a. n.a. 9.1 ± 8.9 113.1  ± 20.6 9.5 ± 23.5 93.5 ± 7.1 < 70
244 
 
Chapter 9  
Discussion, future perspectives and conclusions 
 
9.1 Discussion and future perspectives 
There is much evidence in the literature to suggest that ovarian cancer may be 
detected and destroyed by the immune system (Table 1.1). However, ovarian cancer 
cells as well as the cells present in its microenvironment have developed strategies 
to escape destruction by the immune system (Table 1.2), allowing the cancer to 
present itself clinically. In particular, PD-L1 expression on ovarian cancer cells, as 
well as on tumour-associated immune cells, has been widely implicated as an 
immune escape strategy in cancer. PD-L1 interacts with its receptor, PD-1, which is 
expressed on activated T cells to cause T cell anergy and apoptosis. In addition, PD-
L1 interacts with CD80, expressed on APCs, causing the depletion of CD80 that is 
needed for T cell co-stimulation. Due to this immune inhibitory nature, the PD-L1 
molecule may serve as a good candidate for investigation as a target for potential 
tumour immunotherapy. In this regard, blocking antibodies have shown tremendous 
potential in increasing T cell function and reducing tumour burden. The recent 2015 
American Society of Clinical Oncology (ASCO) meeting highlighted that an IgG1 
monoclonal anti PD-L1 antibody named Avelumab (also known as MSB0010718C), 
produced by Merck KGaA and partner Pfizer Ltd., resulted in an overall response 
rate of nearly 55% in a phase Ib study involving a cohort of 75 ovarian cancer 
patients (M. L. Disis, June 2015). Avelumab works by inhibiting PD-L1 interactions, 
which enables the activation of T-cells and the adaptive immune system. 
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Furthermore, as it contains a native Fc-region, Avelumab is thought to also engage 
the innate immune system and may induce antibody-dependent cell-mediated 
cytotoxicity (ADCC). PD-L1 is also expressed on healthy tissue such as the placenta, 
activated vascular endothelial cells and activated hematopoietic cells and may 
function as a homeostatic molecule to prevent the over activation of T cells (Curiel et 
al., 2003, Dong et al., 1999, Hamanishi et al., 2007, Zou and Chen, 2008). However, 
antibodies do not distinguish between PD-L1 protein expressed on cancer and 
healthy tissue. They therefore block all interactions between PD-L1 and PD-1 and 
this may lead to toxicity problems. Nucleic acid delivery using synthetic polymers, on 
the other hand, offers the possibility of targeted cell therapy. Among the polymers 
studied for gene delivery, PEI was of particular interest as it has shown considerable 
success as a gene transfection agent for both in vitro and in vivo applications. 
Unfortunately, the unfavourable toxicity profile of PEI-10 limits its use. Low molecular 
weight PEI 1.8 kDa (Mn 1.8 kDa, PEI-1.8) on the other hand, is less cytotoxic but it is 
also an inefficient gene transfecting agent.  
The aim of this thesis was to develop an immunotherapeutic strategy in ovarian 
cancer by the development of more efficient and less toxic PEI-based nucleic acid 
transfecting agents, which can be used to knockdown PD-L1 specifically in cancer 
cells. A second aim of the work was to establish an acoustic detection assay for the 
quantification of soluble (sPD-L1) as a potential biomarker for ovarian cancer 
diagnosis. 
To develop more efficient and less toxic PEI transfection agents, the hydrophobic 
modification of PEI-1.8 was studied in chapter 4. The motivation to carry out this 
work was based on previous studies which showed that the conjugation of 
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hydrophobic functional groups to the amines of PEI-1.8 resulted in amphiphilic 
polymers with increased gene transfection efficiencies and low cytotoxicity (Zheng et 
al., 2011, Kim et al., 2009, Han et al., 2001). It has been widely accepted that 
hydrophobic groups increase cell membrane penetration ability of the polymer. 
However, the rationale behind the choice of conjugated functional groups remained 
elusive. The aim of this study was to perform a systematic study by judiciously 
conjugating PEI-1.8 to various functional groups namely ethyl, octyl, deodecyl, 
benzyl and phenylurea using an established MTC monomer platform (Nederberg et 
al., 2007, Pratt et al., 2008). The work demonstrated that hydrophobic groups 
comprising of shorter alkyl chains (MTC-ethyl) and aromatic groups (MTC-benzyl 
and MTC-phenylurea) mediated the greatest increase of luciferase-expressing 
plasmid DNA transfection efficiency of PEI-1.8 in SKOV-3 ovarian cancer cells as 
well as HepG2 liver cancer cells (Figure 4.6) (Teo et al., 2013). Importantly, the 
percentage of amine substitution with hydrophobic groups also played a major role in 
determining the transfection efficiency of the polymer. PEI-1.8 modified with MTC-
ethyl, MTC-benzyl and MTC-phenylurea at amine substitution percentages of 10%, 
2.5% and 2.5% mediated the highest transfection efficiency. This work is significant 
because it provides an understanding of how different molecular structures improve 
gene transfection properties. This knowledge may also have translational potential to 
shape the modification strategies and design of other gene carrier systems. 
However, despite improvements in plasmid DNA transfection efficiency, modified 
PEI-1.8 polymers still functioned as low efficiency transfection agents compared to 
PEI-10 and viruses.  
To develop PEI-based polymers with better transfection efficiencies, the hydrophobic 
modification of higher molecular weight PEI-10, was investigated in chapter 5. 
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Previous studies have shown that the substitution of primary amines on PEI-10 with 
hydrophobic side groups not only increased gene transfection efficiency but also 
reduced the cytotoxicity of PEI-10 (Thomas and Klibanov, 2002, Tian et al., 2012, 
Gabrielson and Pack, 2006). Specifically, the amines of PEI-10 were substituted with 
functional groups, MTC-ethyl, MTC-benzyl and MTC-phenylurea, at corresponding 
amine substitution percentages of 10%, 2.5% and 2.5%. PEI-1.8 modified with these 
functional groups, at the respective percentage amine substitution values, had 
resulted in the highest increase of gene transfection efficiency compared to 
unmodified PEI-1.8. Modification of PEI-10 with MTC-ethyl significantly reduced the 
cytotoxicity of PEI-10 (Figure 5.4) (Yang et al., 2013). This was attributed to the 
reduction of cationic charge density, which may de-stabilize cellular membrane 
components leading to cell toxicity. Importantly, hydrophobic group modification also 
enhanced the GFP transfection efficiencies compared to unmodified PEI-10 (Figure 
5.5). However, when ethyl-modified PEI-10 was used to deliver PD-L1 siRNA, the 
knockdown of PD-L1 was greater when unmodified PEI-10 was used instead (Figure 
5.6). The lower siRNA transfection efficiency of ethyl-modified PEI-10 may have 
been due to the reduced charge density of the modified polymer. Unlike plasmid 
DNA which have molecular weights of approximately 100 kilo base pairs, short and 
rigid siRNA molecules (19-21 base pairs) require polymers with higher charge 
densities for efficient transfection. This shows that polymeric carriers need to be 
individually optimised for the nucleic acid cargo being delivered. Furthermore, 
although the study on hydrophobic modifications have provided insight for the 
development of less toxic and more effective PEI-based gene carriers, the 
translation of this knowledge into other gene delivery systems may not be entirely 
straight forward. This may be due to the different materials used (e.g. lipid-based, 
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inorganic formulations), which have different properties such as polarity and charge 
density and may therefore require different designs for effective nucleic acid delivery.  
The goal of this work was to knockdown PD-L1 in ovarian cancer, using either PD-L1 
shRNA or siRNA. PEI-10 modified with hydrophobic groups resulted in decreased 
siRNA transfection efficiency compared to unmodified PEI-10. Therefore, a different 
approach to improve PEI-10 siRNA transfection efficiency was employed in chapter 
6. PEI-10 was modified with FA and/or PEG in a 1:1 molar ratio, such that 0.4% of 
amines on PEI were substituted with FA or PEG-FA. The attachment of FA groups 
has been shown to enhance nanoparticle uptake into cells by receptor mediated 
endocytosis, whereas PEG has been widely used to increase nanoparticle stability in 
serum (Park, 2010). Although PEI10-FA(1) and PEI10-PEG-FA(1) resulted in similar 
levels of PD-L1 knockdown in ovarian cancer cells compared to unmodified PEI-10 
(Figure 6.6A), the modified polymers were substantially less cytotoxic than the 
unmodified counterpart. This could be attributed to the lower charge density of the 
modified polymers. In addition, FA modified PEI-10 polymers were able to mediate 
preferential uptake of siRNA into SKOV-3-Luc tumour cells and had lower unspecific 
uptake by PBMCs compared to unmodified PEI-10/siRNA polyplexes (Figure 6.11). 
Despite efficient PD-L1 mRNA knockdown (~80%) in a firefly luciferase-expressing 
SKOV-3 (SKOV-3-Luc) ovarian cancer cell line, the knockdown of PD-L1 protein on 
the plasma cell membrane was low (~50%). This was also observed in another 
ovarian cancer cell line, OVCAR-8 (Figure 6.7). Interestingly, the membranous PD-
L1 protein expressed remained low for up to 10 days post transfection in SKOV-3-
Luc cells. The difficulty to knockdown membrane expression of PD-L1 may be 
attributed to the remaining 20% of mRNA which may be translated to provide for 
50% of membranous PD-L1 protein expression. Alternatively, it could be due to the 
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presence of pre-existing PD-L1 protein (presence before siRNA transfection), stored 
in secretory lysosomes, which may be presented on the cell surface in a process 
mediated by ras-related protein, Rab27a (Figure 6.13). If the latter explanation was 
true or dominant, the use of shRNA to generate stable PD-L1 knockdown SKOV-3-
Luc cell lines was expected to overcome this problem as the PD-L1 protein stored in 
secretory lysosomes should eventually decrease over time. However, despite 
culturing stable PD-L1 knockdown SKOV-3-Luc cells for up to a month, membranous 
PD-L1 protein still had an expression of ~50% (Figure 6.8). Liu et al. had transduced 
mouse glioma 261 (Gl261) cells with PD-L1 shRNA and had observed approximately 
80% PD-L1 knockdown (Liu et al., 2013). Iwamura et al. had achieved almost 100% 
PD-L1 knockdown in human CD4 and CD8 positive T-cell clones, specific for 
melanoma associated antigen, after electroporation with PD-L1 siRNA (Iwamura et 
al., 2012). Chen et al. transfected 344SQ lung cancer cells with PD-L1 shRNA and 
reduced PD-L1 expression to that of the isotype control (Chen et al., 2014). Future 
work may involve the improvement of PD-L1 knockdown in ovarian cancer cells. One 
proposed method is to use the CRISPR/CAS-9 technology to specifically remove the 
genetic portion of PD-L1 for the creation of stable PD-L1 knockdown cells. However, 
as the efficiency for many CRISPR/CAS-9 systems is low (~20%), cell sorting by flow 
cytometry may be necessary to select for highly transfected cells.  
In chapter 7, the effects of PD-L1 knockdown in ovarian cancer cell lines on the 
tumouricidal activity of ErbB-family targeting CAR T cells was investigated both in 
vitro and in vivo. The bulk of the studies investigating PD-L1 expression on T cell 
function had been done using blocking antibodies (Brahmer et al., 2012, Herbst et 
al., 2014, Dong et al., 2002). As activated T cells also express PD-L1, it was unclear 
how tumour specific PD-L1 expression affected T cell function and proliferation. Only 
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a few recent papers have used shRNA or siRNA to knockdown PD-L1 in tumour 
cells for the study of T cell function (Chen et al., 2014). In this work, PD-L1 
knockdown in ovarian cancer cells enhanced T cell functions (release of IFN-γ 
(Figure 7.6), perforin and granzymes (Figure 7.7)) and rendered cancer cells to be 
more susceptible to T cell killing in in vitro experiments (Figure 7.8). These results 
prompted further in vivo study which involved treating SKOV-3-Luc cells with PEI10-
FA(1)/siRNA polyplexes ex vivo before inoculating SCID beige mice with the cancer 
via intraperitoneal (i.p.) injection. The mice were administered with T4 cells by i.p. 
injection five days post tumour inoculation. Mice inoculated with PD-L1 knockdown 
tumour cells responded marginally better than mice inoculated with scrambled siRNA 
treated tumour cells. However the difference in both treatment groups were not 
significant. This could be due to an insufficient knockdown of PD-L1 in tumour cells 
or the recovery of PD-L1 expression on the tumour cells after five days in the mouse. 
It would be useful to be able to administer another dose of PEI10-FA(1)/siRNA 
treatment in vivo before treatment with T4 cells. However prior in vivo studies such 
as the optimization of siRNA dose, toxicity studies of PEI10-FA(1)/siRNA polyplexes, 
PD-L1 knockdown efficiency and biodistribution would be necessary and may be 
performed as future work. PEG-FA conjugated PEI-10 (PEI10-PEG-FA(1)) is 
expected to have greater stability than PEI10-FA(1) and should be tested for future 
in vivo applications. Despite strategies to increase gene transfection efficiency and 
lower cytotoxicity of PEI-based polymers, clinical applications of these gene delivery 
agents are still limited. This is mainly due to the high cationic charge which may 
cause aggregation, especially within the lungs. The development of delivery vectors 
that can bind nucleic acids by non-electrostatic forces, e.g., by pH or glutathione 
sensitive chemical conjugation or hydrophobic forces may allow polymers or indeed 
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other classes of material to further realise their potential as non-viral vectors. In 
addition, future work should focus on combination therapies involving the blockade of 
multiple co-inhibitory pathways such as PD-L1/PD-1, CTLA-4/CD80 and TIM-
3/galactin-9. Various studies have already shown that blocking PD-1 in combination 
with CTLA-4 has resulted in enhanced T cell activity and tumour killing (Duraiswamy 
et al., 2014, Quezada and Peggs, 2013, Curran et al., 2010). Another strategy to 
enhance T cell killing would be to knockdown PD-1 in T4 cells. This could be done 
by including a PD-1 knockdown sequence in the CAR construct for transduction of 
primary human T cells.    
In addition to the potential of PD-L1 as a therapeutic target, the soluble form of PD-
L1 (sPD-L1) may also serve as a biomarker. sPD-L1 found in patient plasma or 
serum has been shown to correlate with tumour stage and grade in studies of renal 
cell carcinoma and diffuse large B cell lymphoma (Frigola et al., 2011, Rossille et al., 
2014, Rossille et al., 2013). High levels of sPD-L1 were also associated with poor 
prognosis (Frigola et al., 2011, Rossille et al., 2014, Rossille et al., 2013). Work 
performed by a previous member of the lab, Dr Jayanta Chatterjee, showed that 
there was a significantly higher concentration of sPD-L1 in women with ovarian 
cancer compared to healthy female volunteers and women with benign ovarian 
tumours (p<0.0001) (Figure 8.1). The concentration of sPD-L1 in plasma samples 
was measured by using an in-house ELISA. However, the ELISA was not sensitive 
enough to accurately distinguish all the patients with stage I tumours from benign 
tumours. It is important to stratify patients so that they are able to receive the 
necessary treatments from the correct treatment centres. The aim of chapter 8 was 
to develop a more sensitive sPD-L1 detection assay so that the usefulness of sPD-
L1 to differentiate patients with stage I ovarian cancer and benign tumours could be 
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evaluated. This assay was based on a frequency-modulating technology from 
BioScale, Inc. named the ViBE Bioanalyzer (ViBE) which detects acoustic micro 
magnetic particle (AMMP) as an output function. Although the ViBE assay was more 
sensitive than the in-house ELISA for measuring rPD-L1, it was not able to 
accurately quantify endogenous sPD-L1 (endo-sPD-L1) in patient plasma. Future 
work should focus on the study of the nature of endo-sPD-L1. The understanding of 
the protein structure and form may help researchers to develop better techniques to 
quantify the protein. 
 
9.2 Conclusion 
This thesis has shown insights into the modification of PEI-based polymers with 
hydrophobic functional groups, FA targeting ligand as well as PEG for improved 
nucleic acid delivery. The synthesized polymers were used to knockdown PD-L1 
expressed in tumour cells to investigate its role as a therapeutic target in ovarian 
cancer immunotherapy. These findings agree with similar studies in the literature and 
suggest that the PD-L1 pathway is a potential target for ovarian cancer therapy. 
Future work on this project should focus on combination therapy, involving blocking 
antibodies targeting co-inhibitory molecules as well as chemotherapy, which have 
been shown to sensitize ovarian cancer cells to immunotherapy. 
 
 
 
253 
 
References 
ABDALLAH, B., HASSAN, A., BENOIST, C., GOULA, D., BEHR, J. P. & DEMENEIX, B. A. 1996. A powerful 
nonviral vector for in vivo gene transfer into the adult mammalian brain: polyethylenimine. 
Hum Gene Ther, 7, 1947-54. 
ABIKO, K., MANDAI, M., HAMANISHI, J., YOSHIOKA, Y., MATSUMURA, N., BABA, T., YAMAGUCHI, K., 
MURAKAMI, R., YAMAMOTO, A., KHARMA, B., KOSAKA, K. & KONISHI, I. 2013. PD-L1 on 
tumor cells is induced in ascites and promotes peritoneal dissemination of ovarian cancer 
through CTL dysfunction. Clin Cancer Res, 19, 1363-74. 
ADAMS, S. F., LEVINE, D. A., CADUNGOG, M. G., HAMMOND, R., FACCIABENE, A., OLVERA, N., RUBIN, 
S. C., BOYD, J., GIMOTTY, P. A. & COUKOS, G. 2009. Intraepithelial T cells and tumor 
proliferation: impact on the benefit from surgical cytoreduction in advanced serous ovarian 
cancer. Cancer, 115, 2891-902. 
AGARWAL, R., SINGH, V., JURNEY, P., SHI, L., SREENIVASAN, S. V. & ROY, K. 2013. Mammalian cells 
preferentially internalize hydrogel nanodiscs over nanorods and use shape-specific uptake 
mechanisms. Proceedings of the National Academy of Sciences, 110, 17247-17252. 
AHMADZADEH, M., JOHNSON, L. A., HEEMSKERK, B., WUNDERLICH, J. R., DUDLEY, M. E., WHITE, D. 
E. & ROSENBERG, S. A. 2009. Tumor antigen-specific CD8 T cells infiltrating the tumor 
express high levels of PD-1 and are functionally impaired. Blood, 114, 1537-44. 
AKBARI, O., STOCK, P., SINGH, A. K., LOMBARDI, V., LEE, W. L., FREEMAN, G. J., SHARPE, A. H., 
UMETSU, D. T. & DEKRUYFF, R. H. 2010. PD-L1 and PD-L2 modulate airway inflammation and 
iNKT-cell-dependent airway hyperreactivity in opposing directions. Mucosal Immunol, 3, 81-
91. 
AKINC, A., THOMAS, M., KLIBANOV, A. M. & LANGER, R. 2005. Exploring polyethylenimine-mediated 
DNA transfection and the proton sponge hypothesis. J Gene Med, 7, 657-63. 
ALAO, J. P. 2007. The regulation of cyclin D1 degradation: roles in cancer development and the 
potential for therapeutic invention. Mol Cancer, 6, 24. 
ALBERTSSON, A.-C. & EKLUND, M. 1995. Influence of molecular structure on the degradation 
mechanism of degradable polymers: In vitro degradation of poly(trimethylene carbonate), 
poly(trimethylene carbonate-co-caprolactone), and poly(adipic anhydride). Journal of 
Applied Polymer Science, 57, 87-103. 
ALEXIS, F., PRIDGEN, E., MOLNAR, L. K. & FAROKHZAD, O. C. 2008. Factors affecting the clearance 
and biodistribution of polymeric nanoparticles. Mol Pharm, 5, 505-15. 
ALLEN, M. H., GREEN, M. D., GETANEH, H. K., MILLER, K. M. & LONG, T. E. 2011. Tailoring charge 
density and hydrogen bonding of imidazolium copolymers for efficient gene delivery. 
Biomacromolecules, 12, 2243-50. 
ALLEN, T. D., CRONSHAW, J. M., BAGLEY, S., KISELEVA, E. & GOLDBERG, M. W. 2000. The nuclear 
pore complex: mediator of translocation between nucleus and cytoplasm. J Cell Sci, 113 ( Pt 
10), 1651-9. 
ALVAREZ, R. D. & CURIEL, D. T. 1997. A phase I study of recombinant adenovirus vector-mediated 
intraperitoneal delivery of herpes simplex virus thymidine kinase (HSV-TK) gene and 
intravenous ganciclovir for previously treated ovarian and extraovarian cancer patients. Hum 
Gene Ther, 8, 597-613. 
ANDTBACKA, R. H. I., COLLICHIO, F. A., AMATRUDA, T., SENZER, N. N., CHESNEY, J., DELMAN, K. A., 
SPITLER, L. E., PUZANOV, I., DOLEMAN, S. & YE, Y. OPTiM: A randomized phase III trial of 
talimogene laherparepvec (T-VEC) versus subcutaneous (SC) granulocyte-macrophage 
colony-stimulating factor (GM-CSF) for the treatment (tx) of unresected stage IIIB/C and IV 
melanoma.  ASCO Annual Meeting Proceedings, 2013. LBA9008. 
ANGLESIO, M. S., KOMMOSS, S., TOLCHER, M. C., CLARKE, B., GALLETTA, L., PORTER, H., DAMARAJU, 
S., FEREDAY, S., WINTERHOFF, B. J., KALLOGER, S. E., SENZ, J., YANG, W., STEED, H., ALLO, G., 
254 
 
FERGUSON, S., SHAW, P., TEOMAN, A., GARCIA, J. J., SCHOOLMEESTER, J. K., BAKKUM-
GAMEZ, J., TINKER, A. V., BOWTELL, D. D., HUNTSMAN, D. G., GILKS, C. B. & MCALPINE, J. N. 
2013. Molecular characterization of mucinous ovarian tumours supports a stratified 
treatment approach with HER2 targeting in 19% of carcinomas. J Pathol, 229, 111-20. 
ANSELL, S. M., LESOKHIN, A. M., BORRELLO, I., HALWANI, A., SCOTT, E. C., GUTIERREZ, M., 
SCHUSTER, S. J., MILLENSON, M. M., CATTRY, D. & FREEMAN, G. J. 2014. PD-1 blockade with 
nivolumab in relapsed or refractory Hodgkin's lymphoma. New England Journal of Medicine. 
AOKI, Y., TAKAKUWA, K., KODAMA, S., TANAKA, K., TAKAHASHI, M., TOKUNAGA, A. & TAKAHASHI, T. 
1991. Use of adoptive transfer of tumor-infiltrating lymphocytes alone or in combination 
with cisplatin-containing chemotherapy in patients with epithelial ovarian cancer. Cancer 
Res, 51, 1934-9. 
ARBUZOVA, A., WANG, L., WANG, J., HANGYÁS-MIHÁLYNÉ, G., MURRAY, D., HONIG, B. & 
MCLAUGHLIN, S. 2000. Membrane Binding of Peptides Containing Both Basic and Aromatic 
Residues. Experimental Studies with Peptides Corresponding to the Scaffolding Region of 
Caveolin and the Effector Region of MARCKS†. Biochemistry, 39, 10330-10339. 
ARIMA, Y., TODA, M. & IWATA, H. 2008. Complement activation on surfaces modified with ethylene 
glycol units. Biomaterials, 29, 551-60. 
ARRIBAS, J. & BORROTO, A. 2002. Protein ectodomain shedding. Chem Rev, 102, 4627-38. 
ATEFI, M., AVRAMIS, E., LASSEN, A., WONG, D. J., ROBERT, L., FOULAD, D., CERNIGLIA, M., TITZ, B., 
CHODON, T., GRAEBER, T. G., COMIN-ANDUIX, B. & RIBAS, A. 2014. Effects of MAPK and PI3K 
pathways on PD-L1 expression in melanoma. Clin Cancer Res, 20, 3446-57. 
BAGNATO, A., SALANI, D., DI CASTRO, V., WU-WONG, J. R., TECCE, R., NICOTRA, M. R., VENUTI, A. & 
NATALI, P. G. 1999. Expression of endothelin 1 and endothelin A receptor in ovarian 
carcinoma: evidence for an autocrine role in tumor growth. Cancer Res, 59, 720-7. 
BAGNOLI, M., CANEVARI, S., FIGINI, M., MEZZANZANICA, D., RASPAGLIESI, F., TOMASSETTI, A. & 
MIOTTI, S. 2003. A step further in understanding the biology of the folate receptor in ovarian 
carcinoma. Gynecol Oncol, 88, S140-4. 
BAHADUR, K. C., LANDRY, B., ALIABADI, H. M., LAVASANIFAR, A. & ULUDAG, H. 2011. Lipid 
substitution on low molecular weight (0.6-2.0 kDa) polyethylenimine leads to a higher zeta 
potential of plasmid DNA and enhances transgene expression. Acta Biomater, 7, 2209-17. 
BALAZS, D. A. & GODBEY, W. 2011. Liposomes for use in gene delivery. J Drug Deliv, 2011, 326497. 
BALD, T., LANDSBERG, J., LOPEZ-RAMOS, D., RENN, M., GLODDE, N., JANSEN, P., GAFFAL, E., STEITZ, 
J., TOLBA, R., KALINKE, U., LIMMER, A., JONSSON, G., HOLZEL, M. & TUTING, T. 2014. 
Immune cell-poor melanomas benefit from PD-1 blockade after targeted type I IFN 
activation. Cancer Discov, 4, 674-87. 
BANCHEREAU, J. & STEINMAN, R. M. 1998. Dendritic cells and the control of immunity. Nature, 392, 
245-252. 
BANERJEE, S. & KAYE, S. B. 2013. New Strategies in the Treatment of Ovarian Cancer: Current Clinical 
Perspectives and Future Potential. Clinical Cancer Research, 19, 961-968. 
BARBER, D. L., WHERRY, E. J., MASOPUST, D., ZHU, B., ALLISON, J. P., SHARPE, A. H., FREEMAN, G. J. 
& AHMED, R. 2006. Restoring function in exhausted CD8 T cells during chronic viral infection. 
Nature, 439, 682-7. 
BAREFORD, L. M. & SWAAN, P. W. 2007. Endocytic mechanisms for targeted drug delivery. Advanced 
Drug Delivery Reviews, 59, 748-758. 
BARTLETT, D. W., SU, H., HILDEBRANDT, I. J., WEBER, W. A. & DAVIS, M. E. 2007. Impact of tumor-
specific targeting on the biodistribution and efficacy of siRNA nanoparticles measured by 
multimodality in vivo imaging. Proceedings of the National Academy of Sciences, 104, 15549-
15554. 
BAST, R. C., JR., HENNESSY, B. & MILLS, G. B. 2009. The biology of ovarian cancer: new opportunities 
for translation. Nat Rev Cancer, 9, 415-28. 
255 
 
BAUD, M. 1993. Methods of Immunological Analysis Volume 1: Fundamentals New York, NY VCH 
Publishers, Inc. 
BAUSINGER, R., VON GERSDORFF, K., BRAECKMANS, K., OGRIS, M., WAGNER, E., BRAUCHLE, C. & 
ZUMBUSCH, A. 2006. The transport of nanosized gene carriers unraveled by live-cell 
imaging. Angew Chem Int Ed Engl, 45, 1568-72. 
BEATTY, G. L., HAAS, A. R., MAUS, M. V., TORIGIAN, D. A., SOULEN, M. C., PLESA, G., CHEW, A., ZHAO, 
Y., LEVINE, B. L., ALBELDA, S. M., KALOS, M. & JUNE, C. H. 2014. Mesothelin-Specific Chimeric 
Antigen Receptor mRNA-Engineered T Cells Induce Antitumor Activity in Solid Malignancies. 
Cancer Immunology Research, 2, 112-120. 
BECKER, J. C. & SCHRAMA, D. 2013. The dark side of cyclophosphamide: cyclophosphamide-
mediated ablation of regulatory T cells. J Invest Dermatol, 133, 1462-5. 
BEHR, J.-P. 1997. The Proton Sponge: a Trick to Enter Cells the Viruses Did Not Exploit. CHIMIA 
International Journal for Chemistry, 51, 34-36. 
BENENCIA, F., COURREGES, M. C., FRASER, N. W. & COUKOS, G. 2008. Herpes virus oncolytic therapy 
reverses tumor immune dysfunction and facilitates tumor antigen presentation. Cancer Biol 
Ther, 7, 1194-205. 
BENJAMINSEN, R. V., MATTEBJERG, M. A., HENRIKSEN, J. R., MOGHIMI, S. M. & ANDRESEN, T. L. 
2013. The Possible “Proton Sponge ” Effect of Polyethylenimine (PEI) Does Not Include 
Change in Lysosomal pH. Molecular Therapy, 21, 149-157. 
BERGER, R., ROTEM-YEHUDAR, R., SLAMA, G., LANDES, S., KNELLER, A., LEIBA, M., KOREN-
MICHOWITZ, M., SHIMONI, A. & NAGLER, A. 2008. Phase I safety and pharmacokinetic study 
of CT-011, a humanized antibody interacting with PD-1, in patients with advanced 
hematologic malignancies. Clin Cancer Res, 14, 3044-51. 
BETTS, M. R. & KOUP, R. A. 2004. Detection of T-cell degranulation: CD107a and b. Methods in cell 
biology, 75, 497-512. 
BEYERLE, A., IRMLER, M., BECKERS, J., KISSEL, T. & STOEGER, T. 2010. Toxicity pathway focused gene 
expression profiling of PEI-based polymers for pulmonary applications. Mol Pharm, 7, 727-
37. 
BIEBER, T., MEISSNER, W., KOSTIN, S., NIEMANN, A. & ELSASSER, H. P. 2002. Intracellular route and 
transcriptional competence of polyethylenimine-DNA complexes. J Control Release, 82, 441-
54. 
BISSELL, M. J. & HINES, W. C. 2011. Why don't we get more cancer? A proposed role of the 
microenvironment in restraining cancer progression. Nat Med, 17, 320-329. 
BISWAS, S. & TORCHILIN, V. P. 2013. Dendrimers for siRNA Delivery. Pharmaceuticals, 6, 161-183. 
BLANK, C., BROWN, I., PETERSON, A. C., SPIOTTO, M., IWAI, Y., HONJO, T. & GAJEWSKI, T. F. 2004. 
PD-L1/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) 
transgenic CD8+ T cells. Cancer Res, 64, 1140-5. 
BLANKENSTEIN, T., COULIE, P. G., GILBOA, E. & JAFFEE, E. M. 2012. The determinants of tumour 
immunogenicity. Nat Rev Cancer, 12, 307-313. 
BLESSING, T., KURSA, M., HOLZHAUSER, R., KIRCHEIS, R. & WAGNER, E. 2001. Different strategies for 
formation of pegylated EGF-conjugated PEI/DNA complexes for targeted gene delivery. 
Bioconjug Chem, 12, 529-37. 
BLOTT, E. J., BOSSI, G., CLARK, R., ZVELEBIL, M. & GRIFFITHS, G. M. 2001. Fas ligand is targeted to 
secretory lysosomes via a proline-rich domain in its cytoplasmic tail. J Cell Sci, 114, 2405-16. 
BLOTT, E. J. & GRIFFITHS, G. M. 2002. Secretory lysosomes. Nat Rev Mol Cell Biol, 3, 122-31. 
BOLCATO-BELLEMIN, A. L., BONNET, M. E., CREUSAT, G., ERBACHER, P. & BEHR, J. P. 2007. Sticky 
overhangs enhance siRNA-mediated gene silencing. Proc Natl Acad Sci U S A, 104, 16050-5. 
BOUSSIF, O., LEZOUALC'H, F., ZANTA, M. A., MERGNY, M. D., SCHERMAN, D., DEMENEIX, B. & BEHR, 
J. P. 1995. A versatile vector for gene and oligonucleotide transfer into cells in culture and in 
vivo: polyethylenimine. Proc Natl Acad Sci U S A, 92, 7297-301. 
256 
 
BOUTET, P., AGUERA-GONZALEZ, S., ATKINSON, S., PENNINGTON, C. J., EDWARDS, D. R., MURPHY, 
G., REYBURN, H. T. & VALES-GOMEZ, M. 2009. Cutting edge: the metalloproteinase 
ADAM17/TNF-alpha-converting enzyme regulates proteolytic shedding of the MHC class I-
related chain B protein. J Immunol, 182, 49-53. 
BRAHMER, J. R., DRAKE, C. G., WOLLNER, I., POWDERLY, J. D., PICUS, J., SHARFMAN, W. H., 
STANKEVICH, E., PONS, A., SALAY, T. M., MCMILLER, T. L., GILSON, M. M., WANG, C., SELBY, 
M., TAUBE, J. M., ANDERS, R., CHEN, L., KORMAN, A. J., PARDOLL, D. M., LOWY, I. & 
TOPALIAN, S. L. 2010. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in 
refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic 
correlates. J Clin Oncol, 28, 3167-75. 
BRAHMER, J. R., TYKODI, S. S., CHOW, L. Q. M., HWU, W.-J., TOPALIAN, S. L., HWU, P., DRAKE, C. G., 
CAMACHO, L. H., KAUH, J., ODUNSI, K., PITOT, H. C., HAMID, O., BHATIA, S., MARTINS, R., 
EATON, K., CHEN, S., SALAY, T. M., ALAPARTHY, S., GROSSO, J. F., KORMAN, A. J., PARKER, S. 
M., AGRAWAL, S., GOLDBERG, S. M., PARDOLL, D. M., GUPTA, A. & WIGGINTON, J. M. 2012. 
Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer. New England 
Journal of Medicine, 366, 2455-2465. 
BRANDEN, L. J., MOHAMED, A. J. & SMITH, C. I. 1999. A peptide nucleic acid-nuclear localization 
signal fusion that mediates nuclear transport of DNA. Nat Biotechnol, 17, 784-7. 
BRAYBROOKE, J. P., SLADE, A., DEPLANQUE, G., HARROP, R., MADHUSUDAN, S., FORSTER, M. D., 
GIBSON, R., MAKRIS, A., TALBOT, D. C., STEINER, J., WHITE, L., KAN, O., NAYLOR, S., CARROLL, 
M. W., KINGSMAN, S. M. & HARRIS, A. L. 2005. Phase I study of MetXia-P450 gene therapy 
and oral cyclophosphamide for patients with advanced breast cancer or melanoma. Clin 
Cancer Res, 11, 1512-20. 
BROWN, J. A., DORFMAN, D. M., MA, F. R., SULLIVAN, E. L., MUNOZ, O., WOOD, C. R., GREENFIELD, 
E. A. & FREEMAN, G. J. 2003. Blockade of programmed death-1 ligands on dendritic cells 
enhances T cell activation and cytokine production. J Immunol, 170, 1257-66. 
BRUMMELKAMP, T. R., BERNARDS, R. & AGAMI, R. 2002. A system for stable expression of short 
interfering RNAs in mammalian cells. Science, 296, 550-3. 
BRUNNER, S., SAUER, T., CAROTTA, S., COTTEN, M., SALTIK, M. & WAGNER, E. 2000. Cell cycle 
dependence of gene transfer by lipoplex, polyplex and recombinant adenovirus. Gene Ther, 
7, 401-7. 
BRUNO, K. 2011. Using drug-excipient interactions for siRNA delivery. Adv Drug Deliv Rev, 63, 1210-
26. 
BUCKANOVICH, R. J., FACCIABENE, A., KIM, S., BENENCIA, F., SASAROLI, D., BALINT, K., KATSAROS, D., 
O'BRIEN-JENKINS, A., GIMOTTY, P. A. & COUKOS, G. 2008. Endothelin B receptor mediates 
the endothelial barrier to T cell homing to tumors and disables immune therapy. Nat Med, 
14, 28-36. 
BUSCAIL, L., BOURNET, B., VERNEJOUL, F., CAMBOIS, G., LULKA, H., HANOUN, N., DUFRESNE, M., 
MEULLE, A., VIGNOLLE-VIDONI, A., LIGAT, L., SAINT-LAURENT, N., PONT, F., DEJEAN, S., 
GAYRAL, M., MARTINS, F., TORRISANI, J., BARBEY, O., GROSS, F., GUIMBAUD, R., OTAL, P., 
LOPEZ, F., TIRABY, G. & CORDELIER, P. 2015. First-in-man Phase 1 Clinical Trial of Gene 
Therapy for Advanced Pancreatic Cancer: Safety, Biodistribution, and Preliminary Clinical 
Findings. Mol Ther, 23, 779-789. 
BUTLER, V. P., SCHMIDT, D. H., SMITH, T. W., HABER, E., RAYNOR, B. D. & DEMARTINI, P. 1977. 
Effects of sheep digoxin-specific antibodies and their Fab fragments on digoxin 
pharmacokinetics in dogs. Journal of Clinical Investigation, 59, 345-359. 
BUTTE, M. J., KEIR, M. E., PHAMDUY, T. B., SHARPE, A. H. & FREEMAN, G. J. 2007. Programmed 
death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell 
responses. Immunity, 27, 111-22. 
257 
 
C. A JANEWAY, J., P. TRAVERS, M. WALPORT & SHLOMCHIK, M. J. 2005. Immunobiology : the 
immune system in health and disease. In: JANEWAY, C. (ed.) 6th ed. ed. New York :: Garland 
Science. 
CAMPBELL, I. G., JONES, T. A., FOULKES, W. D. & TROWSDALE, J. 1991. Folate-binding protein is a 
marker for ovarian cancer. Cancer Res, 51, 5329-38. 
CARLSTEN, M., NORELL, H., BRYCESON, Y. T., POSCHKE, I., SCHEDVINS, K., LJUNGGREN, H. G., 
KIESSLING, R. & MALMBERG, K. J. 2009. Primary human tumor cells expressing CD155 impair 
tumor targeting by down-regulating DNAM-1 on NK cells. J Immunol, 183, 4921-30. 
CARPENITO, C., MILONE, M. C., HASSAN, R., SIMONET, J. C., LAKHAL, M., SUHOSKI, M. M., VARELA-
ROHENA, A., HAINES, K. M., HEITJAN, D. F., ALBELDA, S. M., CARROLL, R. G., RILEY, J. L., 
PASTAN, I. & JUNE, C. H. 2009. Control of large, established tumor xenografts with 
genetically retargeted human T cells containing CD28 and CD137 domains. Proc Natl Acad Sci 
U S A, 106, 3360-5. 
CARRENO, B. M. & COLLINS, M. 2002. The B7 family of ligands and its receptors: new pathways for 
costimulation and inhibition of immune responses. Annu Rev Immunol, 20, 29-53. 
CARVER, L. A. & SCHNITZER, J. E. 2003. Caveolae: mining little caves for new cancer targets. Nat Rev 
Cancer, 3, 571-81. 
CHAPOVAL, A. I., NI, J., LAU, J. S., WILCOX, R. A., FLIES, D. B., LIU, D., DONG, H., SICA, G. L., ZHU, G., 
TAMADA, K. & CHEN, L. 2001. B7-H3: a costimulatory molecule for T cell activation and IFN-
gamma production. Nat Immunol, 2, 269-74. 
CHEMNITZ, J. M., PARRY, R. V., NICHOLS, K. E., JUNE, C. H. & RILEY, J. L. 2004. SHP-1 and SHP-2 
associate with immunoreceptor tyrosine-based switch motif of programmed death 1 upon 
primary human T cell stimulation, but only receptor ligation prevents T cell activation. J 
Immunol, 173, 945-54. 
CHEN, L., GIBBONS, D. L., GOSWAMI, S., CORTEZ, M. A., AHN, Y.-H., BYERS, L. A., ZHANG, X., YI, X., 
DWYER, D., LIN, W., DIAO, L., WANG, J., ROYBAL, J. D., PATEL, M., UNGEWISS, C., PENG, D., 
ANTONIA, S., MEDIAVILLA-VARELA, M., ROBERTSON, G., JONES, S., SURAOKAR, M., WELSH, J. 
W., EREZ, B., WISTUBA, I. I., CHEN, L., PENG, D., WANG, S., ULLRICH, S. E., HEYMACH, J. V., 
KURIE, J. M. & QIN, F. X.-F. 2014. Metastasis is regulated via microRNA-200/ZEB1 axis control 
of tumour cell PD-L1 expression and intratumoral immunosuppression. Nat Commun, 5. 
CHEN, Y., WANG, Q., SHI, B., XU, P., HU, Z., BAI, L. & ZHANG, X. 2011. Development of a sandwich 
ELISA for evaluating soluble PD-L1 (CD274) in human sera of different ages as well as 
supernatants of PD-L1+ cell lines. Cytokine, 56, 231-8. 
CHEUNG, C. Y., MURTHY, N., STAYTON, P. S. & HOFFMAN, A. S. 2001. A pH-sensitive polymer that 
enhances cationic lipid-mediated gene transfer. Bioconjug Chem, 12, 906-10. 
CHIANESE-BULLOCK, K. A., IRVIN, W. P., JR., PETRONI, G. R., MURPHY, C., SMOLKIN, M., OLSON, W. 
C., COLEMAN, E., BOERNER, S. A., NAIL, C. J., NEESE, P. Y., YUAN, A., HOGAN, K. T. & 
SLINGLUFF, C. L., JR. 2008. A multipeptide vaccine is safe and elicits T-cell responses in 
participants with advanced stage ovarian cancer. J Immunother, 31, 420-30. 
CHILEWSKI, S. D., DICKERSON, W. M., MORA, J. R., SAAB, A. & ALDERMAN, E. M. 2014. Evaluation of 
acoustic membrane microparticle (AMMP) technology for a sensitive ligand binding assay to 
support pharmacokinetic determinations of a biotherapeutic. Aaps j, 16, 1366-71. 
CHIU, S. J., UENO, N. T. & LEE, R. J. 2004. Tumor-targeted gene delivery via anti-HER2 antibody 
(trastuzumab, Herceptin) conjugated polyethylenimine. J Control Release, 97, 357-69. 
CHOI, I. H., ZHU, G., SICA, G. L., STROME, S. E., CHEVILLE, J. C., LAU, J. S., ZHU, Y., FLIES, D. B., 
TAMADA, K. & CHEN, L. 2003. Genomic organization and expression analysis of B7-H4, an 
immune inhibitory molecule of the B7 family. J Immunol, 171, 4650-4. 
CHOMPOOSOR, A., SAHA, K., GHOSH, P. S., MACARTHY, D. J., MIRANDA, O. R., ZHU, Z. J., ARCARO, K. 
F. & ROTELLO, V. M. 2010. The role of surface functionality on acute cytotoxicity, ROS 
generation and DNA damage by cationic gold nanoparticles. Small, 6, 2246-9. 
258 
 
CHOOSAKOONKRIANG, S., LOBO, B. A., KOE, G. S., KOE, J. G. & MIDDAUGH, C. R. 2003. Biophysical 
characterization of PEI/DNA complexes. J Pharm Sci, 92, 1710-22. 
CHU, C., BOYER, J., SCHULLERY, D., GIMOTTY, P., GAMERMAN, V., BENDER, J., LEVINE, B., COUKOS, 
G., RUBIN, S., MORGAN, M., VONDERHEIDE, R. & JUNE, C. 2012. Phase I/II randomized trial 
of dendritic cell vaccination with or without cyclophosphamide for consolidation therapy of 
advanced ovarian cancer in first or second remission. Cancer Immunology, Immunotherapy, 
61, 629-641. 
CLARKE, B., TINKER, A. V., LEE, C. H., SUBRAMANIAN, S., VAN DE RIJN, M., TURBIN, D., KALLOGER, S., 
HAN, G., CEBALLOS, K., CADUNGOG, M. G., HUNTSMAN, D. G., COUKOS, G. & GILKS, C. B. 
2009. Intraepithelial T cells and prognosis in ovarian carcinoma: novel associations with 
stage, tumor type, and BRCA1 loss. Mod Pathol, 22, 393-402. 
COLLINS, A. V., BRODIE, D. W., GILBERT, R. J., IABONI, A., MANSO-SANCHO, R., WALSE, B., STUART, D. 
I., VAN DER MERWE, P. A. & DAVIS, S. J. 2002. The interaction properties of costimulatory 
molecules revisited. Immunity, 17, 201-10. 
COLLINS, C. M., YUI, S., ROBERTS, C. E. & KOJIC, I. 2013. Thrombin detection using a piezoelectric 
aptamer-linked immunosorbent assay. Anal Biochem, 443, 97-103. 
CONG, L., RAN, F. A., COX, D., LIN, S., BARRETTO, R., HABIB, N., HSU, P. D., WU, X., JIANG, W., 
MARRAFFINI, L. A. & ZHANG, F. 2013. Multiplex genome engineering using CRISPR/Cas 
systems. Science, 339, 819-23. 
CONNER, S. D. & SCHMID, S. L. 2003. Regulated portals of entry into the cell. Nature, 422, 37-44. 
COUZIN-FRANKEL, J. 2013. Cancer Immunotherapy. Science, 342, 1432-1433. 
COWARD, J., KULBE, H., CHAKRAVARTY, P., LEADER, D., VASSILEVA, V., LEINSTER, D. A., THOMPSON, 
R., SCHIOPPA, T., NEMETH, J., VERMEULEN, J., SINGH, N., AVRIL, N., CUMMINGS, J., 
REXHEPAJ, E., JIRSTROM, K., GALLAGHER, W. M., BRENNAN, D. J., MCNEISH, I. A. & 
BALKWILL, F. R. 2011. Interleukin-6 as a therapeutic target in human ovarian cancer. Clin 
Cancer Res, 17, 6083-96. 
CRADICK, T. J., FINE, E. J., ANTICO, C. J. & BAO, G. 2013. CRISPR/Cas9 systems targeting β-globin and 
CCR5 genes have substantial off-target activity. Nucleic Acids Research. 
CRUZ, L. J., TACKEN, P. J., FOKKINK, R. & FIGDOR, C. G. 2011. The influence of PEG chain length and 
targeting moiety on antibody-mediated delivery of nanoparticle vaccines to human dendritic 
cells. Biomaterials, 32, 6791-6803. 
CURIEL, T. J., COUKOS, G., ZOU, L., ALVAREZ, X., CHENG, P., MOTTRAM, P., EVDEMON-HOGAN, M., 
CONEJO-GARCIA, J. R., ZHANG, L., BUROW, M., ZHU, Y., WEI, S., KRYCZEK, I., DANIEL, B., 
GORDON, A., MYERS, L., LACKNER, A., DISIS, M. L., KNUTSON, K. L., CHEN, L. & ZOU, W. 2004. 
Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and 
predicts reduced survival. Nat Med, 10, 942-9. 
CURIEL, T. J., WEI, S., DONG, H., ALVAREZ, X., CHENG, P., MOTTRAM, P., KRZYSIEK, R., KNUTSON, K. 
L., DANIEL, B., ZIMMERMANN, M. C., DAVID, O., BUROW, M., GORDON, A., DHURANDHAR, 
N., MYERS, L., BERGGREN, R., HEMMINKI, A., ALVAREZ, R. D., EMILIE, D., CURIEL, D. T., CHEN, 
L. & ZOU, W. 2003. Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor 
immunity. Nat Med, 9, 562-7. 
CURRAN, M. A., MONTALVO, W., YAGITA, H. & ALLISON, J. P. 2010. PD-1 and CTLA-4 combination 
blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 
melanoma tumors. Proceedings of the National Academy of Sciences, 107, 4275-4280. 
D'SOUZA, M., FONTENOT, A. P., MACK, D. G., LOZUPONE, C., DILLON, S., MEDITZ, A., WILSON, C. C., 
CONNICK, E. & PALMER, B. E. 2007. Programmed death 1 expression on HIV-specific CD4+ T 
cells is driven by viral replication and associated with T cell dysfunction. J Immunol, 179, 
1979-87. 
DADMARZ, R. D., ORDOUBADI, A., MIXON, A., THOMPSON, C. O., BARRACCHINI, K. C., HIJAZI, Y. M., 
STELLER, M. A., ROSENBERG, S. A. & SCHWARTZENTRUBER, D. J. 1996. Tumor-infiltrating 
259 
 
lymphocytes from human ovarian cancer patients recognize autologous tumor in an MHC 
class II-restricted fashion. Cancer J Sci Am, 2, 263-72. 
DANGAJ, D., LANITIS, E., ZHAO, A., JOSHI, S., CHENG, Y., SANDALTZOPOULOS, R., RA, H. J., DANET-
DESNOYERS, G., POWELL, D. J., JR. & SCHOLLER, N. 2013. Novel recombinant human b7-h4 
antibodies overcome tumoral immune escape to potentiate T-cell antitumor responses. 
Cancer Res, 73, 4820-9. 
DAUTY, E. & VERKMAN, A. S. 2005. Actin cytoskeleton as the principal determinant of size-
dependent DNA mobility in cytoplasm: a new barrier for non-viral gene delivery. J Biol Chem, 
280, 7823-8. 
DAVIES, D. M., FOSTER, J., VAN DER STEGEN, S. J., PARENTE-PEREIRA, A. C., CHIAPERO-STANKE, L., 
DELINASSIOS, G. J., BURBRIDGE, S. E., KAO, V., LIU, Z., BOSSHARD-CARTER, L., VAN 
SCHALKWYK, M. C., BOX, C., ECCLES, S. A., MATHER, S. J., WILKIE, S. & MAHER, J. 2012. 
Flexible targeting of ErbB dimers that drive tumorigenesis by using genetically engineered T 
cells. Mol Med, 18, 565-76. 
DAVIS, M. E., ZUCKERMAN, J. E., CHOI, C. H. J., SELIGSON, D., TOLCHER, A., ALABI, C. A., YEN, Y., 
HEIDEL, J. D. & RIBAS, A. 2010. Evidence of RNAi in humans from systemically administered 
siRNA via targeted nanoparticles. Nature, 464, 1067-1070. 
DAY, C. L., KAUFMANN, D. E., KIEPIELA, P., BROWN, J. A., MOODLEY, E. S., REDDY, S., MACKEY, E. W., 
MILLER, J. D., LESLIE, A. J., DEPIERRES, C., MNCUBE, Z., DURAISWAMY, J., ZHU, B., 
EICHBAUM, Q., ALTFELD, M., WHERRY, E. J., COOVADIA, H. M., GOULDER, P. J. R., 
KLENERMAN, P., AHMED, R., FREEMAN, G. J. & WALKER, B. D. 2006. PD-1 expression on HIV-
specific T cells is associated with T-cell exhaustion and disease progression. Nature, 443, 
350-354. 
DE BRUIN, K., RUTHARDT, N., VON GERSDORFF, K., BAUSINGER, R., WAGNER, E., OGRIS, M. & 
BRAUCHLE, C. 2007. Cellular Dynamics of EGF Receptor-Targeted Synthetic Viruses. Mol 
Ther, 15, 1297-1305. 
DE LAPORTE, L., CRUZ REA, J. & SHEA, L. D. 2006. Design of modular non-viral gene therapy vectors. 
Biomaterials, 27, 947-54. 
DICK, C. R. & HAM, G. E. 1970. Characterization of Polyethylenimine. Journal of Macromolecular 
Science: Part A - Chemistry, 4, 1301-1314. 
DIEFENBACH, C. S., GNJATIC, S., SABBATINI, P., AGHAJANIAN, C., HENSLEY, M. L., SPRIGGS, D. R., 
IASONOS, A., LEE, H., DUPONT, B., PEZZULLI, S., JUNGBLUTH, A. A., OLD, L. J. & DUPONT, J. 
2008. Safety and immunogenicity study of NY-ESO-1b peptide and montanide ISA-51 
vaccination of patients with epithelial ovarian cancer in high-risk first remission. Clin Cancer 
Res, 14, 2740-8. 
DIGHE, A. S., RICHARDS, E., OLD, L. J. & SCHREIBER, R. D. 1994. Enhanced in vivo growth and 
resistance to rejection of tumor cells expressing dominant negative IFN gamma receptors. 
Immunity, 1, 447-56. 
DIXIT, C. K., VASHIST, S. K., O’NEILL, F. T., O’REILLY, B., MACCRAITH, B. D. & O’KENNEDY, R. 2010. 
Development of a High Sensitivity Rapid Sandwich ELISA Procedure and Its Comparison with 
the Conventional Approach. Analytical Chemistry, 82, 7049-7052. 
DOBROVOLSKAIA, M. A., AGGARWAL, P., HALL, J. B. & MCNEIL, S. E. 2008. Preclinical studies to 
understand nanoparticle interaction with the immune system and its potential effects on 
nanoparticle biodistribution. Mol Pharm, 5, 487-95. 
DONG, H., STROME, S. E., MATTESON, E. L., MODER, K. G., FLIES, D. B., ZHU, G., TAMURA, H., 
DRISCOLL, C. L. & CHEN, L. 2003. Costimulating aberrant T cell responses by B7-H1 
autoantibodies in rheumatoid arthritis. J Clin Invest, 111, 363-70. 
DONG, H., STROME, S. E., SALOMAO, D. R., TAMURA, H., HIRANO, F., FLIES, D. B., ROCHE, P. C., LU, J., 
ZHU, G., TAMADA, K., LENNON, V. A., CELIS, E. & CHEN, L. 2002. Tumor-associated B7-H1 
promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med, 8, 793-800. 
260 
 
DONG, H., ZHU, G., TAMADA, K. & CHEN, L. 1999. B7-H1, a third member of the B7 family, co-
stimulates T-cell proliferation and interleukin-10 secretion. Nat Med, 5, 1365-9. 
DONG, H., ZHU, G., TAMADA, K., FLIES, D. B., VAN DEURSEN, J. M. & CHEN, L. 2004. B7-H1 
determines accumulation and deletion of intrahepatic CD8+ T lymphocytes. Immunity, 20, 
327-336. 
DOODY, A. M., KORLEY, J. N., DANG, K. P., ZAWANEH, P. N. & PUTNAM, D. 2006. Characterizing the 
structure/function parameter space of hydrocarbon-conjugated branched polyethylenimine 
for DNA delivery in vitro. Journal of Controlled Release, 116, 227-237. 
DROESER, R. A., HIRT, C., VIEHL, C. T., FREY, D. M., NEBIKER, C., HUBER, X., ZLOBEC, I., EPPENBERGER-
CASTORI, S., TZANKOV, A., ROSSO, R., ZUBER, M., MURARO, M. G., AMICARELLA, F., 
CREMONESI, E., HEBERER, M., IEZZI, G., LUGLI, A., TERRACCIANO, L., SCONOCCHIA, G., 
OERTLI, D., SPAGNOLI, G. C. & TORNILLO, L. 2013. Clinical impact of programmed cell death 
ligand 1 expression in colorectal cancer. Eur J Cancer, 49, 2233-42. 
DUA, P., YOO, J. W., KIM, S. & LEE, D.-K. 2011. Modified siRNA Structure With a Single Nucleotide 
Bulge Overcomes Conventional siRNA-mediated Off-target Silencing. Mol Ther, 19, 1676-
1687. 
DUNN, G. P., BRUCE, A. T., IKEDA, H., OLD, L. J. & SCHREIBER, R. D. 2002. Cancer immunoediting: 
from immunosurveillance to tumor escape. Nat Immunol, 3, 991-8. 
DUNN, G. P., KOEBEL, C. M. & SCHREIBER, R. D. 2006. Interferons, immunity and cancer 
immunoediting. Nat Rev Immunol, 6, 836-48. 
DUNN, G. P., OLD, L. J. & SCHREIBER, R. D. 2004. The immunobiology of cancer immunosurveillance 
and immunoediting. Immunity, 21, 137-48. 
DUNN, G. P., OLD, L. J. & SCHREIBER, R. D. 2004. The three Es of cancer immunoediting. Annu Rev 
Immunol, 22, 329-60. 
DURAISWAMY, J., FREEMAN, G. J. & COUKOS, G. 2013. Therapeutic PD-1 pathway blockade 
augments with other modalities of immunotherapy T-cell function to prevent immune 
decline in ovarian cancer. Cancer Res, 73, 6900-12. 
DURAISWAMY, J., FREEMAN, G. J. & COUKOS, G. 2014. Dual blockade of PD-1 and CTLA-4 combined 
with tumor vaccine effectively restores T-cell rejection function in tumors--response. Cancer 
Res, 74, 633-4; discussion 635. 
DURAISWAMY, J., IBEGBU, C. C., MASOPUST, D., MILLER, J. D., ARAKI, K., DOHO, G. H., TATA, P., 
GUPTA, S., ZILLIOX, M. J., NAKAYA, H. I., PULENDRAN, B., HAINING, W. N., FREEMAN, G. J. & 
AHMED, R. 2011. Phenotype, Function, and Gene Expression Profiles of Programmed Death-
1hi CD8 T Cells in Healthy Human Adults. The Journal of Immunology, 186, 4200-4212. 
DURAND-PANTEIX, S., FARHAT, M., YOULYOUZ-MARFAK, I., ROUAUD, P., OUK-MARTIN, C., DAVID, A., 
FAUMONT, N., FEUILLARD, J. & JAYAT-VIGNOLES, C. 2012. B7-H1, Which Represses EBV-
Immortalized B Cell Killing by Autologous T and NK Cells, Is Oppositely Regulated by c-Myc 
and EBV Latency III Program at Both mRNA and Secretory Lysosome Levels. The Journal of 
Immunology, 189, 181-190. 
EHRLICH, P. 1908. Über den jetzigen Stand der Karzinomforschung. 
EICHMAN, J. D., BIELINSKA, A. U., KUKOWSKA-LATALLO, J. F. & BAKER, J. R., JR. 2000. The use of 
PAMAM dendrimers in the efficient transfer of genetic material into cells. Pharm Sci 
Technolo Today, 3, 232-245. 
ELBASHIR, S. M., HARBORTH, J., LENDECKEL, W., YALCIN, A., WEBER, K. & TUSCHL, T. 2001. Duplexes 
of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature, 411, 
494-8. 
ELBASHIR, S. M., HARBORTH, J., LENDECKEL, W., YALCIN, A., WEBER, K. & TUSCHL, T. 2001. Duplexes 
of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature, 411, 
494-498. 
261 
 
ENGLER, A. C., BONNER, D. K., BUSS, H. G., CHEUNG, E. Y. & HAMMOND, P. T. 2011. The synthetic 
tuning of clickable pH responsive cationic polypeptides and block copolypeptides. Soft 
Matter, 7, 5627-5637. 
ERICKSON, J. J., GILCHUK, P., HASTINGS, A. K., TOLLEFSON, S. J., JOHNSON, M., DOWNING, M. B., 
BOYD, K. L., JOHNSON, J. E., KIM, A. S., JOYCE, S. & WILLIAMS, J. V. 2012. Viral acute lower 
respiratory infections impair CD8+ T cells through PD-1. The Journal of Clinical Investigation, 
122, 2967-2982. 
FACCIABENE, A., PENG, X., HAGEMANN, I. S., BALINT, K., BARCHETTI, A., WANG, L. P., GIMOTTY, P. 
A., GILKS, C. B., LAL, P., ZHANG, L. & COUKOS, G. 2011. Tumour hypoxia promotes tolerance 
and angiogenesis via CCL28 and T(reg) cells. Nature, 475, 226-30. 
FERLAY, J., SHIN, H. R., BRAY, F., FORMAN, D., MATHERS, C. & PARKIN, D. M. 2010. Estimates of 
worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer, 127, 2893-917. 
FIFE, B. T., PAUKEN, K. E., EAGAR, T. N., OBU, T., WU, J., TANG, Q., AZUMA, M., KRUMMEL, M. F. & 
BLUESTONE, J. A. 2009. Interactions between PD-1 and PD-L1 promote tolerance by blocking 
the TCR-induced stop signal. Nat Immunol, 10, 1185-92. 
FIGO. 2014. FIGO Ovarian Cancer Staging [Online]. Available: http://www.figo.org/. 
FIRE, A., XU, S., MONTGOMERY, M. K., KOSTAS, S. A., DRIVER, S. E. & MELLO, C. C. 1998. Potent and 
specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature, 
391, 806-11. 
FISCHER, D., BIEBER, T., LI, Y., ELSASSER, H. P. & KISSEL, T. 1999. A novel non-viral vector for DNA 
delivery based on low molecular weight, branched polyethylenimine: effect of molecular 
weight on transfection efficiency and cytotoxicity. Pharm Res, 16, 1273-9. 
FISCHER, D., VON HARPE, A., KUNATH, K., PETERSEN, H., LI, Y. & KISSEL, T. 2002. Copolymers of 
ethylene imine and N-(2-hydroxyethyl)-ethylene imine as tools to study effects of polymer 
structure on physicochemical and biological properties of DNA complexes. Bioconjug Chem, 
13, 1124-33. 
FISK, B., BLEVINS, T. L., WHARTON, J. T. & IOANNIDES, C. G. 1995. Identification of an 
immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-
specific cytotoxic T lymphocyte lines. J Exp Med, 181, 2109-17. 
FLIES, D. B., WANG, S., XU, H. & CHEN, L. 2011. Cutting edge: A monoclonal antibody specific for the 
programmed death-1 homolog prevents graft-versus-host disease in mouse models. J 
Immunol, 187, 1537-41. 
FRANCISCO, L. M., SALINAS, V. H., BROWN, K. E., VANGURI, V. K., FREEMAN, G. J., KUCHROO, V. K. & 
SHARPE, A. H. 2009. PD-L1 regulates the development, maintenance, and function of 
induced regulatory T cells. J Exp Med, 206, 3015-29. 
FRASER, S., CAMERON, M., O'CONNOR, E., SCHWICKART, M., TANEN, M. & WARE, M. 2014. Next 
generation ligand binding assays-review of emerging real-time measurement technologies. 
Aaps j, 16, 914-24. 
FREEMAN, G. J. 2008. Structures of PD-1 with its ligands: Sideways and dancing cheek to cheek. 
Proceedings of the National Academy of Sciences, 105, 10275-10276. 
FREEMAN, G. J., LONG, A. J., IWAI, Y., BOURQUE, K., CHERNOVA, T., NISHIMURA, H., FITZ, L. J., 
MALENKOVICH, N., OKAZAKI, T., BYRNE, M. C., HORTON, H. F., FOUSER, L., CARTER, L., LING, 
V., BOWMAN, M. R., CARRENO, B. M., COLLINS, M., WOOD, C. R. & HONJO, T. 2000. 
Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to 
negative regulation of lymphocyte activation. J Exp Med, 192, 1027-34. 
FREEMAN, G. J. & SHARPE, A. H. 2012. A new therapeutic strategy for malaria: targeting T cell 
exhaustion. Nat Immunol, 13, 113-115. 
FREYTAG, S. O., KHIL, M., STRICKER, H., PEABODY, J., MENON, M., DEPERALTA-VENTURINA, M., 
NAFZIGER, D., PEGG, J., PAIELLI, D., BROWN, S., BARTON, K., LU, M., AGUILAR-CORDOVA, E. 
& KIM, J. H. 2002. Phase I study of replication-competent adenovirus-mediated double 
262 
 
suicide gene therapy for the treatment of locally recurrent prostate cancer. Cancer Res, 62, 
4968-76. 
FREYTAG, S. O., STRICKER, H., MOVSAS, B. & KIM, J. H. 2007. Prostate Cancer Gene Therapy Clinical 
Trials. Mol Ther, 15, 1042-1052. 
FRIGOLA, X., INMAN, B. A., KRCO, C. J., LIU, X., HARRINGTON, S. M., BULUR, P. A., DIETZ, A. B., DONG, 
H. & KWON, E. D. 2012. Soluble B7-H1: differences in production between dendritic cells and 
T cells. Immunol Lett, 142, 78-82. 
FRIGOLA, X., INMAN, B. A., LOHSE, C. M., KRCO, C. J., CHEVILLE, J. C., THOMPSON, R. H., LEIBOVICH, 
B., BLUTE, M. L., DONG, H. & KWON, E. D. 2011. Identification of a soluble form of B7-H1 
that retains immunosuppressive activity and is associated with aggressive renal cell 
carcinoma. Clin Cancer Res, 17, 1915-23. 
FRÖHLICH, E. 2012. The role of surface charge in cellular uptake and cytotoxicity of medical 
nanoparticles. International Journal of Nanomedicine, 7, 5577-5591. 
FUJITA, K., IKARASHI, H., TAKAKUWA, K., KODAMA, S., TOKUNAGA, A., TAKAHASHI, T. & TANAKA, K. 
1995. Prolonged disease-free period in patients with advanced epithelial ovarian cancer 
after adoptive transfer of tumor-infiltrating lymphocytes. Clin Cancer Res, 1, 501-7. 
FUNHOFF, A. M., VAN NOSTRUM, C. F., KONING, G. A., SCHUURMANS-NIEUWENBROEK, N. M., 
CROMMELIN, D. J. & HENNINK, W. E. 2004. Endosomal escape of polymeric gene delivery 
complexes is not always enhanced by polymers buffering at low pH. Biomacromolecules, 5, 
32-9. 
GABRIELSON, N. P. & PACK, D. W. 2006. Acetylation of polyethylenimine enhances gene delivery via 
weakened polymer/DNA interactions. Biomacromolecules, 7, 2427-35. 
GABRILOVICH, D. I., BRONTE, V., CHEN, S. H., COLOMBO, M. P., OCHOA, A., OSTRAND-ROSENBERG, 
S. & SCHREIBER, H. 2007. The terminology issue for myeloid-derived suppressor cells. Cancer 
Res, 67, 425; author reply 426. 
GABRILOVICH, D. I., CHEN, H. L., GIRGIS, K. R., CUNNINGHAM, H. T., MENY, G. M., NADAF, S., 
KAVANAUGH, D. & CARBONE, D. P. 1996. Production of vascular endothelial growth factor 
by human tumors inhibits the functional maturation of dendritic cells. Nat Med, 2, 1096-103. 
GAJ, T., GERSBACH, C. A. & BARBAS, C. F., 3RD 2013. ZFN, TALEN, and CRISPR/Cas-based methods for 
genome engineering. Trends Biotechnol, 31, 397-405. 
GALON, J., COSTES, A., SANCHEZ-CABO, F., KIRILOVSKY, A., MLECNIK, B., LAGORCE-PAGES, C., 
TOSOLINI, M., CAMUS, M., BERGER, A., WIND, P., ZINZINDOHOUE, F., BRUNEVAL, P., 
CUGNENC, P. H., TRAJANOSKI, Z., FRIDMAN, W. H. & PAGES, F. 2006. Type, density, and 
location of immune cells within human colorectal tumors predict clinical outcome. Science, 
313, 1960-4. 
GAO, F. G., KHAMMANIVONG, V., LIU, W. J., LEGGATT, G. R., FRAZER, I. H. & FERNANDO, G. J. 2002. 
Antigen-specific CD4+ T-cell help is required to activate a memory CD8+ T cell to a fully 
functional tumor killer cell. Cancer Res, 62, 6438-41. 
GARY, D. J., PURI, N. & WON, Y. Y. 2007. Polymer-based siRNA delivery: perspectives on the 
fundamental and phenomenological distinctions from polymer-based DNA delivery. J Control 
Release, 121, 64-73. 
GASTL, G., PLANTE, M., FINSTAD, C. L., WONG, G. Y., FEDERICI, M. G., BANDER, N. H. & RUBIN, S. C. 
1993. High IL-6 levels in ascitic fluid correlate with reactive thrombocytosis in patients with 
epithelial ovarian cancer. Br J Haematol, 83, 433-41. 
GEBHART, C. L. & KABANOV, A. V. 2001. Evaluation of polyplexes as gene transfer agents. J Control 
Release, 73, 401-16. 
GEORGESCU, L., VAKKALANKA, R. K., ELKON, K. B. & CROW, M. K. 1997. Interleukin-10 promotes 
activation-induced cell death of SLE lymphocytes mediated by Fas ligand. Journal of Clinical 
Investigation, 100, 2622-2633. 
263 
 
GILHAM, D. E., DEBETS, R., PULE, M., HAWKINS, R. E. & ABKEN, H. 2012. CAR–T cells and solid 
tumors: tuning T cells to challenge an inveterate foe. Trends in Molecular Medicine, 18, 377-
384. 
GINN, S. L., ALEXANDER, I. E., EDELSTEIN, M. L., ABEDI, M. R. & WIXON, J. 2013. Gene therapy clinical 
trials worldwide to 2012–an update. J Gene Med, 15, 65-77. 
GLIMCHER, L. H., TOWNSEND, M. J., SULLIVAN, B. M. & LORD, G. M. 2004. Recent developments in 
the transcriptional regulation of cytolytic effector cells. Nat Rev Immunol, 4, 900-911. 
GODBEY, W. T., BARRY, M. A., SAGGAU, P., WU, K. K. & MIKOS, A. G. 2000. Poly(ethylenimine)-
mediated transfection: a new paradigm for gene delivery. J Biomed Mater Res, 51, 321-8. 
GODBEY, W. T., WU, K. K. & MIKOS, A. G. 1999. Size matters: molecular weight affects the efficiency 
of poly(ethylenimine) as a gene delivery vehicle. J Biomed Mater Res, 45, 268-75. 
GONG, M. C., LATOUCHE, J. B., KRAUSE, A., HESTON, W. D., BANDER, N. H. & SADELAIN, M. 1999. 
Cancer patient T cells genetically targeted to prostate-specific membrane antigen specifically 
lyse prostate cancer cells and release cytokines in response to prostate-specific membrane 
antigen. Neoplasia, 1, 123-7. 
GOODELL, V., SALAZAR, L. G., URBAN, N., DRESCHER, C. W., GRAY, H., SWENSEN, R. E., MCINTOSH, 
M. W. & DISIS, M. L. 2006. Antibody immunity to the p53 oncogenic protein is a prognostic 
indicator in ovarian cancer. J Clin Oncol, 24, 762-8. 
GOODEN, M. J., DE BOCK, G. H., LEFFERS, N., DAEMEN, T. & NIJMAN, H. W. 2011. The prognostic 
influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-
analysis. Br J Cancer, 105, 93-103. 
GRANT, B. D. & DONALDSON, J. G. 2009. Pathways and mechanisms of endocytic recycling. Nature 
reviews. Molecular cell biology, 10, 597-608. 
GRATTON, S. E., ROPP, P. A., POHLHAUS, P. D., LUFT, J. C., MADDEN, V. J., NAPIER, M. E. & 
DESIMONE, J. M. 2008. The effect of particle design on cellular internalization pathways. 
Proc Natl Acad Sci U S A, 105, 11613-8. 
GREEN, J. J., LANGER, R. & ANDERSON, D. G. 2008. A Combinatorial Polymer Library Approach Yields 
Insight into Nonviral Gene Delivery. Accounts of Chemical Research, 41, 749-759. 
GREENWALD, R. J., FREEMAN, G. J. & SHARPE, A. H. 2005. The B7 family revisited. Annu Rev 
Immunol, 23, 515-48. 
GRESCH, O. & ALTROGGE, L. 2012. Transfection of difficult-to-transfect primary mammalian cells. 
Methods Mol Biol, 801, 65-74. 
GREWAL, I. S. & FLAVELL, R. A. 1998. CD40 and CD154 in cell-mediated immunity. Annu Rev 
Immunol, 16, 111-35. 
GRIESENBACH, U., INOUE, M., MENG, C., FARLEY, R., CHAN, M., NEWMAN, N. K., BRUM, A., YOU, J., 
KERTON, A., SHOEMARK, A., BOYD, A. C., DAVIES, J. C., HIGGINS, T. E., GILL, D. R., HYDE, S. C., 
INNES, J. A., PORTEOUS, D. J., HASEGAWA, M. & ALTON, E. W. 2012. Assessment of F/HN-
pseudotyped lentivirus as a clinically relevant vector for lung gene therapy. Am J Respir Crit 
Care Med, 186, 846-56. 
GRIFFITH, L. G. & SWARTZ, M. A. 2006. Capturing complex 3D tissue physiology in vitro. Nat Rev Mol 
Cell Biol, 7, 211-224. 
GRIGSBY, C. L. & LEONG, K. W. 2010. Balancing protection and release of DNA: tools to address a 
bottleneck of non-viral gene delivery. J R Soc Interface, 7 Suppl 1, S67-82. 
GRUPP, S. A., KALOS, M., BARRETT, D., APLENC, R., PORTER, D. L., RHEINGOLD, S. R., TEACHEY, D. T., 
CHEW, A., HAUCK, B., WRIGHT, J. F., MILONE, M. C., LEVINE, B. L. & JUNE, C. H. 2013. 
Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med, 368, 
1509-18. 
GRZELCZAK, M., VERMANT, J., FURST, E. M. & LIZ-MARZÁN, L. M. 2010. Directed Self-Assembly of 
Nanoparticles. ACS Nano, 4, 3591-3605. 
GU, F. X., KARNIK, R., WANG, A. Z., ALEXIS, F., LEVY-NISSENBAUM, E., HONG, S., LANGER, R. S. & 
FAROKHZAD, O. C. 2007. Targeted nanoparticles for cancer therapy. Nano Today, 2, 14-21. 
264 
 
GULLEY, J. L., ARLEN, P. M., TSANG, K. Y., YOKOKAWA, J., PALENA, C., POOLE, D. J., REMONDO, C., 
CEREDA, V., JONES, J. L., PAZDUR, M. P., HIGGINS, J. P., HODGE, J. W., STEINBERG, S. M., 
KOTZ, H., DAHUT, W. L. & SCHLOM, J. 2008. Pilot study of vaccination with recombinant CEA-
MUC-1-TRICOM poxviral-based vaccines in patients with metastatic carcinoma. Clin Cancer 
Res, 14, 3060-9. 
HAGERMAN, P. J. 1988. Flexibility of DNA. Annu Rev Biophys Biophys Chem, 17, 265-86. 
HALAPI, E., YAMAMOTO, Y., JUHLIN, C., JEDDI-TEHRANI, M., GRUNEWALD, J., ANDERSSON, R., 
HISING, C., MASUCCI, G., MELLSTEDT, H. & KIESSLING, R. 1993. Restricted T cell receptor V-
beta and J-beta usage in T cells from interleukin-2-cultured lymphocytes of ovarian and renal 
carcinomas. Cancer Immunol Immunother, 36, 191-7. 
HALPERN, A. C. & SCHUCHTER, L. M. 1997. Prognostic models in melanoma. Semin Oncol, 24, S2-7. 
HAMANISHI, J., MANDAI, M., ABIKO, K., MATSUMURA, N., BABA, T., YOSHIOKA, Y., KOSAKA, K. & 
KONISHI, I. 2011. The comprehensive assessment of local immune status of ovarian cancer 
by the clustering of multiple immune factors. Clin Immunol, 141, 338-47. 
HAMANISHI, J., MANDAI, M., IWASAKI, M., OKAZAKI, T., TANAKA, Y., YAMAGUCHI, K., HIGUCHI, T., 
YAGI, H., TAKAKURA, K., MINATO, N., HONJO, T. & FUJII, S. 2007. Programmed cell death 1 
ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian 
cancer. Proc Natl Acad Sci U S A, 104, 3360-5. 
HAMID, O., ROBERT, C., DAUD, A., HODI, F. S., HWU, W.-J., KEFFORD, R., WOLCHOK, J. D., HERSEY, P., 
JOSEPH, R. W., WEBER, J. S., DRONCA, R., GANGADHAR, T. C., PATNAIK, A., ZAROUR, H., 
JOSHUA, A. M., GERGICH, K., ELASSAISS-SCHAAP, J., ALGAZI, A., MATEUS, C., BOASBERG, P., 
TUMEH, P. C., CHMIELOWSKI, B., EBBINGHAUS, S. W., LI, X. N., KANG, S. P. & RIBAS, A. 2013. 
Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma. New England 
Journal of Medicine, 369, 134-144. 
HAN, L. Y., FLETCHER, M. S., URBAUER, D. L., MUELLER, P., LANDEN, C. N., KAMAT, A. A., LIN, Y. G., 
MERRITT, W. M., SPANNUTH, W. A., DEAVERS, M. T., DE GEEST, K., GERSHENSON, D. M., 
LUTGENDORF, S. K., FERRONE, S. & SOOD, A. K. 2008. HLA class I antigen processing 
machinery component expression and intratumoral T-Cell infiltrate as independent 
prognostic markers in ovarian carcinoma. Clin Cancer Res, 14, 3372-9. 
HAN, S.-O., MAHATO, R. I. & KIM, S. W. 2001. Water-Soluble Lipopolymer for Gene Delivery. 
Bioconjugate Chemistry, 12, 337-345. 
HANAHAN, D. & WEINBERG, ROBERT A. 2011. Hallmarks of Cancer: The Next Generation. Cell, 144, 
646-674. 
HANNON, G. J. 2002. RNA interference. Nature, 418, 244-251. 
HARADA-SHIBA, M., YAMAUCHI, K., HARADA, A., TAKAMISAWA, I., SHIMOKADO, K. & KATAOKA, K. 
2002. Polyion complex micelles as vectors in gene therapy--pharmacokinetics and in vivo 
gene transfer. Gene Ther, 9, 407-14. 
HARUSH-FRENKEL, O., ROZENTUR, E., BENITA, S. & ALTSCHULER, Y. 2008. Surface charge of 
nanoparticles determines their endocytic and transcytotic pathway in polarized MDCK cells. 
Biomacromolecules, 9, 435-43. 
HAXHINASTO, S., MATHIS, D. & BENOIST, C. 2008. The AKT–mTOR axis regulates de novo 
differentiation of CD4+Foxp3+ cells. The Journal of Experimental Medicine, 205, 565-574. 
HAYASHI, K., YONAMINE, K., MASUKO-HONGO, K., IIDA, T., YAMAMOTO, K., NISHIOKA, K. & KATO, T. 
1999. Clonal expansion of T cells that are specific for autologous ovarian tumor among 
tumor-infiltrating T cells in humans. Gynecol Oncol, 74, 86-92. 
HE, X.-H., XU, L.-H. & LIU, Y. 2005. Identification of a novel splice variant of human PD-L1 mRNA 
encoding an isoform-lacking Igv-like domain. Acta Pharmacol Sin, 26, 462-468. 
HE, X. H., LIU, Y., XU, L. H. & ZENG, Y. Y. 2004. Cloning and identification of two novel splice variants 
of human PD-L2. Acta Biochim Biophys Sin (Shanghai), 36, 284-9. 
HE, X. H., XU, L. H. & LIU, Y. 2005. Identification of a novel splice variant of human PD-L1 mRNA 
encoding an isoform-lacking Igv-like domain. Acta Pharmacol Sin, 26, 462-8. 
265 
 
HEINRICH, L., TISSOT, N., HARTMANN, D. J. & COHEN, R. 2010. Comparison of the results obtained by 
ELISA and surface plasmon resonance for the determination of antibody affinity. J Immunol 
Methods, 352, 13-22. 
HER, M., KIM, D., OH, M., JEONG, H. & CHOI, I. 2009. Increased expression of soluble inducible 
costimulator ligand (ICOSL) in patients with systemic lupus erythematosus. Lupus, 18, 501-7. 
HERBST, R. S., SORIA, J. C., KOWANETZ, M., FINE, G. D., HAMID, O., GORDON, M. S., SOSMAN, J. A., 
MCDERMOTT, D. F., POWDERLY, J. D., GETTINGER, S. N., KOHRT, H. E., HORN, L., LAWRENCE, 
D. P., ROST, S., LEABMAN, M., XIAO, Y., MOKATRIN, A., KOEPPEN, H., HEGDE, P. S., 
MELLMAN, I., CHEN, D. S. & HODI, F. S. 2014. Predictive correlates of response to the anti-
PD-L1 antibody MPDL3280A in cancer patients. Nature, 515, 563-7. 
HERNANDO, J. J., PARK, T. W., KUBLER, K., OFFERGELD, R., SCHLEBUSCH, H. & BAUKNECHT, T. 2002. 
Vaccination with autologous tumour antigen-pulsed dendritic cells in advanced 
gynaecological malignancies: clinical and immunological evaluation of a phase I trial. Cancer 
Immunol Immunother, 51, 45-52. 
HEYES, J. A., NICULESCU-DUVAZ, D., COOPER, R. G. & SPRINGER, C. J. 2002. Synthesis of novel 
cationic lipids: effect of structural modification on the efficiency of gene transfer. J Med 
Chem, 45, 99-114. 
HILTBOLD, E. M. & ROCHE, P. A. 2002. Trafficking of MHC class II molecules in the late secretory 
pathway. Curr Opin Immunol, 14, 30-5. 
HIRANO, F., KANEKO, K., TAMURA, H., DONG, H., WANG, S., ICHIKAWA, M., RIETZ, C., FLIES, D. B., 
LAU, J. S., ZHU, G., TAMADA, K. & CHEN, L. 2005. Blockade of B7-H1 and PD-1 by monoclonal 
antibodies potentiates cancer therapeutic immunity. Cancer Res, 65, 1089-96. 
HODI, F. S., BUTLER, M., OBLE, D. A., SEIDEN, M. V., HALUSKA, F. G., KRUSE, A., MACRAE, S., NELSON, 
M., CANNING, C., LOWY, I., KORMAN, A., LAUTZ, D., RUSSELL, S., JAKLITSCH, M. T., RAMAIYA, 
N., CHEN, T. C., NEUBERG, D., ALLISON, J. P., MIHM, M. C. & DRANOFF, G. 2008. 
Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated 
antigen 4 in previously vaccinated cancer patients. Proc Natl Acad Sci U S A, 105, 3005-10. 
HODI, F. S., BUTLER, M., OBLE, D. A., SEIDEN, M. V., HALUSKA, F. G., KRUSE, A., MACRAE, S., NELSON, 
M., CANNING, C., LOWY, I., KORMAN, A., LAUTZ, D., RUSSELL, S., JAKLITSCH, M. T., RAMAIYA, 
N., CHEN, T. C., NEUBERG, D., ALLISON, J. P., MIHM, M. C. & DRANOFF, G. 2008. 
Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated 
antigen 4 in previously vaccinated cancer patients. Proceedings of the National Academy of 
Sciences, 105, 3005-3010. 
HODI, F. S., MIHM, M. C., SOIFFER, R. J., HALUSKA, F. G., BUTLER, M., SEIDEN, M. V., DAVIS, T., 
HENRY-SPIRES, R., MACRAE, S., WILLMAN, A., PADERA, R., JAKLITSCH, M. T., SHANKAR, S., 
CHEN, T. C., KORMAN, A., ALLISON, J. P. & DRANOFF, G. 2003. Biologic activity of cytotoxic T 
lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic 
melanoma and ovarian carcinoma patients. Proc Natl Acad Sci U S A, 100, 4712-7. 
HODI, F. S., O'DAY, S. J., MCDERMOTT, D. F., WEBER, R. W., SOSMAN, J. A., HAANEN, J. B., 
GONZALEZ, R., ROBERT, C., SCHADENDORF, D., HASSEL, J. C., AKERLEY, W., VAN DEN 
EERTWEGH, A. J., LUTZKY, J., LORIGAN, P., VAUBEL, J. M., LINETTE, G. P., HOGG, D., 
OTTENSMEIER, C. H., LEBBE, C., PESCHEL, C., QUIRT, I., CLARK, J. I., WOLCHOK, J. D., WEBER, 
J. S., TIAN, J., YELLIN, M. J., NICHOL, G. M., HOOS, A. & URBA, W. J. 2010. Improved survival 
with ipilimumab in patients with metastatic melanoma. N Engl J Med, 363, 711-23. 
HOFMEYER, K. A., RAY, A. & ZANG, X. 2008. The contrasting role of B7-H3. Proceedings of the 
National Academy of Sciences, 105, 10277-10278. 
HOLT, G. E., PODACK, E. R. & RAEZ, L. E. 2011. Immunotherapy as a strategy for the treatment of 
non-small-cell lung cancer. Therapy, 8, 43-54. 
HORI, J., WANG, M., MIYASHITA, M., TANEMOTO, K., TAKAHASHI, H., TAKEMORI, T., OKUMURA, K., 
YAGITA, H. & AZUMA, M. 2006. B7-H1-induced apoptosis as a mechanism of immune 
privilege of corneal allografts. J Immunol, 177, 5928-35. 
266 
 
HORTOBAGYI, G. N., UENO, N. T., XIA, W., ZHANG, S., WOLF, J. K., PUTNAM, J. B., WEIDEN, P. L., 
WILLEY, J. S., CAREY, M., BRANHAM, D. L., PAYNE, J. Y., TUCKER, S. D., BARTHOLOMEUSZ, C., 
KILBOURN, R. G., DE JAGER, R. L., SNEIGE, N., KATZ, R. L., ANKLESARIA, P., IBRAHIM, N. K., 
MURRAY, J. L., THERIAULT, R. L., VALERO, V., GERSHENSON, D. M., BEVERS, M. W., HUANG, 
L., LOPEZ-BERESTEIN, G. & HUNG, M.-C. 2001. Cationic Liposome-Mediated E1A Gene 
Transfer to Human Breast and Ovarian Cancer Cells and Its Biologic Effects: A Phase I Clinical 
Trial. Journal of Clinical Oncology, 19, 3422-3433. 
HSU, C. Y. M., HENDZEL, M. & ULUDAǦ, H. 2011. Improved transfection efficiency of an aliphatic lipid 
substituted 2 kDa polyethylenimine is attributed to enhanced nuclear association and 
uptake in rat bone marrow stromal cell. The Journal of Gene Medicine, 13, 46-59. 
HU, J. C., COFFIN, R. S., DAVIS, C. J., GRAHAM, N. J., GROVES, N., GUEST, P. J., HARRINGTON, K. J., 
JAMES, N. D., LOVE, C. A., MCNEISH, I., MEDLEY, L. C., MICHAEL, A., NUTTING, C. M., 
PANDHA, H. S., SHORROCK, C. A., SIMPSON, J., STEINER, J., STEVEN, N. M., WRIGHT, D. & 
COOMBES, R. C. 2006. A phase I study of OncoVEXGM-CSF, a second-generation oncolytic 
herpes simplex virus expressing granulocyte macrophage colony-stimulating factor. Clin 
Cancer Res, 12, 6737-47. 
HUNTER, A. C. 2006. Molecular hurdles in polyfectin design and mechanistic background to 
polycation induced cytotoxicity. Adv Drug Deliv Rev, 58, 1523-31. 
HWANG, W. T., ADAMS, S. F., TAHIROVIC, E., HAGEMANN, I. S. & COUKOS, G. 2012. Prognostic 
significance of tumor-infiltrating T cells in ovarian cancer: a meta-analysis. Gynecol Oncol, 
124, 192-8. 
HWU, P., YANG, J. C., COWHERD, R., TREISMAN, J., SHAFER, G. E., ESHHAR, Z. & ROSENBERG, S. A. 
1995. In vivo antitumor activity of T cells redirected with chimeric antibody/T-cell receptor 
genes. Cancer Res, 55, 3369-73. 
IIDA, T., OHNO, H., NAKASEKO, C., SAKUMA, M., TAKEDA-EZAKI, M., ARASE, H., KOMINAMI, E., 
FUJISAWA, T. & SAITO, T. 2000. Regulation of cell surface expression of CTLA-4 by secretion 
of CTLA-4-containing lysosomes upon activation of CD4+ T cells. J Immunol, 165, 5062-8. 
INABA, T., INO, K., KAJIYAMA, H., YAMAMOTO, E., SHIBATA, K., NAWA, A., NAGASAKA, T., AKIMOTO, 
H., TAKIKAWA, O. & KIKKAWA, F. 2009. Role of the immunosuppressive enzyme indoleamine 
2,3-dioxygenase in the progression of ovarian carcinoma. Gynecol Oncol, 115, 185-92. 
INTRA, J. & SALEM, A. K. 2008. Characterization of the transgene expression generated by branched 
and linear polyethylenimine-plasmid DNA nanoparticles in vitro and after intraperitoneal 
injection in vivo. J Control Release, 130, 129-38. 
IRVING, B. A. & WEISS, A. 1991. The cytoplasmic domain of the T cell receptor zeta chain is sufficient 
to couple to receptor-associated signal transduction pathways. Cell, 64, 891-901. 
ISHIDA, Y., AGATA, Y., SHIBAHARA, K. & HONJO, T. 1992. Induced expression of PD-1, a novel 
member of the immunoglobulin gene superfamily, upon programmed cell death. Embo j, 11, 
3887-95. 
IWAMURA, K., KATO, T., MIYAHARA, Y., NAOTA, H., MINENO, J., IKEDA, H. & SHIKU, H. 2012. siRNA-
mediated silencing of PD-1 ligands enhances tumor-specific human T-cell effector functions. 
Gene Ther, 19, 959-966. 
JACKSON, A. L., BURCHARD, J., LEAKE, D., REYNOLDS, A., SCHELTER, J., GUO, J., JOHNSON, J. M., LIM, 
L., KARPILOW, J., NICHOLS, K., MARSHALL, W., KHVOROVA, A. & LINSLEY, P. S. 2006. 
Position-specific chemical modification of siRNAs reduces “off-target” transcript silencing. 
RNA, 12, 1197-1205. 
JACKSON, A. L., BURCHARD, J., SCHELTER, J., CHAU, B. N., CLEARY, M., LIM, L. & LINSLEY, P. S. 2006. 
Widespread siRNA "off-target" transcript silencing mediated by seed region sequence 
complementarity. Rna, 12, 1179-87. 
JAIN, R. K. & STYLIANOPOULOS, T. 2010. Delivering nanomedicine to solid tumors. Nat Rev Clin 
Oncol, 7, 653-64. 
267 
 
JALALI-YAZDI, F., CORBIN, J. M., TAKAHASHI, T. T. & ROBERTS, R. W. 2014. Robust, Quantitative 
Analysis of Proteins using Peptide Immunoreagents, in Vitro Translation, and an 
Ultrasensitive Acoustic Resonant Sensor. Analytical Chemistry, 86, 4715-4722. 
JANSSEN, E. M., LEMMENS, E. E., WOLFE, T., CHRISTEN, U., VON HERRATH, M. G. & SCHOENBERGER, 
S. P. 2003. CD4+ T cells are required for secondary expansion and memory in CD8+ T 
lymphocytes. Nature, 421, 852-6. 
JEONG, J. H., KIM, S. W. & PARK, T. G. 2007. Molecular design of functional polymers for gene 
therapy. Progress in Polymer Science, 32, 1239-1274. 
JOHN, L. B., DEVAUD, C., DUONG, C. P., YONG, C. S., BEAVIS, P. A., HAYNES, N. M., CHOW, M. T., 
SMYTH, M. J., KERSHAW, M. H. & DARCY, P. K. 2013. Anti-PD-1 antibody therapy potently 
enhances the eradication of established tumors by gene-modified T cells. Clin Cancer Res, 
19, 5636-46. 
JUNE, C. H., BLUESTONE, J. A., NADLER, L. M. & THOMPSON, C. B. 1994. The B7 and CD28 receptor 
families. Immunol Today, 15, 321-31. 
KALLI, K. R., KRCO, C. J., HARTMANN, L. C., GOODMAN, K., MAURER, M. J., YU, C., JOHNSON, E. M., 
ERSKINE, C. L., DISIS, M. L., WETTSTEIN, P. J., FIKES, J. D., BEEBE, M., ISHIOKA, G. & 
KNUTSON, K. L. 2008. An HLA-DR-degenerate epitope pool detects insulin-like growth factor 
binding protein 2-specific immunity in patients with cancer. Cancer Res, 68, 4893-901. 
KAMEN, B. A. & CASTON, J. D. 1986. Properties of a folate binding protein (FBP) isolated from 
porcine kidney. Biochem Pharmacol, 35, 2323-9. 
KANASTY, R. L., WHITEHEAD, K. A., VEGAS, A. J. & ANDERSON, D. G. 2012. Action and Reaction: The 
Biological Response to siRNA and Its Delivery Vehicles. Mol Ther, 20, 513-524. 
KANASTY, R. L., WHITEHEAD, K. A., VEGAS, A. J. & ANDERSON, D. G. 2012. Action and reaction: the 
biological response to siRNA and its delivery vehicles. Mol Ther, 20, 513-24. 
KANDALAFT, L. E., POWELL, D. J., JR. & COUKOS, G. 2012. A phase I clinical trial of adoptive transfer 
of folate receptor-alpha redirected autologous T cells for recurrent ovarian cancer. J Transl 
Med, 10, 157. 
KANDALAFT, L. E., POWELL, D. J., SINGH, N. & COUKOS, G. 2011. Immunotherapy for Ovarian Cancer: 
What's Next? Journal of Clinical Oncology, 29, 925-933. 
KANE, M. A. & WAXMAN, S. 1989. Role of folate binding proteins in folate metabolism. Lab Invest, 
60, 737-46. 
KANTOFF, P. W., HIGANO, C. S., SHORE, N. D., BERGER, E. R., SMALL, E. J., PENSON, D. F., REDFERN, 
C. H., FERRARI, A. C., DREICER, R., SIMS, R. B., XU, Y., FROHLICH, M. W. & SCHELLHAMMER, P. 
F. 2010. Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer. New England 
Journal of Medicine, 363, 411-422. 
KAPLAN, D. H., SHANKARAN, V., DIGHE, A. S., STOCKERT, E., AGUET, M., OLD, L. J. & SCHREIBER, R. D. 
1998. Demonstration of an interferon gamma-dependent tumor surveillance system in 
immunocompetent mice. Proc Natl Acad Sci U S A, 95, 7556-61. 
KAPLAN, D. H., SHANKARAN, V., DIGHE, A. S., STOCKERT, E., AGUET, M., OLD, L. J. & SCHREIBER, R. D. 
1998. Demonstration of an interferon γ-dependent tumor surveillance system in 
immunocompetent mice. Proceedings of the National Academy of Sciences of the United 
States of America, 95, 7556-7561. 
KARMAN, J., JIANG, J. L., GUMLAW, N., ZHAO, H., CAMPOS-RIVERA, J., SANCHO, J., ZHANG, J., JIANG, 
C., CHENG, S. H. & ZHU, Y. 2012. Ligation of cytotoxic T lymphocyte antigen-4 to T cell 
receptor inhibits T cell activation and directs differentiation into Foxp3+ regulatory T cells. J 
Biol Chem, 287, 11098-107. 
KATAYOSE, S. & KATAOKA, K. 1997. Water-soluble polyion complex associates of DNA and 
poly(ethylene glycol)-poly(L-lysine) block copolymer. Bioconjug Chem, 8, 702-7. 
KATAYOSE, S. & KATAOKA, K. 1998. Remarkable increase in nuclease resistance of plasmid DNA 
through supramolecular assembly with poly(ethylene glycol)-poly(L-lysine) block copolymer. 
J Pharm Sci, 87, 160-3. 
268 
 
KAY, M. A., GLORIOSO, J. C. & NALDINI, L. 2001. Viral vectors for gene therapy: the art of turning 
infectious agents into vehicles of therapeutics. Nat Med, 7, 33-40. 
KEIR, M. E., BUTTE, M. J., FREEMAN, G. J. & SHARPE, A. H. 2008. PD-1 and its ligands in tolerance and 
immunity. Annu Rev Immunol, 26, 677-704. 
KEIR, M. E., LIANG, S. C., GULERIA, I., LATCHMAN, Y. E., QIPO, A., ALBACKER, L. A., KOULMANDA, M., 
FREEMAN, G. J., SAYEGH, M. H. & SHARPE, A. H. 2006. Tissue expression of PD-L1 mediates 
peripheral T cell tolerance. J Exp Med, 203, 883-95. 
KERSHAW, M. H., WESTWOOD, J. A., PARKER, L. L., WANG, G., ESHHAR, Z., MAVROUKAKIS, S. A., 
WHITE, D. E., WUNDERLICH, J. R., CANEVARI, S., ROGERS-FREEZER, L., CHEN, C. C., YANG, J. 
C., ROSENBERG, S. A. & HWU, P. 2006. A phase I study on adoptive immunotherapy using 
gene-modified T cells for ovarian cancer. Clin Cancer Res, 12, 6106-15. 
KERSHAW, M. H., WESTWOOD, J. A., SLANEY, C. Y. & DARCY, P. K. 2014. Clinical application of 
genetically modified T cells in cancer therapy. Clin Trans Immunol, 3, e16. 
KHALIL, I. A., KOGURE, K., AKITA, H. & HARASHIMA, H. 2006. Uptake pathways and subsequent 
intracellular trafficking in nonviral gene delivery. Pharmacol Rev, 58, 32-45. 
KHONG, H. T. & RESTIFO, N. P. 2002. Natural selection of tumor variants in the generation of "tumor 
escape" phenotypes. Nat Immunol, 3, 999-1005. 
KICHLER, A. 2004. Gene transfer with modified polyethylenimines. The Journal of Gene Medicine, 6, 
S3-S10. 
KICHLER, A. 2004. Gene transfer with modified polyethylenimines. J Gene Med, 6 Suppl 1, S3-10. 
KIM, H.-J. & CANTOR, H. 2014. CD4 T-cell Subsets and Tumor Immunity: The Helpful and the Not-so-
Helpful. Cancer Immunology Research, 2, 91-98. 
KIM, H., KIM, H. A., BAE, Y. M., CHOI, J. S. & LEE, M. 2009. Dexamethasone-conjugated 
polyethylenimine as an efficient gene carrier with an anti-apoptotic effect to 
cardiomyocytes. The Journal of Gene Medicine, 11, 515-522. 
KIM, S. H., TAN, J. P. K., NEDERBERG, F., FUKUSHIMA, K., COLSON, J., YANG, C., NELSON, A., YANG, Y.-
Y. & HEDRICK, J. L. 2010. Hydrogen bonding-enhanced micelle assemblies for drug delivery. 
Biomaterials, 31, 8063-8071. 
KIM, Y. H., PARK, J. H., LEE, M., KIM, Y.-H., PARK, T. G. & KIM, S. W. 2005. Polyethylenimine with acid-
labile linkages as a biodegradable gene carrier. Journal of Controlled Release, 103, 209-219. 
KIRCHEIS, R., WIGHTMAN, L. & WAGNER, E. 2001. Design and gene delivery activity of modified 
polyethylenimines. Adv Drug Deliv Rev, 53, 341-58. 
KLEEMANN, E., JEKEL, N., DAILEY, L. A., ROESLER, S., FINK, L., WEISSMANN, N., SCHERMULY, R., 
GESSLER, T., SCHMEHL, T., ROBERTS, C. J., SEEGER, W. & KISSEL, T. 2009. Enhanced gene 
expression and reduced toxicity in mice using polyplexes of low-molecular-weight 
poly(ethylene imine) for pulmonary gene delivery. J Drug Target, 17, 638-51. 
KNORR, V., OGRIS, M. & WAGNER, E. 2008. An acid sensitive ketal-based polyethylene glycol-
oligoethylenimine copolymer mediates improved transfection efficiency at reduced toxicity. 
Pharm Res, 25, 2937-45. 
KNUTSON, K. L., KRCO, C. J., ERSKINE, C. L., GOODMAN, K., KELEMEN, L. E., WETTSTEIN, P. J., LOW, P. 
S., HARTMANN, L. C. & KALLI, K. R. 2006. T-cell immunity to the folate receptor alpha is 
prevalent in women with breast or ovarian cancer. J Clin Oncol, 24, 4254-61. 
KOCHENDERFER, J. N., DUDLEY, M. E., CARPENTER, R. O., KASSIM, S. H., ROSE, J. J., TELFORD, W. G., 
HAKIM, F. T., HALVERSON, D. C., FOWLER, D. H., HARDY, N. M., MATO, A. R., HICKSTEIN, D. 
D., GEA-BANACLOCHE, J. C., PAVLETIC, S. Z., SPORTES, C., MARIC, I., FELDMAN, S. A., 
HANSEN, B. G., WILDER, J. S., BLACKLOCK-SCHUVER, B., JENA, B., BISHOP, M. R., GRESS, R. E. 
& ROSENBERG, S. A. 2013. Donor-derived CD19-targeted T cells cause regression of 
malignancy persisting after allogeneic hematopoietic stem cell transplantation. Blood, 122, 
4129-39. 
269 
 
KOGUCHI, Y., THAULAND, T. J., SLIFKA, M. K. & PARKER, D. C. 2007. Preformed CD40 ligand exists in 
secretory lysosomes in effector and memory CD4+ T cells and is quickly expressed on the cell 
surface in an antigen-specific manner. Blood, 110, 2520-7. 
KOOI, S., FREEDMAN, R. S., RODRIGUEZ-VILLANUEVA, J. & PLATSOUCAS, C. D. 1993. Cytokine 
production by T-cell lines derived from tumor-infiltrating lymphocytes from patients with 
ovarian carcinoma: tumor-specific immune responses and inhibition of antigen-independent 
cytokine production by ovarian tumor cells. Lymphokine Cytokine Res, 12, 429-37. 
KOPATZ, I., REMY, J. S. & BEHR, J. P. 2004. A model for non-viral gene delivery: through syndecan 
adhesion molecules and powered by actin. J Gene Med, 6, 769-76. 
KREMPSKI, J., KARYAMPUDI, L., BEHRENS, M. D., ERSKINE, C. L., HARTMANN, L., DONG, H., GOODE, 
E. L., KALLI, K. R. & KNUTSON, K. L. 2011. Tumor-infiltrating programmed death receptor-1+ 
dendritic cells mediate immune suppression in ovarian cancer. J Immunol, 186, 6905-13. 
KRYCZEK, I., ZOU, L., RODRIGUEZ, P., ZHU, G., WEI, S., MOTTRAM, P., BRUMLIK, M., CHENG, P., 
CURIEL, T., MYERS, L., LACKNER, A., ALVAREZ, X., OCHOA, A., CHEN, L. & ZOU, W. 2006. B7-
H4 expression identifies a novel suppressive macrophage population in human ovarian 
carcinoma. J Exp Med, 203, 871-81. 
KRZEWSKI, K., GIL-KRZEWSKA, A., NGUYEN, V., PERUZZI, G. & COLIGAN, J. E. 2013. LAMP1/CD107a is 
required for efficient perforin delivery to lytic granules and NK-cell cytotoxicity. Blood, 121, 
4672-83. 
KUMAR, V., QIN, J., JIANG, Y., DUNCAN, R. G., BRIGHAM, B., FISHMAN, S., NAIR, J. K., AKINC, A., 
BARROS, S. A. & KASPERKOVITZ, P. V. 2014. Shielding of Lipid Nanoparticles for siRNA 
Delivery: Impact on Physicochemical Properties, Cytokine Induction, and Efficacy. Mol Ther 
Nucleic Acids, 3, e210. 
KUNATH, K., VON HARPE, A., FISCHER, D. & KISSEL, T. 2003. Galactose-PEI-DNA complexes for 
targeted gene delivery: degree of substitution affects complex size and transfection 
efficiency. J Control Release, 88, 159-72. 
LABRIE, M., VLADOIU, M. C., GROSSET, A. A., GABOURY, L. & ST-PIERRE, Y. 2014. Expression and 
functions of galectin-7 in ovarian cancer. Oncotarget, 5, 7705-21. 
LAM, J. K., ARMES, S. P., LEWIS, A. L. & STOLNIK, S. 2009. Folate conjugated phosphorylcholine-based 
polycations for specific targeting in nucleic acids delivery. J Drug Target, 17, 512-23. 
LANITIS, E., POUSSIN, M., HAGEMANN, I. S., COUKOS, G., SANDALTZOPOULOS, R., SCHOLLER, N. & 
POWELL, D. J., JR. 2012. Redirected antitumor activity of primary human lymphocytes 
transduced with a fully human anti-mesothelin chimeric receptor. Mol Ther, 20, 633-43. 
LATCHMAN, Y., WOOD, C. R., CHERNOVA, T., CHAUDHARY, D., BORDE, M., CHERNOVA, I., IWAI, Y., 
LONG, A. J., BROWN, J. A., NUNES, R., GREENFIELD, E. A., BOURQUE, K., BOUSSIOTIS, V. A., 
CARTER, L. L., CARRENO, B. M., MALENKOVICH, N., NISHIMURA, H., OKAZAKI, T., HONJO, T., 
SHARPE, A. H. & FREEMAN, G. J. 2001. PD-L2 is a second ligand for PD-1 and inhibits T cell 
activation. Nat Immunol, 2, 261-8. 
LATCHMAN, Y. E., LIANG, S. C., WU, Y., CHERNOVA, T., SOBEL, R. A., KLEMM, M., KUCHROO, V. K., 
FREEMAN, G. J. & SHARPE, A. H. 2004. PD-L1-deficient mice show that PD-L1 on T cells, 
antigen-presenting cells, and host tissues negatively regulates T cells. Proceedings of the 
National Academy of Sciences of the United States of America, 101, 10691-10696. 
LAURENT, S., QUEIROLO, P., BOERO, S., SALVI, S., PICCIOLI, P., BOCCARDO, S., MINGHELLI, S., 
MORABITO, A., FONTANA, V., PIETRA, G., CARREGA, P., FERRARI, N., TOSETTI, F., CHANG, L. 
J., MINGARI, M. C., FERLAZZO, G., POGGI, A. & PISTILLO, M. P. 2013. The engagement of 
CTLA-4 on primary melanoma cell lines induces antibody-dependent cellular cytotoxicity and 
TNF-alpha production. J Transl Med, 11, 108. 
LEBLOND, J., MIGNET, N., LARGEAU, C., SPANEDDA, M. V., SEGUIN, J., SCHERMAN, D. & HERSCOVICI, 
J. 2007. Lipopolythioureas: a new non-cationic system for gene transfer. Bioconjug Chem, 18, 
484-93. 
270 
 
LEE, M. & KIM, S. W. 2005. Polyethylene glycol-conjugated copolymers for plasmid DNA delivery. 
Pharm Res, 22, 1-10. 
LEE, S. H., CHUNG, B. H., PARK, T. G., NAM, Y. S. & MOK, H. 2012. Small-interfering RNA (siRNA)-
based functional micro- and nanostructures for efficient and selective gene silencing. Acc 
Chem Res, 45, 1014-25. 
LEE, S. H., MOK, H., LEE, Y. & PARK, T. G. 2011. Self-assembled siRNA-PLGA conjugate micelles for 
gene silencing. J Control Release, 152, 152-8. 
LEMKINE, G. F. & DEMENEIX, B. A. 2001. Polyethylenimines for in vivo gene delivery. Curr Opin Mol 
Ther, 3, 178-82. 
LEROUEIL, P. R., BERRY, S. A., DUTHIE, K., HAN, G., ROTELLO, V. M., MCNERNY, D. Q., BAKER, J. R., 
JR., ORR, B. G. & HOLL, M. M. 2008. Wide varieties of cationic nanoparticles induce defects 
in supported lipid bilayers. Nano Lett, 8, 420-4. 
LETOURNEUR, F. & KLAUSNER, R. D. 1991. T-cell and basophil activation through the cytoplasmic tail 
of T-cell-receptor zeta family proteins. Proc Natl Acad Sci U S A, 88, 8905-9. 
LI, J., CHENG, D., YIN, T., CHEN, W., LIN, Y., CHEN, J., LI, R. & SHUAI, X. 2014. Copolymer of 
poly(ethylene glycol) and poly(l-lysine) grafting polyethylenimine through a reducible 
disulfide linkage for siRNA delivery. Nanoscale, 6, 1732-1740. 
LI, Y., TIAN, H., DING, J., DONG, X., CHEN, J. & CHEN, X. 2014. Thiourea modified polyethylenimine 
for efficient gene delivery mediated by the combination of electrostatic interactions and 
hydrogen bonds. Polymer Chemistry, 5, 3598-3607. 
LIANG, S. C., LATCHMAN, Y. E., BUHLMANN, J. E., TOMCZAK, M. F., HORWITZ, B. H., FREEMAN, G. J. & 
SHARPE, A. H. 2003. Regulation of PD-1, PD-L1, and PD-L2 expression during normal and 
autoimmune responses. Eur J Immunol, 33, 2706-16. 
LIPSON, E. J., VINCENT, J. G., LOYO, M., KAGOHARA, L. T., LUBER, B. S., WANG, H., XU, H., NAYAR, S. 
K., WANG, T. S., SIDRANSKY, D., ANDERS, R. A., TOPALIAN, S. L. & TAUBE, J. M. 2013. PD-L1 
expression in the Merkel cell carcinoma microenvironment: Association with inflammation, 
Merkel cell polyomavirus and overall survival. Cancer immunology research, 1, 
10.1158/2326-6066.CIR-13-0034. 
LIU, J., HAMROUNI, A., WOLOWIEC, D., COITEUX, V., KULICZKOWSKI, K., HETUIN, D., SAUDEMONT, A. 
& QUESNEL, B. 2007. Plasma cells from multiple myeloma patients express B7-H1 (PD-L1) 
and increase expression after stimulation with IFN-{gamma} and TLR ligands via a MyD88-, 
TRAF6-, and MEK-dependent pathway. Blood, 110, 296-304. 
LIU, P., QI, X., SUN, Y., WANG, H., LI, Y. & DUAN, Y. 2011. RGD-conjugated PLA-PLL nanoparticles 
targeting to Bacp-37 breast cancer xenografts in vivo. J Nanosci Nanotechnol, 11, 10760-4. 
LIU, Y., CARLSSON, R., AMBJORN, M., HASAN, M., BADN, W., DARABI, A., SIESJO, P. & ISSAZADEH-
NAVIKAS, S. 2013. PD-L1 expression by neurons nearby tumors indicates better prognosis in 
glioblastoma patients. J Neurosci, 33, 14231-45. 
LIU, Y., NGUYEN, J., STEELE, T., MERKEL, O. & KISSEL, T. 2009. A new synthesis method and 
degradation of hyper-branched polyethylenimine grafted polycaprolactone block mono-
methoxyl poly (ethylene glycol) copolymers (hy-PEI-g-PCL-b-mPEG) as potential DNA delivery 
vectors. Polymer, 50, 3895-3904. 
LIU, Y., YU, Y., YANG, S., ZENG, B., ZHANG, Z., JIAO, G., ZHANG, Y., CAI, L. & YANG, R. 2009. 
Regulation of arginase I activity and expression by both PD-1 and CTLA-4 on the myeloid-
derived suppressor cells. Cancer Immunol Immunother, 58, 687-97. 
LIVAK, K. J. & SCHMITTGEN, T. D. 2001. Analysis of relative gene expression data using real-time 
quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods, 25, 402-8. 
LOKE, P. N. & ALLISON, J. P. 2003. PD-L1 and PD-L2 are differentially regulated by Th1 and Th2 cells. 
Proceedings of the National Academy of Sciences of the United States of America, 100, 5336-
5341. 
LUKACS, G. L., HAGGIE, P., SEKSEK, O., LECHARDEUR, D., FREEDMAN, N. & VERKMAN, A. S. 2000. 
Size-dependent DNA mobility in cytoplasm and nucleus. J Biol Chem, 275, 1625-9. 
271 
 
LUO, D. & SALTZMAN, W. M. 2000. Synthetic DNA delivery systems. Nat Biotech, 18, 33-37. 
LUTZ, M. B. & SCHULER, G. 2002. Immature, semi-mature and fully mature dendritic cells: which 
signals induce tolerance or immunity? Trends Immunol, 23, 445-9. 
LUTZKY, J., ANTONIA, S. J., BLAKE-HASKINS, A., LI, X., ROBBINS, P. B., SHALABI, A. M., VASSELLI, J., 
IBRAHIM, R. A., KHLEIF, S. & SEGAL, N. H. A phase 1 study of MEDI4736, an anti-PD-L1 
antibody, in patients with advanced solid tumors.  ASCO Annual Meeting Proceedings, 2014. 
3001. 
M. L. DISIS, M. R. P., S. PANT, J. R. INFANTE, A. C. LOCKHART, K. KELLY, J. T. BECK, M. S. GORDON, G. 
J. WEISS, S. EJADI, M. H. TAYLOR, A. VON HEYDEBRECK, K. M. CHIN, J. CUILLEROT, J. L. 
GULLEY. June 2015. Avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with 
previously treated, recurrent or refractory ovarian cancer: A phase Ib, open-label expansion 
trial. [Online]. American Society of Clinical Oncology. Available: 
http://meetinglibrary.asco.org/content/147268-156. 
MAEDA, H. 2010. Tumor-selective delivery of macromolecular drugs via the EPR effect: background 
and future prospects. Bioconjug Chem, 21, 797-802. 
MAHATO, R. I., LEE, M., HAN, S., MAHESHWARI, A. & KIM, S. W. 2001. Intratumoral delivery of 
p2CMVmIL-12 using water-soluble lipopolymers. Mol Ther, 4, 130-8. 
MAHER, J., BRENTJENS, R. J., GUNSET, G., RIVIERE, I. & SADELAIN, M. 2002. Human T-lymphocyte 
cytotoxicity and proliferation directed by a single chimeric TCRzeta /CD28 receptor. Nat 
Biotechnol, 20, 70-5. 
MAINE, C. J., AZIZ, N. H., CHATTERJEE, J., HAYFORD, C., BREWIG, N., WHILDING, L., GEORGE, A. J. & 
GHAEM-MAGHAMI, S. 2014. Programmed death ligand-1 over-expression correlates with 
malignancy and contributes to immune regulation in ovarian cancer. Cancer Immunol 
Immunother, 63, 215-24. 
MALEK, A., MERKEL, O., FINK, L., CZUBAYKO, F., KISSEL, T. & AIGNER, A. 2009. In vivo 
pharmacokinetics, tissue distribution and underlying mechanisms of various PEI(-PEG)/siRNA 
complexes. Toxicol Appl Pharmacol, 236, 97-108. 
MALI, P., YANG, L., ESVELT, K. M., AACH, J., GUELL, M., DICARLO, J. E., NORVILLE, J. E. & CHURCH, G. 
M. 2013. RNA-guided human genome engineering via Cas9. Science, 339, 823-6. 
MANNISTO, M., RONKKO, S., MATTO, M., HONKAKOSKI, P., HYTTINEN, M., PELKONEN, J. & URTTI, A. 
2005. The role of cell cycle on polyplex-mediated gene transfer into a retinal pigment 
epithelial cell line. J Gene Med, 7, 466-76. 
MARROGI, A. J., MUNSHI, A., MEROGI, A. J., OHADIKE, Y., EL-HABASHI, A., MARROGI, O. L. & 
FREEMAN, S. M. 1997. Study of tumor infiltrating lymphocytes and transforming growth 
factor-beta as prognostic factors in breast carcinoma. Int J Cancer, 74, 492-501. 
MARTIN-OROZCO, N., MURANSKI, P., CHUNG, Y., YANG, X. O., YAMAZAKI, T., LU, S., HWU, P., 
RESTIFO, N. P., OVERWIJK, W. W. & DONG, C. 2009. T helper 17 cells promote cytotoxic T cell 
activation in tumor immunity. Immunity, 31, 787-98. 
MARTIN, M. E. & RICE, K. G. 2007. Peptide-guided gene delivery. Aaps j, 9, E18-29. 
MATSUE, H., ROTHBERG, K. G., TAKASHIMA, A., KAMEN, B. A., ANDERSON, R. G. & LACEY, S. W. 1992. 
Folate receptor allows cells to grow in low concentrations of 5-methyltetrahydrofolate. Proc 
Natl Acad Sci U S A, 89, 6006-9. 
MATSUMOTO, K., FUKUYAMA, S., EGUCHI-TSUDA, M., NAKANO, T., MATSUMOTO, T., MATSUMURA, 
M., MORIWAKI, A., KAN-O, K., WADA, Y., YAGITA, H., SHIN, T., PARDOLL, D. M., PATCHAREE, 
R., AZUMA, M., NAKANISHI, Y. & INOUE, H. 2008. B7-DC induced by IL-13 works as a 
feedback regulator in the effector phase of allergic asthma. Biochem Biophys Res Commun, 
365, 170-5. 
MATSUZAKI, J., GNJATIC, S., MHAWECH-FAUCEGLIA, P., BECK, A., MILLER, A., TSUJI, T., EPPOLITO, C., 
QIAN, F., LELE, S., SHRIKANT, P., OLD, L. J. & ODUNSI, K. 2010. Tumor-infiltrating NY-ESO-1-
specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer. 
Proc Natl Acad Sci U S A, 107, 7875-80. 
272 
 
MAYOR, S. & PAGANO, R. E. 2007. Pathways of clathrin-independent endocytosis. Nat Rev Mol Cell 
Biol, 8, 603-12. 
MAZANET, M. M. & HUGHES, C. C. 2002. B7-H1 is expressed by human endothelial cells and 
suppresses T cell cytokine synthesis. J Immunol, 169, 3581-8. 
MCANUFF, M. A., RETTIG, G. R. & RICE, K. G. 2007. Potency of siRNA versus shRNA mediated 
knockdown in vivo. J Pharm Sci, 96, 2922-30. 
MCKARNS, S. C., HANSCH, C., CALDWELL, W. S., MORGAN, W. T., MOORE, S. K. & DOOLITTLE, D. J. 
1997. Correlation between hydrophobicity of short-chain aliphatic alcohols and their ability 
to alter plasma membrane integrity. Fundam Appl Toxicol, 36, 62-70. 
MCKEEHAN, W. & HARDESTY, B. 1969. The mechanism of cycloheximide inhibition of protein 
synthesis in rabbit reticulocytes. Biochemical and Biophysical Research Communications, 36, 
625-630. 
MELLMAN, I., COUKOS, G. & DRANOFF, G. 2011. Cancer immunotherapy comes of age. Nature, 480, 
480-9. 
MELLMAN, I. & STEINMAN, R. M. 2001. Dendritic cells: specialized and regulated antigen processing 
machines. Cell, 106, 255-8. 
MENETRIER-CAUX, C., MONTMAIN, G., DIEU, M. C., BAIN, C., FAVROT, M. C., CAUX, C. & BLAY, J. Y. 
1998. Inhibition of the differentiation of dendritic cells from CD34(+) progenitors by tumor 
cells: role of interleukin-6 and macrophage colony-stimulating factor. Blood, 92, 4778-91. 
MERKEL, O. M., BEYERLE, A., BECKMANN, B. M., ZHENG, M., HARTMANN, R. K., STOGER, T. & KISSEL, 
T. H. 2011. Polymer-related off-target effects in non-viral siRNA delivery. Biomaterials, 32, 
2388-98. 
MERKEL, O. M., MINTZER, M. A., LIBRIZZI, D., SAMSONOVA, O., DICKE, T., SPROAT, B., GARN, H., 
BARTH, P. J., SIMANEK, E. E. & KISSEL, T. 2010. Triazine dendrimers as nonviral vectors for in 
vitro and in vivo RNAi: the effects of peripheral groups and core structure on biological 
activity. Mol Pharm, 7, 969-83. 
MERKEL, O. M., URBANICS, R., BEDOCS, P., ROZSNYAY, Z., ROSIVALL, L., TOTH, M., KISSEL, T. & 
SZEBENI, J. 2011. In vitro and in vivo complement activation and related anaphylactic effects 
associated with polyethylenimine and polyethylenimine-graft-poly(ethylene glycol) block 
copolymers. Biomaterials, 32, 4936-42. 
MERRITT, W. M., LIN, Y. G., HAN, L. Y., KAMAT, A. A., SPANNUTH, W. A., SCHMANDT, R., URBAUER, 
D., PENNACCHIO, L. A., CHENG, J.-F., NICK, A. M., DEAVERS, M. T., MOURAD-ZEIDAN, A., 
WANG, H., MUELLER, P., LENBURG, M. E., GRAY, J. W., MOK, S., BIRRER, M. J., LOPEZ-
BERESTEIN, G., COLEMAN, R. L., BAR-ELI, M. & SOOD, A. K. 2008. Dicer, Drosha, and 
Outcomes in Patients with Ovarian Cancer. New England Journal of Medicine, 359, 2641-
2650. 
MIDOUX, P. & MONSIGNY, M. 1999. Efficient gene transfer by histidylated polylysine/pDNA 
complexes. Bioconjug Chem, 10, 406-11. 
MILLER, A. M. & DEAN, D. A. 2008. Cell-specific nuclear import of plasmid DNA in smooth muscle 
requires tissue-specific transcription factors and DNA sequences. Gene Ther, 15, 1107-1115. 
MILLER, A. M. & DEAN, D. A. 2009. Tissue-specific and transcription factor-mediated nuclear entry of 
DNA. Adv Drug Deliv Rev, 61, 603-613. 
MINDEMARK, J. & BOWDEN, T. 2010. Efficient DNA Binding and Condensation Using Low Molecular 
Weight, Low Charge Density Cationic Polymer Amphiphiles. Macromolecular Rapid 
Communications, 31, 1378-1382. 
MITOMO, K., GRIESENBACH, U., INOUE, M., SOMERTON, L., MENG, C., AKIBA, E., TABATA, T., UEDA, 
Y., FRANKEL, G. M., FARLEY, R., SINGH, C., CHAN, M., MUNKONGE, F., BRUM, A., XENARIOU, 
S., ESCUDERO-GARCIA, S., HASEGAWA, M. & ALTON, E. W. 2010. Toward gene therapy for 
cystic fibrosis using a lentivirus pseudotyped with Sendai virus envelopes. Mol Ther, 18, 
1173-82. 
273 
 
MIYAHIRA, A. 2012. PBMC Basics [Online]. Sanguine Biosciences, Inc. Available: 
http://technical.sanguinebio.com/category/pbmc-basics/. 
MOGHIMI, S. M., HUNTER, A. C. & MURRAY, J. C. 2001. Long-Circulating and Target-Specific 
Nanoparticles: Theory to Practice. Pharmacological Reviews, 53, 283-318. 
MOGHIMI, S. M., SYMONDS, P., MURRAY, J. C., HUNTER, A. C., DEBSKA, G. & SZEWCZYK, A. 2005. A 
two-stage poly(ethylenimine)-mediated cytotoxicity: implications for gene transfer/therapy. 
Mol Ther, 11, 990-995. 
MOK, H., LEE, S. H., PARK, J. W. & PARK, T. G. 2010. Multimeric small interfering ribonucleic acid for 
highly efficient sequence-specific gene silencing. Nat Mater, 9, 272-278. 
MÖLLER-HACKBARTH, K., DEWITZ, C., SCHWEIGERT, O., TRAD, A., GARBERS, C., ROSE-JOHN, S. & 
SCHELLER, J. 2013. A Disintegrin and Metalloprotease (ADAM) 10 and ADAM17 Are Major 
Sheddases of T Cell Immunoglobulin and Mucin Domain 3 (Tim-3). Journal of Biological 
Chemistry, 288, 34529-34544. 
MORIKAWA, W., IKI, R., TERANO, T., FUNATSU, A., SUGIUCHI, H., UJI, Y. & OKABE, H. 1995. 
Comparison of monoclonal and polyclonal enzyme-linked immunoabsorbent (ELISA) assays 
for serum Lp(a) and differences in reactivities to Lp(a) phenotypes. J Clin Lab Anal, 9, 173-7. 
MOTULSKY, H. 1996. The GraphPad guide to nonlinear regression, in GraphPad Prism 
Software User Manual [Online]. San Diego: GraphPad Software Inc. 
MOTZ, G. T. & COUKOS, G. 2011. The parallel lives of angiogenesis and immunosuppression: cancer 
and other tales. Nat Rev Immunol, 11, 702-711. 
MOTZ, G. T., SANTORO, S. P., WANG, L.-P., GARRABRANT, T., LASTRA, R. R., HAGEMANN, I. S., LAL, P., 
FELDMAN, M. D., BENENCIA, F. & COUKOS, G. 2014. Tumor endothelium FasL establishes a 
selective immune barrier promoting tolerance in tumors. Nat Med, 20, 607-615. 
MUELLER, S. N., VANGURI, V. K., HA, S. J., WEST, E. E., KEIR, M. E., GLICKMAN, J. N., SHARPE, A. H. & 
AHMED, R. 2010. PD-L1 has distinct functions in hematopoietic and nonhematopoietic cells 
in regulating T cell responses during chronic infection in mice. J Clin Invest, 120, 2508-15. 
MUKHERJEE, S. 2010. The emperor of all maladies : a biography of cancer, New York, Scribner. 
MULLARD, A. 2013. New checkpoint inhibitors ride the immunotherapy tsunami. Nat Rev Drug 
Discov, 12, 489-492. 
MULLIGAN, R. C. 1993. The basic science of gene therapy. Science, 260, 926-32. 
MUNN, D. H., SHARMA, M. D. & MELLOR, A. L. 2004. Ligation of B7-1/B7-2 by human CD4+ T cells 
triggers indoleamine 2,3-dioxygenase activity in dendritic cells. J Immunol, 172, 4100-10. 
MUNN, D. H., ZHOU, M., ATTWOOD, J. T., BONDAREV, I., CONWAY, S. J., MARSHALL, B., BROWN, C. 
& MELLOR, A. L. 1998. Prevention of allogeneic fetal rejection by tryptophan catabolism. 
Science, 281, 1191-3. 
NAGARAJ, S. & GABRILOVICH, D. I. 2008. Tumor escape mechanism governed by myeloid-derived 
suppressor cells. Cancer Res, 68, 2561-3. 
NAITO, Y., SAITO, K., SHIIBA, K., OHUCHI, A., SAIGENJI, K., NAGURA, H. & OHTANI, H. 1998. CD8+ T 
cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. 
Cancer Res, 58, 3491-4. 
NAKANO, O., SATO, M., NAITO, Y., SUZUKI, K., ORIKASA, S., AIZAWA, M., SUZUKI, Y., SHINTAKU, I., 
NAGURA, H. & OHTANI, H. 2001. Proliferative activity of intratumoral CD8(+) T-lymphocytes 
as a prognostic factor in human renal cell carcinoma: clinicopathologic demonstration of 
antitumor immunity. Cancer Res, 61, 5132-6. 
NEAMNARK, A., SUWANTONG, O., K. C, R. B., HSU, C. Y. M., SUPAPHOL, P. & ULUDAĞ, H. 2009. 
Aliphatic Lipid Substitution on 2 kDa Polyethylenimine Improves Plasmid Delivery and 
Transgene Expression. Molecular Pharmaceutics, 6, 1798-1815. 
NEDERBERG, F., LOHMEIJER, B. G. G., LEIBFARTH, F., PRATT, R. C., CHOI, J., DOVE, A. P., WAYMOUTH, 
R. M. & HEDRICK, J. L. 2007. Organocatalytic Ring Opening Polymerization of Trimethylene 
Carbonate. Biomacromolecules, 8, 153-160. 
274 
 
NEGUS, R. P., STAMP, G. W., HADLEY, J. & BALKWILL, F. R. 1997. Quantitative assessment of the 
leukocyte infiltrate in ovarian cancer and its relationship to the expression of C-C 
chemokines. Am J Pathol, 150, 1723-34. 
NEL, A. E., MADLER, L., VELEGOL, D., XIA, T., HOEK, E. M. V., SOMASUNDARAN, P., KLAESSIG, F., 
CASTRANOVA, V. & THOMPSON, M. 2009. Understanding biophysicochemical interactions at 
the nano-bio interface. Nat Mater, 8, 543-557. 
NETWORK, T. C. G. A. R. 2011. Integrated genomic analyses of ovarian carcinoma. Nature, 474, 609-
615. 
NEU, M., FISCHER, D. & KISSEL, T. 2005. Recent advances in rational gene transfer vector design 
based on poly(ethylene imine) and its derivatives. J Gene Med, 7, 992-1009. 
NICHOLAS, K. J., ZERN, E. K., BARNETT, L., SMITH, R. M., LOREY, S. L., COPELAND, C. A., SADAGOPAL, 
S. & KALAMS, S. A. 2013. B cell responses to HIV antigen are a potent correlate of viremia in 
HIV-1 infection and improve with PD-1 blockade. PLoS One, 8, e84185. 
NIELSEN, C., OHM-LAURSEN, L., BARINGTON, T., HUSBY, S. & LILLEVANG, S. T. 2005. Alternative 
splice variants of the human PD-1 gene. Cellular Immunology, 235, 109-116. 
NISHIMURA, H., AGATA, Y., KAWASAKI, A., SATO, M., IMAMURA, S., MINATO, N., YAGITA, H., 
NAKANO, T. & HONJO, T. 1996. Developmentally regulated expression of the PD-1 protein 
on the surface of double-negative (CD4-CD8-) thymocytes. Int Immunol, 8, 773-80. 
NISHIMURA, H., NOSE, M., HIAI, H., MINATO, N. & HONJO, T. 1999. Development of lupus-like 
autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying 
immunoreceptor. Immunity, 11, 141-51. 
NISHIMURA, T., IWAKABE, K., SEKIMOTO, M., OHMI, Y., YAHATA, T., NAKUI, M., SATO, T., HABU, S., 
TASHIRO, H., SATO, M. & OHTA, A. 1999. Distinct role of antigen-specific T helper type 1 
(Th1) and Th2 cells in tumor eradication in vivo. J Exp Med, 190, 617-27. 
NURIEVA, R., THOMAS, S., NGUYEN, T., MARTIN-OROZCO, N., WANG, Y., KAJA, M. K., YU, X. Z. & 
DONG, C. 2006. T-cell tolerance or function is determined by combinatorial costimulatory 
signals. Embo j, 25, 2623-33. 
O'SHEA, J. J., GADINA, M. & SCHREIBER, R. D. 2002. Cytokine Signaling in 2002: New Surprises in the 
Jak/Stat Pathway. Cell, 109, S121-S131. 
OBA, M., AOYAGI, K., MIYATA, K., MATSUMOTO, Y., ITAKA, K., NISHIYAMA, N., YAMASAKI, Y., 
KOYAMA, H. & KATAOKA, K. 2008. Polyplex micelles with cyclic RGD peptide ligands and 
disulfide cross-links directing to the enhanced transfection via controlled intracellular 
trafficking. Mol Pharm, 5, 1080-92. 
OCANA, A., VERA-BADILLO, F., SERUGA, B., TEMPLETON, A., PANDIELLA, A. & AMIR, E. 2013. HER3 
overexpression and survival in solid tumors: a meta-analysis. J Natl Cancer Inst, 105, 266-73. 
ODUNSI, K., MATSUZAKI, J., JAMES, S. R., MHAWECH-FAUCEGLIA, P., TSUJI, T., MILLER, A., ZHANG, 
W., AKERS, S. N., GRIFFITHS, E. A., MILIOTTO, A., BECK, A., BATT, C. A., RITTER, G., LELE, S., 
GNJATIC, S. & KARPF, A. R. 2014. Epigenetic potentiation of NY-ESO-1 vaccine therapy in 
human ovarian cancer. Cancer Immunol Res, 2, 37-49. 
ODUNSI, K., QIAN, F., MATSUZAKI, J., MHAWECH-FAUCEGLIA, P., ANDREWS, C., HOFFMAN, E. W., 
PAN, L., RITTER, G., VILLELLA, J., THOMAS, B., RODABAUGH, K., LELE, S., SHRIKANT, P., OLD, 
L. J. & GNJATIC, S. 2007. Vaccination with an NY-ESO-1 peptide of HLA class I/II specificities 
induces integrated humoral and T cell responses in ovarian cancer. Proceedings of the 
National Academy of Sciences of the United States of America, 104, 12837-12842. 
OGRIS, M., BRUNNER, S., SCHULLER, S., KIRCHEIS, R. & WAGNER, E. 1999. PEGylated 
DNA/transferrin-PEI complexes: reduced interaction with blood components, extended 
circulation in blood and potential for systemic gene delivery. Gene Ther, 6, 595-605. 
OH, P., BORGSTROM, P., WITKIEWICZ, H., LI, Y., BORGSTROM, B. J., CHRASTINA, A., IWATA, K., ZINN, 
K. R., BALDWIN, R., TESTA, J. E. & SCHNITZER, J. E. 2007. Live dynamic imaging of caveolae 
pumping targeted antibody rapidly and specifically across endothelium in the lung. Nat 
Biotech, 25, 327-337. 
275 
 
ONG, Z. Y., FUKUSHIMA, K., COADY, D. J., YANG, Y.-Y., EE, P. L. R. & HEDRICK, J. L. 2011. Rational 
design of biodegradable cationic polycarbonates for gene delivery. Journal of Controlled 
Release, 152, 120-126. 
OSADA, K., CHRISTIE, R. J. & KATAOKA, K. 2009. Polymeric micelles from poly(ethylene glycol)–
poly(amino acid) block copolymer for drug and gene delivery. Journal of The Royal Society 
Interface, 6, S325-S339. 
OTA, T., SUZUKI, Y., NISHIKAWA, T., OTSUKI, T., SUGIYAMA, T., IRIE, R., WAKAMATSU, A., HAYASHI, 
K., SATO, H., NAGAI, K., KIMURA, K., MAKITA, H., SEKINE, M., OBAYASHI, M., NISHI, T., 
SHIBAHARA, T., TANAKA, T., ISHII, S., YAMAMOTO, J.-I., SAITO, K., KAWAI, Y., ISONO, Y., 
NAKAMURA, Y., NAGAHARI, K., MURAKAMI, K., YASUDA, T., IWAYANAGI, T., WAGATSUMA, 
M., SHIRATORI, A., SUDO, H., HOSOIRI, T., KAKU, Y., KODAIRA, H., KONDO, H., SUGAWARA, 
M., TAKAHASHI, M., KANDA, K., YOKOI, T., FURUYA, T., KIKKAWA, E., OMURA, Y., ABE, K., 
KAMIHARA, K., KATSUTA, N., SATO, K., TANIKAWA, M., YAMAZAKI, M., NINOMIYA, K., 
ISHIBASHI, T., YAMASHITA, H., MURAKAWA, K., FUJIMORI, K., TANAI, H., KIMATA, M., 
WATANABE, M., HIRAOKA, S., CHIBA, Y., ISHIDA, S., ONO, Y., TAKIGUCHI, S., WATANABE, S., 
YOSIDA, M., HOTUTA, T., KUSANO, J., KANEHORI, K., TAKAHASHI-FUJII, A., HARA, H., TANASE, 
T.-O., NOMURA, Y., TOGIYA, S., KOMAI, F., HARA, R., TAKEUCHI, K., ARITA, M., IMOSE, N., 
MUSASHINO, K., YUUKI, H., OSHIMA, A., SASAKI, N., AOTSUKA, S., YOSHIKAWA, Y., 
MATSUNAWA, H., ICHIHARA, T., SHIOHATA, N., SANO, S., MORIYA, S., MOMIYAMA, H., 
SATOH, N., TAKAMI, S., TERASHIMA, Y., SUZUKI, O., NAKAGAWA, S., SENOH, A., MIZOGUCHI, 
H., GOTO, Y., SHIMIZU, F., WAKEBE, H., HISHIGAKI, H., WATANABE, T., SUGIYAMA, A., et al. 
2004. Complete sequencing and characterization of 21,243 full-length human cDNAs. Nat 
Genet, 36, 40-45. 
OTT, P. A., HODI, F. S. & ROBERT, C. 2013. CTLA-4 and PD-1/PD-L1 blockade: new 
immunotherapeutic modalities with durable clinical benefit in melanoma patients. Clin 
Cancer Res, 19, 5300-9. 
OWADA, T., WATANABE, N., OKI, M., OYA, Y., SAITO, Y., SAITO, T., IWAMOTO, I., MURPHY, T. L., 
MURPHY, K. M. & NAKAJIMA, H. 2010. Activation-induced accumulation of B and T 
lymphocyte attenuator at the immunological synapse in CD4+ T cells. J Leukoc Biol, 87, 425-
32. 
OZPOLAT, B., SOOD, A. K. & LOPEZ-BERESTEIN, G. 2014. Liposomal siRNA nanocarriers for cancer 
therapy. Adv Drug Deliv Rev, 66, 110-6. 
PAATERO, I., LASSUS, H., JUNTTILA, T. T., KASKINEN, M., BUTZOW, R. & ELENIUS, K. 2013. CYT-1 
isoform of ErbB4 is an independent prognostic factor in serous ovarian cancer and 
selectively promotes ovarian cancer cell growth in vitro. Gynecol Oncol, 129, 179-87. 
PACK, D. W., HOFFMAN, A. S., PUN, S. & STAYTON, P. S. 2005. Design and development of polymers 
for gene delivery. Nat Rev Drug Discov, 4, 581-593. 
PADDISON, P. J., CAUDY, A. A., BERNSTEIN, E., HANNON, G. J. & CONKLIN, D. S. 2002. Short hairpin 
RNAs (shRNAs) induce sequence-specific silencing in mammalian cells. Genes Dev, 16, 948-
58. 
PARDOLL, D. M. 2012. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev 
Cancer, 12, 252-64. 
PARENTE-PEREIRA, A. C., WHILDING, L. M., BREWIG, N., VAN DER STEGEN, S. J., DAVIES, D. M., 
WILKIE, S., VAN SCHALKWYK, M. C., GHAEM-MAGHAMI, S. & MAHER, J. 2013. Synergistic 
Chemoimmunotherapy of Epithelial Ovarian Cancer Using ErbB-Retargeted T Cells Combined 
with Carboplatin. J Immunol, 191, 2437-45. 
PARK, K. 2010. To PEGylate or not to PEGylate, that is not the question. Journal of Controlled 
Release, 142, 147-148. 
PARK, T. G., JEONG, J. H. & KIM, S. W. 2006. Current status of polymeric gene delivery systems. Adv 
Drug Deliv Rev, 58, 467-86. 
276 
 
PARRY, R. V., CHEMNITZ, J. M., FRAUWIRTH, K. A., LANFRANCO, A. R., BRAUNSTEIN, I., KOBAYASHI, S. 
V., LINSLEY, P. S., THOMPSON, C. B. & RILEY, J. L. 2005. CTLA-4 and PD-1 receptors inhibit T-
cell activation by distinct mechanisms. Mol Cell Biol, 25, 9543-53. 
PARSA, A. T., WALDRON, J. S., PANNER, A., CRANE, C. A., PARNEY, I. F., BARRY, J. J., CACHOLA, K. E., 
MURRAY, J. C., TIHAN, T., JENSEN, M. C., MISCHEL, P. S., STOKOE, D. & PIEPER, R. O. 2007. 
Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance 
in glioma. Nat Med, 13, 84-8. 
PARTON, R. G. & SIMONS, K. 2007. The multiple faces of caveolae. Nat Rev Mol Cell Biol, 8, 185-94. 
PATHAK, A., KUMAR, P., CHUTTANI, K., JAIN, S., MISHRA, A. K., VYAS, S. P. & GUPTA, K. C. 2009. Gene 
expression, biodistribution, and pharmacoscintigraphic evaluation of chondroitin sulfate-PEI 
nanoconstructs mediated tumor gene therapy. ACS Nano, 3, 1493-505. 
PATSNER, B. & DAY JR, T. G. 1987. Predictive value of CA-125 levels in advanced ovarian cancer. 
American Journal of Obstetrics and Gynecology, 156, 440-441. 
PATSOUKIS, N., BROWN, J., PETKOVA, V., LIU, F., LI, L. & BOUSSIOTIS, V. A. 2012. Selective effects of 
PD-1 on Akt and Ras pathways regulate molecular components of the cell cycle and inhibit T 
cell proliferation. Sci Signal, 5, ra46. 
PATSOUKIS, N., SARI, D. & BOUSSIOTIS, V. A. 2012. PD-1 inhibits T cell proliferation by upregulating 
p27 and p15 and suppressing Cdc25A. Cell Cycle, 11, 4305-9. 
PAULOS, C. M., REDDY, J. A., LEAMON, C. P., TURK, M. J. & LOW, P. S. 2004. Ligand Binding and 
Kinetics of Folate Receptor Recycling in Vivo: Impact on Receptor-Mediated Drug Delivery. 
Molecular Pharmacology, 66, 1406-1414. 
PENTCHEVA-HOANG, T., CHEN, L., PARDOLL, D. M. & ALLISON, J. P. 2007. Programmed death-1 
concentration at the immunological synapse is determined by ligand affinity and availability. 
Proc Natl Acad Sci U S A, 104, 17765-70. 
PEOPLES, G. E., ANDERSON, B. W., FISK, B., KUDELKA, A. P., WHARTON, J. T. & IOANNIDES, C. G. 
1998. Ovarian cancer-associated lymphocyte recognition of folate binding protein peptides. 
Ann Surg Oncol, 5, 743-50. 
PEOPLES, G. E., GOEDEGEBUURE, P. S., SMITH, R., LINEHAN, D. C., YOSHINO, I. & EBERLEIN, T. J. 
1995. Breast and ovarian cancer-specific cytotoxic T lymphocytes recognize the same 
HER2/neu-derived peptide. Proc Natl Acad Sci U S A, 92, 432-6. 
PEOPLES, G. E., SCHOOF, D. D., ANDREWS, J. V., GOEDEGEBUURE, P. S. & EBERLEIN, T. J. 1993. T-cell 
recognition of ovarian cancer. Surgery, 114, 227-34. 
PETROFF, M. G., CHEN, L., PHILLIPS, T. A. & HUNT, J. S. 2002. B7 family molecules: novel 
immunomodulators at the maternal-fetal interface. Placenta, 23 Suppl A, S95-101. 
PHAN, G. Q., YANG, J. C., SHERRY, R. M., HWU, P., TOPALIAN, S. L., SCHWARTZENTRUBER, D. J., 
RESTIFO, N. P., HAWORTH, L. R., SEIPP, C. A., FREEZER, L. J., MORTON, K. E., MAVROUKAKIS, 
S. A., DURAY, P. H., STEINBERG, S. M., ALLISON, J. P., DAVIS, T. A. & ROSENBERG, S. A. 2003. 
Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 
4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci U S A, 100, 8372-7. 
PICHON, C., BILLIET, L. & MIDOUX, P. 2010. Chemical vectors for gene delivery: uptake and 
intracellular trafficking. Curr Opin Biotechnol, 21, 640-5. 
PINKOSKI, M. J., WATERHOUSE, N. J., HEIBEIN, J. A., WOLF, B. B., KUWANA, T., GOLDSTEIN, J. C., 
NEWMEYER, D. D., BLEACKLEY, R. C. & GREEN, D. R. 2001. Granzyme B-mediated Apoptosis 
Proceeds Predominantly through a Bcl-2-inhibitable Mitochondrial Pathway. Journal of 
Biological Chemistry, 276, 12060-12067. 
PLANK, C., OBERHAUSER, B., MECHTLER, K., KOCH, C. & WAGNER, E. 1994. The influence of 
endosome-disruptive peptides on gene transfer using synthetic virus-like gene transfer 
systems. J Biol Chem, 269, 12918-24. 
POON, Z., CHEN, S., ENGLER, A. C., LEE, H.-I., ATAS, E., VON MALTZAHN, G., BHATIA, S. N. & 
HAMMOND, P. T. 2010. Ligand-Clustered “Patchy” Nanoparticles for Modulated Cellular 
277 
 
Uptake and In Vivo Tumor Targeting. Angewandte Chemie International Edition, 49, 7266-
7270. 
PORICHIS, F., KWON, D. S., ZUPKOSKY, J., TIGHE, D. P., MCMULLEN, A., BROCKMAN, M. A., PAVLIK, D. 
F., RODRIGUEZ-GARCIA, M., PEREYRA, F., FREEMAN, G. J., KAVANAGH, D. G. & KAUFMANN, 
D. E. 2011. Responsiveness of HIV-specific CD4 T cells to PD-1 blockade. Blood, 118, 965-74. 
PRASAD, D. V., RICHARDS, S., MAI, X. M. & DONG, C. 2003. B7S1, a novel B7 family member that 
negatively regulates T cell activation. Immunity, 18, 863-73. 
PRATT, R. C., NEDERBERG, F., WAYMOUTH, R. M. & HEDRICK, J. L. 2008. Tagging alcohols with cyclic 
carbonate: a versatile equivalent of (meth)acrylate for ring-opening polymerization. 
Chemical Communications, 114-116. 
PRICE, C. P. & NEWMAN, D. J. 1997. Principles and Practice of Immunoassay, Macmillan Reference 
Limited. 
PUCADYIL, T. J. & SCHMID, S. L. 2009. Conserved Functions of Membrane Active GTPases in Coated 
Vesicle Formation. Science (New York, N.Y.), 325, 1217-1220. 
PUTNAM, D., GENTRY, C. A., PACK, D. W. & LANGER, R. 2001. Polymer-based gene delivery with low 
cytotoxicity by a unique balance of side-chain termini. Proceedings of the National Academy 
of Sciences, 98, 1200-1205. 
QUEZADA, S. A. & PEGGS, K. S. 2013. Exploiting CTLA-4, PD-1 and PD-L1 to reactivate the host 
immune response against cancer. Br J Cancer, 108, 1560-5. 
QUEZADA, S. A., SIMPSON, T. R., PEGGS, K. S., MERGHOUB, T., VIDER, J., FAN, X., BLASBERG, R., 
YAGITA, H., MURANSKI, P., ANTONY, P. A., RESTIFO, N. P. & ALLISON, J. P. 2010. Tumor-
reactive CD4(+) T cells develop cytotoxic activity and eradicate large established melanoma 
after transfer into lymphopenic hosts. J Exp Med, 207, 637-50. 
RAINOV, N. G. 2000. A phase III clinical evaluation of herpes simplex virus type 1 thymidine kinase 
and ganciclovir gene therapy as an adjuvant to surgical resection and radiation in adults with 
previously untreated glioblastoma multiforme. Hum Gene Ther, 11, 2389-401. 
RAMAKRISHNAN, S., SUBRAMANIAN, I. V., YOKOYAMA, Y. & GELLER, M. 2005. Angiogenesis in 
normal and neoplastic ovaries. Angiogenesis, 8, 169-82. 
RAMAKRISHNAN, S., XU, F. J., BRANDT, S. J., NIEDEL, J. E., BAST, R. C., JR. & BROWN, E. L. 1989. 
Constitutive production of macrophage colony-stimulating factor by human ovarian and 
breast cancer cell lines. J Clin Invest, 83, 921-6. 
RAO, D. D., SENZER, N., CLEARY, M. A. & NEMUNAITIS, J. 2009. Comparative assessment of siRNA 
and shRNA off target effects: what is slowing clinical development. Cancer Gene Ther, 16, 
807-9. 
RAPER, S. E., CHIRMULE, N., LEE, F. S., WIVEL, N. A., BAGG, A., GAO, G. P., WILSON, J. M. & 
BATSHAW, M. L. 2003. Fatal systemic inflammatory response syndrome in a ornithine 
transcarbamylase deficient patient following adenoviral gene transfer. Mol Genet Metab, 80, 
148-58. 
RAPOSO, G. & STOORVOGEL, W. 2013. Extracellular vesicles: Exosomes, microvesicles, and friends. 
The Journal of Cell Biology, 200, 373-383. 
RAPPOPORT, J. Z. 2008. Focusing on clathrin-mediated endocytosis. Biochem J, 412, 415-23. 
REINARTZ, S., KOHLER, S., SCHLEBUSCH, H., KRISTA, K., GIFFELS, P., RENKE, K., HUOBER, J., MOBUS, 
V., KREIENBERG, R., DUBOIS, A., SABBATINI, P. & WAGNER, U. 2004. Vaccination of patients 
with advanced ovarian carcinoma with the anti-idiotype ACA125: immunological response 
and survival (phase Ib/II). Clin Cancer Res, 10, 1580-7. 
REJMAN, J., BRAGONZI, A. & CONESE, M. 2005. Role of clathrin- and caveolae-mediated endocytosis 
in gene transfer mediated by lipo- and polyplexes. Mol Ther, 12, 468-74. 
REJMAN, J., CONESE, M. & HOEKSTRA, D. 2006. Gene transfer by means of lipo- and polyplexes: role 
of clathrin and caveolae-mediated endocytosis. J Liposome Res, 16, 237-47. 
278 
 
REJMAN, J., OBERLE, V., ZUHORN, I. S. & HOEKSTRA, D. 2004. Size-dependent internalization of 
particles via the pathways of clathrin- and caveolae-mediated endocytosis. Biochem J, 377, 
159-69. 
RESEARCH, A. A. O. C. 2015. Nivolumab Approved for Lung Cancer. Cancer Discovery. 
RIBAS, A. 2012. Tumor immunotherapy directed at PD-1. N Engl J Med, 366, 2517-9. 
RIBBECK, K. & GÖRLICH, D. 2002. The permeability barrier of nuclear pore complexes appears to 
operate via hydrophobic exclusion. The EMBO Journal, 21, 2664-2671. 
RIJNBOUTT, S., JANSEN, G., POSTHUMA, G., HYNES, J. B., SCHORNAGEL, J. H. & STROUS, G. J. 1996. 
Endocytosis of GPI-linked membrane folate receptor-alpha. J Cell Biol, 132, 35-47. 
RILEY, J. L. 2009. PD-1 signaling in primary T cells. Immunol Rev, 229, 114-25. 
RITTER, C. A., PEREZ-TORRES, M., RINEHART, C., GUIX, M., DUGGER, T., ENGELMAN, J. A. & ARTEAGA, 
C. L. 2007. Human breast cancer cells selected for resistance to trastuzumab in vivo 
overexpress epidermal growth factor receptor and ErbB ligands and remain dependent on 
the ErbB receptor network. Clin Cancer Res, 13, 4909-19. 
RIVIERE, I., WANG, X., BARTIDO, S., STEFANSKI, J., HE, Q., BORQUEZ-OJEDA, O., TAYLOR, C., 
WASIELEWSKA, T., QU, J., BOUHASSIRA, D. C. G., BERNAL, Y. J., YOO, S., PURDON, T., 
HALTON, E., QUINTANILLA, H., PARK, J. H., CURRAN, K. J., SADELAIN, M. & BRENTJENS, R. J. 
2013. Safe and Effective Re-Induction Of Complete Remissions In Adults With Relapsed B-ALL 
Using 19-28z CAR CD19-Targeted T Cell Therapy. Blood, 122, 69-69. 
ROBBINS, P. F., LU, Y. C., EL-GAMIL, M., LI, Y. F., GROSS, C., GARTNER, J., LIN, J. C., TEER, J. K., 
CLIFTEN, P., TYCKSEN, E., SAMUELS, Y. & ROSENBERG, S. A. 2013. Mining exomic sequencing 
data to identify mutated antigens recognized by adoptively transferred tumor-reactive T 
cells. Nat Med, 19, 747-52. 
ROBERT, C., RIBAS, A., WOLCHOK, J. D., HODI, F. S., HAMID, O., KEFFORD, R., WEBER, J. S., JOSHUA, 
A. M., HWU, W. J., GANGADHAR, T. C., PATNAIK, A., DRONCA, R., ZAROUR, H., JOSEPH, R. W., 
BOASBERG, P., CHMIELOWSKI, B., MATEUS, C., POSTOW, M. A., GERGICH, K., ELASSAISS-
SCHAAP, J., LI, X. N., IANNONE, R., EBBINGHAUS, S. W., KANG, S. P. & DAUD, A. 2014. Anti-
programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory 
advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet, 384, 
1109-17. 
ROGUIN, L. P. & RETEGUI, L. A. 2003. Monoclonal Antibodies Inducing Conformational Changes on 
the Antigen Molecule. Scandinavian Journal of Immunology, 58, 387-394. 
ROMEO, C., AMIOT, M. & SEED, B. 1992. Sequence requirements for induction of cytolysis by the T 
cell antigen/Fc receptor zeta chain. Cell, 68, 889-97. 
ROMEO, C. & SEED, B. 1991. Cellular immunity to HIV activated by CD4 fused to T cell or Fc receptor 
polypeptides. Cell, 64, 1037-46. 
RONCAROLO, M. G., LEVINGS, M. K. & TRAVERSARI, C. 2001. Differentiation of T regulatory cells by 
immature dendritic cells. J Exp Med, 193, F5-9. 
ROSENWALD, A., WRIGHT, G., LEROY, K., YU, X., GAULARD, P., GASCOYNE, R. D., CHAN, W. C., ZHAO, 
T., HAIOUN, C., GREINER, T. C., WEISENBURGER, D. D., LYNCH, J. C., VOSE, J., ARMITAGE, J. 
O., SMELAND, E. B., KVALOY, S., HOLTE, H., DELABIE, J., CAMPO, E., MONTSERRAT, E., LOPEZ-
GUILLERMO, A., OTT, G., MULLER-HERMELINK, H. K., CONNORS, J. M., BRAZIEL, R., GROGAN, 
T. M., FISHER, R. I., MILLER, T. P., LEBLANC, M., CHIORAZZI, M., ZHAO, H., YANG, L., POWELL, 
J., WILSON, W. H., JAFFE, E. S., SIMON, R., KLAUSNER, R. D. & STAUDT, L. M. 2003. Molecular 
diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of 
diffuse large B cell lymphoma related to Hodgkin lymphoma. J Exp Med, 198, 851-62. 
ROSSI, S., LAURINO, L., FURLANETTO, A., CHINELLATO, S., ORVIETO, E., CANAL, F., FACCHETTI, F. & 
DEI TOS, A. P. 2005. Rabbit monoclonal antibodies: a comparative study between a novel 
category of immunoreagents and the corresponding mouse monoclonal antibodies. Am J 
Clin Pathol, 124, 295-302. 
279 
 
ROSSILLE, D., GRESSIER, M., DAMOTTE, D., MAUCORT-BOULCH, D., PANGAULT, C., SEMANA, G., LE 
GOUILL, S., HAIOUN, C., TARTE, K., LAMY, T., MILPIED, N. & FEST, T. 2014. High level of 
soluble programmed cell death ligand 1 in blood impacts overall survival in aggressive 
diffuse large B-Cell lymphoma: results from a French multicenter clinical trial. Leukemia, 28, 
2367-75. 
ROSSILLE, D., GRESSIER, M., MAUCORT-BOULCH, D., DAMOTTE, D., PANGAULT, C., LE GOUILL, S., 
TARTE, K., LAMY, T. & MILPIED, N. 2013. Blood Soluble PD-L1 Protein In Aggressive Diffuse 
Large B-Cell Lymphoma Impacts patient’s Overall Survival. Blood, 122, 361-361. 
ROTHBERG, K. G., YING, Y. S., KOLHOUSE, J. F., KAMEN, B. A. & ANDERSON, R. G. 1990. The 
glycophospholipid-linked folate receptor internalizes folate without entering the clathrin-
coated pit endocytic pathway. J Cell Biol, 110, 637-49. 
ROUT, M. P. & WENTE, S. R. 1994. Pores for thought: nuclear pore complex proteins. Trends Cell Biol, 
4, 357-65. 
RUDD, C. E., TAYLOR, A. & SCHNEIDER, H. 2009. CD28 and CTLA-4 coreceptor expression and signal 
transduction. Immunol Rev, 229, 12-26. 
RYE, H. S., YUE, S., WEMMER, D. E., QUESADA, M. A., HAUGLAND, R. P., MATHIES, R. A. & GLAZER, A. 
N. 1992. Stable fluorescent complexes of double-stranded DNA with bis-intercalating 
asymmetric cyanine dyes: properties and applications. Nucleic Acids Research, 20, 2803-
2812. 
SADELAIN, M. 2009. T-cell engineering for cancer immunotherapy. Cancer J, 15, 451-5. 
SADELAIN, M., BRENTJENS, R. & RIVIERE, I. 2009. The promise and potential pitfalls of chimeric 
antigen receptors. Curr Opin Immunol, 21, 215-23. 
SADELAIN, M., BRENTJENS, R. & RIVIÈRE, I. 2013. The Basic Principles of Chimeric Antigen Receptor 
Design. Cancer Discovery, 3, 388-398. 
SAHAY, G., ALAKHOVA, D. Y. & KABANOV, A. V. 2010. Endocytosis of nanomedicines. J Control 
Release, 145, 182-95. 
SAHAY, G., BATRAKOVA, E. V. & KABANOV, A. V. 2008. Different internalization pathways of 
polymeric micelles and unimers and their effects on vesicular transport. Bioconjug Chem, 19, 
2023-9. 
SAHAY, G., KIM, J. O., KABANOV, A. V. & BRONICH, T. K. 2010. The exploitation of differential 
endocytic pathways in normal and tumor cells in the selective targeting of nanoparticulate 
chemotherapeutic agents. Biomaterials, 31, 923-33. 
SAKAGUCHI, S., SAKAGUCHI, N., SHIMIZU, J., YAMAZAKI, S., SAKIHAMA, T., ITOH, M., KUNIYASU, Y., 
NOMURA, T., TODA, M. & TAKAHASHI, T. 2001. Immunologic tolerance maintained by CD25+ 
CD4+ regulatory T cells: their common role in controlling autoimmunity, tumor immunity, 
and transplantation tolerance. Immunol Rev, 182, 18-32. 
SANDERS, D. P., FUKUSHIMA, K., COADY, D. J., NELSON, A., FUJIWARA, M., YASUMOTO, M. & 
HEDRICK, J. L. 2010. A Simple and Efficient Synthesis of Functionalized Cyclic Carbonate 
Monomers Using a Versatile Pentafluorophenyl Ester Intermediate. Journal of the American 
Chemical Society, 132, 14724-14726. 
SANTIN, A. D., BELLONE, S., RAVAGGI, A., PECORELLI, S., CANNON, M. J. & PARHAM, G. P. 2000. 
Induction of ovarian tumor-specific CD8+ cytotoxic T lymphocytes by acid-eluted peptide-
pulsed autologous dendritic cells. Obstet Gynecol, 96, 422-30. 
SANTIN, A. D., HERMONAT, P. L., RAVAGGI, A., BELLONE, S., ROMAN, J. J., SMITH, C. V., PECORELLI, 
S., RADOMINSKA-PANDYA, A., CANNON, M. J. & PARHAM, G. P. 2001. Phenotypic and 
functional analysis of tumor-infiltrating lymphocytes compared with tumor-associated 
lymphocytes from ascitic fluid and peripheral blood lymphocytes in patients with advanced 
ovarian cancer. Gynecol Obstet Invest, 51, 254-61. 
SATO, E., OLSON, S. H., AHN, J., BUNDY, B., NISHIKAWA, H., QIAN, F., JUNGBLUTH, A. A., FROSINA, D., 
GNJATIC, S., AMBROSONE, C., KEPNER, J., ODUNSI, T., RITTER, G., LELE, S., CHEN, Y. T., 
OHTANI, H., OLD, L. J. & ODUNSI, K. 2005. Intraepithelial CD8+ tumor-infiltrating 
280 
 
lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis 
in ovarian cancer. Proc Natl Acad Sci U S A, 102, 18538-43. 
SAUDEMONT, A., JOUY, N., HETUIN, D. & QUESNEL, B. 2005. NK cells that are activated by CXCL10 
can kill dormant tumor cells that resist CTL-mediated lysis and can express B7-H1 that 
stimulates T cells. Blood, 105, 2428-35. 
SAVOLDO, B., RAMOS, C. A., LIU, E., MIMS, M. P., KEATING, M. J., CARRUM, G., KAMBLE, R. T., 
BOLLARD, C. M., GEE, A. P., MEI, Z., LIU, H., GRILLEY, B., ROONEY, C. M., HESLOP, H. E., 
BRENNER, M. K. & DOTTI, G. 2011. CD28 costimulation improves expansion and persistence 
of chimeric antigen receptor-modified T cells in lymphoma patients. J Clin Invest, 121, 1822-
6. 
SCHLEE, M., HOLZEL, M., BERNARD, S., MAILHAMMER, R., SCHUHMACHER, M., RESCHKE, J., EICK, D., 
MARINKOVIC, D., WIRTH, T., ROSENWALD, A., STAUDT, L. M., EILERS, M., BARAN-MARSZAK, 
F., FAGARD, R., FEUILLARD, J., LAUX, G. & BORNKAMM, G. W. 2007. C-myc activation impairs 
the NF-kappaB and the interferon response: implications for the pathogenesis of Burkitt's 
lymphoma. Int J Cancer, 120, 1387-95. 
SCHLIENGER, K., CHU, C. S., WOO, E. Y., RIVERS, P. M., TOLL, A. J., HUDSON, B., MAUS, M. V., RILEY, J. 
L., CHOI, Y., COUKOS, G., KAISER, L. R., RUBIN, S. C., LEVINE, B. L., CARROLL, R. G. & JUNE, C. 
H. 2003. TRANCE- and CD40 ligand-matured dendritic cells reveal MHC class I-restricted T 
cells specific for autologous tumor in late-stage ovarian cancer patients. Clin Cancer Res, 9, 
1517-27. 
SCHOLZ, C. & WAGNER, E. 2012. Therapeutic plasmid DNA versus siRNA delivery: Common and 
different tasks for synthetic carriers. Journal of Controlled Release, 161, 554-565. 
SCHREIBER, R. D., OLD, L. J. & SMYTH, M. J. 2011. Cancer Immunoediting: Integrating Immunity’s 
Roles in Cancer Suppression and Promotion. Science, 331, 1565-1570. 
SCHRODER, K., HERTZOG, P. J., RAVASI, T. & HUME, D. A. 2004. Interferon-γ: an overview of signals, 
mechanisms and functions. Journal of Leukocyte Biology, 75, 163-189. 
SCHÜLER, T., QIN, Z., IBE, S., NOBEN-TRAUTH, N. & BLANKENSTEIN, T. 1999. T Helper Cell Type 1–
associated and Cytotoxic T Lymphocyte–mediated Tumor Immunity Is Impaired in 
Interleukin 4–deficient Mice. The Journal of Experimental Medicine, 189, 803-810. 
SCHUMACHER, K., HAENSCH, W., ROEFZAAD, C. & SCHLAG, P. M. 2001. Prognostic significance of 
activated CD8(+) T cell infiltrations within esophageal carcinomas. Cancer Res, 61, 3932-6. 
SCHWANK, G., KOO, B. K., SASSELLI, V., DEKKERS, J. F., HEO, I., DEMIRCAN, T., SASAKI, N., BOYMANS, 
S., CUPPEN, E., VAN DER ENT, C. K., NIEUWENHUIS, E. E., BEEKMAN, J. M. & CLEVERS, H. 
2013. Functional repair of CFTR by CRISPR/Cas9 in intestinal stem cell organoids of cystic 
fibrosis patients. Cell Stem Cell, 13, 653-8. 
SEGAL, N. H., ANTONIA, S. J., BRAHMER, J. R., MAIO, M., BLAKE-HASKINS, A. & LI, X. 2014. 
Preliminary data from a multi-arm expansion study of MEDI4736, an anti-PD-L1 antibody. J 
Clin Oncol, 32, 134136-144. 
SEGAL, N. H., PARSONS, D. W., PEGGS, K. S., VELCULESCU, V., KINZLER, K. W., VOGELSTEIN, B. & 
ALLISON, J. P. 2008. Epitope landscape in breast and colorectal cancer. Cancer Res, 68, 889-
92. 
SENZER, N. N., KAUFMAN, H. L., AMATRUDA, T., NEMUNAITIS, M., REID, T., DANIELS, G., GONZALEZ, 
R., GLASPY, J., WHITMAN, E., HARRINGTON, K., GOLDSWEIG, H., MARSHALL, T., LOVE, C., 
COFFIN, R. & NEMUNAITIS, J. J. 2009. Phase II clinical trial of a granulocyte-macrophage 
colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with 
unresectable metastatic melanoma. J Clin Oncol, 27, 5763-71. 
SERGINA, N. V., RAUSCH, M., WANG, D., BLAIR, J., HANN, B., SHOKAT, K. M. & MOASSER, M. M. 
2007. Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3. 
Nature, 445, 437-41. 
SEYMOUR, L. W., DUNCAN, R., STROHALM, J. & KOPEČEK, J. 1987. Effect of molecular weight (Mw) of 
N-(2-hydroxypropyl)methacrylamide copolymers on body distribution and rate of excretion 
281 
 
after subcutaneous, intraperitoneal, and intravenous administration to rats. Journal of 
Biomedical Materials Research, 21, 1341-1358. 
SHAH, C. A., ALLISON, K. H., GARCIA, R. L., GRAY, H. J., GOFF, B. A. & SWISHER, E. M. 2008. 
Intratumoral T cells, tumor-associated macrophages, and regulatory T cells: association with 
p53 mutations, circulating tumor DNA and survival in women with ovarian cancer. Gynecol 
Oncol, 109, 215-9. 
SHANKARAN, V., IKEDA, H., BRUCE, A. T., WHITE, J. M., SWANSON, P. E., OLD, L. J. & SCHREIBER, R. D. 
2001. IFNgamma and lymphocytes prevent primary tumour development and shape tumour 
immunogenicity. Nature, 410, 1107-11. 
SHARMA, P., WAGNER, K., WOLCHOK, J. D. & ALLISON, J. P. 2011. Novel cancer immunotherapy 
agents with survival benefit: recent successes and next steps. Nat Rev Cancer, 11, 805-12. 
SHI, L., CHEN, S., YANG, L. & LI, Y. 2013. The role of PD-1 and PD-L1 in T-cell immune suppression in 
patients with hematological malignancies. Journal of Hematology & Oncology, 6, 1-6. 
SHIN, D. S. & RIBAS, A. 2015. The evolution of checkpoint blockade as a cancer therapy: what's here, 
what's next? Curr Opin Immunol, 33c, 23-35. 
SICA, G. L., CHOI, I. H., ZHU, G., TAMADA, K., WANG, S. D., TAMURA, H., CHAPOVAL, A. I., FLIES, D. B., 
BAJORATH, J. & CHEN, L. 2003. B7-H4, a molecule of the B7 family, negatively regulates T cell 
immunity. Immunity, 18, 849-61. 
SIDI, A. A., OHANA, P., BENJAMIN, S., SHALEV, M., RANSOM, J. H., LAMM, D., HOCHBERG, A. & 
LEIBOVITCH, I. 2008. Phase I/II marker lesion study of intravesical BC-819 DNA plasmid in 
H19 over expressing superficial bladder cancer refractory to bacillus Calmette-Guerin. J Urol, 
180, 2379-83. 
SIMOES, S., FILIPE, A., FANECA, H., MANO, M., PENACHO, N., DUZGUNES, N. & DE LIMA, M. P. 2005. 
Cationic liposomes for gene delivery. Expert Opin Drug Deliv, 2, 237-54. 
SIMONS, K. & TOOMRE, D. 2000. Lipid rafts and signal transduction. Nat Rev Mol Cell Biol, 1, 31-9. 
SIOLAS, D., LERNER, C., BURCHARD, J., GE, W., LINSLEY, P. S., PADDISON, P. J., HANNON, G. J. & 
CLEARY, M. A. 2005. Synthetic shRNAs as potent RNAi triggers. Nat Biotechnol, 23, 227-31. 
SIVA, A., XIN, H., QIN, F., OLTEAN, D., BOWDISH, K. S. & KRETZ-ROMMEL, A. 2008. Immune 
modulation by melanoma and ovarian tumor cells through expression of the 
immunosuppressive molecule CD200. Cancer Immunol Immunother, 57, 987-96. 
SIWAK, D. R., CAREY, M., HENNESSY, B. T., NGUYEN, C. T., MCGAHREN MURRAY, M. J., NOLDEN, L. & 
MILLS, G. B. 2010. Targeting the epidermal growth factor receptor in epithelial ovarian 
cancer: current knowledge and future challenges. J Oncol, 2010, 568938. 
SMITH, J. B., STASHWICK, C. & POWELL, D. J., JR. 2014. B7-H4 as a potential target for 
immunotherapy for gynecologic cancers: a closer look. Gynecol Oncol, 134, 181-9. 
SMYTH, M. J., DUNN, G. P. & SCHREIBER, R. D. 2006. Cancer immunosurveillance and 
immunoediting: the roles of immunity in suppressing tumor development and shaping 
tumor immunogenicity. Adv Immunol, 90, 1-50. 
SMYTH, M. J., THIA, K. Y., STREET, S. E., MACGREGOR, D., GODFREY, D. I. & TRAPANI, J. A. 2000. 
Perforin-mediated cytotoxicity is critical for surveillance of spontaneous lymphoma. J Exp 
Med, 192, 755-60. 
SOM, A., REUTER, A. & TEW, G. N. 2012. Protein Transduction Domain Mimics: The Role of Aromatic 
Functionality. Angewandte Chemie International Edition, 51, 980-983. 
SOMIA, N. & VERMA, I. M. 2000. Gene therapy: trials and tribulations. Nat Rev Genet, 1, 91-9. 
SONAWANE, N. D., SZOKA, F. C. & VERKMAN, A. S. 2003. Chloride Accumulation and Swelling in 
Endosomes Enhances DNA Transfer by Polyamine-DNA Polyplexes. Journal of Biological 
Chemistry, 278, 44826-44831. 
SONG, D.-G., YE, Q., CARPENITO, C., POUSSIN, M., WANG, L.-P., JI, C., FIGINI, M., JUNE, C. H., 
COUKOS, G. & POWELL, D. J. 2011. In Vivo Persistence, Tumor Localization, and Antitumor 
Activity of CAR-Engineered T Cells Is Enhanced by Costimulatory Signaling through CD137 (4-
1BB). Cancer Research, 71, 4617-4627. 
282 
 
SONG, D. G., YE, Q., SANTORO, S., FANG, C., BEST, A. & POWELL, D. J., JR. 2013. Chimeric NKG2D 
CAR-expressing T cell-mediated attack of human ovarian cancer is enhanced by histone 
deacetylase inhibition. Hum Gene Ther, 24, 295-305. 
SPRANGER, S., SPAAPEN, R. M., ZHA, Y., WILLIAMS, J., MENG, Y., HA, T. T. & GAJEWSKI, T. F. 2013. 
Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven 
by CD8(+) T cells. Sci Transl Med, 5, 200ra116. 
STEINMAN, R. M., TURLEY, S., MELLMAN, I. & INABA, K. 2000. The induction of tolerance by dendritic 
cells that have captured apoptotic cells. J Exp Med, 191, 411-6. 
STEITZ, J., BRUCK, J., LENZ, J., KNOP, J. & TUTING, T. 2001. Depletion of CD25(+) CD4(+) T cells and 
treatment with tyrosinase-related protein 2-transduced dendritic cells enhance the 
interferon alpha-induced, CD8(+) T-cell-dependent immune defense of B16 melanoma. 
Cancer Res, 61, 8643-6. 
STERMAN, D. H., GILLESPIE, C. T., CARROLL, R. G., COUGHLIN, C. M., LORD, E. M., SUN, J., HAAS, A., 
RECIO, A., KAISER, L. R., COUKOS, G., JUNE, C. H., ALBELDA, S. M. & VONDERHEIDE, R. H. 
2006. Interferon [beta] adenoviral gene therapy in a patient with ovarian cancer. Nat Clin 
Prac Oncol, 3, 633-639. 
STORTELERS, C., VAN DE POLL, M. L., LENFERINK, A. E., GADELLAA, M. M., VAN ZOELEN, C. & VAN 
ZOELEN, E. J. 2002. Epidermal growth factor contains both positive and negative 
determinants for interaction with ErbB-2/ErbB-3 heterodimers. Biochemistry, 41, 4292-301. 
STREET, S. E., TRAPANI, J. A., MACGREGOR, D. & SMYTH, M. J. 2002. Suppression of lymphoma and 
epithelial malignancies effected by interferon gamma. J Exp Med, 196, 129-34. 
STRONACH, E. A., CHEN, M., MAGINN, E. N., AGARWAL, R., MILLS, G. B., WASAN, H. & GABRA, H. 
2011. DNA-PK mediates AKT activation and apoptosis inhibition in clinically acquired 
platinum resistance. Neoplasia, 13, 1069-80. 
SUBUDHI, S. K., ZHOU, P., YERIAN, L. M., CHIN, R. K., LO, J. C., ANDERS, R. A., SUN, Y., CHEN, L., 
WANG, Y., ALEGRE, M. L. & FU, Y. X. 2004. Local expression of B7-H1 promotes organ-
specific autoimmunity and transplant rejection. J Clin Invest, 113, 694-700. 
SUH, J., WIRTZ, D. & HANES, J. 2003. Efficient active transport of gene nanocarriers to the cell 
nucleus. Proc Natl Acad Sci U S A, 100, 3878-82. 
SUI, G., SOOHOO, C., AFFAR EL, B., GAY, F., SHI, Y., FORRESTER, W. C. & SHI, Y. 2002. A DNA vector-
based RNAi technology to suppress gene expression in mammalian cells. Proc Natl Acad Sci 
U S A, 99, 5515-20. 
SUTMULLER, R. P., VAN DUIVENVOORDE, L. M., VAN ELSAS, A., SCHUMACHER, T. N., WILDENBERG, 
M. E., ALLISON, J. P., TOES, R. E., OFFRINGA, R. & MELIEF, C. J. 2001. Synergism of cytotoxic T 
lymphocyte-associated antigen 4 blockade and depletion of CD25(+) regulatory T cells in 
antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T 
lymphocyte responses. J Exp Med, 194, 823-32. 
SUYAMA, T. & TOKIWA, Y. 1997. Enzymatic degradation of an aliphatic polycarbonate, 
poly(tetramethylene carbonate). Enzyme and Microbial Technology, 20, 122-126. 
SWANN, J. B. & SMYTH, M. J. 2007. Immune surveillance of tumors. J Clin Invest, 117, 1137-46. 
TABERNERO, J., SHAPIRO, G. I., LORUSSO, P. M., CERVANTES, A., SCHWARTZ, G. K., WEISS, G. J., PAZ-
ARES, L., CHO, D. C., INFANTE, J. R., ALSINA, M., GOUNDER, M. M., FALZONE, R., HARROP, J., 
WHITE, A. C. S., TOUDJARSKA, I., BUMCROT, D., MEYERS, R. E., HINKLE, G., SVRZIKAPA, N., 
HUTABARAT, R. M., CLAUSEN, V. A., CEHELSKY, J., NOCHUR, S. V., GAMBA-VITALO, C., 
VAISHNAW, A. K., SAH, D. W. Y., GOLLOB, J. A. & BURRIS, H. A. 2013. First-in-Humans Trial of 
an RNA Interference Therapeutic Targeting VEGF and KSP in Cancer Patients with Liver 
Involvement. Cancer Discovery, 3, 406-417. 
TAIT, D. L., OBERMILLER, P. S., HATMAKER, A. R., REDLIN-FRAZIER, S. & HOLT, J. T. 1999. Ovarian 
Cancer BRCA1 Gene Therapy: Phase I and II Trial Differences in Immune Response and 
Vector Stability. Clinical Cancer Research, 5, 1708-1714. 
283 
 
TAIT, D. L., OBERMILLER, P. S., REDLIN-FRAZIER, S., JENSEN, R. A., WELCSH, P., DANN, J., KING, M. C., 
JOHNSON, D. H. & HOLT, J. T. 1997. A phase I trial of retroviral BRCA1sv gene therapy in 
ovarian cancer. Clin Cancer Res, 3, 1959-68. 
TAKAE, S., MIYATA, K., OBA, M., ISHII, T., NISHIYAMA, N., ITAKA, K., YAMASAKI, Y., KOYAMA, H. & 
KATAOKA, K. 2008. PEG-detachable polyplex micelles based on disulfide-linked block 
catiomers as bioresponsive nonviral gene vectors. J Am Chem Soc, 130, 6001-9. 
TALAY, O., SHEN, C.-H., CHEN, L. & CHEN, J. 2009. B7-H1 (PD-L1) on T cells is required for T-cell-
mediated conditioning of dendritic cell maturation. Proceedings of the National Academy of 
Sciences, 106, 2741-2746. 
TAMMANA, S., HUANG, X., WONG, M., MILONE, M. C., MA, L., LEVINE, B. L., JUNE, C. H., WAGNER, J. 
E., BLAZAR, B. R. & ZHOU, X. 2010. 4-1BB and CD28 signaling plays a synergistic role in 
redirecting umbilical cord blood T cells against B-cell malignancies. Hum Gene Ther, 21, 75-
86. 
TAMURA, H., DONG, H., ZHU, G., SICA, G. L., FLIES, D. B., TAMADA, K. & CHEN, L. 2001. B7-H1 
costimulation preferentially enhances CD28-independent T-helper cell function. Blood, 97, 
1809-16. 
TAUBE, J. M., ANDERS, R. A., YOUNG, G. D., XU, H., SHARMA, R., MCMILLER, T. L., CHEN, S., KLEIN, A. 
P., PARDOLL, D. M., TOPALIAN, S. L. & CHEN, L. 2012. Colocalization of Inflammatory 
Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive 
Resistance Mechanism of Immune Escape. Science translational medicine, 4, 127ra37-
127ra37. 
TAUBE, J. M., KLEIN, A. P., BRAHMER, J. R., XU, H., PAN, X., KIM, J. H., CHEN, L., PARDOLL, D. M., 
TOPALIAN, S. L. & ANDERS, R. A. 2014. Association of PD-1, PD-1 ligands, and other features 
of the tumor immune microenvironment with response to anti-PD-1 therapy. Clinical Cancer 
Research. 
TEAM, C. A. E. O. L. C. A. 2014. Cancer Registration Statistics, England, 2012. In: DIVISION, L. E. A. P. 
S. (ed.). United Kingdom. 
TEO, P. Y., YANG, C., HEDRICK, J. L., ENGLER, A. C., COADY, D. J., GHAEM-MAGHAMI, S., GEORGE, A. J. 
& YANG, Y. Y. 2013. Hydrophobic modification of low molecular weight polyethylenimine for 
improved gene transfection. Biomaterials, 34, 7971-9. 
TEO, P. Y., YANG, C., WHILDING, L. M., PARENTE-PEREIRA, A. C., MAHER, J., GEORGE, A. J. T., 
HEDRICK, J. L., YANG, Y. Y. & GHAEM-MAGHAMI, S. 2015. Ovarian Cancer Immunotherapy 
Using PD-L1 siRNA Targeted Delivery from Folic Acid-Functionalized Polyethylenimine: 
Strategies to Enhance T Cell Killing. Advanced Healthcare Materials, 4, n/a-n/a. 
THIBODEAUX, S. R. & CURIEL, T. J. 2011. Immune therapy for ovarian cancer: promise and pitfalls. Int 
Rev Immunol, 30, 102-19. 
THOMAS, C. E., EHRHARDT, A. & KAY, M. A. 2003. Progress and problems with the use of viral 
vectors for gene therapy. Nat Rev Genet, 4, 346-58. 
THOMAS, M. & KLIBANOV, A. M. 2002. Enhancing polyethylenimine's delivery of plasmid DNA into 
mammalian cells. Proc Natl Acad Sci U S A, 99, 14640-5. 
TIAN, H., LI, F., CHEN, J., HUANG, Y. & CHEN, X. 2012. N-isopropylacrylamide-modified 
polyethylenimines as effective gene carriers. Macromol Biosci, 12, 1680-8. 
TILL, B. G., JENSEN, M. C., WANG, J., QIAN, X., GOPAL, A. K., MALONEY, D. G., LINDGREN, C. G., LIN, 
Y., PAGEL, J. M., BUDDE, L. E., RAUBITSCHEK, A., FORMAN, S. J., GREENBERG, P. D., RIDDELL, 
S. R. & PRESS, O. W. 2012. CD20-specific adoptive immunotherapy for lymphoma using a 
chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results. 
Blood, 119, 3940-50. 
TIVOL, E. A., BORRIELLO, F., SCHWEITZER, A. N., LYNCH, W. P., BLUESTONE, J. A. & SHARPE, A. H. 
1995. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue 
destruction, revealing a critical negative regulatory role of CTLA-4. Immunity, 3, 541-7. 
284 
 
TODA, M., MARTUZA, R. L., KOJIMA, H. & RABKIN, S. D. 1998. In situ cancer vaccination: an IL-12 
defective vector/replication-competent herpes simplex virus combination induces local and 
systemic antitumor activity. J Immunol, 160, 4457-64. 
TOFFOLI, G., CERNIGOI, C., RUSSO, A., GALLO, A., BAGNOLI, M. & BOIOCCHI, M. 1997. 
Overexpression of folate binding protein in ovarian cancers. Int J Cancer, 74, 193-8. 
TOPALIAN, S. L., DRAKE, C. G. & PARDOLL, D. M. 2012. Targeting the PD-1/B7-H1(PD-L1) pathway to 
activate anti-tumor immunity. Curr Opin Immunol, 24, 207-12. 
TOPALIAN, S. L., HODI, F. S., BRAHMER, J. R., GETTINGER, S. N., SMITH, D. C., MCDERMOTT, D. F., 
POWDERLY, J. D., CARVAJAL, R. D., SOSMAN, J. A., ATKINS, M. B., LEMING, P. D., SPIGEL, D. 
R., ANTONIA, S. J., HORN, L., DRAKE, C. G., PARDOLL, D. M., CHEN, L., SHARFMAN, W. H., 
ANDERS, R. A., TAUBE, J. M., MCMILLER, T. L., XU, H., KORMAN, A. J., JURE-KUNKEL, M., 
AGRAWAL, S., MCDONALD, D., KOLLIA, G. D., GUPTA, A., WIGGINTON, J. M. & SZNOL, M. 
2012. Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer. New England 
Journal of Medicine, 366, 2443-2454. 
TOPALIAN, S. L., SZNOL, M., MCDERMOTT, D. F., KLUGER, H. M., CARVAJAL, R. D., SHARFMAN, W. H., 
BRAHMER, J. R., LAWRENCE, D. P., ATKINS, M. B., POWDERLY, J. D., LEMING, P. D., LIPSON, E. 
J., PUZANOV, I., SMITH, D. C., TAUBE, J. M., WIGGINTON, J. M., KOLLIA, G. D., GUPTA, A., 
PARDOLL, D. M., SOSMAN, J. A. & HODI, F. S. 2014. Survival, Durable Tumor Remission, and 
Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab. Journal of 
Clinical Oncology, 32, 1020-1030. 
TOTHILL, R. W., TINKER, A. V., GEORGE, J., BROWN, R., FOX, S. B., LADE, S., JOHNSON, D. S., TRIVETT, 
M. K., ETEMADMOGHADAM, D., LOCANDRO, B., TRAFICANTE, N., FEREDAY, S., HUNG, J. A., 
CHIEW, Y. E., HAVIV, I., GERTIG, D., DEFAZIO, A. & BOWTELL, D. D. 2008. Novel molecular 
subtypes of serous and endometrioid ovarian cancer linked to clinical outcome. Clin Cancer 
Res, 14, 5198-208. 
TSENG, S. Y., OTSUJI, M., GORSKI, K., HUANG, X., SLANSKY, J. E., PAI, S. I., SHALABI, A., SHIN, T., 
PARDOLL, D. M. & TSUCHIYA, H. 2001. B7-DC, a new dendritic cell molecule with potent 
costimulatory properties for T cells. J Exp Med, 193, 839-46. 
TSUDA, N., MOCHIZUKI, K., HARADA, M., SUKEHIRO, A., KAWANO, K., YAMADA, A., USHIJIMA, K., 
SUGIYAMA, T., NISHIDA, T., YAMANA, H., ITOH, K. & KAMURA, T. 2004. Vaccination with 
predesignated or evidence-based peptides for patients with recurrent gynecologic cancers. J 
Immunother, 27, 60-72. 
TUMEH, P. C., HARVIEW, C. L., YEARLEY, J. H., SHINTAKU, I. P., TAYLOR, E. J., ROBERT, L., 
CHMIELOWSKI, B., SPASIC, M., HENRY, G., CIOBANU, V., WEST, A. N., CARMONA, M., 
KIVORK, C., SEJA, E., CHERRY, G., GUTIERREZ, A. J., GROGAN, T. R., MATEUS, C., TOMASIC, G., 
GLASPY, J. A., EMERSON, R. O., ROBINS, H., PIERCE, R. H., ELASHOFF, D. A., ROBERT, C. & 
RIBAS, A. 2014. PD-1 blockade induces responses by inhibiting adaptive immune resistance. 
Nature, 515, 568-71. 
TUSCHL, T. 2001. RNA interference and small interfering RNAs. Chembiochem, 2, 239-45. 
U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, F. A. D. A. 2011. Guidance for Industry and 
Food and Drug Administration Staff - Establishing the Performance Characteristics of In Vitro 
Diagnostic Devices for the Detection or Detection and Differentiation of Human 
Papillomaviruses [Online]. Available: 
http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/u
cm181509.htm. 
UDUEHI, A. N., STAMMBERGER, U., KUBISA, B., GUGGER, M., BUEHLER, T. A. & SCHMID, R. A. 2001. 
Effects of Linear Polyethylenimine and Polyethylenimine/DNA on Lung Function after Airway 
Instillation to Rat Lungs. Mol Ther, 4, 52-57. 
UK, C. R. 2014. Ovarian cancer tests. United Kingdom. 
285 
 
URBANSKA, K., LANITIS, E., POUSSIN, M., LYNN, R. C., GAVIN, B. P., KELDERMAN, S., YU, J., SCHOLLER, 
N. & POWELL, D. J., JR. 2012. A universal strategy for adoptive immunotherapy of cancer 
through use of a novel T-cell antigen receptor. Cancer Res, 72, 1844-52. 
VANDENBROUCKE, R. E., LUCAS, B., DEMEESTER, J., DE SMEDT, S. C. & SANDERS, N. N. 2007. Nuclear 
accumulation of plasmid DNA can be enhanced by non-selective gating of the nuclear pore. 
Nucleic Acids Research, 35, e86. 
VAUGHAN, E. E. & DEAN, D. A. 2006. Intracellular trafficking of plasmids during transfection is 
mediated by microtubules. Mol Ther, 13, 422-8. 
VAUGHAN, S., COWARD, J. I., BAST, R. C., JR., BERCHUCK, A., BEREK, J. S., BRENTON, J. D., COUKOS, 
G., CRUM, C. C., DRAPKIN, R., ETEMADMOGHADAM, D., FRIEDLANDER, M., GABRA, H., KAYE, 
S. B., LORD, C. J., LENGYEL, E., LEVINE, D. A., MCNEISH, I. A., MENON, U., MILLS, G. B., 
NEPHEW, K. P., OZA, A. M., SOOD, A. K., STRONACH, E. A., WALCZAK, H., BOWTELL, D. D. & 
BALKWILL, F. R. 2011. Rethinking ovarian cancer: recommendations for improving outcomes. 
Nat Rev Cancer, 11, 719-25. 
VELCHETI, V., SCHALPER, K. A., CARVAJAL, D. E., ANAGNOSTOU, V. K., SYRIGOS, K. N., SZNOL, M., 
HERBST, R. S., GETTINGER, S. N., CHEN, L. & RIMM, D. L. 2014. Programmed death ligand-1 
expression in non-small cell lung cancer. Lab Invest, 94, 107-116. 
VENKATARAMAN, S., ONG, W. L., ONG, Z. Y., JOACHIM LOO, S. C., EE, P. L. & YANG, Y. Y. 2011. The 
role of PEG architecture and molecular weight in the gene transfection performance of 
PEGylated poly(dimethylaminoethyl methacrylate) based cationic polymers. Biomaterials, 
32, 2369-78. 
VENKATARAMAN, S., ONG, W. L., ONG, Z. Y., JOACHIM LOO, S. C., RACHEL EE, P. L. & YANG, Y. Y. 
2011. The role of PEG architecture and molecular weight in the gene transfection 
performance of PEGylated poly(dimethylaminoethyl methacrylate) based cationic polymers. 
Biomaterials, 32, 2369-2378. 
VESALAINEN, S., LIPPONEN, P., TALJA, M. & SYRJANEN, K. 1994. Histological grade, perineural 
infiltration, tumour-infiltrating lymphocytes and apoptosis as determinants of long-term 
prognosis in prostatic adenocarcinoma. Eur J Cancer, 30a, 1797-803. 
VESELY, M. D., KERSHAW, M. H., SCHREIBER, R. D. & SMYTH, M. J. 2011. Natural Innate and Adaptive 
Immunity to Cancer. Annual Review of Immunology, 29, 235-271. 
VON GERSDORFF, K., SANDERS, N. N., VANDENBROUCKE, R., DE SMEDT, S. C., WAGNER, E. & OGRIS, 
M. 2006. The internalization route resulting in successful gene expression depends on both 
cell line and polyethylenimine polyplex type. Mol Ther, 14, 745-53. 
VON HARPE, A., PETERSEN, H., LI, Y. & KISSEL, T. 2000. Characterization of commercially available 
and synthesized polyethylenimines for gene delivery. J Control Release, 69, 309-22. 
WAGNER, E., OGRIS, M. & ZAUNER, W. 1998. Polylysine-based transfection systems utilizing 
receptor-mediated delivery. Adv Drug Deliv Rev, 30, 97-113. 
WAN, B., NIE, H., LIU, A., FENG, G., HE, D., XU, R., ZHANG, Q., DONG, C. & ZHANG, J. Z. 2006. 
Aberrant regulation of synovial T cell activation by soluble costimulatory molecules in 
rheumatoid arthritis. J Immunol, 177, 8844-50. 
WANG, J., JENSEN, M., LIN, Y., SUI, X., CHEN, E., LINDGREN, C. G., TILL, B., RAUBITSCHEK, A., 
FORMAN, S. J., QIAN, X., JAMES, S., GREENBERG, P., RIDDELL, S. & PRESS, O. W. 2007. 
Optimizing adoptive polyclonal T cell immunotherapy of lymphomas, using a chimeric T cell 
receptor possessing CD28 and CD137 costimulatory domains. Hum Gene Ther, 18, 712-25. 
WANG, L., RUBINSTEIN, R., LINES, J. L., WASIUK, A., AHONEN, C., GUO, Y., LU, L. F., GONDEK, D., 
WANG, Y., FAVA, R. A., FISER, A., ALMO, S. & NOELLE, R. J. 2011. VISTA, a novel mouse Ig 
superfamily ligand that negatively regulates T cell responses. J Exp Med, 208, 577-92. 
WANG, S., LEE, R. J., MATHIAS, C. J., GREEN, M. A. & LOW, P. S. 1996. Synthesis, purification, and 
tumor cell uptake of 67Ga-deferoxamine--folate, a potential radiopharmaceutical for tumor 
imaging. Bioconjug Chem, 7, 56-62. 
286 
 
WANG, S., LUO, J., LANTRIP, D. A., WATERS, D. J., MATHIAS, C. J., GREEN, M. A., FUCHS, P. L. & LOW, 
P. S. 1997. Design and synthesis of [111In]DTPA-folate for use as a tumor-targeted 
radiopharmaceutical. Bioconjug Chem, 8, 673-9. 
WANG, W., LAU, R., YU, D., ZHU, W., KORMAN, A. & WEBER, J. 2009. PD1 blockade reverses the 
suppression of melanoma antigen-specific CTL by CD4+ CD25(Hi) regulatory T cells. Int 
Immunol, 21, 1065-77. 
WANG, Y., KE, C. Y., WEIJIE BEH, C., LIU, S. Q., GOH, S. H. & YANG, Y. Y. 2007. The self-assembly of 
biodegradable cationic polymer micelles as vectors for gene transfection. Biomaterials, 28, 
5358-68. 
WANG, Y., MIAO, L., SATTERLEE, A. & HUANG, L. 2015. Delivery of oligonucleotides with lipid 
nanoparticles. Adv Drug Deliv Rev. 
WANG, Y., ZHENG, M., MENG, F., ZHANG, J., PENG, R. & ZHONG, Z. 2011. Branched polyethylenimine 
derivatives with reductively cleavable periphery for safe and efficient in vitro gene transfer. 
Biomacromolecules, 12, 1032-40. 
WEBB, J. R., MILNE, K., WATSON, P., DELEEUW, R. J. & NELSON, B. H. 2014. Tumor-infiltrating 
lymphocytes expressing the tissue resident memory marker CD103 are associated with 
increased survival in high-grade serous ovarian cancer. Clin Cancer Res, 20, 434-44. 
WEI, S., KRYCZEK, I., ZOU, L., DANIEL, B., CHENG, P., MOTTRAM, P., CURIEL, T., LANGE, A. & ZOU, W. 
2005. Plasmacytoid dendritic cells induce CD8+ regulatory T cells in human ovarian 
carcinoma. Cancer Res, 65, 5020-6. 
WEN, J., MAO, H.-Q., LI, W., LIN, K. Y. & LEONG, K. W. 2004. Biodegradable polyphosphoester 
micelles for gene delivery. Journal of Pharmaceutical Sciences, 93, 2142-2157. 
WENNEMERS, M., BUSSINK, J., VAN DEN BEUCKEN, T., SWEEP, F. C. & SPAN, P. N. 2012. Regulation 
of TRIB3 mRNA and protein in breast cancer. PLoS One, 7, e49439. 
WHITE, E. A., KENNY, H. A. & LENGYEL, E. 2014. Three-dimensional modeling of ovarian cancer. 
Advanced Drug Delivery Reviews, 79–80, 184-192. 
WHITE, S. H. & WIMLEY, W. C. 1999. Membrane protein folding and stability: physical principles. 
Annu Rev Biophys Biomol Struct, 28, 319-65. 
WIBOWO, A. S., SINGH, M., REEDER, K. M., CARTER, J. J., KOVACH, A. R., MENG, W., RATNAM, M., 
ZHANG, F. & DANN, C. E. 2013. Structures of human folate receptors reveal biological 
trafficking states and diversity in folate and antifolate recognition. Proceedings of the 
National Academy of Sciences, 110, 15180-15188. 
WIETHOFF, C. M. & MIDDAUGH, C. R. 2003. Barriers to nonviral gene delivery. J Pharm Sci, 92, 203-
17. 
WIGHTMAN, L., KIRCHEIS, R., ROSSLER, V., CAROTTA, S., RUZICKA, R., KURSA, M. & WAGNER, E. 
2001. Different behavior of branched and linear polyethylenimine for gene delivery in vitro 
and in vivo. J Gene Med, 3, 362-72. 
WILKIE, S., BURBRIDGE, S. E., CHIAPERO-STANKE, L., PEREIRA, A. C., CLEARY, S., VAN DER STEGEN, S. 
J., SPICER, J. F., DAVIES, D. M. & MAHER, J. 2010. Selective expansion of chimeric antigen 
receptor-targeted T-cells with potent effector function using interleukin-4. J Biol Chem, 285, 
25538-44. 
WILLNER, I., EICHEN, Y., FRANK, A. J. & FOX, M. A. 1993. Photoinduced electron-transfer processes 
using organized redox-functionalized bipyridinium-polyethylenimine-titania colloids and 
particulate assemblies. The Journal of Physical Chemistry, 97, 7264-7271. 
WIMLEY, W. C. & WHITE, S. H. 1996. Experimentally determined hydrophobicity scale for proteins at 
membrane interfaces. Nat Struct Biol, 3, 842-8. 
WONG, R. M., SCOTLAND, R. R., LAU, R. L., WANG, C., KORMAN, A. J., KAST, W. M. & WEBER, J. S. 
2007. Programmed death-1 blockade enhances expansion and functional capacity of human 
melanoma antigen-specific CTLs. Int Immunol, 19, 1223-34. 
WONG, S. Y., PELET, J. M. & PUTNAM, D. 2007. Polymer systems for gene delivery—Past, present, 
and future. Progress in Polymer Science, 32, 799-837. 
287 
 
WOO, E. Y., CHU, C. S., GOLETZ, T. J., SCHLIENGER, K., YEH, H., COUKOS, G., RUBIN, S. C., KAISER, L. R. 
& JUNE, C. H. 2001. Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-
stage non-small cell lung cancer and late-stage ovarian cancer. Cancer Res, 61, 4766-72. 
WOOD, K. J. & SAKAGUCHI, S. 2003. Regulatory T cells in transplantation tolerance. Nat Rev 
Immunol, 3, 199-210. 
WU, W., HODGES, E., REDELIUS, J. & HÖÖG, C. 2004. A novel approach for evaluating the efficiency 
of siRNAs on protein levels in cultured cells. Nucleic Acids Research, 32, e17. 
WURTELE, H., LITTLE, K. C. & CHARTRAND, P. 2003. Illegitimate DNA integration in mammalian cells. 
Gene Ther, 10, 1791-9. 
XIANG, S., SU, J., TONG, H., YANG, F., TONG, W., YUAN, W., WU, F., WANG, C., JIN, T., DAI, K. & 
ZHANG, X. 2012. Biscarbamate cross-linked low molecular weight PEI for delivering IL-1 
receptor antagonist gene to synoviocytes for arthritis therapy. Biomaterials, 33, 6520-6532. 
XIAO, Y., YU, S., ZHU, B., BEDORET, D., BU, X., FRANCISCO, L. M., HUA, P., DUKE-COHAN, J. S., 
UMETSU, D. T., SHARPE, A. H., DEKRUYFF, R. H. & FREEMAN, G. J. 2014. RGMb is a novel 
binding partner for PD-L2 and its engagement with PD-L2 promotes respiratory tolerance. 
The Journal of Experimental Medicine, 211, 943-959. 
YAMAZAKI, T., AKIBA, H., IWAI, H., MATSUDA, H., AOKI, M., TANNO, Y., SHIN, T., TSUCHIYA, H., 
PARDOLL, D. M., OKUMURA, K., AZUMA, M. & YAGITA, H. 2002. Expression of programmed 
death 1 ligands by murine T cells and APC. J Immunol, 169, 5538-45. 
YAN, Z. H., MADISON, L. L., BURKHARDT, A., YU, J., TAYBER, O., LI, Z., WU, D., LOKE, H. K., WYSONG, 
D. R., IARTCHOUK, N., SMITH, M. D., KURANDA, M., LI, P. & BEMBENEK, M. E. 2011. Analysis 
of two pharmacodynamic biomarkers using acoustic micro magnetic particles on the ViBE 
bioanalyzer. Anal Biochem, 410, 13-8. 
YANG, C., CHENG, W., TEO, P. Y., ENGLER, A. C., COADY, D. J., HEDRICK, J. L. & YANG, Y. Y. 2013. 
Mitigated cytotoxicity and tremendously enhanced gene transfection efficiency of PEI 
through facile one-step carbamate modification. Adv Healthc Mater, 2, 1304-8. 
YANG, C., ONG, Z. Y., YANG, Y.-Y., EE, P. L. R. & HEDRICK, J. L. 2011. Novel Biodegradable Block 
Copolymers of Poly(ethylene glycol) (PEG) and Cationic Polycarbonate: Effects of PEG 
Configuration on Gene Delivery. Macromolecular Rapid Communications, 32, 1826-1833. 
YAU, W.-M., WIMLEY, W. C., GAWRISCH, K. & WHITE, S. H. 1998. The Preference of Tryptophan for 
Membrane Interfaces. Biochemistry, 37, 14713-14718. 
YIN, H., XUE, W., CHEN, S., BOGORAD, R. L., BENEDETTI, E., GROMPE, M., KOTELIANSKY, V., SHARP, P. 
A., JACKS, T. & ANDERSON, D. G. 2014. Genome editing with Cas9 in adult mice corrects a 
disease mutation and phenotype. Nat Biotech, 32, 551-553. 
YOSHINAGA, S. K., ZHANG, M., PISTILLO, J., HORAN, T., KHARE, S. D., MINER, K., SONNENBERG, M., 
BOONE, T., BRANKOW, D., DAI, T., DELANEY, J., HAN, H., HUI, A., KOHNO, T., MANOUKIAN, 
R., WHORISKEY, J. S. & COCCIA, M. A. 2000. Characterization of a new human B7-related 
protein: B7RP-1 is the ligand to the co-stimulatory protein ICOS. International Immunology, 
12, 1439-1447. 
YUE, Y., JIN, F., DENG, R., CAI, J., DAI, Z., LIN, M. C., KUNG, H. F., MATTEBJERG, M. A., ANDRESEN, T. L. 
& WU, C. 2011. Revisit complexation between DNA and polyethylenimine--effect of length of 
free polycationic chains on gene transfection. J Control Release, 152, 143-51. 
ZAMORE, P. D., TUSCHL, T., SHARP, P. A. & BARTEL, D. P. 2000. RNAi: double-stranded RNA directs 
the ATP-dependent cleavage of mRNA at 21 to 23 nucleotide intervals. Cell, 101, 25-33. 
ZANG, X., LOKE, P. N., KIM, J., MURPHY, K., WAITZ, R. & ALLISON, J. P. 2003. B7x: A widely expressed 
B7 family member that inhibits T cell activation. Proceedings of the National Academy of 
Sciences, 100, 10388-10392. 
ZHANG, J. Y., ZHANG, Z., WANG, X., FU, J. L., YAO, J., JIAO, Y., CHEN, L., ZHANG, H., WEI, J., JIN, L., 
SHI, M., GAO, G. F., WU, H. & WANG, F. S. 2007. PD-1 up-regulation is correlated with HIV-
specific memory CD8+ T-cell exhaustion in typical progressors but not in long-term 
nonprogressors. Blood, 109, 4671-8. 
288 
 
ZHANG, L., CONEJO-GARCIA, J. R., KATSAROS, D., GIMOTTY, P. A., MASSOBRIO, M., REGNANI, G., 
MAKRIGIANNAKIS, A., GRAY, H., SCHLIENGER, K., LIEBMAN, M. N., RUBIN, S. C. & COUKOS, G. 
2003. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J 
Med, 348, 203-13. 
ZHANG, P.-C., WANG, J., LEONG, K. W. & MAO, H.-Q. 2005. Ternary Complexes Comprising 
Polyphosphoramidate Gene Carriers with Different Types of Charge Groups Improve 
Transfection Efficiency†. Biomacromolecules, 6, 54-60. 
ZHANG, X., SCHWARTZ, J. C., GUO, X., BHATIA, S., CAO, E., LORENZ, M., CAMMER, M., CHEN, L., 
ZHANG, Z. Y., EDIDIN, M. A., NATHENSON, S. G. & ALMO, S. C. 2004. Structural and 
functional analysis of the costimulatory receptor programmed death-1. Immunity, 20, 337-
47. 
ZHANG, Y., LI, H., SUN, J., GAO, J., LIU, W., LI, B., GUO, Y. & CHEN, J. 2010. DC-Chol/DOPE cationic 
liposomes: A comparative study of the influence factors on plasmid pDNA and siRNA gene 
delivery. International Journal of Pharmaceutics, 390, 198-207. 
ZHENG, M., ZHONG, Y., MENG, F., PENG, R. & ZHONG, Z. 2011. Lipoic Acid Modified Low Molecular 
Weight Polyethylenimine Mediates Nontoxic and Highly Potent in Vitro Gene Transfection. 
Molecular Pharmaceutics, 8, 2434-2443. 
ZHONG, X. S., MATSUSHITA, M., PLOTKIN, J., RIVIERE, I. & SADELAIN, M. 2010. Chimeric antigen 
receptors combining 4-1BB and CD28 signaling domains augment PI3kinase/AKT/Bcl-XL 
activation and CD8+ T cell-mediated tumor eradication. Mol Ther, 18, 413-20. 
ZHOU, G. & LEVITSKY, H. 2012. Towards curative cancer immunotherapy: overcoming posttherapy 
tumor escape. Clin Dev Immunol, 2012, 124187. 
ZHOU, P. 2004. Determining protein half-lives. Methods Mol Biol, 284, 67-77. 
ZHU, L. & MAHATO, R. I. 2010. Lipid and polymeric carrier-mediated nucleic acid delivery. Expert 
Opin Drug Deliv, 7, 1209-26. 
ZITVOGEL, L., TESNIERE, A. & KROEMER, G. 2006. Cancer despite immunosurveillance: 
immunoselection and immunosubversion. Nat Rev Immunol, 6, 715-27. 
ZOLNIK, B. S., GONZÁLEZ-FERNÁNDEZ, Á., SADRIEH, N. & DOBROVOLSKAIA, M. A. 2010. 
Nanoparticles and the Immune System. Endocrinology, 151, 458-465. 
ZOU, W. & CHEN, L. 2008. Inhibitory B7-family molecules in the tumour microenvironment. Nat Rev 
Immunol, 8, 467-77. 
ZOU, W., MACHELON, V., COULOMB-L'HERMIN, A., BORVAK, J., NOME, F., ISAEVA, T., WEI, S., 
KRZYSIEK, R., DURAND-GASSELIN, I., GORDON, A., PUSTILNIK, T., CURIEL, D. T., GALANAUD, 
P., CAPRON, F., EMILIE, D. & CURIEL, T. J. 2001. Stromal-derived factor-1 in human tumors 
recruits and alters the function of plasmacytoid precursor dendritic cells. Nat Med, 7, 1339-
46. 
 
 
 
 
 
 
 
 
289 
 
Appendix 6.1  
PD-L1 mRNA targeting regions by PD-L1 siRNA and 
shRNA  
 
siRNA targeting sequences are represented in bold red 
shRNA targeting sequences are highlighted yellow 
Single-nucleotide polymorphisms are represented in bold green with underscore 
 
Homo sapiens CD274 molecule (CD274), transcript variant 1 (full length), mRNA 
NCBI Reference Sequence: NM_014143.3 
http://www.ncbi.nlm.nih.gov/nuccore/292658763?report=fasta 
 
GGCGCAACGCTGAGCAGCTGGCGCGTCCCGCGCGGCCCCAGTTCTGCGCAG
CTTCCCGAGGCTCCGCACCAGCCGCGCTTCTGTCCGCCTGCAGGGCATTCCA
GAAAGATGAGGATATTTGCTGTCTTTATATTCATGACCTACTGGCATTTGCTGAA
CGCATTTACTGTCACGGTTCCCAAGGACCTATATGTGGTAGAGTATGGTAGCA
ATATGACAATTGAATGCAAATTCCCAGTAGAAAAACAATTAGACCTGGCTGCAC
TAATTGTCTATTGGGAAATGGAGGATAAGAACATTATTCAATTTGTGCATGGAGA
GGAAGACCTGAAGGTTCAGCATAGTAGCTACAGACAGAGGGCCCGGCTGTTGA
AGGACCAGCTCTCCCTGGGAAATGCTGCACTTCAGATCACAGATGTGAAATTGC
AGGATGCAGGGGTGTACCGCTGCATGATCAGCTATGGTGGTGCCGACTACAA
GCGAATTACTGTGAAAGTCAATGCCCCATACAACAAAATCAACCAAAGAATTTT
GGTTGTGGATCCAGTCACCTCTGAACATGAACTGACATGTCAGGCTGAGGGCT
ACCCCAAGGCCGAAGTCATCTGGACAAGCAGTGACCATCAAGTCCTGAGTGGA
GATTAGATCCTGAGGAAAACCATACAGCTGAATTGGTCATCCCAGAACTACCTC
TGGCACATCCTCCAAATGAAAGGACTCACTTGGGAGAATGATGGATGTGAAAAA
ATGTGGCATCCAAGATACAAACTCAAAGAAGCAAAGTGATACACATTTGGAGGA
GACGTAATCCAGCATTGGAACTTCTGATCTTCAAGCAGGGATTCTCAACCTGTG
GTTTAGGGGTTCATCGGGGCTGAGCGTGACAAGAGGAAGGAATGGGCCCGTG
GGATGCAGGCAATGTGGGACTTAAAAGGCCCAAGCACTGAAAATGGAACCTG
290 
 
GCGAAAGCAGAGGAGGAGAATGAAGAAAGATGGAGTCAAACAGGGAGCCTGG
AGGGAGACCTTGATACTTTCAAATGCCTGAGGGGCTCATCGACGCCTGTGACA
GGGAGAAAGGATACTTCTGAACAAGGAGCCTCCAAGCAAATCATCCATTGCTCA
TCCTAGGAAGACGGGTTGAGAATCCCTAATTTGAGGGTCAGTTCCTGCAGAAGT
GCCCTTTGCCTCCACTCAATGCCTCAATTTGTTTTCTGCATGACTGAGAGTCTCA
GTGTTGGAACGGGACAGTATTTATGTATGAGTTTTTCCTATTTATTTTGAGTCTG
TGAGGTCTTCTTGTCATGTGAGTGTGGTTGTGAATGATTTCTTTTGAAGATATAT
TGTAGTAGATGTTACAATTTTGTCGCCAAACTAAACTTGCTGCTTAATGATTTGC
TCACATCTAGTAAAACATGGAGTATTTGTAAGGTGCTTGGTCTCCTCTATAACTA
CAAGTATACATTGGAAGCATAAAGATCAAACCGTTGGTTGCATAGGATGTCACC
TTTATTTAACCCATTAATACTCTGGTTGACCTAATCTTATTCTCAGACCTCAAGTG
TCTGTGCAGTATCTGTTCCATTTAAATATCAGCTTTACAATTATGTGGTAGCCTA
CACACATAATCTCATTTCATCGCTGTAACCACCCTGTTGTGATAACCACTATTAT
TTTACCCATCGTACAGCTGAGGAAGCAAACAGATTAAGTAACTTGCCCAAACCA
GTAAATAGCAGACCTCAGACTGCCACCCACTGTCCTTTTATAATACAATTTACAG
CTATATTTTACTTTAAGCAATTCTTTTATTCAAAAACCATTTATTAAGTGCCCTTG
CAATATCAATCGCTGTGCCAGGCATTGAATCTACAGATGTGAGCAAGACAAAGT
ACCTGTCCTCAAGGAGCTCATAGTATAATGAGGAGATTAACAAGAAAATGTATTA
TTACAATTTAGTCCAGTGTCATAGCATAAGGATGATGCGAGGGGAAAACCCGAG
CAGTGTTGCCAAGAGGAGGAAATAGGCCAATGTGGTCTGGGACGGTTGGATAT
ACTTAAACATCTTAATAATCAGAGTAATTTTCATTTACAAAGAGAGGTCGGTACT
TAAAATAACCCTGAAAAATAACACTGGAATTCCTTTTCTAGCATTATATTTATTCC
TGATTTGCCTTTGCCATATAATCTAATGCTTGTTTATATAGTGTCTGGTATTGTTT
AACAGTTCTGTCTTTTCTATTTAAATGCCACTAAATTTTAAATTCATACCTTTCCA
TGATTCAAAATTCAAAAGATCCCATGGGAGATGGTTGGAAAATCTCCACTTCATC
CTCCAAGCCATTCAAGTTTCCTTTCCAGAAGCAACTGCTACTGCCTTTCATTCAT
ATGTTCTTCTAAAGATAGTCTACATTTGGAAATGTATGTTAAAAGCACGTATTTTT
AAAATTTTTTTCCTAAATAGTAACACATTGTATGTCTGCTGTGTACTTTGCTATTT
TTATTTATTTTAGTGTTTCTTATATAGCAGATGGAATGAATTTGAAGTTCCCAGG
GCTGAGGATCCATGCCTTCTTTGTTTCTAAGTTATCTTTCCCATAGCTTTTCATTA
TCTTTCATATGATCCAGTATATGTTAAATATGTCCTACATATACATTTAGACAACC
ACCATTTGTTAAGTATTTGCTCTAGGACAGAGTTTGGATTTGTTTATGTTTGCTC
AAAAGGAGACCCATGGGCTCTCCAGGGTGCACTGAGTCAATCTAGTCCTAAAA
AGCAATCTTATTATTAACTCTGTATGACAGAATCATGTCTGGAACTTTTGTTTTCT
291 
 
GCTTTCTGTCAAGTATAAACTTCACTTTGATGCTGTACTTGCAAAATCACATTTTC
TTTCTGGAAATTCCGGCAGTGTACCTTGACTGCTAGCTACCCTGTGCCAGAAAA
GCCTCATTCGTTGTGCTTGAACCCTTGAATGCCACCAGCTGTCATCACTACACA
GCCCTCCTAAGAGGCTTCCTGGAGGTTTCGAGATTCAGATGCCCTGGGAGATC
CCAGAGTTTCCTTTCCCTCTTGGCCATATTCTGGTGTCAATGACAAGGAGTACC
TTGGCTTTGCCACATGTCAAGGCTGAAGAAACAGTGTCTCCAACAGAGCTCCTT
GTGTTATCTGTTTGTACATGTGCATTTGTACAGTAATTGGTGTGACAGTGTTCTT
TGTGTGAATTACAGGCAAGAATTGTGGCTGAGCAAGGCACATAGTCTACTCAGT
CTATTCCTAAGTCCTAACTCCTCCTTGTGGTGTTGGATTTGTAAGGCACTTTATC
CCTTTTGTCTCATGTTTCATCGTAAATGGCATAGGCAGAGATGATACCTAATTCT
GCATTTGATTGTCACTTTTTGTACCTGCATTAATTTAATAAAATATTCTTATTTATT
TTGTTACTTGGTACACCAGCATGTCCATTTTCTTGTTTATTTTGTGTTTAATAAAA
TGTTCAGTTTAACATCCCAGTGGAGAAAGTTAAAAAA 
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Appendix 7.1  
Vector construct for 4αβ and T1E28z 
 
GGATCCGGATTAGTCCAATTTGTTAAAGACAGGATATCAGTGGTCCAGGCTCTA
GTTTTGACTCAACAATATCACCAGCTGAAGCCTATAGAGTACGAGCCATAGATA
AAATAAAAGATTTTATTTAGTCTCCAGAAAAAGGGGGGAATGAAAGACCCCACC
TGTAGGTTTGGCAAGCTAGCTTAAGTAACGCCATTTTGCAAGGCATGGAAAAAT
ACATAACTGAGAATAGAGAAGTTCAGATCAAGGTCAGGAACAGATGGAACAGCT
GAATATGGGCCAAACAGGATATCTGTGGTAAGCAGTTCCTGCCCCGGCTCAGG
GCCAAGAACAGATGGAACAGCTGAATATGGGCCAAACAGGATATCTGTGGTAA
GCAGTTCCTGCCCCGGCTCAGGGCCAAGAACAGATGGTCCCCAGATGCGGTC
CAGCCCTCAGCAGTTTCTAGAGAACCATCAGATGTTTCCAGGGTGCCCCAAGG
ACCTGAAATGACCCTGTGCCTTATTTGAACTAACCAATCAGTTCGCTTCTCGCTT
CTGTTCGCGCGCTTCTGCTCCCCGAGCTCAATAAAAGAGCCCACAACCCCTCA
CTCGGGGCGCCAGTCCTCCGATTGACTGAGTCGCCCGGGTACCCGTGTATCCA
ATAAACCCTCTTGCAGTTGCATCCGACTTGTGGTCTCGCTGTTCCTTGGGAGGG
TCTCCTCTGAGTGATTGACTACCCGTCAGCGGGGGTCTTTCACACATGCAGCAT
GTATCAAAATTAATTTGGTTTTTTTTCTTAAGTATTTACATTAAATGGCCATAGTA
CTTAAAGTTACATTGGCTTCCTTGAAATAAACATGGAGTATTCAGAATGTGTCAT
AAATATTTCTAATTTTAAGATAGTATCTCCATTGGCTTTCTACTTTTTCTTTTATTT
TTTTTTGTCCTCTGTCTTCCATTTGTTGTTGTTGTTGTTTGTTTGTTTGTTTGTTG
GTTGGTTGGTTAATTTTTTTTTAAAGATCCTACACTATAGTTCAAGCTAGACTATT
AGCTACTCTGTAACCCAGGGTGACCTTGAAGTCATGGGTAGCCTGCTGTTTTAG
CCTTCCCACATCTAAGATTACAGGTATGAGCTATCATTTTTGGTATATTGATTGA
TTGATTGATTGATGTGTGTGTGTGTGATTGTGTTTGTGTGTGTGACTGTGAAAAT
GTGTGTATGGGTGTGTGTGAATGTGTGTATGTATGTGTGTGTGTGAGTGTGTGT
GTGTGTGTGTGCATGTGTGTGTGTGTGACTGTGTCTATGTGTATGACTGTGTGT
GTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTTGTGAAAAAATATT
CTATGGTAGTGAGAGCCAACGCTCCGGCTCAGGTGTCAGGTTGGTTTTTGAGA
CAGAGTCTTTCACTTAGCTTGGAATTCACTGGCCGTCGTTTTACAACGTCGTGA
CTGGGAAAACCCTGGCGTTACCCAACTTAATCGCCTTGCAGCACATCCCCCTTT
CGCCAGCTGGCGTAATAGCGAAGAGGCCCGCACCGATCGCCCTTCCCAACAG
TTGCGCAGCCTGAATGGCGAATGGCGCCTGATGCGGTATTTTCTCCTTACGCAT
CTGTGCGGTATTTCACACCGCATATGGTGCACTCTCAGTACAATCTGCTCTGAT
GCCGCATAGTTAAGCCAGCCCCGACACCCGCCAACACCCGCTGACGCGCCCT
GACGGGCTTGTCTGCTCCCGGCATCCGCTTACAGACAAGCTGTGACCGTCTCC
GGGAGCTGCATGTGTCAGAGGTTTTCACCGTCATCACCGAAACGCGCGATGAC
GAAAGGGCCTCGTGATACGCCTATTTTTATAGGTTAATGTCATGATAATAATGGT
TTCTTAGACGTCAGGTGGCACTTTTCGGGGAAATGTGCGCGGAACCCCTATTTG
TTTATTTTTCTAAATACATTCAAATATGTATCCGCTCATGAGACAATAACCCTGAT
AAATGCTTCAATAATATTGAAAAAGGAAGAGTATGAGTATTCAACATTTCCGTGT
CGCCCTTATTCCCTTTTTTGCGGCATTTTGCCTTCCTGTTTTTGCTCACCCAGAA
293 
 
ACGCTGGTGAAAGTAAAAGATGCTGAAGATCAGTTGGGTGCACGAGTGGGTTA
CATCGAACTGGATCTCAACAGCGGTAAGATCCTTGAGAGTTTTCGCCCCGAAGA
ACGTTTTCCAATGATGAGCACTTTTAAAGTTCTGCTATGTGGCGCGGTATTATCC
CGTATTGACGCCGGGCAAGAGCAACTCGGTCGCCGCATACACTATTCTCAGAA
TGACTTGGTTGAGTACTCACCAGTCACAGAAAAGCATCTTACGGATGGCATGAC
AGTAAGAGAATTATGCAGTGCTGCCATAACCATGAGTGATAACACTGCGGCCAA
CTTACTTCTGACAACGATCGGAGGACCGAAGGAGCTAACCGCTTTTTTGCACAA
CATGGGGGATCATGTAACTCGCCTTGATCGTTGGGAACCGGAGCTGAATGAAG
CCATACCAAACGACGAGCGTGACACCACGATGCCTGTAGCAATGGCAACAACG
TTGCGCAAACTATTAACTGGCGAACTACTTACTCTAGCTTCCCGGCAACAATTAA
TAGACTGGATGGAGGCGGATAAAGTTGCAGGACCACTTCTGCGCTCGGCCCTT
CCGGCTGGCTGGTTTATTGCTGATAAATCTGGAGCCGGTGAGCGTGGGTCTCG
CGGTATCATTGCAGCACTGGGGCCAGATGGTAAGCCCTCCCGTATCGTAGTTA
TCTACACGACGGGGAGTCAGGCAACTATGGATGAACGAAATAGACAGATCGCT
GAGATAGGTGCCTCACTGATTAAGCATTGGTAACTGTCAGACCAAGTTTACTCA
TATATACTTTAGATTGATTTAAAACTTCATTTTTAATTTAAAAGGATCTAGGTGAA
GATCCTTTTTGATAATCTCATGACCAAAATCCCTTAACGTGAGTTTTCGTTCCAC
TGAGCGTCAGACCCCGTAGAAAAGATCAAAGGATCTTCTTGAGATCCTTTTTTT
CTGCGCGTAATCTGCTGCTTGCAAACAAAAAAACCACCGCTACCAGCGGTGGT
TTGTTTGCCGGATCAAGAGCTACCAACTCTTTTTCCGAAGGTAACTGGCTTCAG
CAGAGCGCAGATACCAAATACTGTCCTTCTAGTGTAGCCGTAGTTAGGCCACCA
CTTCAAGAACTCTGTAGCACCGCCTACATACCTCGCTCTGCTAATCCTGTTACC
AGTGGCTGCTGCCAGTGGCGATAAGTCGTGTCTTACCGGGTTGGACTCAAGAC
GATAGTTACCGGATAAGGCGCAGCGGTCGGGCTGAACGGGGGGTTCGTGCAC
ACAGCCCAGCTTGGAGCGAACGACCTACACCGAACTGAGATACCTACAGCGTG
AGCATTGAGAAAGCGCCACGCTTCCCGAAGGGAGAAAGGCGGACAGGTATCC
GGTAAGCGGCAGGGTCGGAACAGGAGAGCGCACGAGGGAGCTTCCAGGGGG
AAACGCCTGGTATCTTTATAGTCCTGTCGGGTTTCGCCACCTCTGACTTGAGCG
TCGATTTTTGTGATGCTCGTCAGGGGGGCGGAGCCTATGGAAAAACGCCAGCA
ACGCGGCCTTTTTACGGTTCCTGGCCTTTTGCTGGCCTTTTGCTCACATGTTCTT
TCCTGCGTTATCCCCTGATTCTGTGGATAACCGTATTACCGCCTTTGAGTGAGC
TGATACCGCTCGCCGCAGCCGAACGACCGAGCGCAGCGAGTCAGTGAGCGAG
GAAGCGGAAGAGCGCCCAATACGCAAACCGCCTCTCCCCGCGCGTTGGCCGA
TTCATTAATGCAGCTGGCACGACAGGTTTCCCGACTGGAAAGCGGGCAGTGAG
CGCAACGCAATTAATGTGAGTTAGCTCACTCATTAGGCACCCCAGGCTTTACAC
TTTATGCTTCCGGCTCGTATGTTGTGTGGAATTGTGAGCGGATAACAATTTCAC
ACAGGAAACAGCTATGACCATGATTACGCCAAGCTTTGCTCTTAGGAGTTTCCT
AATACATCCCAAACTCAAATATATAAAGCATTTGACTTGTTCTATGCCCTAGGGG
GCGGGGGGAAGCTAAGCCAGCTTTTTTTAACATTTAAAATGTTAATTCCATTTTA
AATGCACAGATGTTTTTATTTCATAAGGGTTTCAATGTGCATGAATGCTGCAATA
TTCCTGTTACCAAAGCTAGTATAAATAAAAATAGATAAACGTGGAAATTACTTAG
AGTTTCTGTCATTAACGTTTCCTTCCTCAGTTGACAACATAAATGCGCTGCTGAG
CAAGCCAGTTTGCATCTGTCAGGATCAATTTCCCATTATGCCAGTCATATTAATT
ACTAGTCAATTAGTTGATTTTTATTTTTGACATATACATGTGAATGAAAGACCCCA
CCTGTAGGTTTGGCAAGCTAGCTTAAGTAACGCCATTTTGCAAGGCATGGAAAA
ATACATAACTGAGAATAGAAAAGTTCAGATCAAGGTCAGGAACAGATGGAACAG
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CTGAATATGGGCCAAACAGGATATCTGTGGTAAGCAGTTCCTGCCCCGGCTCA
GGGCCAAGAACAGATGGAACAGCTGAATATGGGCCAAACAGGATATCTGTGGT
AAGCAGTTCCTGCCCCGGCTCAGGGCCAAGAACAGATGGTCCCCAGATGCGG
TCCAGCCCTCAGCAGTTTCTAGAGAACCATCAGATGTTTCCAGGGTGCCCCAA
GGACCTGAAATGACCCTGTGCCTTATTTGAACTAACCAATCAGTTCGCTTCTCG
CTTCTGTTCGCGCGCTTATGCTCCCCGAGCTCAATAAAAGAGCCCACAACCCCT
CACTCGGGGCGCCAGTCCTCCGATTGACTGAGTCGCCCGGGTACCCGTGTATC
CAATAAACCCTCTTGCAGTTGCATCCGACTTGTGGTCTCGCTGTTCCTTGGGAG
GGTCTCCTCTGAGTGATTGACTACCCGTCAGCGGGGGTCTTTCATTTGGGGGC
TCGTCCGGGATCGGGAGACCCCTGCCCAGGGACCACCGACCCACCACCGGGA
GGTAAGCTGGCCAGCAACTTATCTGTGTCTGTCCGATTGTCTAGTGTCTATGAC
TGATTTTATGCGCCTGCGTCGGTACTAGTTAGCTAACTAGCTCTGTATCTGGCG
GACCCGTGGTGGAACTGACGAGTTCGGAACACCCGGCCGCAACCCTGGGAGA
CGTCCCAGGGACTTCGGGGGCCGTTTTTGTGGCCCGACCTGAGTCCTAAAATC
CCGATCGTTTAGGACTCTTTGGTGCACCCCCCTTAGAGGAGGGATATGTGGTT
CTGGTAGGAGACGAGAACCTAAAACAGTTCCCGCCTCCGTCTGAATTTTTGCTT
TCGGTTTGGGACCGAAGCCGCGCCGCGCGTCTTGTCTGCTGCAGCATCGTTCT
GTGTTGTCTCTGTCTGACTGTGTTTCTGTATTTGTCTGAAAATATGGGCCCGGG
CTAGACTGTTACCACTCCCTTAAGTTTGACCTTAGGTCACTGGAAAGATGTCGA
GCGGATCGCTCACAACCAGTCGGTAGATGTCAAGAAGAGACGTTGGGTTACCT
TCTGCTCTGCAGAATGGCCAACCTTTAACGTCGGATGGCCGCGAGACGGCACC
TTTAACCGAGACCTCATCACCCAGGTTAAGATCAAGGTCTTTTCACCTGGCCCG
CATGGACACCCAGACCAGGTCCCCTACATCGTGACCTGGGAAGCCTTGGCTTT
TGACCCCCCTCCCTGGGTCAAGCCCTTTGTACACCCTAAGCCTCCGCCTCCTC
TTCCTCCATCCGCCCCGTCTCTCCCCCTTGAACCTCCTCGTTCGACCCCGCCTC
GATCCTCCCTTTATCCAGCCCTCACTCCTTCTCTAGGCGCCCCCATATGGCCAT
ATGAGATCTTATATGGGGCACCCCCGCCCCTTGTAAACTTCCCTGACCCTGACA
TGACAAGAGTTACTAACAGCCCCTCTCTCCAAGCTCACTTACAGGCTCTCTACT
TAGTCCAGCACGAAGTCTGGAGACCTCTGGCGGCAGCCTACCAAGAACAACTG
GACCGACCGGTGGTACCTCACCCTTACCGAGTCGGCGACACAGTGTGGGTCC
GCCGACACCAGACTAAGAACCTAGAACCTCGCTGGAAAGGACCTTACACAGTC
CTGCTGACCACCCCCACCGCCCTCAAAGTAGACGGCATCGCAGCTTGGATACA
CGCCTGAAGGCTGCCGACCCCGGGGGTGGACCATCCTCTAGACTGCCATGGG
CTGGCTGTGCAGCGGCCTGCTGTTCCCCGTGAGCTGCCTGGTGCTGCTGCAG
GTGGCCAGCAGCGGCAACATGAAAGTGCTGCAGGAGCCCACATGTGTGTCCG
ACTACATGTCCATCTCTACATGTGAGTGGAAGATGAACGGCCCCACAAACTGCT
CTACCGAGCTGCGGCTGCTGTACCAGCTGGTGTTTCTGCTGAGCGAGGCCCAC
ACCTGTATCCCAGAAAATAATGGCGGGGCCGGGTGTGTGTGCCACCTGCTGAT
GGATGACGTGGTGTCTGCCGACAATTACACCCTGGACCTGTGGGCCGGACAG
CAGCTGCTGTGGAAGGGGTCCTTCAAACCCTCTGAGCACGTGAAGCCAAGGGC
CCCCGGCAACCTGACAGTGCACACCAACGTGTCTGATACACTGCTGCTGACAT
GGAGCAATCCATACCCTCCTGACAACTACCTGTACAACCACCTGACCTACGCC
GTGAATATCTGGAGCGAAAATGATCCTGCCGACTTTCGGATTTACAATGTGACC
TATCTGGAGCCCTCCCTGAGAATTGCCGCCTCTACCCTGAAATCTGGAATCTCC
TACCGCGCCAGGGTGCGGGCCTGGGCCCAGTGTTACAACACCACCTGGTCTG
AGTGGAGCCCAAGCACCAAGTGGCACAATTCTTATCGGGAGCCTTTTGAGCAG
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CACCTATCCCCTGGCTGGGACACCTGCTGGTGGGGCTGTCTGGCGCCTTTGG
CTTCATCATTCTGGTGTACCTGCTGATCAACTGTAGGAATACAGGCCCTTGGCT
GAAGAAGGTGCTGAAGTGTAACACCCCCGACCCCTCTAAGTTCTTCAGCCAGC
TGTCCTCTGAACACGGGGGAGATGTGCAGAAGTGGCTGTCCAGCCCTTTCCCA
TCCAGCTCCTTTAGCCCCGGGGGCCTGGCCCCTGAGATCTCTCCACTGGAAGT
GCTGGAGCGGGACAAGGTGACCCAGCTGCTGCTGCAGCAGGACAAGGTGCCA
GAACCCGCCTCCCTGAGCTCCAACCACAGCCTGACATCTTGCTTTACAAATCAG
GGATACTTCTTCTTCCACCTGCCCGATGCCCTGGAGATCGAGGCCTGCCAGGT
GTACTTCACCTACGATCCCTACTCTGAGGAAGACCCAGATGAGGGCGTGGCCG
GGGCCCCAACCGGGTCCAGCCCACAGCCACTGCAGCCACTGTCCGGCGAAGA
TGACGCCTACTGCACATTCCCTTCCAGGGATGACCTGCTGCTGTTCAGCCCATC
TCTGCTGGGCGGACCCTCTCCTCCAAGCACAGCCCCAGGGGGATCCGGCGCC
GGGGAAGAGAGGATGCCCCCTAGCCTGCAGGAGCGCGTGCCCAGAGACTGG
GACCCCCAGCCCCTGGGCCCTCCAACCCCTGGGGTGCCCGACCTGGTGGACT
TCCAGCCTCCACCCGAGCTGGTGCTGAGGGAGGCCGGCGAAGAGGTGCCCGA
CGCCGGCCCCCGGGAGGGCGTGTCCTTCCCTTGGTCCAGACCTCCAGGACAG
GGCGAGTTCCGCGCCCTGAACGCCAGGCTGCCTCTGAACACCGATGCCTACCT
GTCTCTGCAGGAACTGCAGGGCCAGGACCCAACCCACCTGGTGCGGAGAAAG
CGCAGCGGCTCCGGCGAGGGCCGGGGCAGCCTGCTGACCTGCGGCGACGTG
GAAGAGAACCCCGGACCCATGGCTCTCCCAGTGACTGCCCTACTGCTTCCCCT
AGCGCTTCTCCTGCATGCAGTGGTGTCGCACTTCAATGACTGTCCACTGTCGCA
CGATGGATACTGCCTCCATGATGGTGTGTGCATGTACATCGAGGCATTGGACA
AGTATGCATGCAACTGTGTCGTCGGCTACATCGGAGAGCGATGTCAGTACCGA
GACCTGAAGTGGTGGGAACTGAGAGCGGCCGCAATTGAAGTTATGTATCCTCC
TCCTTACCTAGACAATGAGAAGAGCAATGGAACCATTATCCATGTGAAAGGGAA
ACACCTTTGTCCAAGTCCCCTATTTCCCGGACCTTCTAAGCCCTTTTGGGTGCT
GGTGGTGGTTGGTGGAGTCCTGGCTTGCTATAGCTTGCTAGTAACAGTGGCCT
TTATTATTTTCTGGGTGAGGAGTAAGAGGAGCAGGCTCCTGCACAGTGACTACA
TGAACATGACTCCCCGCCGCCCCGGGCCCACCCGCAAGCATTACCAGCCCTAT
GCCCCACCACGCGACTTCGCAGCCTATCGCTCCAGAGTGAAGTTCAGCAGGAG
CGCAGAGCCCCCCGCGTACCAGCAGGGCCAGAACCAGCTCTATAACGAGCTC
AATCTAGGACGAAGAGAGGAGTACGATGTTTTGGACAAGAGACGTGGCCGGGA
CCCTGAGATGGGGGGAAAGCCGAGAAGGAAGAACCCTCAGGAAGGCCTGTAC
AATGAACTGCAGAAAGATAAGATGGCGGAGGCCTACAGTGAGATTGGGATGAA
AGGCGAGCGCCGGAGGGGCAAGGGGCACGATGGCCTTTACCAGGGTCTCAGT
ACAGCCACCAAGGACACCTACGACGCCCTTCACATGCAGGCCCTGCCCCCTCG
CTAACAGCCACTCGAG 
 
Promotor for amplicilin resistance 
amplicilin resistance 
Signal peptide for IL-4 receptor 
Extracellular IL-4 receptor subunit α 
IL-2 receptor subunit β 
 4αβ  
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IL-2 receptor subunit β cytoplasmic region 
Furin linker 
T2A peptide 
Furin 2A peptide 
TGFα (First 7 amino acids) 
EGF 
CD28 transmembrane and cytoplasmic regions 
CD3ζ cytoplasmic region 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  T1E CAR 
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Appendix 8.1  
Determination of lower limit of detection of sPD-L1  
 
The lower limit of detection (LLOD) is defined as the lowest concentration of analyte 
that can be determined to be statistically different from a blank at a 99% confidence 
level (Price and Newman, 1997).  
Taking the example of the standard curve obtained from the sPD-L1 ELISA assay 
(Figure A8.1), the LLOD for the optical density (OD) reading was first calculated 
using the formula (Dixit et al., 2010):  
𝑂𝐷𝐿𝐿𝑂𝐷 = 𝐵𝑙𝑎𝑛𝑘𝑎𝑣𝑒 + 10(𝐵𝑙𝑎𝑛𝑘𝑆𝐷)       (Equation A8.1) 
Where 𝑂𝐷𝐿𝐿𝑂𝐷 is the lowest optical density reading, 𝐵𝑙𝑎𝑛𝑘𝑎𝑣𝑒 is the mean OD value 
obtained from the blank sample (0 pg/mL rPD-L1) and 10(𝐵𝑙𝑎𝑛𝑘𝑆𝐷) is 10 times the 
value of the standard deviation of the blank. 
The LLOD was then calculated by fitting 𝑂𝐷𝐿𝑂𝐷 into the linear equation obtained from 
the standard curve. 
𝐿𝐿𝑂𝐷 =  (𝑂𝐷𝐿𝑂𝐷 − 0.1056)/0.0003       (Equation A8.2)
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Figure A8.1. Representative OD values and plot obtained by measuring various 
concentrations of rPD-L1 by the ELISA. 
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Appendix 8.2  
5-parameter nonlinear (5-PL) regression model 
 
 
Figure 8.2. An example of a typical standard curve fitted using the 5-PL nonlinear 
regression model. 
(Figure obtained from http://www.dartmouth.edu/~dartlab/uploads/Bio-
RadTechNote2861_principles_of_curve_fitting.pdf) 
 
5-PL: 𝑦 = 𝑑 +
𝑎−𝑑
[1+(
𝑥
𝑐
)
𝑏
]
𝑔                              (Equation A8.3) 
Where: a is the signal value at zero concentration, b is the slope factor, c is the mid-
range concentration (C50), d is the estimated response at infinite concentration and g 
is the asymmetry factor. 
After the curve is fitted to a data set by 5-PL, values for all five of the parameters 
may be determined and the equation can then be used to calculate unknown 
concentrations (x) from the signal value (y). If the curve is S-shaped and has similar 
shapes on both ends of the ‘S’ (symmetrical), a 4-parameter nonlinear (4-PL) or 5-PL 
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regression would yield similar results. However, when the curve is asymmetrical, a 
better fit would be achieved using a 5-PL regression. 
The quality of curve fit may be assessed by calculating the root mean square error 
(RMSE). 
𝑅𝑜𝑜𝑡 𝑚𝑒𝑎𝑛 𝑠𝑞𝑢𝑎𝑟𝑒 𝑒𝑟𝑟𝑜𝑟 (𝑅𝑀𝑆𝐸) = √
1
𝑛
∑ (𝑦𝑗 − 𝑦?̂?)
2𝑛
𝑗=1              (Equation A8.4) 
Where 𝑛 is the number of samples,  𝑦𝑗 is the observed value and 𝑦?̂? is the predicted 
value for the jth observation. (𝑦𝑗 − 𝑦𝑗)̂ is known as the residual value, which may be 
positive or negative.  
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Appendix 8.3  
Determination of antibody affinity 
 
Antibody affinity is the measurement of the strength of the interaction between an 
epitope and an antibody’s antigen binding site (Price and Newman, 1997). The 
interaction is dynamic and can be described by the following equation at given 
conditions of temperature, ionic strength and pH: 
[𝐴] + [𝐵] ↔ [𝐴𝐵]                  (Equation A8.5) 
Where [A] denotes the antigen concentration, [B] the antibody concentration and 
[AB] the concentration of complex AB.  
According to the Law of Mass Action, the association constant Ka, with physical 
dimensions of a concentration-1 (M-1) may be defined as the following: 
𝐾𝑎 =
[AB]
[A][B]
                              (Equation A8.6) 
A second constant known as the dissociation constant or Kd describes the affinity of 
the reverse reaction and has the physical dimension of concentration (M): 
𝐾𝑑 =
[𝐴][𝐵]
[𝐴𝐵]
                   (Equation A8.7) 
Kd may be derived from reactions when half the concentration of antigen is bound to 
the antibody. Therefore, [𝐴] = [𝐴𝐵] and equation simplifies to: 
𝐾𝑑 = [𝐵]         (Equation A8.8) 
Ka may then be calculated by: 
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𝐾𝑎 =
1
𝐾𝑑
         (Equation A8.9) 
The reported concentration of rPD-L1 which resulted in 50% of output signal was 
557.1 pg/mL (Figure 8.6). 
𝐾𝑑 = 557.1 𝑝𝑔/𝑚𝐿 
𝐾𝑎 = (
1
557.1
) = 1.8 × 10−3
𝑚𝐿
𝑝𝑔
 
= 1.8 × 10−6
𝑑𝑚3
𝑝𝑔
 
= (1.8 × 10−6)(1.5 × 1017)
𝑑𝑚3
𝑚𝑜𝑙
 
= 2.7 × 1011𝑀−1 
Based on antibody molecular weight of 150,000 kDa. 
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licence. 
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